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The last decades, tremendous progress has been made in improving treatment, and 
thereby prognosis, of patients with cardiovascular disease (CVD). Several breakthroughs 
in CVD management and prevention include the introduction of percutaneous coronary 
interventions in 19791 and the introduction of aspirin and cholesterol lowering with 
statins for treatment of CVD, both in the 1980s.2,3 Despite this all, CVD remains a primary 
cause of morbidity and mortality in the western world. In the 2012 update of the heart 
disease and stroke statistics,4 it was estimated that the prevalence of CVD in the United 
States in 2008 was 82.6 million individuals. Each year 785,000 Americans will have a 
new coronary event and approximately 470,000 will have a recurrent attack. In addition, 
795,000 people will have a new or recurrent stroke each year. The 2008 overall rate of 
CVD death was 245 per 100,000 individuals. Although these numbers are somewhat 
better in the Netherlands,5 also there the CVD burden is troublesome, indicating that 
we have a long road ahead of further improving the available treatment modalities and 
developing new and better treatment options and preventive measures.
Research on CVD has taught us a long time ago that disease development is an 
interplay of both genetic and environmental factors. In order to develop new treatment 
modalities, it is of paramount importance that we further increase our knowledge of 
the exact biological mechanisms and the genetic background of CVD. However, the 
multifactorial nature of CVD complicates the interpretation of genetic associations. 
Although many genetic factors have been associated with the different aspects of CVD, 
consistent replication has proven difficult.6-9 The reported genetic factors have small 
effect sizes and, even taken together, only explain a minor part of the suspected genetic 
component of the disease.10,11 This so called missing heritability has puzzled the scien-
tific field and encouraged development of improved genotyping methods and data 
analysis possibilities.12,13 First it was only possible to determine one single nucleotide 
polymorphism (SNP) at a time. Therefore, research focused on candidate genes that 
were hypothesized to be involved in the disease.14 Examples of this approach include 
the angiotensin-converting enzyme gene,15 the platelet glycoprotein IIIa gene16 and the 
matrix metalloproteinase 3 gene.17 This candidate gene approach was taken to a higher 
level when it became possible to genotype multiple SNPs at a time on so called multi-
plexes. After completion of the Human Genome Project18 and the HapMap project19 it 
became evident that SNPs were present in large quantities spread across the genome. 
In 2005 a new technique became available that enabled simultaneous genotyping of 
thousands of SNPs. This led to the development of genome-wide association studies, 
in which exploration of large amounts of common SNPs (> 100,000) across the whole 
genome became possible.20 Since no prior biologic knowledge was needed for these 
types of analyses, new unforeseen risk loci could be identified, possibly leading to better 
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understanding of the disease in question and potentially resulting in novel treatment 
targets. However, this hypothesis-free approach soon proved to bring along new diffi-
culties as well, since most identified loci were intergenic or even located in gene-deserts 
and therefore had unclear functions. This biological relevance item is currently the issue 
most studies try to resolve.
In the current thesis, several aspects of the above described development will be 
addressed. The first and second part of the thesis will focus on elucidating the genetic 
background of coronary restenosis and other aspects of CVD using candidate genes 
approaches, GWAS and post-GWAS analyses. The third and last part of this thesis will 
address the more clinical side of genetic research, pharmacogenetics. Pharmacogenet-
ics, focusses on the genetic determinants of response to drug therapy with the ultimate 
goal of applying personalized medicine.
outLine of this thesis
Part i – Genetics of coronary restenosis
Since its introduction, PCI has become widely accepted as an effective and safe treat-
ment modality for single vessel and multi-vessel coronary atherosclerotic disease. How-
ever, an important drawback of PCI is the renarrowing of the treated vessel, resulting in 
renewed symptoms and the need for repeat intervention.14 This phenomenon is called 
restenosis and it is an important cause of morbidity and possibly even mortality after 
PCI. 21 Restenosis is a complex disease for which the causative mechanisms have not yet 
been fully identified. In part 1, the genetic determinants of restenosis and the long-term 
consequences of this disease are explored.
In chapter 2 and chapter 3 an extensive overview of the current knowledge of re-
stenosis is given. In chapter 2 the different mechanisms involved in the development of 
restenosis are discussed together with the known clinical, biological and procedural risk 
factors contributing to the individual risk of restenosis. chapter 3 provides an overview 
of the latest innovations of optimizing outcomes of coronary stenting and discusses the 
available preventive and therapeutic measures of in-stent restenosis.
In chapter 4 we describe the results of the very first GWAS published on restenosis 
that was performed in the GENetic DEterminants of Restenosis (GENDER) study popula-
tion. Follow-up studies of this GWAS data resulted in the other 3 chapters in this part of 
the thesis. After obtaining the GWAS data, we used this data in chapter 5 to clarify the 
inconsistent results, reported in literature, on the association of genetic variation in ma-
trix metalloproteinases 2 and 3 and restenosis. Next, in chapter 6 we examine all SNPs 
in the genomic region of all other previously described candidate genes of restenosis. 
The aim of this study is to explore whether the joint effect of all these SNPs together 
1
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indeed is associated with restenosis, despite all the inconsistent results from previous 
studies. chapter 7 describes the next step in unraveling the genetic background of 
restenosis. In this study we performed pathway analysis of a wide range of biological 
pathways, related to the key mechanisms involved in restenosis development, with the 
aim to identify new additional candidate genes for further research. Finally, in chapter 
8 the 10-year follow-up of the GENDER population is presented. In this chapter we ex-
amine whether the development of restenosis has an effect on long-term mortality rate. 
Moreover, we compare the GENDER study with the general Dutch population to see if 
patients with coronary artery disease still have a worse outcome, despite all therapeutic 
advances that were made during the last decade.
Part ii – Genetics of (cardio)vascular diseases
In this second part of this thesis genetic determinants of two other (cardio)vascular 
conditions are studied. In chapter 9 we investigate the possible role of DNA repair 
mechanisms in CVD development by performing a gene set analysis of DNA repair 
pathways for their association with the CVD events myocardial infarction and stroke. 
Besides the GENDER population, we include in this study the 5,244 participants of the 
PROspective Study of Pravastatin in the Elderly at Risk (PROSPER) study. In chapter 10 
we make a sidestep towards nephrology to study a condition with a likely mechanistic 
overlap with coronary restenosis, i. e. arteriovenous access failure in hemodialysis pa-
tients. We determine a wide range of SNPs in the Netherlands Cooperative Study on the 
Adequacy of Dialysis (NECOSAD) population and analyze them for their association with 
arteriovenous access failure.
Part iii – Pharmacogenetics of cardiovascular diseases
The fact that not all patients have a similar adequate response to drug therapy poses a 
major problem in guideline-based clinical practice. Several underlying mechanisms for 
this aberrant response have been proposed and genetic variation is thought to play a 
major role. Pharmacogenetics is the field of research that examines genetic variation 
that influences responses to drug therapy in the individual patient. The ultimate goal of 
pharmacogenetics is the realization of personalized therapy in which determination of 
genetic polymorphisms can guide pharmacotherapy to choose agents with the greatest 
potential for efficacy and the least risk of toxicity. Pharmacogenetics also informs clini-
cians for dose adaptations to specific drugs in patients with aberrant metabolism.
In the first chapter of the final part of this thesis (chapter 11) a comprehensive 
overview is provided of the available pharmacogenetic evidence of the five major 
drug classes of cardiovascular diseases; statins, antiplatelet agents, anticoagulants, 
beta-blockers and angiotensin-converting enzyme inhibitors. In chapter 12, the eight 
best replicated SNPs, related to aspirin- and clopidogrel efficacy, are investigated in a 
14  
large population of ST-segment elevation myocardial infarction patients, to see whether 
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abstract
Restenosis is a complex disease for which the identified pathophysiological mechanisms 
have not yet been fully elucidated, but are thought to include inflammation, proliferation, 
and matrix remodeling. Over the years, many predictive clinical, biological, (epi)genetic, 
and procedural risk factors for restenosis have been identified. These factors are not only 
are useful in risk stratification of patients, they also contribute to our understanding of 
this condition. Furthermore, these factors provide evidence on which to base treatment 
tailored to the individual and aid in the development of novel therapeutic modalities. In 
this Review, we will evaluate the available evidence on the pathophysiological mecha-
nisms of restenosis and provide an overview of the various risk factors, together with the 
possibility of clinical application of this knowledge.
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introDuction
Percutaneous coronary intervention (PCI) was introduced as an alternative means of 
coronary revascularization to CABG surgery in 1979.1 Since then, PCI has become widely 
accepted as an effective and safe treatment modality for single vessel and multivessel 
coronary atherosclerotic disease. However, the major drawback of PCI is restenosis of the 
treated vessel, resulting in renewed symptoms and the need for repeat intervention.2 
Restenosis is a complex disease for which the causative mechanisms have not yet been 
fully identified. This condition can be defined by follow-up angiography or by recurrent 
ischemia-related symptoms in the patient. Binary angiographic restenosis is defined as 
the renarrowing of the vessel lumen to > 50% occlusion, usually within 3–6 months after 
PCI.3 Clinical restenosis is characterized by recurrent angina pectoris requiring target 
vessel revascularization (TVR).4 In many studies, follow-up coronary angiography has 
been used to define restenosis. Although the severity of angiographically determined 
restenosis correlates with TVR, up to 50% of patients with restenosis detected during 
angiography do not manifest clinical symptoms.5,6 Results of a 2011 meta-analysis of 29 
randomized controlled trials on the use of drug-eluting stents (DESs) demonstrated that 
two-thirds of patients with > 50% stenosis on angiography had ischemia-driven TVR.7
Before the introduction of the intracoronary bare-metal stent (BMS) in the late 
1980s,8 restenosis was a common complication that occurred in up to 50% of patients 
treated with balloon angioplasty.9 Various pharmacological strategies were shown to be 
disappointing for the prevention of restenosis, probably owing to the failure to target 
the appropriate pathway and to the poor local effects and penetrance of the drug into 
the vessel wall. Only after the introduction of the BMSs did the incidence of restenosis 
begin to diminish (20-30%).10 DESs have been proven to reduce restenosis even more ef-
fectively than BMSs (5-10%), although the problem was still not completely eradicated.11 
The effectiveness and safety of DESs were demonstrated by the results of large random-
ized controlled trials, leading to their current widespread use in daily clinical practice. 
However, implantation of DESs in unselected patients with complex lesions, and even 
off-label use, has resulted in a small resurge in the incidence of restenosis from 5% to 
15%.12-15 Furthermore, the new phenomena of ‘in-stent restenosis’ and, specifically for 
DESs, the ‘late catch-up phenomenon’ of restenosis beyond 1 year after implantation 
have been recognized.16-18
Restenosis is not a random phenomenon; certain patients appear to be at increased 
risk of developing this complication.19 Owing to the increasing number of patients being 
treated with multiple PCI procedures, the increasing cost of interventional cardiology 
as a result of adjuvant medication and devices,20 and the difficulty in treating in-stent 
restenosis, defining the subsets of patients at increased risk for restenosis would be 
useful. These patients could benefit from additional treatment modalities, such as 
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CABG surgery.2 Until now, identification of at-risk subgroups of patients on the basis 
of clinical, lesion-related, procedural, and biological markers has been only partially 
successful.2,19,21-24 Identification of the risk factors for the development for restenosis 
is not only helpful for patient stratification, but also provides valuable information on 
the underlying molecular and cellular mechanism of restenosis, with implications for 
new therapeutic modalities. An improved understanding of the processes of restenosis 
could lead to its prevention, saving patients from undergoing further procedures and 
reducing costs for society.
In this Review, we will evaluate the available evidence on the pathophysiological 
mechanisms of restenosis and explain that, although the exact mechanisms are not fully 
understood, an inflammatory response evoked by the procedure is probably is the main 
causative process (Figure 1).
We will also discuss many of the reported clinical, biological, (epi)genetic, lesion-
related, and procedural risk factors for restenosis, the strength of the evidence for their 
association with this condition, and the possible clinical application of this knowledge.
Figure 1 Factors involved in the development of restenosis.
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In this Review, we will evaluate the available evidence 
on the pathophysiologica  mechanisms of restenosis
and explain that, although the exact mechanisms are 
not fully understood, an inflammatory response evoked 
by the proce dure is probably the main causative process 
(Figure 1). We will also discuss any of the reported clini­
cal, biological, (epi)genetic, le ion­related, and procedural 
risk factors for restenosis, the strength of the evidence for 
their association with this condition, and the possible 
clinical application of this knowledge.
Pathophysiology
Although not completely elucidated, our current under­
standing of the restenotic process is that the stimulus 
triggering the cascade of events leading to restenosis 
co es from the vascular injury caused by balloon dila­
tion (b rotrauma) and stent placem t during PCI.19 
This cascade is a very broad concept and many pro­
cesses have been proposed to be involved (Figure 2). 
The inflammatory response to the endothelial denuda­
tion and sub intimal hemorrhage caused by the balloon 
Key points
 ■ Restenosis is a complex disease for which the causative mechanisms have not 
yet been fully identified
 ■ Diabetes mellitus is the most consistently reported clinical parameter increasing 
the risk of restenosis
 ■ The inflammatory response evoked by vascular damage during angioplasty  
is thought to be the main contributor to the development of restenosis
 ■ Some patients seem to have an inherent predisposition toward developing 
restenosis, which can be partly explained by their specific genetic background
 ■ Risk models including clinical, procedural, and biological factors are likely to  
be the best method of implementing available evidence for risk prediction and 
patient stratification
 ■ An improved understanding of the mechanisms of restenosis is important for risk 
stratification of patients and for identifying new and optimal targets for therapy
angioplasty has a key role, resulting in the onset of several 
proliferative processes, including vascular smooth muscle 
cell (VSMC) proliferation and migration, extracellular 
matrix formation, and neointimal hyperplasia.2,19 These 
events are set into motion by an elaborate interplay 
of systems—activation of platelets and related growth 
factors and proinflammatory cytokines, leukocytes, and 
the coagulation–fibrinolysis system, as well as events 
at the platelet surface.2,25 Although this reaction is physio­
logical, in some patients the proliferative response ‘over­
shoots’ resulting in renarrowing of the treated vessel. Why 
this hyper­response occurs in some individuals and not 
others is not well understood.
Although the mechanisms of restenosis are basically 
the same after balloon angioplasty alone and after PCI with 
stent placement, implantation of a stent does introduce 
some additional factors influencing the risk of restenosis. 
Vessel recoil, a major contributor to restenosis after balloon 
angioplasty, is virtually eliminated by coronary stenting.8 
However, stent underexpansion during implanta tion 
is a procedure­related equivalent of vessel recoil.26,27 In 
addition, the vascular response to barotrauma­induced 
inflammation is partially avoided with stent placement.26 
Moses et al. reported that the margins of the region of 
balloon injury that were not covered by stents were the 
primary sites of restenosis, and thus recommended the use 
of longer single stents to ensure adequate stent coverage of 
the entire zone of balloon injury to decrease the influence 
of barotrauma.28
Hypersensitivity to one or more components of the 
implanted stent is a rare, but nevertheless important, 
problem.26 Nickel allergy is a proposed mechanism trig­
gering the development of restenosis, although not con­
firmed by all studies.29–31 Hypersensitivity reactions to 
DESs, especially to the drug­carrying polymers, have 
also been reported, but are mainly associated with stent 
thrombosis and not restenosis,32 as will be discussed in 
more detail in Part 2 of this Review.33 Research into the 
molecular mechanisms involved in the interplay between 
the implanted stent and the vessel wall has contributed 
to our understanding of the role of stent components in 
resteno sis development. Pallero et al. reported that stain­
less steel ions stimulated thrombospondin­1­dependent 
activation of transforming growth factor β, which con­
tributed to restenosis formation by increasing extracellular 
ma rix and downregulating desmin in VSMCs.34
Another factor related to the implanted stent itself 
is stent fracture. The process resulting in stent fracture is 
thought to involve mechanical fatigue caused by repetitive 
cardiac contraction exposing the stent to compression, 
torsion, bending, and shear stress.35 The incidence of stent 
fracture is reasonably low (~4%),35 but could be under­
reported because intravascular ultrasound (IVUS), which 
is the method of choice to detect stent fracture, is not 
routinely used in all studies. The mechanisms by which 
stent fracture leads to restenosis are not known; however 
it is conceivable that the integrity of the stent is lost with 
fracture, allowing vessel recoil to occur again, or that 
the fractured stent strut protrudes into the lumen thereby 
contributing to partial occlusion of the vessel, particularly 
Figure 1 | Factors involved in the development of restenosis. Flowchart showing 
the interactions between the main contributors to the development of restenosis. 
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Flowchart showing interaction between the main contributors to the development of restenosis. 
Abbreviation: VSMC, vascular smooth muscle cells.
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2
PathoPhysioLoGy
Although not completely elucidated, our current understanding of the restenotic process 
is that the stimulus triggering the cascade of events leading to restenosis comes from 
the vascular injury caused by balloon dilation (barotrauma) and stent placement during 
PCI.19 This cascade is a very broad concept and many processes have been proposed to 
be involved (Figure 2). The inflammatory response to the endothelial denudation and 
subintimal hemorrhage caused by the balloon angioplasty has a key role, resulting in the 
onset of several proliferative processes, including vascular smooth muscle cell (VSMC) 
Figure 2 Mechanisms of restenosis.
NATURE REVIEWS | CARDIOLOGY  ADVANCE ONLINE PUBLICATION | 3
in the presence of neointima formation. A meta­analysis 
by Chakravarty et al. showed that lesions with fractured 
stents had a significantly higher rate of revascularization 
than those without stent fracture (17.0% versus 5.6%, 
P <0.01).35 Conversely, the probability of stent fracture was 
higher in patients with restenosis than in those without 
this condition (12.8% versus 2.8%, P <0.01).35 Another 
study, not included in this meta­analysis, demonstrated 
that late restenosis was not observed at stent fracture 
sites without early restenosis during midterm follow­up, 
indicating that the late catch­up phenomenon reported 
with DES restenosis is not associated with stent fracture.36 
Further research in identification of patients and lesions 
at risk of stent fracture is needed.
Risk factors for restenosis
Although most risk factors for restenosis are somehow 
associated with one or more of the pathophysiological pro­
cesses discussed above, these relationships are not always 
clear or are as yet unknown.
Clinical risk factors
Since clinical parameters are collected in every trial, 
these baseline characteristics are relatively easy to analyze 
(Table 1). The most­consistent clinical para meter that 
increases the risk of restenosis is diabetes mellitus.37 
Patients with insulin­dependent diabetes are at partic­
ularly high risk of adverse events following PCI.38 The 
generally accepted hypothesis of this phenomenon is 
that hyperglycemia induces endothelial dysfunction and 
a proinflammatory state with increased growth factor 
and cytokine production.25,39 These processes result in 
extensive neointima formation, thereby promoting the 
development of restenosis. The prothrombotic environ­
ment in patients with diabetes further increases the risk 
of events.40 An increased risk of restenosis has not been 
detected in patients with metabolic syndrome for which 
the clinical characteristics are more varied than diabetes, 
thus resulting in a more heterogeneous patient group.41
Although some investigators have reported a higher 
risk of restenosis in male patients than in females,42–44 the 
Figure 2 | Mechanisms of restenosis. Intravascular ultrasound images of the various stages of coronary artery  
disease. Indicated are the outer border of the vessel (green), the lumen (red), and the coronary stent (pink). Schematic 
representations are shown to the right of these images. The processes occurring in the vessel immediately after PCI with 
stent placement are highlighted in detail. Abbreviations: ADMA, asymmetric dimethylarginine; ECM, extra cellular matrix; 
MMPs, matrix metalloproteinases; mTOR, mammalian target of rapamycin; PAI-1, plasminogen activator inhibitor 1; 
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Intravascular ultrasound images of the various stages of coronary artery disease. Indicated are the outer 
bo der of the ves el (green), the lumen (red) and the coronary stent (pink). Sch matic representations 
are shown to the right of these images. The processes occurring in the vessel immediately after PCI with 
stent placement are highlighted in detail. Abbreviations: ADMA, asymmetric dimethylarginine; ECM, 
extra cellular matrix; MMPs, matrix metalloproteinases; mTOR, mammalian target of rapamycin; PAI-1, 
plasminogen activator inhibitor-1; PCI, percut neous coron ry interventions; TNF, tumor necrosis factor; 
VSMC, v scular smooth muscle cells
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proliferation and migration, extracellular matrix formation, and neointimal hyperpla-
sia.2,19 These events are set into motion by an elaborate interplay of systems—activation 
of platelets and related growth factors and proinflammatory cytokines, leukocytes, and 
the coagulation–fibrinolysis system, as well as events at the platelet surface.2,25 Although 
this reaction is physiological, in some patients the proliferative response ‘overshoots’ 
resulting in renarrowing of the treated vessel. Why this hyper-response occurs in some 
individuals and not others is not well understood.
Although the mechanisms of restenosis are basically the same after balloon angio-
plasty and after PCI with stent placement, implantation of a stent does introduce some 
additional factors influencing the risk of restenose. Vessel recoil, a major contributor to 
restenosis after balloon angioplasty, is virtually eliminated by coronary stenting.8 How-
ever, stent under-expansion during implantation is a procedure-related equivalent of 
vessel recoil.26,27 In addition, the vascular reponse to the inflammatory response induced 
by the barotrauma of balloon angioplasty, as mentioned before, is partially avoided with 
stent placement.26 Moses et al. reported that the margins of the region of balloon injury 
that were not covered by stents were the primary sites of restenosis, and thus recom-
mended the use of longer single stents in order to ensure adequate stent coverage of 
the entire zone of balloon injury to decrease the influence of the barotrauma.28
Hypersensitivity to one or more components of the implanted stent is a rare, but nev-
ertheless important, problem.26 Nickel allergy is a proposed mechanism triggering the 
development of restenosis, although not confirmed by all studies.29-31 Hypersensitivity 
reactions to DESs, especially to the drug-carrying polymers, have also been reported but 
are mainly associated with stent thrombosis and not restenosis,32 as will be discussed in 
more detail in Part 2 of this Review.33 Research into the molecular mechanisms involved 
in the interplay between the implanted stent and the vessel wall has contributed to our 
understanding of the role of stent components in restenosis development. Pallero et al. 
reported that stainless steel ions stimulated thrombospondin-1-dependent transform-
ing growth factor β activation, which contributed to restenosis formation by increasing 
extracellular matrix and downregulating desmin in VSMC.34
Another factor related to the implanted stent itself is stent fracture. The process 
resulting in stent fracture is thought to involve mechanical fatigue caused by repeti-
tive cardiac contraction exposing the stent to compression, torsion, bending, and shear 
stress.35 The incidence of stent fracture is reasonably low (~4%),35 but could be under-
reported because intravascular ultrasound (IVUS), which is the method of choice to 
detect stent fracture, is not routinely used in all studies. The mechanisms by which stent 
fracture leads to restenosis are not known; however it is conceivable that the integrity of 
the stent is lost with fracture, allowing vessel recoil to occur again, or that the fractured 
stent strut protrudes into the lumen thereby contributing to partial occlusion of the ves-
sel, particularly in the presence of neointima formation. A meta-analysis by Chakravarty 
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et al. showed that lesions with fractured stents had a significantly higher rate of revas-
cularization than those without stent fracture (17.0% versus 5.6%, P < 0.01). Conversely, 
the probability of stent fracture was higher in patients with restenosis than in those 
without this condition (12.8% versus 2.8%, P < 0.01).35 Another study, not included in this 
meta-analysis, demonstrated that late restenosis was not observed at stent fracture sites 
without early restenosis during midterm follow-up, indicating that the late catch-up 
phenomenon reported with DES restenosis is not associated with stent fracture.36 Fur-
ther research in identification of patients and lesions at risk of stent fracture is needed.
risk factors for restenosis
Although most risk factors for restenosis are somehow associated with one or more of 
the pathophysiological processes discussed above, these relationships are not always 
clear or are as yet unknown.
clinical risk factors
Since clinical parameters are collected in every trial, these baseline characteristics are 
relatively easy to analyze (Table 1). The most consistent clinical parameter that increases 
the risk of restenosis is diabetes mellitus.37 Patients with insulin-dependent diabetes 
are at particularly high risk of adverse events following PCI.38 The generally accepted 
hypothesis of this phenomenon is that hyperglycemia induces endothelial dysfunction 
and a proinflammatory state with increased growth factor and cytokine production.25,39 
These processes result in extensive neointima formation, thereby promoting the devel-
opment of restenosis. The prothrombotic environment in patients with diabetes further 
increases the risk of events.40 An increased risk of restenosis has not been detected in 
patients with metabolic syndrome for which the clinical characteristics are more varied 
than diabetes, thus resulting in a more heterogeneous patient group.41
Table 1 Clinical risk factors for restenosis
risk factor risk of restenosis strength of evidence*
Male sex Increased42 Poor
Older age Increased21 Mediocre
Hypertension Increased43 Mediocre
Diabetes mellitus Increased37 Strong
History of restenosis Increased44 Strong
Smoking Decreased45-48 Strong
*Poor: one or two studies have shown this association with restenosis, but most studies did not find this 
relationship. Mediocre: around half of the studies report this association and the other half do not. Strong: 
commonly reported risk factor for restenosis.
28 Part I – Genetics of restenosis
Although some investigators have reported a higher risk of restenosis in male pa-
tients than in females,42,49,50 the data are not consistent. The relationship between patient 
age and restenosis is also inconclusive; a trend towards increased risk of restenosis with 
increasing age21 has not been not demonstrated in all studies.24
Hypertension has frequently been reported as a risk factor for restenosis,43,45,51 
although this association is probably not of a causal nature. One of the possible explana-
tions for the observed relationship is the underlying endothelial dysfunction involved in 
both hypertension and restenosis.
A clinical factor applicable to the entire coronary system is a history of restenosis.44 
As will be discussed later in detail, some patients seem to have an inherent predisposi-
tion toward develop restenosis, which can be partly explained by their specific genetic 
background.
Paradoxically, although cigarette smoking is known to be a risk factor for coronary 
artery disease, a possible protective effect of smoking might exist for the development 
of restenosis after PCI. Although still controversial, the concept that cigarette smoking 
is associated with a lower rate of restenosis was already in existence over 10 years ago46 
and is supported by the results of several studies.45,47,48 An interesting hypothesis of the 
mechanism was suggested by Binder in 2006.52 He postulated that the contribution of 
bone-marrow-derived endothelial precursor cells to endothelial repair and inhibition of 




Inflammation has probably the most important role of all the known biological risk 
factors in the development coronary restenosis53 and many studies have explored this 
association. An extensive review on the subject was published by Niccoli et al. in 2010.54 
Elevation of plasma C-reactive protein (CRP) is commonly used as a marker of inflam-
mation and is associated with the progression of cardiovascular disease.55 Two meta-
analyses on the relation between CRP and restenosis, which included different studies, 
both showed that increased serum CRP levels predicted the development of restenosis 
BMS implantation.56,57 Moreover, elevated baseline CRP levels have also been associated 
with a diffuse pattern and, thus a more aggressive type, of restenosis.58 However, no re-
lationship between CRP and restenosis was demonstrated after implantation of DESs.54 
In a small study comparing CRP levels after implantation of various stents, Kim et al. con-
cluded that patients receiving DESs had significantly lower CRP levels than those that 
received BMSs, which probably reflects the modulation of the inflammatory response 
by the eluted drug.59 Whether the association between CRP and BMS-related restenosis 
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is a reflection of the inflammatory response evoked by angioplasty, or whether a pos-
sible direct response of CRP on the vascular wall also contributes to this phenomenon, 
remains to be elucidated (Table 2).54
Inflammatory responsiveness is highly genetically determined. Several studies 
have demonstrated associations between genetic polymorphisms in inflammatory 
factors and the risk of restenosis.66-68 Comprehensive research on genetic inflammatory 
factors was performed by Monraats et al. in the Genetic Determinants of Restenosis 
(GENDER) study population, consisting of 3,104 patients treated with PCI.69 Several 
significant genetic determinants were identified in an explorative study; the 16Gly 
variant of the β2-adrenergic receptor was associated with an increased risk of target 
vessel revascularization (TVR). By contrast, the rare alleles of the CD14 gene (-260T/T), 
colony-stimulating factor 2 (CSF2) gene (1944C/C; coding for 117Thr/Thr), and eotaxin 
(CCL11) gene (-1328A/A) were associated with decreased risk of TVR.69 If validated in 
other cohorts, these factors might be valuable in stratification of patients with elevated 
risk for restenosis.
Tumor necrosis factor (TNF) is a key mediator in the inflammatory response. This 
cytokine acts locally at sites of tissue injury induced by vessel wall damage and has 
many biological functions.66,70 In the GENDER study population, two polymorphisms 
(–238G>A and–1031T>C) in the TNF gene promoter were associated with a decreased 
risk of restenosis.66 Both markers where hypothesized to lead to lower serum TNF levels. 
The concept was supported by experiments in a mouse model for reactive stenosis that 
showed upregulation of TNF gene expression upon vascular injury, and reduction of 
neointima formation in TNF-knockout mice as well as after administration of the anti-TNF 
compound thalidomide.66 These results indicate that intervention in the development of 
Table 2 Biological risk factors for restenosis
risk factor risk of restenosis strength of evidence*
Genetic variation Variable19 Variable
Elevated TNF level Increased60 Mediocre
Elevated levels of certain complement components 
(C3a and C5a)
Increased61 Mediocre
Elevated levels of certain MMPs (MMP2, MMP3, MMP9) Increased62 Mediocre
Elevated ADMA level Increased63 Preliminary
Elevated CRP level Increased56 Strong
Elevated PAI-1 level Increased64 Strong
Elevated nitric oxide level Decreased65 Strong
*Variable: dependent on the nature of the variation. Mediocre: around half of the studies report this 
association and the other half do not. Preliminary: one or two papers reporting the association, no 
extensive replication yet. Strong: commonly reported risk factor for restenosis. Abbreviations: ADMA, 
asymmetric dimethylarginine; CRP, C-reactive protein; MMP, matrix metalloproteinase; PAI-1, plasminogen 
activator inhibitor 1; TNF, tumor necrosis factor
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restenosis might be possible by modulating the TNF response. Other studies in rats71 
and in humans60 confirmed these findings; however, by contrast, Koch et al. reported 
that TNF gene polymorphisms were not associated with an increased risk of restenosis 
in patients with coronary artery disease.70
Other interesting inflammatory markers for restenosis that have been identified, 
but have yet to be replicated in human studies, include complement components61 and 
genetic variation in the genes for interleukin 10 (IL10),61 annexin A5 (ANXA5),68 and 
the vitamin D receptor (VDR).67,72,73 Some of these associations were confirmed in animal 
models,74,75 but not yet in clinical studies.
Several lines of evidence indicate that, besides its role in thrombus formation,the 
plasmin activation system is also involved in restenosis, by increasing neointima hyper-
plasia.76-78 The role of plasminogen activator inhibitor 1 (PAI-1) has been investigated 
in multiple studies. Although conflicting results have been published,79 most studies 
indicate that PAI-1 might be useful as a predictive marker.64,80 In addition, therapeutic 
options utilizing inhibitors for plasminogen activators or PAI-1 have been explored in 
preclinical studies.76,77,81-83 Moreover, variation in the PAI-1 gene (SERPINE1) has also been 
related to restenosis.84
Vascular remodeling and function
Matrix metalloproteinases (MMPs) are a group of enzymes with proteolytic activity 
against a variety of extracellular matrix components and they are involved in vascular 
remodeling and inflammation. Several studies have reported associations between 
increased serum levels of MMP2, MMP3, and MMP9 and an increased risk of resteno-
sis.62,85-87 However, no link between genetic variation in the MMP2 and MMP3 genes has 
been established.88
VSMCs have an important role in the development of restenosis. Cyclin-dependent 
kinase inhibitor 1B (p27kip1) has been implicated in the regulation of VSMC prolifera-
tion89 and is, therefore, CDKN1B is a good candidate gene for involvement in the devel-
opment of restenosis. Van Tiel et al. reported that the promoter polymorphism -838C>A 
(rs36228499) in CDKN1B was associated with a decreased risk of restenosis.90 Moreover, 
in functional experiments, these investigators demonstrated a 20-fold increase in tran-
scriptional gene activity in cases of the -838A allele.90 Since this study was the first to 
implicate genetic variation in CDKN1B in the development of restenosis, more studies 
are needed to confirm these findings before the -838A allele can be established as a 
marker for stratification of patients at risk of restenosis.
Endogenous circulating bone-marrow-derived stem cells have been implicated 
in various aspects of vascular disease and function. With respect to restenosis the 
evidence is two-sided. On the one hand, circulating endothelial progenitor cells 
enhance re-endothelialization after vascular injury and thereby prevent excessive cell 
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proliferation.91,92 This concept underlies the implementation of endothelial progenitor 
cell (EPC) capturing coronary stents, which will be discussed in more detail in Part 2 of 
this Review.33 On the other hand, EPC homing has been suggested to contribute to the 
development of restenosis.93 Pelliccia et al. demonstrated that patients who developed 
restenosis had increased concentrations of specific subpopulations of EPCs compared 
with controls.93 A similar difference could not be demonstrated in patients with either 
stable or progressive coronary atherosclerosis, underlining the mechanistic differences 
between arteriosclerosis and restenosis. Variations in the time point at which stem cells 
were measured, and the differences between the specific subpopulations of EPCs and 
their functions, could provide an explanation for the conflicting results regarding the 
relationship between EPC and restenosis.94 Therefore, although bone-marrow-derived 
stem cells have, without question, a role in the response to vascular injury, the exact 
mechanism involved is still unclear and needs to be further elucidated.
Nitric oxide is a vasodilatory molecule known to decrease proliferation and migra-
tion of VSMCs95 and decreased nitric oxide synthase (NOS) expression has been related 
to restenosis.65 However, conflicting reports on the influence of genetic variation in 
NOS have lead to the hypothesis that the effects of nitric oxide only become apparent 
under specific ‘environmental’ conditions such as endothelial dysfunction.96 Pons et al. 
emphasized this hypothesis by reporting that several polymorphisms in the NOS3 gene 
were associated with restenosis in patients with, but not in those without, concurrent 
metabolic syndrome.96 Owing to the advantageous effects of nitric oxide in the arterial 
lumen, a number of nitric oxide releasing systems, including drugs and polymers, have 
been explored for clinical application. Since the in vivo half-life of nitric oxide is very 
short (~2–5 s) and because it has potential cardiovascular side effects, precise and timely 
delivery is essential. Gene therapy is one method of achieving this goal, and preliminary 
studies in humans have shown the positive and safe results of this treatment.97-99
In 2010, another contributor to nitric oxide metabolism was associated with re-
stenosis. Ari et al. reported that patients who developed restenosis had significantly 
higher asymmetric dimethylarginine (ADMA) serum levels than those who did not 
develop restenosis.63 ADMA competitively inhibits nitric oxide synthesis by blocking 
NOS; therefore, an increase in ADMA level will lead to a decrease in nitric oxide activity 
and concentration. The serum level of ADMA can be reduced by inhibiting its synthesis 
or stimulating its excretion, meaning that ADMA is a potential treatment target as well 
as a predictive marker.63
Genetic factors
Much evidence exists to support a role for genetic factors in the risk of restenosis, in-
dependent of conventional clinical variables. In patients with multivessel disease, the 
incidence of restenosis of a second lesion was 2.5-times higher if the first lesion had 
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restenosis, even after adjustments for well-known patient-related risk factors, making a 
genetic predisposition to restenosis conceivable.44 Identification of genetic markers for 
restenosis could prove to be useful in two ways. First, risk stratification according to the 
genetic make-up of the patient can enable treatment to be tailored to the individual. 
Second, identification of related genes might aid our understanding of the mechanisms 
involved in restenosis (Table 3), thereby leading to new prevention strategies. Many 
studies have focused on genetic variation influencing the risk of restenosis, together 
covering a wide array of candidate genes. Significant associations have been reported 
with polymorphisms in genes of the hemostatic system, for example, PIA1/A2 (rs5918) 
in the platelet glycoprotein IIIa gene (ITGB3),100 the prothrombotic factor V Leiden poly-
morphism (rs6025) of the F5 gene,84 and the platelet receptor P2Y12 gene haplotypes;101 
in the rennin–angiotensin system, for example, 1166A>C (rs5186) of the angiotensin II 
type 1 receptor gene (AGTR1);102 and in glucose metabolism, for example 7,067,365C>A 
of the insulin receptor gene (INSR),103 and 161C>T (rs3856806) of the peroxisome 
proliferator-activated receptor γ (PPARG) gene.104
Table 3 Genetic risk factors for restenosis




β2-adrenergic receptor (ADRB2) Arg16Gly Increased69 Preliminary
Annexin A5 (ANXA5) rs4833229 and rs6830321 Increased72 Preliminary
Vitamin D receptor (VDR) Haplotypes Increased73 Preliminary
P2Y12 receptor (P2Y12) Haplotypes Increased
101 Preliminary
Interleukin 10 (IL10) –2849G>A, –1082G>A and 
+4259A>G
Increased67 Mediocre
Platelet glycoprotein IIIa (ITGB3) PlA1/A2 Increased100 Mediocre
Nitric oxide synthase 3 (NOS3) 949A/G, -716C/T and Glu298Asp Increased96 Strong
CD14 –260C/T Decreased69 Preliminary
Colony-stimulating factor 2 (CSF2) Ile117Thr Decreased69 Preliminary
Eotaxin (CCL11) –1328G/A Decreased69 Preliminary
Factor V (F5) Leiden mutation Decreased84 Preliminary
cyclin-dependent kinase inhibitor 
p27kip1 (CDKN1B)
-838C>A Decreased90 Preliminary
P300/CBP associated factor (KAT2B) -2481G>C Decreased105 Preliminary
Tumor necrosis factor (TNF) –238G/A and –1031T/C Decreased66 Mediocre
Matrix metalloproteinase 2 (MMP2) and 
matrix metalloproteinase 3 (MMP3)
Multiple single nucleotide 
polymorphisms
No association88 Strong
Angiotensin-converting enzyme (ACE) I/D No association106 Strong
*Preliminary: one or two papers reporting the association, no extensive replication yet. Mediocre: around 
half of the studies report this association and the other half do not. Strong: commonly reported risk factor 
for restenosis
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Epigenetics is an upcoming field of increasing research interest. Epigenetic processes 
modulate gene expression patterns without modifying the actual DNA sequence. Part 
of the gene–environment interaction relevant for complex diseases is regulated by epi-
genetic mechanisms such as histone acetylation and DNA methylation.107,108 Epigenetic 
processes have been related to restenosis by the association between the -2481G>C 
polymorphism (rs2948080) of the gene (KAT2B) encoding P300/CBP associated factor 
was associated with a reduced risk of both clinical and angiographic restenosis after 
PCI.105 Since this study is the first on epigenetics and restenosis, the concept is prelimi-
nary; however, it is an interesting new development that is likely to shed new light on 
our understanding of the molecular mechanisms of restenosis.
The remaining issue with genetic studies is the problem of replication of the results 
in other cohorts. Many studies in which genetic determinants of restenosis have been 
investigated have fairly small sample sizes, increasing the risk of false positive, as well as 
false negative, findings. Furthermore, publication bias contributes to a distortion of the 
evidence. A striking example is the insertion/deletion polymorphism in the gene encod-
ing angiotensin I converting enzyme (ACE I/D), a supposed risk marker of restenosis.109,110 
In a meta-analysis, Agema et al. demonstrated that the initial identification of this poly-
morphism as a risk factor for restenosis was made on the basis of results from a number 
of small positive studies, not specifically designed for genetic epidemiologic research, 
where positive studies were published and negative ones were not.106 This meta-analysis 
clearly demonstrated that after correction for publication bias, the assumption that the 
ACE I/D polymorphism was associated with restenosis after PCI proved to be false.106 
Therefore, available evidence should be weighted and interpreted with caution. More, 
large studies specifically designed to investigate the genetics of restenosis are needed 
to confirm the currently available evidence and provide the opportunity to utilize our 
knowledge of genetic risk markers in clinical practice.
Risk factors related to lesion and procedure
Several lesion characteristics have been shown to increase the restenotic risk (Table 
4). The lesion-related factor most consistently associated with restenosis is lesion 
length.23,43,45,111,112 The longer the stented lesion the higher the risk of restenosis. Other 
factors include small vessel diameter and minimal lumen diameter after stenting.43,113-115 
In addition, more-complex lesions, such as ACC/AHA type C lesions, tortuous and calci-
fied lesions, and chronic total occlusions, tend to be associated with an increased risk of 
restenosis, although not as consistently reported as the other factors (Table 4).23,24,43,116 A 
history of restenosis increases the risk of a subsequent episode of restenosis;44 however, 
PCI of a restenotic lesion carries an even higher risk.23,24,45 Apparently the local tendency 
of renarrowing after dilatation, with or without stenting, seems to be considerable in 
these lesions.
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Several characteristics related to the PCI procedure itself have been related to 
restenosis (Table 5). First, as mentioned previously, development of the technique has 
resulted in improved outcomes. Therefore, in studies where various revascularisation 
strategies are used - balloon angioplasty alone or with BMS of DES implantation - the 
treatment modality should always be taken into account.117-119
Second, implantation of multiple stents during PCI is related to an increased risk of 
restenosis.22,23 This observation probably relates to the longer lesion length or the larger 
surface area covered by stent material, or both. A third factor, directly related to the 
procedure, is the use of IVUS to guide stent implantation. Several studies have shown 
that patients treated with IVUS guidance had lower rates of stent under-expansion121 
and a reduced risk of restenosis.122 IVUS has been shown to be particularly beneficial 
for stenting of longer lesions (> 20 mm).120 A meta-analysis on IVUS versus angiographic 
guidance of PCI with BMS implantation demonstrated that IVUS improved patient out-
comes by reducing the incidence of angiographic restenosis, repeat revascularization, 
and major adverse cardiac events.122 Routine use of IVUS during DES implantation has 
not yet been proven to be better than non-IVUS guided stenting.123-125
Table 4 Lesion-related risk factors for restenosis
risk factor risk of restenosis strength of evidence*
Chronic total occlusions Increased24 Strong
Restenotic lesions Increased24 Strong
Tortuous vessel Increased24 Strong
Long lesion length Increased45 Strong
ACC/AHA type C lesions Increased43 Strong
Small vessel diameter Increased113 Strong
Calcified lesions Increased116 Strong
*Strong: commonly reported risk factor for restenosis.
Table 5 Procedural risk factors for restenosis
risk factor risk of restenosis strength of evidence*
Multiple stents Increased23 Mediocre
Stent fracture Increased35 Mediocre
Minimal lumen diameter after PCI Increased113 Strong
Balloon angioplasty‡ Increased119 Strong
Bare metal stent implantation§ Increased119 Strong
IVUS guidance Decreased120 Strong
*Mediocre: around half of the studies report this association and the other half do not. Strong: commonly 
reported risk factor for restenosis. ‡Compared with stenting. §Compared with drug-eluting stent. 
Abbreviations: PCI, percutaneous coronary intervention; IVUS, intravascular ultrasound.
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concLusions
Restenosis is a complex disease for which the pathophysiological mechanisms are not 
yet fully understood, but are thought to include inflammation, proliferation, and matrix 
remodeling. Over the years many predictive clinical, biological, (epi)genetic, and proce-
dural factors have been identified as being associated with the development of resteno-
sis. These factors are not only useful in stratification of the patients at risk for restenosis, 
they also contribute to our understanding of this complex disease. Furthermore, they 
provide evidence for tailored therapy and subsequently aid in the development of novel 
treatment modalities.
Considering the multifactorial nature of the disease, development of a risk model 
including various factors, is likely to be the optimal method for implementation of the 
current evidence. Stolker et al. demonstrated that such a model, including six clinical 
and angiographic variables, could be used to identify individuals with a very low risk 
(< 2%) of developing restenosis and those with an increase risk (> 7%).14 Although yet far 
from ideal, we believe that future studies exploring various risk models could optimize 
patient stratification enabling identification of individuals at risk so that appropriate 
treatment can be given.
Developments in genetic research, such as genome-wide association studies and 
sequencing, are likely to result in identification of new genetic loci involved in the 
pathophysiology of restenosis. Efforts are ongoing to replicate these findings and 
those from the small genetic trials in larger study populations. Validation of the genetic 
associations with functional experiments and animal models will greatly improve our 
knowledge about restenosis. Collaboration between different study groups might over-
come the problem of the small sample size of the individual studies and will increase the 
power to detect associations. Increasing our understanding of the mechanisms involved 
in restenosis could lead to improved preventive measures and treatment modalities for 
this potentially devastating complication of PCI.
reVieW criteria
The articles on which this Review is based were identified by searching MEDLINE using 
the following keywords and Medical Subject Headings (MeSH) terms: “coronary reste-
nosis”, “risk factors”, “inflammation”, “genetics” and “epigenetics”. We checked for papers 
published up to May 2011. Only papers in the English language were included. Although 
we realize that not all available evidence could be incorporated, the most relevant and 
influential articles were selected.
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abstract
The techniques and materials used during percutaneous coronary intervention have 
advanced considerably over the past three decades, yet restenosis remains one of the 
major drawbacks of this procedure. Many innovative technologies, including drug-
eluting stents, with or without specific polymers, and fully biodegradable stents have 
been and continue to be developed in the search for a safe and effective antirestenosis 
therapy. Remarkable advances in stent design and nanoparticle delivery systems (‘nano-
vehicles’) have already fueled revolutionary changes in the prevention and treatment of 
in-stent restenosis. In this Review we provide an overview of the latest innovations for 
optimizing outcomes of coronary stenting, and up-to-date information about preven-
tion and treatment of in-stent restenosis.
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introDuction
Since its introduction in the late 1970s,1 percutaneous coronary intervention (PCI) has 
become the most important and widely used treatment for patients with obstructive 
coronary disease. Although the technique and the materials used during the procedure 
have advanced tremendously, restenosis—the renarrowing of the treated obstruction—
remains one of the major complications of PCI.2 Intravascular stents were developed as 
an adjunct to primary angioplasty for the management of early complications, including 
arterial dissection, and for the treatment for early elastic recoil. Despite the beneficial 
effects of stenting, however, rates of restenosis remained persistently high, giving rise to 
a new problem—in-stent restenosis (ISR). The introduction of drug-eluting stents (DESs) 
was seen as a solution to this problem and, initially, DESs reduced the incidence of ISR 
considerably.3 However, these promising results led to increased use of DESs in a diverse 
range of complex coronary lesions, and for off-label indications, leading to a resurge in 
the rates of ISR.4,5
In light of the increasing number of PCI procedures being performed, the difficulty 
of treating ISR, and the increasing cost of adjuvant medication and devices, defining 
subsets of patients at increased risk for restenosis would be useful. These patients could 
benefit from additional treatment modalities. Until now, identification of subgroups has 
been only partially successful, as was discussed in detail in Part 1 of this Review.6 The 
ongoing efforts to better understand the underlying pathophysiological mechanisms 
of restenosis and vascular biology continuously fuel research on the prevention and 
treatment of ISR. Here, in Part 2 of the Review, we will assess the most important innova-
tions for optimizing the outcomes of coronary stenting, and data on the prevention and 
treatment of restenosis in general, and ISR in particular, published in the 5-year period 
up to August 2011.
Prevention of restenosis
In general, PCI with DESs is currently the best approach for the prevention of restenosis.7 
However, safety concerns about stent malapposition, late stent thrombosis, and delayed 
restenosis have arisen.8,9 The main cause of these problems has, in addition to patient-re-
lated and lesion-related factors, been attributed to the stent polymer.10 Additionally, the 
eluted antiproliferative agent and the stent platform (metal alloys and strut thickness) 
have been implicated in ISR. These concerns have fueled research in stent development, 
utilizing new antiproliferative agents, polymer technology, and metal stent platforms 
(Table 1).
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antiproliferative agents
Sirolimus (rapamycin)-eluting stents (SESs; Cypher®, Cordis Corporation, Bridgewater, 
NJ, USA) and paclitaxel-eluting stents (PESs; Taxus®, Boston Scientific, Maple Grove, MN, 
USA) were the first two DESs to be approved by the FDA for use in humans (in 2003 and 
2004, respectively). Although they both effectively reduce rates of restenosis compared 
with bare-metal stents (BMSs), their local adverse effects on the vasculature are fairly 
divergent. High concentrations of locally released paclitaxel have been shown to have 
detrimental effects on the vascular wall in a mouse model,70 suggesting a narrower 
therapeutic range of this potent drug. On the other hand, sirolimus has a less-harmful 
effect than paclitaxel on the vascular wall.70 Data from comparisons of first-generation 
DESs show that PESs are associated with a higher risk of ISR and stent thrombosis than 
SESs.7,71 Two stents eluting sirolimus analogs—everolimus (Xience V®, Abbott Cardio-
vascular Systems, Inc., Santa Clara, CA, USA) and zotarolimus (Endeavor®, Medtronic 
Vascular, Inc., Santa Rosa, CA, USA)—have also been approved by the FDA.
Table 1 Developments in preventive measures for restenosis
target Development status
Antiproliferative drug Sirolimus derivatives (biolimus A911-13 and novolimus14) Clinical*
Polymer Biolinx® (® (Medtronic Vascular, Inc., Santa Rosa, CA, USA)15,16 Clinical*; preliminary‡
Polymer Polyzene-F17-19 Clinical*; preliminary‡
Polymer Biodegradable (polylactic acid, polylactic-co-glycolic 
acid,20-22 SynBiosys® [InnoCore Technologies, Groningen, the 
Netherlands], Eureka® SOLO [Surmodics, Inc., Eden Prairie, MN, 
USA])23
Clinical*
Stent design Polymer-free stent (Biofreedom®, Biosensors International 
Group, Hamilton, Bermuda)24,25
Clinical*; preliminary‡
Coating Endothelial progenitor cell capturing stent (Genous®,26-29 
Combo Stent®30,31 [both OrbusNeich Medical, Inc., Fort 
Lauderdale, FL, USA])
Clinical*
Coating Titanium-nitride-oxide-coated stents (Titan2™ stent [Hexacath, 
Rueil-Malmaison, France])29,32-37
Clinical*
Stent platform Bioabsorbable stent (magnesium stent [Biotronik, Berlin, 
Germany])38-43
Clinical*
Drug delivery Nanomedicine44,45 Preclinical§
Stent platform/metal
alloys
Platinum–chromium alloy stents (Promus Element® and Taxus 
Element®
(Boston Scientific, Maple Grove, MN, USA)46-49
Clinical*
Drug delivery Magnetic targeting stents50 Preclinical§
Miscellaneous Gene-based therapy51-59 Preclinical§
Miscellaneous Systemic treatment60-69 Clinical*
*Clinical: development is currently being tested in a clinical setting. ‡Preliminary: first clinical results in 
small studies await replication in larger trials. §Preclinical: development is currently being tested in animal 
models
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Many studies have been dedicated to comparing the various available DESs. In 2011, 
the 2-year follow-up results of two large-scale, randomized, controlled trials showed a 
sustained benefit of everolimus-eluting stents (EESs) over PESs in terms of safety and 
efficacy.72,73 On the other hand, zotarolimus-eluting stents (ZESs) were found to have 
a higher angiographic restenosis rate compared with PESs, although clinically driven 
repeat revascularization rates were similar for both stent types.74
In patients receiving routine clinical care, SESs have proven to be superior to ZESs.75 
The 2-year outcomes of the RESOLUTE All Comers trial76 showed sustained similar safety 
and efficacy between ZESs and EESs. Unfortunately, few data are available on the direct 
EES versus SES comparison. Therefore, sirolimus and its analogs seem to be marginally 
superior to paclitaxel, whereas differences between the various limus-eluting stents 
remain to be elucidated.
In search for greater antirestenotic efficacy and improved long-term safety, new 
compounds specifically designed for use with DESs are being developed and studied. 
Biolimus A9 is a novel rapamycin derivative that, like sirolimus, inhibits smooth muscle 
cell proliferation via binding to the FK506-binding protein 1A and subsequent inhibition 
of the mammalian target of rapamycin (mTOR) and is specifically developed for local de-
livery to coronary arteries (Figure 1).11 Besides its anti-inflammatory and antiproliferative 
potential and improved pharmacokinetic profile, the increased lipophilicity of biolimus 
A9 improves uptake by the coronary vessel wall, resulting in a more localized effect and 
Figure 1 Chemical structure of biolimus A9.
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monoclonal murine antihuman CD34 antibodies. These 
antibodies bind bone-marrow-derived EPCs from the 
peripheral blood. These EPCs are hypothesized to differ-
entiate into a functional endo thelial layer after immobiliza-
tion and populate the surface of the stent.47 The safety and 
efficacy of the Genous® stent have been shown in pre-
liminary human studies,48,49 and further evaluation and 
comparison with other stents is currently ongoing.50
Despite its benefit in enhancing re-endothelialization, 
and thereby possibly preventing stent thrombosis, EPC 
capturing is not expected to potently inhibit neointimal 
proliferation. On the contrary, CD34 antibodies have 
even been shown to capture other progenitor cells, for 
example, smooth muscle cell progenitor cells, which could 
exagge rate restenosis.51 Therefore, a major challenge in 
the develop ment of an EPC-capturing DES is to maintain 
sustained inhibition of smooth muscle cell proliferation 
while promoting formation of a functional endothelial 
layer. This concept was tested in an animal study showing 
that immobilization of anti-CD34 antibody on SESs 
enhances endothelialization.52 The REMEDEE study38,53 
investigators are currently testing the Combo Stent® 
(OrbusNeich Medical, Inc.), which incorporates low-dose 
abluminal sirolimus together with EPC-capturing tech-
nology and a biodegradable polymer. The combination 
of an EPC-capturing stent with a drug-eluting balloon 
is also an attractive alternative, as has been shown by the 
results of the PERFECT STENT study.54
Titanium-nitride-oxide-coated stent
The Titan2™ stent (Hexacath, Rueil-Malmaison, France) 
is a stainless-steel stent coated in titanium-nitride oxide 
that has been shown to inhibit platelet aggregation, 
minimize fibrin deposition, reduce inflammation, and 
promote healing.55 This stent significantly reduced late 
lumen loss and TLR compared with a BMS at 6-months 
follow-up,56 with preserved benefits up to 5-years.57 
Additionally, the Titan2™ stent demonstrated favorable 
results compared with the Taxus® PES in a randomized 
controlled trial of 425 patients with ST-segment elevation 
myo cardial infarction,58 as well as in routine clinical prac-
tice.59 Despite the absence of an antiproliferative drug, use 
of the Titan2™ stent resulted in less TLR than the Taxus® 
stent, although this reduction was not statistically signifi-
cant.58 The Titan2™ stent was noninferior to the Xience V® 
EES in the primary results of the large randomized con-
trolled BASE-ACS trial60 conducted in patients with acute 
coronary syndrome. However, the Titan2™ stent failed to 
prove noninferiority to the Endeavor® ZES in terms of 
angiographic in-stent late lumen loss at 6 months in the 
TIDE study,61 although clinical outcomes at 1 year were 
comparable for both stent types.
Future prohealing stent designs
A step further to optimize the prohealing stent design 
is to create a bioactive stent that also elutes a drug (a 
bio eluting stent). Animal studies of a newly designed 
titanium-nitride-oxide stent eluting l-arginine, a precur-
sor of nitric oxide with positive effects on endothelium 
function,62 or a sulfated polysaccharide extracted from 
seaweed have shown up to 50% reduction in late lumen 
loss compared with the standard titanium-nitride-oxide 
stent.63 A future clinical trial (the VINCI first-in-man 
study) is planned to test the efficacy and safety of this 
new generation of stents.63
Another approach to creating a prohealing stent would 
be to reduce the binding of platelets to an implanted 
stent, thereby reducing the inflammatory response 
and allowing surrounding endothelial cells to proper ly 
re- endothelialize the stent.64 A stent created from a 
bioactive ligand, such as an integrin-binding motif, 
has been successfully used in noncardiac applications 
in vivo to promote device integration.65 The ideal ligand 
should only interact with integrins uniquely present on 
endothelial cells and not on platelets, inflammatory cells, 
or smooth muscle cells.64 Continued in vitro and in vivo 
studies with such biomaterials could lead to the creation 
of next-generation prohealing stent surfaces that promote 
the endothelialization of the stent while simultaneously 
inhibiting the adhesion and thrombus formation, and not 
stimulating smooth muscle cell proliferation.
Stent platforms
Metal alloys
A platinum–chromium alloy developed in the early 
2000s has been combined with everolimus on the Promus 
Element® (Boston Scientific) and with paclitaxel on the 
Taxus Element® (Boston Scientific) stents, which were 
granted ‘CE’ European safety marks in November 2009 
and May 2010, respectively. Unlike stainless steel and 
cobalt–chromium alloys, platinum–chromium has the 
advantage of increased radial strength enabling the stent 
to have thinner struts, which have been proven to reduce 
clinical and angiographic restenosis.66,67 In PLATINUM,68 
the Promus Element® stent was shown to have compara-
tive efficacy and safety when compared with Xience V®. 
Similarly, the efficacy and safety of the Taxus Element® 
Figure 1 | Chemical structure of biolimus A9. This compound consists of a 
31-membered triene macrolide lactone that preserves the core sirolimus ring 
structure with a 2-ethoxyethyl group addition to the hydroxyl group at position C (40) 
of the sirolimus molecule. One rationale for the inclusion of the ethoxyethyl group 
was to increase lipophilicity and, thus, to improve uptake by the coronary vessel 
wall. Permission obtained from John Wiley and Sons © Ostojic, M. et al. Catheter. 
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This compound consists of a 31-membered triene macrolide lactone that preserves the core sirolimus ring 
structure with a 2-ethoxyethyl group addition to the hydroxyl group at position C (40) of the sirolimus 
molecule. One rationale for the inclusion of the ethoxyethyl group was to increase lipophilicity and, thus, 
to improve uptake by the coronary vessel wall. Permission obtained from John Wiley and Sons © Ostojic, 
M. et al. Catheter. Cardiovasc. Interv. 72, 901–908 (2008).
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lower systemic drug exposure12 than sirolimus eluted from the Cypher® stent.77,78 Com-
pared with first-generation DESs, biolimus A9-eluting stents (BESs) have been shown to 
be associated with better recovery of endothelial function in coronary arteries, which 
could be partly explained by the better drug release kinetics.13
Novolimus is a metabolite of sirolimus and represents another new antiproliferative 
mTOR inhibitor specifically developed for the stent. The newly developed DESyne® (Elixir 
Medical, Sunnyvale, CA, USA) novolimus-eluting stent has been tested in a clinical study, 
showing superiority over ZESs regarding angiographic in-stent late loss.14
Polymer technology
New-generation polymer coatings have been produced with the specific aim of mim-
icking the endothelial lining in order to prevent late thrombotic complications. Basic 
research has shown that some polymeric materials could potentially upregulate genes 
related to inflammation, proliferation, thrombosis, and vasoconstriction79 —processes 
that are considered to be pivotal in the development of restenosis.6
One example of current progress is the Biolinx® (Medtronic Vascular, Inc.) polymer, 
currently used in the Endeavor Resolute® ZES. This blend of three different polymers—the 
hydrophobic C10 polymer to control drug release, the biocompatible and hydrophilic 
C19 polymer, and polyvinyl pyrrolidone—allows an early burst followed by controlled 
drug release15 so that at least 85% of the zotarolimus is released within 60 days and 
the remainder within 180 days, avoiding long-term release of the drug. Such release 
patterns are designed to match the delayed healing times seen in complex lesions. The 
Resolute® ZES was shown to significantly lower target lesion revascularization (TLR) 
compared with an earlier Endeavor® ZES, which utilized a phosphorylcholine coating.16
Another polymer, polyzene-F is highly biocompatible and has anti-inflammatory, 
bacteria-resistant, and prohealing qualities. The coating ensures that the stent has a very 
low surface thrombogenicity, potentially reducing the risk of stent thrombosis. Evalua-
tion of cobalt chromium stents nanocoated with polyzene-F in an animal model yielded 
favorable results.17 Preliminary studies evaluating the Catania™ (CeloNova Biosciences, 
Newnan, GA, USA) stent in humans demonstrated a good safety profile and high-level 
efficacy.18,19 Efforts to improve polymer stent coatings are ongoing.
biodegradable polymers
Given the issues of polymer-induced inflammation, thrombosis, and restenosis, the 
development of biodegradable polymers has become a focus for research. The most-
studied biodegradable polymers are polylactic acid and polylactic-co-glycolic acid, 
which degrade over time and could, therefore, eliminate the problems associated with 
lack of polymer biocompatibility and polymer-induced inflammation. To date, several 
biodegradable polymer stents eluting biolimus A9, sirolimus, or paclitaxel have been 
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clinically evaluated, which have so far proven to be effective and safe in the short term 
(≤ 30 days) and midterm (≤ 1 year).20-22 In 2010, the 3-year follow-up data from the LEAD-
ERS trial80 was presented, showing the sustained benefit of BESs with a biodegradable 
polymer over SESs with a durable polymer. Great expectations exist within the cardiol-
ogy community that biodegradable-polymer DESs could become the stents of choice 
in years to come; the results of the ongoing ISAR-TEST-6 trial,81 testing the safety and 
efficacy of the Nobori® (Terumo Corporation, Tokyo, Japan) biodegradable polymer BES 
and the Xience V® permanent polymer ZES will, therefore, be eagerly awaited.
New polymer technology presents some challenges, such as establishing the opti-
mal degradation time, biocompatibility, composition, and formulation of the polymer. 
Several factors influence the velocity of degradation; therefore, the balance between 
drug-release kinetics and the rate of polymer degradation, as well as the effects of the 
degradation products all affect the efficacy of biodegradable polymer stent systems in 
the coronary vasculature.82 Furthermore, studies in porcine coronary arteries have shown 
that even biodegradable polymers can cause inflammatory reactions, which could be 
attributable to the combination of the parent polymer compound and the biodegrada-
tion products.83 Two new biodegradable polymers (SynBiosys® [InnoCore Technologies, 
Groningen, the Netherlands] and Eureka® SOLO [SurModics, Inc., Eden Prairie, MN, USA) 
have been tested in animal studies and yielded fewer acidic byproducts, and had a 
better degradation rate and biocompatibility profile than polylactic acid and polylactic-
co-glycolic acid making them well-tolerated in vivo.23 In a pig model, stainless-steel R 
Stents® (OrbusNeich Medical, Inc., Fort Lauderdale, FL, USA) with SynBiosys® coating and 
high-dose sirolimus (5 μg/mm) was associated with the lowest amount of neointima 
thickness after 28 days when compared with Xience V® and Cypher® stents.30
Polymer-free stents
In an attempt to overcome the problems encountered with polymers or their degrada-
tion products, ‘polymerfree’ DESs have been developed and have proven to be safe in 
clinical studies.84,85 In an animal study, polymerfree biolimus A9 coated stents (Biofree-
dom®, Biosensors International Group, Hamilton, Bermuda) demonstrated more sus-
tained intima inhibition, improved healing, and reduced inflammation compared with 
the polymercoated sirolimus eluting Cypher® stent at 180-day followup.24 The ongoing 
first-in-man study of the Biofreedom® stent showed promising results compared with 
the Taxus® PES.25
Polymer-free, dual DESs have been tested over the past few years. No apparent 
benefit was observed by adding estradiol to a polymer-free SES in the ISAR-PEACE 
trial.86 However, results from the ISAR-TEST-2 study87 revealed that a novel, polymer-free 
sirolimus-eluting and probucol- eluting dual DES was noninferior to the Cypher® SES 
and the Endeavor® ZES. The antirestenotic efficacy of both the dual DES and the ZES 
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remained durable during the 2-year follow-up period.87 The larger ISAR-TEST-5 study,88 
which was powered for clinical events, showed similarly durable results for the dual DES.
novel prohealing stent coatings
Endothelial progenitor cell-capturing stent
An increased rate of endothelialization is thought to lead to reductions in restenosis 
and stent thrombosis.89 This hypothesis underlies the development of the endothelial 
progenitor cell (EPC)-capturing stent. The bioengineered Genous® (OrbusNeich Medical, 
Inc.) EPC-capturing stent has a stainless-steel platform that is coated with an abluminal 
polysaccharide matrix and covalently coupled monoclonal murine antihuman CD34 an-
tibodies. These antibodies bind bone-marrow-derived EPCs from the peripheral blood. 
These EPCs are hypothesized to differentiate into a functional endothelial layer after 
immobilization and populate the surface of the stent.90 The safety and efficacy of the 
Genous® stent have been shown in preliminary human studies,26,27 and further evalua-
tion and comparison with other stents is currently ongoing.28
Despite its benefit in enhancing re-endothelialization, and thereby possibly pre-
venting stent thrombosis, EPC capturing is not expected to potently inhibit neointimal 
proliferation. On the contrary, CD34 antibodies have even been shown to capture other 
progenitor cells, for example, smooth muscle cell progenitor cells, which could exagger-
ate restenosis.91 Therefore, a major challenge in the development of an EPC-capturing 
DES is to maintain sustained inhibition of smooth muscle cell proliferation while pro-
moting formation of a functional endothelial layer. This concept was tested in an animal 
study showing that immobilization of anti-CD34 antibody on SESs enhances endotheli-
alization.92 The REMEDEE study30,31 investigators are currently testing the Combo Stent® 
(OrbusNeich Medical, Inc.), which incorporates low-dose abluminal sirolimus together 
with EPC-capturing technology and a biodegradable polymer. The combination of an 
EPC-capturing stent with a drug-eluting balloon is also an attractive alternative, as has 
been shown by the results of the PERFECT STENT study.93
Titanium-nitride-oxide-coated stent
The Titan2™ stent (Hexacath, Rueil-Malmaison, France) is a stainless-steel stent coated 
in titanium-nitride oxide that has been shown to inhibit platelet aggregation, minimize 
fibrin deposition, reduce inflammation, and promote healing.32 This stent significantly 
reduced late lumen loss and TLR compared with a BMS at 6-months follow-up,29 with 
preserved benefits up to 5-years.33 Additionally, the Titan2™ stent demonstrated fa-
vorable results compared with the Taxus® PES in a randomized controlled trial of 425 
patients with ST-segment elevation myocardial infarction,34 as well as in routine clinical 
practice.35 Despite the absence of an antiproliferative drug, use of the Titan2™ stent 
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resulted in less TLR than the Taxus® stent, although this reduction was not statistically 
significant.34 The Titan2™ stent was noninferior to the Xience V® EES in the primary re-
sults of the large randomized controlled BASE-ACS trial36 conducted in patients with 
acute coronary syndrome. However, the Titan2™ stent failed to prove noninferiority to 
the Endeavor® ZES in terms of angiographic in-stent late lumen loss at 6 months in the 
TIDE study,37 although clinical outcomes at 1 year were comparable for both stent types.
Future prohealing stent designs
A step further to optimize the prohealing stent design is to create a bioactive stent that 
also elutes a drug (a bioeluting stent). Animal studies of a newly designed titanium-
nitride-oxide stent eluting l-arginine, a precursor of nitric oxide with positive effects 
on endothelium function,94 or a sulfated polysaccharide extracted from seaweed have 
shown up to 50% reduction in late lumen loss compared with the standard titanium-
nitride-oxide stent.95 A future clinical trial (the VINCI first-in-man study) is planned to test 
the efficacy and safety of this new generation of stents.95
Another approach to creating a prohealing stent would be to reduce the binding 
of platelets to an implanted stent, thereby reducing the inflammatory response and 
allowing surrounding endothelial cells to properly re-endothelialize the stent.96 A stent 
created from a bioactive ligand, such as an integrin-binding motif, has been successfully 
used in noncardiac applications in vivo to promote device integration.97 The ideal ligand 
should only interact with integrins uniquely present on endothelial cells and not on 
platelets, inflammatory cells, or smooth muscle cells.96 Continued in vitro and in vivo 
studies with such biomaterials could lead to the creation of next-generation prohealing 
stent surfaces that promote the endothelialization of the stent while simultaneously 




A platinum–chromium alloy developed in the early 2000s has been combined with 
everolimus on the Promus Element® (Boston Scientific) and with paclitaxel on the Taxus 
Element® (Boston Scientific) stents, which were granted ‘CE’ European safety marks in 
November 2009 and May 2010, respectively. Unlike stainless steel and cobalt–chromium 
alloys, platinum–chromium has the advantage of increased radial strength enabling the 
stent to have thinner struts, which have been proven to reduce clinical and angiographic 
restenosis.46,47 In PLATINUM,48 the Promus Element® stent was shown to have compara-
tive efficacy and safety when compared with Xience V®. Similarly, the efficacy and safety 
of the Taxus Element® stent is comparable with that of the Taxus Express2® (Boston 
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Scientific) stent.49 In a first-in-man study published in 2010, the Taxus® Petal™ (Boston 
Scientific) platinum–chromium bifurcation stent was successfully implanted in 25 of 28 
patients (89.3%), with satisfactory clinical and angiographic outcomes at 1 year.98
Bioabsorbable platforms
The problems encountered with DES have encouraged research into innovative, tempo-
rary vascular scaffolds or bioabsorbable stent platforms, which gradually degrade until 
healing and re-endothelialization have occurred. Eventually, no foreign material is left 
exposed to the blood, thus mitigating the problem of late stent malapposition and stent 
thrombosis. These stents have the potential to preserve endothelial function, reactive 
vasomotion of the artery, and permit late lumen enlargement (expansive remodeling).38 
Initially, a high restenosis rate of 45% was observed in the PROGRESS-AMS trial39 in 
which a non-drug-eluting bioabsorbable magnesium stent (Biotronik, Berlin, Germany) 
was evaluated. Yet more favorable results with stents with a poly-l-lactic acid backbone 
eluting everolimus (Abbott Vascular, Santa Clara, CA, USA) were reported in the ABSORB 
Figure 2 The bioabsorbable stent.
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stent is comparable with that of the Taxus Express2® 
(Boston Scientific) stent.69 In a first-in-man study published 
in 2010, the Taxus® Petal™ (Boston Scientific) platinum–
chromium bifurcation stent was successfully implanted 
in 25 of 28 patients (89.3%), with satisfactory clinical and 
angiographic outcomes at 1 year.70 
Bioabsorbable platforms
The problems encountered with DES have encouraged 
research into innovative, temporary vascular scaffolds or 
bioabsorbable stent platforms, which gradually degrade 
until healing and re-endothelialization have occurred. 
Eventually, no foreign material is left exposed to the 
blood, thus mitigating the problem of late stent malap-
position and stent thrombosis. These stents have the 
potential to preserve endothelial function, reactive vaso-
motion of the artery, and permit late lumen enlargement 
(expansive remodeling).71 Initially, a high restenosis rate 
of 45% was observed in the PROGRESS-AMS trial72 in 
which a non-drug-eluting bioabsorbable magnesium 
stent (Biotronik, Berlin, Germany) was evaluated. Yet 
more favorable results with stents with a poly-l-lactic 
acid backbone eluting everolimus (Abbott Vascular, Santa 
Clara, CA, USA) were reported in the ABSORB trial71,73 
with sustained clinical benefit at 3-years follow-up. The 
first generation (revision 1.0) of bioabsorbable vascular 
scaffolds showed slight signs of shrinkage at 6 months 
contributing to late luminal loss.74 However, the second 
generation (revision 1.1) showed substantial improve-
ments with efficacy comparable to that of current DESs, 
and enhanced conformability to the angulations and 
curvatures of the vessel (Figure 2).75,76
Nanomedicine
In addition to its promising application in cancer chemo-
therapy, great interest has been generated in the appli-
cation of nanotechnology in optimization of local drug 
delivery. Nanoparticles are liposomes consisting of lipids 
and polymers that can be loaded with a drug and used to 
nanotexture stents, in molding processes to make stents, 
and for drug delivery from stents.77 Nanoparticle-mediated 
drug delivery systems are expected to revolu tionize the 
development of innovative therapeutic devices, allowing 
local or targeted delivery of the drug with an excellent bio-
compatibility profile. This strategy controls the concen-
tration and duration of drug release, thereby potentially 
reducing systemic toxicity.78 Of the drugs investigated for 
restenosis prevention and treatment, only paclitaxel and 
sirolimus have been successfully administered through 
nanoparticle-based delivery systems and only in preclinical 
studies.79,80 Paclitaxel eluted from a cobalt–chromium stent 
coated with porous carbon–carbon nanoparticles showed 
promising results with respect to endothelialization and 
neointimal hyperplasia.79 Sirolimus incorporated into 
nanoparticle delivery systems (poly-d,l-lactide) showed 
improved release kinetics.80 Furthermore, these sirolimus-
 loaded nanovehicles selectively inhibited cell viability 
and proliferation of cultured human coronary artery 
smooth muscle cells, while human coronary artery endo-
thelial cells were inhibited to a lesser extent. Endothelial 
cells were, therefore, left viable to a degree that allowed 
re- endothelialization of the stented vessel, yet smooth 
muscle cell proliferation was still prevented.80
In another approach, Chorny et al. investigated the 
novel concept of ‘magnetic targeting stents’ by combi-
ning uniform field-induced magnetization and a bio-
compatible magnetic nanoparticle formulation in a rat 
model of carotid stenting.81 Magnetic targeting allows a 
drug to be delivered on demand to an in vivo site with 
various dosing regimens. These investigators demon-
strated that the magnetic nanoparticles loaded with 
paclitaxel adequately inhibited neointima formation 
after uniform-field-controlled targeting when compared 
with nonmagnetically treated animals.81 Nanomedicine 
is, therefore, an innovative and promising perspective in 
stent design, but has yet to be demonstrated as safe and 
effective in clinical practice.
Gene-based therapy
Gene-based therapy has emerged over the past few years 
as a promising tool for the prevention of ISR. Numerous 
transgenes have been shown to be effective in reducing 
ISR in animal models (Table 2) and various modes of local 
gene delivery have been developed. An effective method 
Figure 2 | The bioabsorbable stent. a | The first-generation 
(revision 1.0) and b | the second-generation (revision 1.1)  
of a bioabsorbable, everolimus-eluting stent. A clear change 
in the device design between the two generations is evident, 
with the out-of-phase zigzag pattern connected directly or by 
straight bridges in revision 1.0 being replaced by the  
in-phase hoops linked by straight bridges in revision 1.1.  
c | In addition, the maximum circular (red circles) 
unsupported cross-sectional areas (green contours) are 
larger in revision 1.0 than in d | revision 1.1. Parts a and b 
reprinted from Journal of the American College of Cardiology, 
56 (Suppl. 10), Garg, S. & Serruys, P. W., Coronary stents: 
looking forward. S43–S78, © 2010, with permission from 
Elsevier. For parts c and d, permission obtained from 
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a ) the first-generation bioabsorbable stent (revision 1.0) and b ) the second-generation bioabsorbable 
stent (revision 1.1). A clear change in the device design between the two generations is evident, with the 
ut-of-phase zigzag pattern connected directly or by straight bridges in revision 1.0 being replaced by the 
i -phase hoops linked by straig t bridges in revision 1.1. c ) In addition, the maximum circular (red circles) 
unsupported cross-s ctional areas (green contours) are larger in Revision 1.0 than in d ) revision 1.1. Parts 
a ) and b ) reprinted from Journal of the American College of Cardiology, 56 (Suppl. 10), Garg, S. & Serruys, 
P. W., Coronary stents: looking forward. S43–S78, © 2010, with permission from Elsevier. Parts c ) and d ) 
Permission obtained from Wolters Kluwer Health © Serruys, P. W. et al. Circulation 122, 2301–2312 (2010).
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trial38,40 with sustained clinical benefit at 3-years follow-up. The first generation (revision 
1.0) of bioabsorbable vascular scaffolds showed slight signs of shrinkage at 6 months 
contributing to late luminal loss.41 However, the second generation (revision 1.1) 
showed substantial improvements with efficacy comparable to that of current DESs, and 
enhanced conformability to the angulations and curvatures of the vessel (Figure 2).42,43
nanomedicine
In addition to its promising application in cancer chemotherapy, great interest has been 
generated in the application of nanotechnology in optimization of local drug delivery. 
Nanoparticles are liposomes consisting of lipids and polymers that can be loaded with a 
drug and used to nanotexture stents, in molding processes to make stents, and for drug 
delivery from stents.99 Nanoparticle-mediated drug delivery systems are expected to rev-
olutionize the development of innovative therapeutic devices, allowing local or targeted 
delivery of the drug with an excellent biocompatibility profile. This strategy controls the 
concentration and duration of drug release, thereby potentially reducing systemic toxic-
ity.100 Of the drugs investigated for restenosis prevention and treatment, only paclitaxel 
and sirolimus have been successfully administered through nanoparticle-based delivery 
systems and only in preclinical studies.79,80 Paclitaxel eluted from a cobalt–chromium 
stent coated with porous carbon–carbon nanoparticles showed promising results with 
respect to endothelialization and neointimal hyperplasia.44 Sirolimus incorporated into 
nanoparticle delivery systems (poly-d,l-lactide) showed improved release kinetics.80 
Furthermore, these sirolimus-loaded nanovehicles selectively inhibited cell viability 
and proliferation of cultured human coronary artery smooth muscle cells, while human 
coronary artery endothelial cells were inhibited to a lesser extent. Endothelial cells were, 
therefore, left viable to a degree that allowed re-endothelialization of the stented vessel, 
yet smooth muscle cell proliferation was still prevented.45
In another approach, Chorny et al. investigated the novel concept of ‘magnetic 
targeting stents’ by combining uniform field-induced magnetization and a biocompat-
ible magnetic nanoparticle formulation in a rat model of carotid stenting.50 Magnetic 
targeting allows a drug to be delivered on demand to an in vivo site with various dosing 
regimens. These investigators demonstrated that the magnetic nanoparticles loaded 
with paclitaxel adequately inhibited neointima formation after uniform-field-controlled 
targeting when compared with nonmagnetically treated animals.50 Nanomedicine is, 
therefore, an innovative and promising perspective in stent design, but has yet to be 
demonstrated as safe and effective in clinical practice.
Gene-based therapy
Gene-based therapy has emerged over the past few years as a promising tool for the 
prevention of ISR. Numerous transgenes have been shown to be effective in reducing 
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ISR in animal models (Table 2) and various modes of local gene delivery have been de-
veloped. An effective method of gene delivery is by means of ‘gene-eluting stents’, which 
elute plasmid DNA or adenoviral vectors.51,52 Pyrrole–imidazole polyamide is a powerful 
gene-regulating compound (‘gene silencer’) that inhibits the interaction between pro-
teins, such as transcription factors, and DNA.53 An in vivo animal study conducted by 
Yao et al. showed that synthetic pyrrole–imidazole polyamide can suppress neointimal 
hyperplasia by downregulation of transforming growth factor β1 and connective tissue 
growth factor,54 as well as monocyte chemotactic protein 1, matrix metalloproteinase 9, 
and intercellular adhesion molecule 1,55 making it a promising next-generation agent.
Nuclear ‘orphan’ receptors comprise a group of ligand-activated receptors for which 
specific ligands have not yet been identified, but which are known to directly bind and 
interact with the promoter of target genes.56 Nuclear receptor related proteins 1 and 77 
have been identified as having a role in ISR development; overexpression of these pro-
teins inhibits intimal proliferation and ISR in animal models.57,58 A small-molecule drug 
that enhances the activity of these receptors, namely 6-mercaptopurine, represents an 
attractive novel target for local intervention in restenosis.58




mode of delivery findings
Brito et al.51 eNOS (NOS3) Plasmid-mediated gene delivery from 
lipopolyplex-embedded stents






Plasmid-mediated gene transfer via cationic 
gelatin-coated stents
Accelerated RE, reduced ISR, 
and inhibition of subacute IST
Fishbein et 
al.101
iNOS (NOS2) Adenoviral-mediated gene delivery from 
stents
Reduced ISR













Plasmid-mediated gene delivery from 
stents
Reduced ISR
Walter et al.105 VEGF2 (VEGFC) gene-eluting stent of naked plasmid DNA Increased RE and reduced ISR
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Abbreviations: Anti-MCP 1, antimonocyte chemoattractant protein 1; CCL2, chemokine (C-C motif ) ligand 
2; ENTPD, ectonucleoside triphosphate diphosphohydrolase; EC-SOD, extracellular superoxide dismutase; 
eNOS: endothelial nitric oxide synthase; iNOS, inducible nitric oxide synthase; ISR, in-stent restenosis; IST, 
in-stent thrombosis; NOS2, nitric oxide synthase 2, inducible; NOS3, nitric oxide synthase 3 (endothelial 
cell); pE-NTPdase, placental ectonucleoside triphosphate diphosphohydrolase; RE, re-endothelialization; 
SOD3, superoxide dismutase 3, extracellular; TIMP3, tissue inhibitor of matrix metalloproteinase 3; VEGF2, 
vascular endothelial growth factor 2; VEGFC, vascular endothelial growth factor C.
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Finally, reducing the proliferative capacity of vascular smooth muscle cells could be 
of benefit in reducing neointimal hyperplasia following PCI. The biology of microRNAs 
and their ability to modify smooth muscle biology has been reviewed by O’Sullivan and 
colleagues.59 Two microRNAs, mir-143 and mir-145, were shown to have a key role in the 
regulation of vascular smooth muscle cells in vivo and might, therefore, have therapeutic 
potential.
systemic treatment
Since local drug delivery does not eradicate ISR completely, systemic treatment has also 
been explored, despite the obvious risk of adverse effects. We will briefly discuss the 
evidence for the antirestenotic effects of several antiproliferative and anti-inflammatory 
drugs.
The major role of the inflammatory system in restenosis formed the rationale for 
using prednisone for the prevention of this condition. The IMPRESS trial60 showed favor-
able results with oral prednisone in patients undergoing coronary BMS implantation 
both in angiographic and clinical outcomes. In addition, a subanalysis from the ongoing 
CEREA-DES trial,107 reported by Pesarini et al. in 2010,61 showed that high doses of oral 
prednisone reduced late lumen loss, probably via a reduction in the release of tumor 
necrosis factor.
Preclinical studies have demonstrated that systemically administered sirolimus 
(rapamycin) reduces neointimal proliferation after vascular injury.108 Several clinical tri-
als confirmed the benefit of oral sirolimus in reducing ISR after BMS implantation,62,63 
making it a possible effective and cost-saving alternative to DES implantation. However, 
the long-term results of the OSIRIS trial,64 reported by Kufner and co-workers in 2009, 
showed an attenuated benefit of oral sirolimus after 4 years and, moreover, raised con-
cerns regarding a related increase in newly diagnosed malignancies.
Cilostazol, a phosphodiesterase III inhibitor, has antiproliferative effects109 and has 
been shown to reduce intimal hyperplasia and restenosis after both BMS and DES im-
plantation.65,66 In a meta-analysis published in 2011, Kamal et al. concluded that addition 
of cilostazol to standard dual antiplatelet therapy reduces angiographic restenosis with-
out significantly affecting rates of major adverse cardiac events or bleeding.67 However, 
cilostazol was associated with an increase in the incidence of minor adverse effects, such 
as headaches, gastrointestinal complaints, and palpitations.110
Pioglitazone, a thiazolidinedione peroxisome proliferator-activated receptor gamma 
agonist, is used for the treatment of diabetes. An additional antiatherogenic effect of the 
drug in vascular cells limiting lesion development in animal models of atherosclerosis 
has been described.111 Several clinical studies have demonstrated a reduced incidence 
of ISR after stent deployment with thiazolidinedione (pioglitazone or rosiglitazone) 
administration.68,69
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Although rates of ISR have been shown to be reduced with the systemic use of various 
drugs, the concentration of drug accumulated at the site of interest is limited by toxicity. 
Systemic treatment will, therefore, probably never be superior to local drug delivery 
with DESs. This strategy could, however, be useful as an adjunct to BMS implantation.
restenosis: Presentation anD outcomes
If measures to prevent the development of restenosis fail, the clinical presentation 
of this condition is not always benign and can have a spectrum of acuity.112 Multiple 
mechanisms underlie myocardial infarction associated with ISR. An occlusive restenosis 
can be difficult to differentiate from a thrombotic event and a highly stenotic ISR le-
sion can promote local nonocclusive thrombosis and lead to a clinical presentation of 
non-ST-segment elevation myocardial infarction or troponin-positive unstable coronary 
Figure 3 Patterns of in-stent restenosis.
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deployment with thiazolidinedione (pioglitazone or 
rosiglitazone) administration.104,105
Although rates of ISR have been shown to be reduced 
with the systemic use of various drugs, the concen tration 
of drug accumulated at the site of interest is limited 
by toxicity. Systemic treatment will, therefore, prob-
ably never be superior to local drug delivery with DESs. 
This strategy could, however, be useful as an adjunct to 
BMS implantation.
Restenosis: presentation and outcomes
If measures to prevent the development of restenosis fail, 
the clinical presentation of this condition is not always 
benign and can have a spectrum of acuity.106 Multiple 
mechanisms underlie myocardial infarction associated 
with ISR. An occlusive restenosis can be difficult to dif-
ferentiate from a thrombotic event and a highly stenotic 
ISR lesion can promote local nonocclusive thrombosis 
and lead to a clinical presentation of non-ST-segment 
elevation myocardial infarction or troponin-positive 
unstable coronary syndrome.107 Whether a difference 
exists between the use of DESs and BMSs in this entity 
of ‘thrombosis on top of restenosis’ remains to be eluci-
dated. A pathology study by Nakazawa et al. confirmed 
the occurrence of neoatherosclerosis in the neointimal 
growth after implantation of both BMSs and DESs, but 
unstable features of neoatherosclerosis were encountered 
more frequently and earlier with DESs.108 Whether this 
finding translates into a difference in outcomes between 
stent types is still questionable.109
One factor that does influence outcomes associated with 
ISR is the angiographic pattern of restenosis (Figure 3), 
which can be broadly classified into focal (<10 mm) and 
nonfocal (>10 mm) lesions. Mehran et al. showed that the 
pattern of ISR independently predicts the long-term need 
for revascularization, with an increase in the rate of TLR 
with increasing ISR class.110 The morphologic patterns of 
DES restenosis are different from those of BMS, favor-
ing a more focal and easily treated pattern with expected 
improved clinical outcomes.111 In DES-treated patients, 
the rates of TLR were significantly higher in diffuse ISR 
compared with focal ISR.112
Treatment of restenosis
The optimal treatment for ISR remains debatable. The 
options include vascular brachytherapy; conventional 
balloon, cutting balloon, or drug-eluting balloon angio-
plasty; BMS or DES implantation; and CABG surgery. 
This diversity of available treatments and the variability 
in the underlying etiology of restenosis make selection 
of the most appropriate modality difficult. In other 
words, the treatment of ISR should be tailored and 
indivi dualized according to the clinical situation and in 
view of the underlying etiological factors. Several of 
the treatment options for restenosis are discussed in 
detail below.
Vascular brachytherapy
Intracoronary brachytherapy was once recommended 
as an effective treatment for ISR on the basis of data 
from several randomized, controlled trials published in 
the early 2000s.113,114 Antiproliferative δ (iridium-192) 
or β (phosphorus-32) irradiation is delivered locally 
to the target lesions via dedicated catheters. Currently, 
however, brachytherapy with either β or δ radiation is of 
very limited use. The difficulty in performing this proce-
dure, particularly handling the radioactive substances, 
and the increasingly widespread use of DESs has gradu-
ally displaced brachytherapy from the armamentarium 
of the interventionist. Nevertheless, the 5-year follow-up 
data from the SISR study, presented at the 2011 ACC i2 
summit, suggest that brachytherapy could be an equivalent 
treatment option to SES implantation for the treatment 
of ISR.115
Cutting-balloon angioplasty
The cutting balloon consists of a balloon catheter with 
three to four blades or ‘atherotomes’ designed to create 
discrete longitudinal incisions in the atherosclerotic 
lesion during balloon inflation. Such controlled dilata-
tion theoreti cally reduces the force needed to dilate an 
obstructive lesion compared with standard balloon angio-
plasty and avoid slipping-induced vessel trauma during 
PCI, potentially decreasing the risk of ISR develop-
ment.116 Although this expected benefit was not demon-
strated when the device first came into use in the early 
1990s,117 the later REDUCE III study did show that an 
IVUS-guided cutting balloon procedure followed by 
BMS implantation yielded restenosis rates similar to 
Figure 3 | Patterns of in-stent restenosis. Schematic image of four patterns of in-
stent restenosis (ISR). a | Pattern I (focal ISR) contains four types (A–D). Restenotic 
lesions are ≤10 mm and are located at the articulation or gap between stents 
(Type IA), at either the distal or proximal margin of the stent (Type IB), within the 
body of a stent (Type IC), or a combination of these distributions (Type ID).  
b | Patterns II–IV (diffuse ISR) are defined according to the anatomical position of 
ISR in relation to the previously implanted stent. Type II lesions are >10 mm and do 
not extend beyond the margins of the stent; Type III lesions are >10 mm and extend 
beyond the stent margins; Type IV lesions represent total occlusion and have a 
Thrombolysis in Myocardial Infarction flow grade of 0. Permission obtained from 
Wolters Kluwer Health © Mehran, R. et al. Circulation 100, 1872–1878 (1999).
a
b
Type IA: articulation or gap Type IB: margin
Type IC: focal body
Type II: intrastent Type III: proliferative
Type IV: total occlusion
Type ID: multifocal
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Schematic image of four patterns of in-stent restenosis(ISR). a ) Pattern I (focal ISR) contains four types 
(A–D). Restenotic lesions are ≤ 10 mm and are located at the articulation or gap between stents (type 
IA), at either the distal or proximal margin of the stent (type IB), within the body of a stent (type IC), or 
a combination of these distributions (type ID). b ) Patterns II–IV (diffuse ISR) are defined according to 
the anatomical position of ISR in relation to the previously implanted stent. Type II lesions are > 10 mm 
and not extending beyond the margins of the stent; type III lesions are > 10 mm and extending beyond 
the stent margins; type IV lesions represent total occlusion and have a TIMI flow grade of 0. Permission 
obtained from Wolters Kluwer Health © Mehran, R. et al. Circulation 100, 1872–1878 (1999).
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syndrome.113 Whether a difference exists between the use of DESs and BMSs in this entity 
of ‘thrombosis on top of restenosis’ remains to be elucidated. A pathology study by Na-
kazawa et al. confirmed the occurrence of neoatherosclerosis in the neointimal growth 
after implantation of both BMSs and DESs, but unstable features of neoatherosclerosis 
were encountered more frequently and earlier with DESs.114 Whether this finding trans-
lates into a difference in outcomes between stent types is still questionable.115
One factor that does influence outcomes associated with ISR is the angiographic 
pattern of restenosis (Figure 3), which can be broadly classified into focal (< 10 mm) and 
nonfocal (> 10 mm) lesions. Mehran et al. showed that the pattern of ISR independently 
predicts the long-term need for revascularization, with an increase in the rate of TLR with 
increasing ISR class.116 The morphologic patterns of DES restenosis are different from 
those of BMS, favoring a more focal and easily treated pattern with expected improved 
clinical outcomes.117 In DES-treated patients, the rates of TLR were significantly higher in 
diffuse ISR compared with focal ISR.118
treatment of restenosis
The optimal treatment for ISR remains debatable. The options include vascular brachy-
therapy; conventional balloon, cutting balloon, or drug-eluting balloon angioplasty; 
BMS or DES implantation; and CABG surgery. This diversity of available treatments and 
the variability in the underlying etiology of restenosis make selection of the most ap-
propriate modality difficult. In other words, the treatment of ISR should be tailored and 
individualized according to the clinical situation and in view of the underlying etiologi-
cal factors. Several of the treatment options for restenosis are discussed in detail below.
Vascular brachytherapy
Intracoronary brachytherapy was once recommended as an effective treatment for ISR 
on the basis of data from several randomized, controlled trials published in the early 
2000s.119,120 Antiproliferative δ (iridium-192) or β (phosphorus-32) irradiation is delivered 
locally to the target lesions via dedicated catheters. Currently, however, brachytherapy 
with either β or δ radiation is of very limited use. The difficulty in performing this proce-
dure, particularly handling the radioactive substances, and the increasingly widespread 
use of DESs has gradually displaced brachytherapy from the armamentarium of the in-
terventionist. Nevertheless, the 5-year follow-up data from the SISR study, presented at 
the 2011 ACC i2 summit, suggest that brachytherapy could be an equivalent treatment 
option to SES implantation for the treatment of ISR.121
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cutting-balloon angioplasty
The cutting balloon consists of a balloon catheter with three to four blades or ‘athero-
tomes’ designed to create discrete longitudinal incisions in the atherosclerotic lesion 
during balloon inflation. Such controlled dilatation theoretically reduces the force 
needed to dilate an obstructive lesion compared with standard balloon angioplasty 
and avoid slipping-induced vessel trauma during PCI, potentially decreasing the risk 
of ISR development.122 Although this expected benefit was not demonstrated when 
the device first came into use in the early 1990s,123 the later REDUCE III study did show 
that an IVUS-guided cutting balloon procedure followed by BMS implantation yielded 
restenosis rates similar to those achieved with DESs, thereby, providing an effective 
alternative.124 However, use of the cutting balloon remains uncommon for the treatment 
of ISR, especially when used without stent placement. In 2010, Park et al. raised concerns 
that cutting-balloon angioplasty might be associated with a higher risk of myocardial 
infarction than conventional balloon angioplasty;125 this technique is, therefore, unlikely 
to become an important ISR treatment modality.
Drug-eluting balloon angioplasty
Non-stent-based local delivery of an antiproliferative drug, particularly using drug-elut-
ing balloons, theoretically represents a very attractive treatment for ISR that avoids the 
limitations associated with DES platforms. Drug-eluting balloons improve drug delivery 
by allowing homogenous drug transfer to the entire vessel wall rather than only to the 
areas covered by stent struts, as with DESs. All currently available drug-eluting balloons 
use paclitaxel in various coating formulations with a typical dose of 3 μg/mm2 of bal-
loon surface. Drug-eluting balloon angioplasty has been shown to be more effective 
than conventional balloon angioplasty,126 and as effective as PES implantation127 for the 
treatment of ISR. However, drug-eluting balloons of course cannot prevent the almost 
immediate elastic recoil phenomenon.
Currently, research in this area is focused on comparisons of the various available 
drug-eluting balloons. For example, in a preclinical study in an advanced porcine 
model of coronary restenosis, Joner et al. found that the Pantera® Lux (Biotronik, Berlin, 
Germany; 3.0 μg/mm2 paclitaxel), the SeQuent® Please (B. Braun Melsungen AG, Berlin, 
Germany; 3.0 μg/mm2 paclitaxel), and the Elutax™ (drug-eluting balloons (Aachen 
Resonance, Aachen, Germany; 2.0 μg/mm2 paclitaxel) all resulted in delayed healing 
when compared with conventional balloon angioplasty.128 However, the investigators 
also demonstrated significant heterogeneity in neointimal suppression between the 
balloons, with superiority of Pantera® Lux.121 This difference was attributed to the ‘excipi-
ent’ used as an effective carrier for paclitaxel in the Pantera® Lux and SeQuent® Please 
balloons. The 6-month results of the PEPPER trial,129 which were presented at the ACC 
i2 summit in April 2011, showed excellent results for the Pantera® Lux balloon for the 
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treatment of ISR both in BMSs and DESs. However, a subgroup analysis revealed a sig-
nificantly lower in-stent late lumen loss in BMS-related ISR compared with DES-related 
ISR, suggesting that the drug effect of the balloon may be decreased in patients with 
DES-related ISR and may differ between DES drug types. A higher number of patients 
with diabetes in the DES-related ISR group may have confounded the results.130
In the 2010 guidelines for myocardial revascularization published by the European 
Society of Cardiology, drug-eluting balloons were considered a class IIa indication for the 
treatment of ISR.131 Nevertheless, further large studies need to be implemented before 
these devices can be fully integrated into clinical practice. Patients are currently being 
recruited for an ongoing trial132 to investigate the efficacy of a drug-eluting balloons for 
the treatment of ISR in patients with DESs.
Drug-eluting stents
DESs are known to have fairly low rates of ISR.4,5 The proportion of restenotic lesions 
treated with DES in the studies providing this data is, however, low. Since restenotic 
lesions have a tendency towards recurrent restenosis, as discussed in Part 1 of this 
Review,6 the outcomes associated with stent (DES) implantation in these lesions is likely 
to be different to those for DES placement in de novo lesions. In addition, ISR after BMS 
implantation differs from ISR associated with DES use and, therefore, a distinction be-
tween these two types of restenosis should also be made in terms of treatment.
Favorable outcomes of DES treatment for BMS-related ISR have been reported in 
several studies, even after long-term follow up.124-127 Treatment with DES placement was 
found to be more effective and safer than conventional balloon angioplasty,133 vascular 
brachytherapy,134,135 or BMS implantation within the original stent.136 DESs should, there-
fore, be the treatment of choice for the treatment of BMS-related ISR. By contrast, the 
same cannot be said for DES-related ISR, which continues to be a therapeutic challenge. 
To date, the treatment of this condition has been investigated in only one randomized 
controlled trial, which showed comparable efficacy for SES reimplantation or a switch to 
PES implantation in patients with SES-related ISR.137 Other small nonrandomized trials 
have produced inconsistent results, limiting the possibility of drawing any definitive 
conclusions about the optimal treatment of DES-related ISR.113
An individual’s resistance to a particular eluted drug can be a factor in restenosis de-
velopment.138,139 This hypothesis provides the rationale for switching to a different DES for 
the treatment of DES-related ISR. However, to date, no clinical study has demonstrated 
clear clinical benefit of implanting an alternative different DES.137,140 Whether resistance 
to sirolimus also implies resistance to other limus derivatives remains questionable, 
as no reports have been published on the use of zotarolimus, everolimus, or biolimus 
A9-eluting stents for the treatment of SES-related ISR. Another uncertainty is whether 
the angiographic pattern of DES-related ISR provides a clue to the involvement of drug 
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resistance. Drug resistance is expected to cause a diffuse pattern of ISR, so perhaps a 
future study focused on patients with diffuse patterns of ISR would clarify the potential 
benefits of changing the agent eluted by the stent. In the ongoing prospective, random-
ized Italian GISE-CROSS trial,141 treatment with a stent that elutes the same drug as the 
original restenosed stent (no CROSS group) is being compared with a crossover to an 
alternative DES in patients with ISR after either PES or SES implantation. The results of 
this study are eagerly awaited. Patients treated with DES for ISR are at high risk for recur-
rent ischemic events and should be maintained on dual antiplatelet therapy unless a 
complication emerges.113 Therefore, individuals who have a contraindication for, or show 
noncompliance with, dual antiplatelet therapy should be considered for CABG surgery.
cabG surgery
CABG surgery is usually considered as the ‘last resort’ treatment for ISR in the clinic. 
However, this strategy is an appropriate first-line therapy for certain complex cases, 
such as multivessel ISR, diffuse ISR, multiple subsequent DES restenosis treated by re-
peat DES implantation, a strong genetic predisposition to ISR that precludes further 
interventional options, or in cases where dual antiplatelet therapy is not appropriate, 
as discussed above. To our knowledge, no studies of CABG surgery for the treatment of 
in-stent restenosis have been conducted.
concLusions
Restenosis is a complex disease with a diversity of underlying mechanisms that are still 
not fully understood. Many innovative technologies, including DESs (with or without 
specific polymers) and fully biodegradable stents, have been and continue to be de-
veloped in the diligent search for an ideal antirestenosis therapy that is both effective 
and safe in the long term. Developments in the field of gene therapy might also impact 
future restenosis therapies. Advances in stent design and nanoparticle delivery systems 
(‘nanovehicles’) in the past 5 years have already fueled revolutionary changes in the 
concept of ISR prevention and treatment. In addition, several clinical algorithms for ISR 
treatment have been proposed on the basis of angiographic pattern of restenosis.113,141,142 
Treatment of ISR should be tailored to the individual, taking into consideration the 
available evidence and the best strategy for the patient, as well as the best method of 
treating the lesion. We believe that investing in the prevention of ISR is worth much 
more than investing in its treatment.
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The articles on which this Review is based were identified by searching MEDLINE us-
ing the following keywords and Medical Subject Headings (MeSH) terms: “coronary 
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“nanomedicine”. We checked for papers published up to August 2011. Only papers in 
the English language were included. Although we realize that not all available evidence 
could be incorporated, the most relevant and influential articles were selected for inclu-
sion in this Review.
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abstract
Percutaneous coronary intervention (PCI) has become an effective therapy to treat 
obstructive coronary artery diseases (CAD). However, one of the major drawbacks of 
PCI is the occurrence of restenosis in 5–25% of all initially treated patients. Restenosis 
is defined as the re-narrowing of the lumen of the blood vessel, resulting in renewed 
symptoms and the need for repeated intervention. To identify genetic variants that are 
associated with restenosis, a genome-wide association study (GWAS) was conducted in 
295 patients who developed restenosis (cases) and 571 who did not (controls) from the 
GENetic Determinants of Restenosis (GENDER) study. Analysis of ~550 000 single nucleo-
tide polymorphisms (SNPs) in GENDER was followed by a replication phase in three 
independent case–control populations (533 cases and 3067 controls). A potential sus-
ceptibility locus for restenosis at chromosome 12, including rs10861032 (Pcombined = 1.11 
× 10−7) and rs9804922 (Pcombined = 1.45 × 10
−6), was identified in the GWAS and replication 
phase. In addition, both SNPs were also associated with coronary events (rs10861032, 
Padditive = 0.005; rs9804922, Padditive = 0.023) in a trial based cohort set of elderly patients 
with (enhanced risk of ) CAD (PROSPER) and all-cause mortality in PROSPER (rs10861032, 
Padditive = 0.007; rs9804922, Padditive = 0.013) and GENDER (rs10861032, Padditive = 0.005; 
rs9804922, Padditive = 0.023). Further analysis suggests that this locus could be involved in 
regulatory functions.
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introDuction
Percutaneous coronary intervention (PCI) for unblocking a narrowed coronary artery is 
a widely used technique for treating patients with angina or an acute coronary event. 
Initially, PCI was performed only with balloon catheters, but technical advances made 
it possible to improve patient outcome by the placement of bare metal stents (BMS), or 
later, drug eluting stents (DES) at the site of blockage.1-3 Patients undergoing PCI may 
suffer from a re-narrowing of the treated lesion, which is called restenosis, with renewed 
symptoms and the need for repeated intervention, typically within 3 to 6 months.4 Re-
stenosis occurs in ~5–25% of all treated patients depending on individual characteristics 
and the techniques used blockage1-3,5,6, thereby still causing a significant clinical and 
economic burden for patients and society.
So far, the etiological basis of restenosis is only partly understood. The injury induced 
by PCI within the vascular wall causes segmental thrombus formation and subsequent 
invasion of macrophages and polymorphonuclear leukocytes in the blood vessel. 
This process is followed by release of numerous growth factors from blood cells and 
stretched smooth muscle cells that lead to the proliferation of smooth muscle cells in 
the treated lesion.4,7,8
In order to prevent restenosis, numerous systemic drugs have been studied for their 
inhibitory effect on smooth muscle cell proliferation but the results have been inconclu-
sive.9 A new solution has been the development of DES.10,11 DES are made by applying 
a drug (such as sirolimus or paclitaxel) on a coronary stent. The drug is released directly 
into the (by PCI) injured area and is thereby preventing the inflammatory response and 
smooth muscle cell proliferation at the site of the coronary intervention. Although DES 
have decreased the incidence of restenosis, restenosis still occurs in all instances.12,13 
Moreover, although several clinical factors, lesion-related, procedural and biological 
markers have been shown to be associated with an elevated risk of restenosis4,14-16, these 
associations have not been consistently replicated in all studies.
There is evidence that systemic factors can explain part of the risk of restenosis inde-
pendently of conventional clinical factors or procedures. For instance, in patients with 
multilesion interventions, the risk that a lesion develops restenosis is 2.5 times higher 
when a companion lesion developed restenosis, independently of clinical factors.17 The 
influence of genetic polymorphisms in the development of restenosis has been investi-
gated by means of candidate gene approaches18-21, with interesting, although sometimes 
controversial or inconsistent results. For instance, an insertion/deletion polymorphism 
in the angiotensin-converting enzyme was associated with restenosis within a French 
population22, but not in a German or a Dutch population.23,24
We conducted the first genome-wide association study (GWAS) to identify new 
genetic risk factors for restenosis in a subpopulation of the GENetic DEterminants of 
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Restenosis (GENDER) study. This was followed by a replication phase in three indepen-
dent restenosis case–control populations (replication I, replication II and replication III). 
In a secondary step, we tested if the most associated single nucleotide polymorphisms 
(SNPs) were also associated with other relevant clinical outcomes such as cardiovascular 
events and all-cause mortality in GENDER and in the PROspective Study of Pravastatin 
in the Elderly at Risk (PROSPER) population. This additional validation effort may add 
worthwhile information with regard to the genetic factors involved in the pathophysiol-
ogy of restenosis.
materiaLs anD methoDs
We investigated the association between genetic variation and clinical restenosis in 
patients from four different cohort studies, a Dutch population (GENDER), an American 
population (replication I) and two populations from Germany, a BMS population (repli-
cation II) and a DES population (replication III). The GWAS was performed in the GENDER 
study (discovery set), whereas the replication was performed in replication I, replication 
II and replication III. In addition, the PROSPER and the GENDER studies were used to 
check whether the top associated SNPs found in the discovery set and validated in the 
replication cohorts are involved in other relevant clinical outcomes such as all-cause 
mortality and cardiovascular events.
All studies were approved by the medical ethical committees of the participating 
hospitals, had independent clinical event committees who adjudicated the endpoints in 
a blinded way. Blood samples were collected at the index procedure for DNA isolation 
after having obtained written informed consent from the patient and the trials were 
conducted in concordance with the Declaration of Helsinki.
Genome-wide association study
The main characteristics of the GENDER population have been described previously.1 
Briefly, 3104 consecutive symptomatic patients treated successfully by PCI for angina 
were included in four referral centers for interventional cardiology in the Netherlands. 
The follow-up protocol included a phone contact or a medical visit at the outpatient 
clinic at 30 days and around 9 months after stent placement. Clinical restenosis was de-
fined as renewed symptoms requiring target vessel revascularization either by repeated 
PCI or coronary artery bypass graft surgery, by death from cardiac causes or myocardial 
infarction not attributable to another coronary event than the target vessel.1 Within the 
9-month follow-up period, 346 patients developed clinical restenosis. Clinical restenosis 
was not angiographically confirmed.
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The GWAS was performed in 325 cases of restenosis (all cases with enough quality 
DNA to perform the experiment) and 630 matched controls. Cases and controls were 
matched by gender, age and some possible confounding clinical variables for restenosis 
in the GENDER study, such as total occlusion, diabetes, current smoking and residual 
stenosis (Table 1).
All-cause mortality long-term follow-up data were collected in March 2011 and are 
defined as death from any cause and the information was collected from death certifi-
cates. Mean time follow-up was 9.5 years (SD = 3 years) and 239 (27.9%) patients died 
during the study. From the patients analysed in the GWAS, only nine subjects (1.0%) 
were not possible to long-term follow-up.
Genotyping and quality control
In the discovery stage, we conducted the genotyping using Illumina Human 610-Quad 
Beadchips and the infiniumII assay following manufacturer’s instructions. These bead-
chips contain 620 901 SNPs and copy number variants covering 89% of the common 
genetic variation in the European population at r2 > 0.8. Initially, 955 samples (325 cases 
and 630 controls) from the GENDER study were genotyped. After excluding bad perform-
ing samples (call rate < 0.98 and manually checked sample quality by means of B-allele 





Ia, n = 265
P-valueb Replication IIc, 
n = 1445
P-valueb Replication 
IIIc, n = 1890
P-valueb
Age (years) 62 ±11 64.5 ± 11.35 64 ± 11 66 ± 11
Sex (male) 636 
(73.44%)
0.50 182 (68.68%) 0.001 1110 (76.81%) 0.78 1478 (79.04%) 0.67
Stentingd 584 
(67.43%)
0.95 265 (100%) 1 1445 (100%) 1 1890 (100%) 1
Diabetes 117 
(20.43%)





















0.07 11 (4.15%) 0.53 54 (3.37%) 0.92 48 (2.54%) 0.08
n, number of individuals in each cohort. aEndpoint: clinical restenosis. bP-values computed between cases 
and controls for each variable . cEndpoint: Target lesion revascularisation (TLR) within one year after PCI. 
dGENDER , Replication I and Replication II are BMS cohorts. Replication III is a DES cohort. eIn replication 1, 
the data represented in the ever are ever smoke and not current smoker
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frequency and LogR ratio), genotype cluster definitions for each SNP were determined 
using the ‘Cluster all SNPs’ option in Illumina Bead-Studio Genotype module version 3.2. 
Genotype calls were made when a genotype yielded a quality metric (Gencall score) of 
0.15 or higher. The final raw data set released from Beadstudio (eliminating intensity 
probes only) contained reliable called genotypes for 592 186 SNPs and 941 samples 
(321 cases and 620 controls), with 14 samples not released due to inadequate quality 
of genotypes. The remaining samples have a call rate ≥ 0.99. Additional quality-control 
measurements were then performed using PLINK.25 Seven samples (four cases and three 
controls) were excluded due to sex discrepancies between the recorded sex and the 
inferred sex by the X-chromosome genotypes. We checked for the presence of popula-
tion substructure in the GENDER study by means of multidimensional scaling (MDS). 
An identical by state distance matrix was calculated for each pair of individuals along 
with the 940 individuals from the human genome diversity project-centre d’Etude du 
polymorphisme humain (HGDP-CEPH) panel.26 We observed that the vast majority of the 
individuals fell in the same cluster along with the European population, but 67 individu-
als were outside this cluster and were considered genetic outliers (see Supplementary 
Material, Fig. S1). One sample was eliminated because it showed a close genetic relation-
ship with another sample from the GENDER study. Furthermore, we excluded SNPs for 
further analyses with a call rate lower than 95% (n = 1731), with a minor allele frequency 
lower than 1% (n = 34250) or with a significant deviation from Hardy–Weinberg equilib-
rium (HWE) in controls (P < 0.00001). The final data set consisted of 866 (295 cases, 571 
controls) individuals and 556 099 SNPs that passed all quality-control criteria.
We applied the genomic-control method on the GWAS data and found that there 
was only a slight inflation of the genomic control parameter (l = 1.01581), which implies 
a high genetic homogeneity between the cases (n = 295) and the controls (n = 571). 
Given that the inflation factor was found to be minimal, all the statistics results are re-
ported without genomic-control correction. At the tail end of the quantile–quantile plot 
(Q–Q plot), the P-values from the Cochrane–Armitage trend test deviate from the null 
distribution expected under the hypothesis of no association (Supplementary Material, 
Fig. S2), which indicates that several modest associations were present.
replication stage
Replication I
The CardioGene Study was an IRB-approved, prospective cohort study of 358 patients 
enrolled at the time of BMS implantation to treat de novo, previously untreated native 
coronary artery lesions at William Beaumont Hospital (Royal Oak, Michigan, USA) and the 
Mayo Clinic (Rochester, Minnesota, USA). Patients were followed for 1 year to determine 
in-stent restenosis (ISR) outcomes. Enrolment began in February 2002 and was closed in 
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September 2003, prior to the approval and clinical use of DES in the USA. Additionally, 
104 individuals were enrolled with historical in-stent restenosis in bare metallic stents, 
with two or more episodes of restenosis in native coronary arteries. The protocol was 
approved by the NHLBI IRB as well as the IRB at each of the clinical enrolment sites. 
Informed consent was provided by each patient. Standardized case report forms were 
used to collect baseline clinical data and outcome information in follow-up.27
For the clinical phenotype, consecutive patients presenting to the cardiac catheter-
ization laboratories of the clinical enrolment sites were approached for participation 
in the study. Follow-up clinical evaluation was performed via patient interview and 
review of all available medical records at 6 months and 12 months post-stent. ISR was 
defined as clinical restenosis27, which was defined by ischemic symptoms after stent 
implantation and evidence of flow limitation in the treated vessel by either invasive 
or non-invasive testing. Follow-up angiography was not specifically performed for the 
CardioGene Study. Any available angiographic data performed as part of each patient’s 
clinical care was recorded.
Genotyping and quality control
Genotypes were assayed using the Affymetrix Genome-Wide Human SNP Array 6.0 
platform, and genotypes were called using the Birdseed algorithm. For this analysis, the 
final sample with genotype data consisted of 265 samples, with 78 in-stent restenosis 
cases and 187 stented no-restenosis controls, from European ancestry participants 
among which call rates and deviations from HWE for all SNPs were calculated. Genotype 
call rates were 95% or greater for all samples. Of these, 35 samples were removed in 
data cleaning steps for sex mismatch, first degree relative of an included individual and 
genetic outlier based upon allele sharing and principal components analysis. Genetic 
analyses were conducted using an additive model, using logistic regression to evalu-
ate the association between the allele dosage and the trait of interest. We adjusted the 
analysis for age and gender. Genomic control was not applied. Data management and 
statistical analysis used R, ProbABEL28 and PLINK software.25
replication ii and replication iii
Patients of replication II and replication III cohorts presented ischemic symptoms or 
evidence of myocardial ischemia in the presence of ≥ 50% de novo stenosis located in 
native coronary vessels. They were treated with PCI and stent implantation at Deutsches 
Herzzentrum München or 1. Medizinische Klinik rechts der Isar der Technischen Univer-
sität München. The main characteristics of the cohorts and the protocols of stent place-
ment and post-stenting therapy have been described previously.23,29 Briefly, replication II 
included 1445 patients treated with implantation of BMS and replication III consisted of 
1890 patients treated with implantation of DES. TLR within 1 year after PCI was consid-
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ered the primary endpoint for both cohorts. Re-hospitalization for repeat angiography 
was scheduled between 6 and 8 months or earlier if non-invasive evaluation or clinical 
presentation suggested the presence of ischemia. The secondary endpoint was defined 
as a diameter stenosis 50% at follow-up angiography at 6 months.
Genotyping and quality control
Initially, 3657 samples were genotyped by means of iPLEX assays. All SNPs showing a 
P-value < 10−4 in the Cochran–Armitage trend test (additive model) in the discovery 
set (n = 91) were selected for replication. Four assays were designed using MassArray 
design software (Sequenom, San Diego, CA, USA). Genotyping was performed using 
iPLEX assays with the use of the MassARRAY methodology (Sequenom), with alleles 
discriminated by mass spectrometry, following manufacturer’s instructions. Four SNP 
pairs were in complete LD (r2 = 1) and thus we ascertained one tagSNP from each pair 
and the other was discarded.
Two SNPs did not fit the assay and four more SNPs failed in the experiment. Samples 
with a call rate < 75% per iPLEX or with a call rate < 90% when considering all iPLEXes 
were removed for further analysis. SNPs with call rate < 90% or out of HWE (P-value < 0.001 
in controls) were also removed. Duplicate samples (~2.5%) showed identical genotypes. 
Blanks and positive controls were added in each experiment. Finally, 79 SNPs and 3335 
samples (2880 controls and 455 cases) passed all quality criteria and were further analyzed.
In order to know if the most associated SNPs in the discovery set contain information 
to detect the presence of population substructure, we performed a MDS extracting the 
genotypes of these SNPs from the HGDP-CEPH panel26, which contains samples belong-
ing to 52 populations all over the world. The MDS did not show any cluster (data not 
shown) in the HGDP-CEPH panel, not even between populations from different conti-
nents, thus indicating that population substructure cannot be considered a confound-
ing factor in the replication cohorts when considering these SNPs.
ProsPer study
The protocol of PROSPER (PROspective Study of Pravastatin in the Elderly at Risk) has 
been described elsewhere.30 PROSPER is a prospective multicenter randomized placebo-
controlled trial to assess whether treatment with pravastatin diminishes the risk of major 
vascular events in elderly individuals. Between December 1997 and May 1999, subjects 
were screened and enrolled in Scotland (Glasgow), Ireland (Cork) and the Netherlands 
(Leiden). Men and women aged 70–82 years were recruited if they had pre-existing 
vascular disease or increased risk of such disease because of smoking, hypertension 
or diabetes. A total number of 5804 subjects were randomly assigned to pravastatin 
or placebo. In this study, the predefined endpoints, coronary events, vascular events, 
vascular mortality and all-cause mortality were evaluated. In particular, coronary events 
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are a combination of fatal and non-fatal myocardial infarction. Information on all-cause 
mortality was received by post-mortem reports, death certificates, hospital records, 
general practitioners’ records and/or interviews of family members or witnesses. All 
endpoints were adjudicated by the study endpoint committee.
Mean follow-up was 3.2 years (range 2.8–4.0) and 604 (10.4%) patients died during 
the study 31. The SNPs were selected from the GWAS performed in 5244 subjects of the 
PROSPER study from whom genotype data were available.
statistical analysis
Statistical analysis was undertaken using R (v2.8), PLINK v1.0625, GenABEL and ProABEL 
softwares implemented in the R package.28,32 Haploview software33 was used to infer the 
LD in the targeted regions. LocusZoom34 was used to draw regional plots for associated 
regions.
Each SNP was tested for association using a Cochran–Armitage test (additive model). 
Inflation in the test statistics was assessed using the genomic-control method and a Q–Q 
plot was computed.35 The genotype counts of the discovery and replication stages were 
combined by means of the Fisher’s trend combined P-value approach. All P-values are 
two-sided. Imputation of genotypes around the top associated SNPs were performed 
using MACH software.36,37
The promoter 2.0 Prediction Server38 was used to predict promoter regions and is-
rSNP for in silico regulatory detection.39 The eQTL analysis was done following methodol-
ogy described in reference 40.
resuLts
The overall GWAS results are summarized in a Manhattan plot (Fig. 1). We found that 
91 SNPs were associated with restenosis at P-value < 10−4 assuming the additive model 
(Supplementary Material, Table S1).
In the replication stage, these 91 SNPs were genotyped in three restenosis popu-
lations, two BMS cohort (replication I and replication II) and a DES cohort (replication 
III) (Table 1). Associations found in the discovery set were replicated for an intergenic 
region on chromosome 12 (Table 2). This was specially found for replication I (Table 
2). In replication I, rs10861032 showed an association with restenosis [P = 3.99 × 10−4; 
odds ratio (OR) = 3.06, 95% confidence interval (CI) (1.64–5.70)]; nominally significant 
at P-value < 0.05 even after Bonferroni correction (0.05/91 SNPs = 5.49 × 10−4). Using 
the Fisher’s trend combined P-value method, we observed that rs10861032 C allele 
was potentially associated with higher risk of restenosis (Padditive = 1.11 × 10
−7) in all four 
populations combined. We computed I2 as a measurement of heterogeneity and we 
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obtained a value of 77.04% for rs10861032 which can be interpreted as the percentage 
of total variation across studies due to heterogeneity.41 A similar association for all four 
combined populations was observed for rs9804922 (Padditive = 1.45 × 10
−6) for the risk al-
lele (T).






































































P-values were obtained by Cochrane-Armitage trend test for 556099 SNPs and 866 individuals (295 cases 
and 571 controls) are plotted in −log10 scale according to their chromosomal position. A horizontal black 
line indicates an additive P-value of 10−4.
Table 2 Association results for rs10861032 and rs9804922 in GENDER (discovery set), replication I, 
replication II and replication III.
Population N(case/
control)
Chr SNP Position Allelesa MAF(case/
control)
Padditive
b OR (CI 95%)c
GWAS 295/571 12 rs10861032 102436636 C/T 0.212/0.133 3.29E-05 1.75(1.35-2.27)
Replication I 78/187 0.192/0.099 3.98E-04 3.06 (1.64-5.70)
Replication II 275/1170 0.159/0.147 4.94E-01 1.09(0.85-1.41)
Replication III 180/1710 0.219/0.177 4.89E-02 1.31(1.00-1.7)
Combined 1.11E-07
GWAS 295/571 12 rs9804922 102437572 T/C 0.114/0.049 1.03E-06 2.48(1.72-3.60)
Replication I 78/187 0.077/0.043 0.063 2.26(0.97-2.14)
Replication II 275/1170 0.077/0.074 8.83E-01 1.03(0.72-1.46)
Replication III 180/1710 0.119/0.092 1.03E-01 1.33(0.95-1.87)
Combined 1.45E-06
Combined p-values are computed by means of Fisher’s trend method. Positions are based on hg18 build. 
aThe first allele is the minor allele. MAF, minor allele frequency. bResults of the Cochran-Armitage test. cOR 
of the minor allele from the two by two allele frequency table.
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In addition, both SNPs were also associated with all-cause mortality in GENDER 
(rs10861032, Padditive = 0.005; rs9804922, Padditive = 0.031) and in the PROSPER study 
(rs10861032, Padditive = 0.007; rs9804922, Padditive = 0.013) (Tables 3 and 4), and also with 
coronary events (rs10861032, Padditive = 0.005; rs9804922, Padditive = 0.023) in PROSPER. Both 
rs10861032 and rs9804922 are located on an intergenic region. An open reading frame 
(C12orf42), a hypothetical protein of unknown function, is located 22.7 kb upstream of 
both SNPs, the gene STAB2 (Stabiline2) is located 68.5 kb downstream and the gene 
NT5DC3 253.5 kb downstream (Fig. 2). Non-genotyped SNPs in the 610-quad array 
were imputed from HapMap CEU reference panel (release 22) within a 500 kb window 
centered on rs1086103.
Analysis on 566 imputed and 140 genotyped SNPs within this region revealed three 
more imputed SNPs that were associated with restenosis, rs4147305 [P = 1.72 × 10−4, 
OR = 2.1 95% CI (3.14–1.41)], rs17034045 [P = 1.72 × 10−4 OR = 2.1 95% CI (3.14–1.41)] 
and rs10861033 (P = 8.91 × 10−4 OR = 1.55 95% CI [2.02–1.20)]. These SNPs are in LD with 
rs10861032 (r2 = 0.37, r2 = 0.37 and r2 = 0.85, respectively).
Inspection of the UCSC genome browser (http://genome.ucsc.edu) database re-
vealed that rs10861032 maps 110 bp downstream and rs9804922 457 bp upstream to a 
DNase I hypersensitivity site (chr12:102436746–102437115). In addition, the promoter 
2.0 Prediction Server predicts with high scores that the surrounding region of the reste-
nosis associated SNP could be a promoter region. Moreover, the is-rSNP algorithm39 for 
in silico detection of genetic variation which affect the ability of a transcription factor 
Table 3: Association results with Coronary events and All-cause mortality for rs10861032 and rs9804922 in 
PROSPER.
Padditive HR(95%CI)
rs10861032 (MAF = 0.14)
Coronary events 0.005 1.25(107-1.46)
All-cause mortality 0.007 1.25(1.06-1.47)
rs9804922 (MAF = 0.06)
Coronary events 0.023 1.30(1.04-1.62)
All-cause mortality 0.013 1.33(1.06-1.67)
MAF, minor allele frequency; HR, Hazard Ratio. Adjusted for sex, age, country and pravastatin used.
Table 4: Association results for All-cause mortality for rs10861032 and rs9804922 in GENDER.
Padditive HR(95%CI)
rs10861032 (MAF = 0.16)
All-cause mortality 0.005 1.39(1.10-1.74)
rs9804922 (MAF = 0.07)
All-cause mortality 0.031 1.42(1.03-1.94)
MAF, minor allele frequency; HR, Hazard Ratio. Adjusted for sex and age
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(TF) to bind to DNA predicts that both SNPs alter the binding affinity of TFs to the DNA 
(Supplementary Material, Table S2). Alleles of rs10861032 alter the binding affinity of 
Htlf (Helicase-like TF) (P = 4.4 × 10−3) and Pax4 (P = 5.7 × 10−3). Members of Htlf family 
have helicase and ATPase activities and are thought to regulate transcription of certain 
genes by altering the chromatin structure around those genes.42 Pax4 is a member of the 
paired box (PAX) family of TFs. These genes play critical roles in cancer growth.43
Alleles of rs9804922 alter the binding affinity of TP53 (4.8 × 10−4) and HoxA (3.3 × 
10−4). TP53 is a tumor suppressor protein that regulates the cell cycle known to be very 
important in the process of restenosis (sirolimus and paclitaxel work by inhibiting the 
cell cycle).44,45 HoxA belongs to the cluster A of the called homeobox genes which may 
regulate gene expression, morphogenesis and differentiation.46
We have also checked if both SNPs are expression quantitative loci (eQTLs) and 
regulate the expression level of genes at the locus (cis-regulation). This experiment was 
performed using cis expression-genotype data derived from 1469 human whole blood 
samples reflecting primary leukocyte gene expression.40 However, in a window of 1 Mb 
surrounding rs10861032 and rs9804922, no significant eQTL effect was detected.
Discussion
To our knowledge, this is the first GWAS that investigates the association between ge-
netic markers and restenosis. Restenosis is a complex phenotype in which the individual 
contribution of genes to the development of the disease might probably be relatively 
small and therefore difficult to detect.16 Using the GENDER population as a discovery set, 
we found several genomic regions that were associated with restenosis. However, this 
study presents some potential caveats. First, we combined patients that underwent PCI 
either by balloon angioplasty alone, BMS or DES as restenosis was and still is the major 
drawback of PCI in all these three cohort populations. The fact that we found similar 
results in the different cohorts independently of whether they used BMS or DES indicates 
that it is unlikely that the involvement of chromosome 12q23.3 region in the pathophysi-
ology of restenosis is based only on the inhibitory effect on smooth muscle cell prolifera-
tion of the drugs coating the DES surface, which is only expected in subjects with DES. 
Secondly, it is also important to point out that in this study we have combined cohorts 
with two clinical endpoints [clinical restenosis (discovery set and replication I) and target 
lesion revascularization (TLR, replication II and replication III)]. Although both endpoints 
are highly comparable, it should be noted that clinical restenosis, although nowadays 
considered the most clinically relevant endpoint, is somewhat a broader endpoint for 
restenosis than TLR. The fact that the replication is mainly in replication I could indicate 
that the top SNPs are mainly associated with clinical restenosis and not with TLR. Finally, 
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it must be noticed that none of the detected SNPs shows traditional GWAS threshold 
significance. Nevertheless, the fact that similar association trends were observed in some 
of these regions when using other data sets suggests that these regions could be indeed 
potentially involved in the restenosis phenotype. From these SNPs, a region on chro-
mosome 12q23.3 comprising rs10861032 and rs9804922 was replicated in three other 
restenosis populations, two BMS cohorts and a DES cohort (Pcombined = 1.11 × 10
−7 and 
Pcombined = 1.45 × 10
−6, respectively, when considering all four populations). Interestingly, 
both SNPs (rs10861032 and rs9804922) are also associated with all-cause mortality in 
GENDER and in PROSPER and also with coronary events in PROSPER (no data available 
for this endpoint in GENDER), which shows that probably this region on chromosome 12 
may play a more general role in the development of coronary artery diseases. These find-
ings require further research to disentangle whether the SNPs associated not only with 
restenosis but also with cardiovascular events and all-cause mortality are for instance 
the result of a pleiotropic effect of single alleles affecting multiple phenotypes.
The associated locus on 12q23.3 is an intergenic region flanked upstream by C12orf42 
and downstream by the gene STAB2 located 68.5 kb and the gene NT5DC3 located 253.5 
kb away from rs10861032 (Fig. 2). The STAB2 gene encodes for a transmembrane recep-






































































On the y axis, the –log10 (P-value) is depicted. The most significant SNP in the meta-analysis (rs10861032) 
is plotted in purple. LD is based on the HapMap CEU sample and is colour-code as red (r2 from 0.8 to 1.0), 
orange (0.6-0.4), green (0.6-0.4), white blue (0.4 to 0.2) and dark blue (0.2 to 0). Recombination rate is 
depicted in light blue. Asterisks display TF site. The plot was generated using LocusZoom.34
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tor protein which may function in angiogenesis, lymphocyte homing, cell adhesion and 
receptor scavenging.47-49 All these processes are described to be of importance in the 
development of restenosis and coronary events16, thereby making it a very plausible 
candidate. NT5DC3 encodes for a protein involved in the progression of pancreatic can-
cer50, therefore it is a gene involved in cell proliferation, an important biological process 
for the development of restenosis.
The top associated SNP in this study, rs10861032, is in low linkage disequilibrium 
(LD) (r2 < 0.2) with SNPs in STAB2, NT5DC3 and C12orf42 (Fig. 2). Moreover, rs10861032 
flanks upstream to a DNaseI hypersensitivity site (chr12:102436746–102437115), a 
universal feature of active cis-regulatory sequences, including promoters, insulators, 
enhancers, boundary elements and locus control regions.51,52 Furthermore, the region 
flanked by rs10861032 and rs9804922 is likely to be a promoter region as predicted by 
the promoter 2.0 Prediction Server.38 In addition, the is-rSNP algorithm39 predicts that 
alleles of both SNPs alter the binding affinity of several TFs to the DNA, making them 
likely to be regulatory SNPs. Furthermore, it has recently been shown that ‘gene desert’ 
regions found by GWAS can be involved in cis-regulatory functions.53-55 This could also 
be the case of rs10861032 and rs9804922 in the regulation of the expression of STAB2 
or NT5DC3, indicating that the region, associated with restenosis on chromosome 12, 
might be involved in the regulation of the expression of these two genes. However, all 
these bioinformatic predictions would require wet lab confirmation; in fact, analysis of 
gene expression and genetic variation on a 1 Mb region surrounding both rs10861032 
and rs9804922 in 1469 whole blood samples40 did not find any significant eQTL effect. 
Nevertheless, this result does not preclude cis-regulating effect in the case of restenosis, 
as this analysis was performed in whole blood and not yet in a restenosis population 
and eQTL effects are often cell-type specific.56 It might be possible that the associated 
SNPs affect gene expression in a more specific tissue such as coronary or even carotid 
tissue. These tissues should be further investigated in order to disentangle the possible 
regulatory functions of rs10861032 and rs9804922 in the development of restenosis.
In conclusion, we have performed the first GWAS to look for genetic variants associ-
ated with the development of restenosis after PCI in the GENDER study followed by three 
independent replication steps and we have identified association for rs10861032 at the 
12q23.3 region. The SNPs, rs10861032 and rs9804922, are also associated with all-cause 
mortality in GENDER and in PROSPER and also with coronary events in PROSPER which 
indicates that this region might play an important role in the broader range of coronary 
events. Further research will be needed to disentangle the biological implication of this 
region in restenosis.
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abstract
objective: Mixed results have been reported of matrix metalloproteinases (MMP) and 
their association with restenosis after percutaneous coronary intervention (PCI). The 
current study examines whether multiple single nucleotide polymorphisms (SNPs), 
covering the full genomic region of MMP2 and MMP3, were associated with restenosis 
in the GENDER study population.
methods and results: The GENetic DEterminants of Restenosis (GENDER) study en-
rolled 3104 consecutive patients after successful PCI. The primary endpoint was clinical 
restenosis, defined as target vessel revascularization (TVR), occurring in 9.8% of the 
patients. From the Hapmap database, 19 polymorphisms of MMP2 and 11 of MMP3 were 
selected. Furthermore, in a subpopulation, a genome-wide association analysis (GWA) 
was performed. No significant association was found with any of the investigated SNPs, 
including the previously reported 5A/6A polymorphism (rs3025058), with regard to TVR 
using single SNP analysis or haplotype analysis.
conclusion: We found no significant association of MMP2 or MMP3 with TVR with this 
SNP-broad gene approach. Although we did not test all the known polymorphisms of 
these genes, using tagging analyses we examined those SNPs covering all known haplo-
types of MMP2 and MMP3 to conclude that these genes do not correlate with a genetic 
risk of coronary restenosis after successful PCI.
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introDuction
Matrix metalloproteinases (MMPs) form a family of over 20 zinc-dependent enzymes 
with proteolytic activity against a variety of extracellular matrix components including 
collagen, proteoglycans and elastin. All MMPs have distinct although overlapping sub-
strate specificities.1 Increased expression and activity of MMPs have been identified in 
various pathological processes, such as general inflammation, tumor metastasis, respira-
tory diseases, myocardial injury, vascular aneurysms, and vascular remodeling.2 Vascular 
remodeling and inflammation are important features of restenosis after percutaneous 
coronary intervention (PCI) and several, mostly small, studies found associations of MMP 
plasma levels or genetic polymorphisms with restenosis.3-5
MMP2 (gelatinase A) is produced by vascular smooth muscle cells (VSMCs) to degrade 
basement membrane components and other matrix proteins during migration and 
proliferation of these cells. Different animal models for restenosis showed upregulation 
of MMP2 during intima formation.6,7 Furthermore, MMP2 plasma levels were found to be 
increased after PCI and associated with restenosis.4,8,9 Although genetic polymorphisms 
in the MMP2 gene have been associated with myocardial infarction (MI)10,11 and heart 
failure12,13, there are no studies published describing their association with coronary 
restenosis.
MMP3 (stromelysin-1) cleaves a wide variety of matrix proteins and is considered 
to reduce the matrix content of the vascular wall. Higher MMP3 expression is associ-
ated with the development of atherosclerotic plaques with less matrix protein and as a 
result smaller and more prone to rupture plaques (i.e. lipid rich plaques). On the other 
hand, low MMP3 expression genotypes are predisposed to develop relatively larger 
and more stable plaques (i.e. fibrotic plaques).2 However, in a MMP3 knockout mouse 
model, Johnson et al. found that in absence of MMP3 the plaques where not only larger 
but that they also had a lower smooth muscle cell content, making them less stable.14 
Part of their explanation was that MMP3 has a broad substrate specific, including 
activation of other MMPs and that therefore many mechanisms could account for the 
effects of MMP3.14 Functional studies have shown that the MMP3 -1612 5A/6A promoter 
polymorphism (rs3025058) is associated with decreased MMP3 expression levels.15-17 In 
addition, several studies describe the association of this polymorphism with restenosis. 
For example, de Maat et al. found an association between the 6A6A MMP3 genotype 
and an increased risk of restenosis after balloon angioplasty.3 The same conclusion was 
made by Humphries et al.5; however other studies could not identify this association.18,19
MMPs have been extensively studied on their association with different cardiovas-
cular endpoints. The results with regard to restenosis have been mixed. To clarify these 
uncertainties we conducted this study in the large prospective GENetic DEterminants 
of Restenosis (GENDER) study population. With this study we systematically examined 
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whether multiple single nucleotide polymorphisms (SNPs), covering the full genomic 




The present study population has been described previously.20 In brief, the GENDER 
project was designed to study the association between various gene polymorphisms 
and clinical restenosis. All included patients were treated successfully for stable angina, 
non-ST-elevation acute coronary syndromes or silent ischemia by PCI in four out of the 
eight academic medical centers in the Netherlands. Patients treated for acute ST eleva-
tion myocardial infarction were excluded. Also excluded from analysis were patients suf-
fering from events occurring within one month after the procedure, since these events 
were mostly attributable to sub-acute stent thrombosis or occluding dissections, and 
not to restenosis. During the study, no drug-eluting stents were used. Follow-up lasted 
for at least nine months, except when a coronary event occurred. Clinical restenosis, 
defined as renewed symptoms requiring target vessel revascularization (TVR), either by 
repeated PCI or CABG, was designated to be the primary endpoint. The study protocol 
met the criteria of the Declaration of Helsinki and was approved by the Medical Ethics 
Committees of each participating institution. Written informed consent was obtained 
from all participating patients in advance of the PCI procedure. Blood was collected in 
EDTA tubes at baseline and genomic DNA was extracted following standard procedures.
candidate gene approach
SNPs of MMP2 and MMP3 were selected from the HapMap database (http://www.hap-
map.org). Using the data from the CEU population, tagging SNPs, with a minor allele 
frequency > 5%, were selected to cover each haplotype block within the genes (using 
Haploview program, version 4.121). Five SNPs in MMP2 were analyzed (rs243866, rs857403, 
rs243849, rs2287076 and rs10775332) and 2 SNPs in MMP3 (rs679620 and rs646910). 
Furthermore, the 5A6A promoter polymorphism of MMP3 (rs3025058) was added to the 
tagging SNPs. All SNPs were genotyped by matrix-assisted laser desorption/ionisation 
time-of-flight (MALDI-TOF) mass spectrometry (MS), using the Sequenom MassAR-
RAYtm methodology (Sequenom Inc, San Diego, CA, USA), following manufacturer’s 
instructions. As quality controls, 368 (11%) of the samples were genotyped in duplo. 
No inconsistencies were observed. All the blanks (5%) were negative. Cluster plots were 
made of the signals from the low and the high mass allele. Independent researchers 
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carried out scoring. Disagreements or vaguely positioned dots (< 1%) produced by Typer 
4.0 (Sequenom Inc.) were left out of the results.
Genome wide association study
A genome wide association study was performed in a selection of cases and controls 
from the GENDER study and has been described previously.22 In brief, cases and controls 
were selected from the total GENDER study population and matched by age, gender 
and other clinical factors such as diabetes and current smoking that have been previ-
ously associated to restenosis. A genome-wide association analysis was conducted 
using the Illumina Human 610-Quad Beadchips following manufacturer’s instructions. 
These beadchips contain 620,901 single nucleotide polymorphism (SNP) and copy 
number variants (CNV) probes, covering 89% of the common genetic variation in the 
European population at r2 > 0.8. After genotyping, samples and genetic markers were 
subjected to a stringent quality control protocol. Of the initially selected patients (321 
cases and 620 controls), 295 cases and 571 controls fulfilled all criteria. The SNPs cap-
tured in the MMP2 region between positions 54060397 and 54102050 on chromosome 
16 and the SNPs in the MMP3 region between positions 102206231 and 102225888 
on chromosome 11 were selected for further analyses (see Table 2 and Table 3 for rs 
numbers).
statistical analysis
Of the baseline characteristics the discrete variables are expressed as counts or percent-
ages and were compared with chi-square tests. Continuous variables are expressed as 
mean (± standard deviation) and were compared by means with unpaired 2-sided t-test. 
Associations of the genotypes of the individual SNPs with TVR were calculated assuming 
an additive model using a Cox proportional hazards model. We controlled for age, sex 
and ethnicity in the Cox-regression by including them as covariates. Furthermore, based 
on the baseline characteristics, we also corrected for diabetes, stenting, total occlusion 
and type C lesions in the analysis of the candidate approach SNPs. These additional cor-
rections were not necessary for the GWAS SNPs, since that subpopulation was matched 
for known risk factors as described above. Recessive and dominant models were also 
tested. After Bonferroni correction for multiple testing, we considered a statistically 
significant association (at p < 0.05) for any SNP with p-value < 0.0017.
The program Haploview was used to estimate allele frequencies, test the consistency 
of the genotype frequencies at each SNP locus with Hardy-Weinberg equilibrium, and 
estimate and plot pairwise linkage disequilibrium (LD) measurements between SNPs.
Haplotypes and haplotype frequencies were calculated using PHASE software 
(http://www.stat.washington.edu/stephens/).23-25 Haplotypes with a frequency of less 
than 5% were combined and included in all analyses, without reporting the results. The 
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haplotype analysis approach performed in this study assumes an additive effect of the 
haplotypes, and details of this approach have been described elsewhere.26 Haplotype 
analyses were performed using STATA for haplotypes with a frequency > 5%. Their ef-
fects were calculated using a Cox proportional hazards model including sex, age, and 
ethnicity and weighted for the probability of having the haplotype.
A p-value < 0.05 was considered statistically significant. Statistical analysis was car-
ried out using SPSS 17.0 for Windows.
resuLts
baseline characteristics
A total of 3,146 patients had a complete follow-up (99.3%) with a median duration of 9.6 
months (interquartile range 3.9). Out of 3,146 patients 42 had an event in the first 30 days. 
These patients were excluded from further analysis, according to the protocol. Baseline 
characteristics of the population are shown in Table 1. Of the 3,104 patients, 304 (9.8%) 
patients underwent TVR during follow-up. 51 patients died (1.6%) and 22 (0.7%) suffered 
from MI. In the total GENDER population use of lipid lowering medication was equal in 
both cases and controls. Diabetes, total occlusion and C-type lesion were significantly 
Figure 1 Linkage disequilibrium structure of 19 MMP2 SNPs on chromosome 16
Values shown in D’, * SNP from GWAS, + SNP from candidate approach
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more frequent in the cases (p-value = 0.001, 0.01 and 0.03 respectively), whereas the 
percentage of patients receiving a coronary stent was significantly higher in the control 
group (p-value = 0.001).
Genotypic analyses
The SNPs included in this study are listed in Table 2 and Table 3 for MMP2 and MMP3, 
respectively. The 19 polymorphisms of MMP2 and 11 polymorphisms of MMP3 provided 
coverage of all haplotype blocks (Figure 1 and Figure 2, respectively) and were all in 
Hardy-Weinberg equilibrium (p-value > 0.05). Associations with TVR as a marker of reste-
Table 1 Demographic, clinical and lesion characteristics of the total GENDER population composed of 
3,104 patients.
cases (n = 304) controls (n = 2,800) p-value
Age (years) 61.7 ± 10.1 62.2 ± 10.8 0.46
BMI (kg.m−2) 26.9 ± 3.7 27.0 ± 3.9 0.70
Male sex 220 (72.4%) 1996 (71.3%) 0.69
Caucasian ancestry 295 (97.0%) 2714 (96.9%) 0.92
Diabetes 63 (20.7%) 390 (13.9%) 0.001
Hypercholesterolemia 188 (61.8%) 1702 (60.8%) 0.72
Hypertension 138 (45.4%) 1121 (40.0%) 0.07
Current smoker 62 (20.4%) 700 (25.0%) 0.08
Family history of MI 121 (39.8%) 977 (34.9%) 0.09
Previous MI 109 (35.9%) 1130 (40.4%) 0.13
Previous PCI 64 (21.1%) 493 (17.6%) 0.14
Previous CABG 36 (11.8%) 340 (12.1%) 0.88
Stable angina 198 (65.1%) 1881 (67.2%) 0.47
Acute coronary syndrome 106 (34.9%) 974 (31.2%) 0.19
Multivessel disease 148 (48.7%) 1284 (45.9%) 0.35
Peripheral vessel disease 12 (3.9%) 92 (3.3%) 0.54
Lipid lowering medication 171 (56.3%) 1516 (54.1%) 0.48
Restenotic lesions 27 (8.9%) 181 (6.5%) 0.11
Total occlusions 56 (18.4%) 372 (13.3%) 0.01
Type C lesion 94 (30.9%) 708 (25.3%) 0.03
Proximal LAD 70 (23.0%) 619 (22.1%) 0.71
RCX 75 (24.7%) 764 (27.3%) 0.33
Stenting 207 (68.1%) 2145 (76.6%) 0.001
Number of stents 0.98 ± 0.05 1.01 ± 0.01 0.58
Values were given as n (%) or mean ± SD. BMI: body mass index, MI: myocardial infarction, LAD: left 
anterior descending branch of the left coronary artery, RCX: circumflex branch of the left coronary artery. 
p-value determined Pearsons Chi-Square (discrete variables) or unpaired 2-sided t-test (continuous 
variables).
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nosis were calculated assuming an additive model. No significant associations were ob-
served between any of the MMP2 and MMP3 polymorphisms, including the previously 
reported 5A/6A polymorphism (rs3025058), and TVR. Dominant and recessive models 
did not alter these effects (data not shown).
After analyzing the subpopulations of patients with (n = 2352) or without (n = 752) 
receiving coronary stents during PCI, similar results were obtained. None of the SNPs 
was associated with TVR in neither of the subpopulations.
Linkage disequilibrium structure is shown in Figure 1 and in Figure 2. MMP2 included 
4 haplotype blocks, whereas MMP3 had only 1. The haplotypes of the different blocks 
of MMP2 were calculated as shown in Table 4. The most frequent haplotype was used 
as reference. None of the haplotypes was significantly associated with the outcome 
parameter TVR. In line with the single SNP analysis, haplotype analysis of MMP3 also did 
not show any significant association with TVR (Table 5).
Figure 2 Linkage disequilibrium structure of 11 MMP3 SNPs on chromosome 11
Values shown in D’, * SNP from GWAS, + SNP from candidate approach
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Discussion
Polymorphisms of MMPs have been associated with different cardiovascular 
events.2,3,11,12,27,28 Studies of their association with restenosis after PCI are however scarce. 
Most of these studies look into the relation of the 5A6A promoter polymorphism of 
MMP3 and restenosis, however those results are mixed.3,5,18,19 The main finding of the 
present study is that after testing several polymorphisms in MMP2 and MMP3 using 
a candidate gene approach we did not find any significant association with coronary 
restenosis. Since in the meantime a GWAS was carried out in a subpopulation of the 
GENDER study22, we decided to include the genotyped polymorphisms in the genomic 
regions of both MMP2 and MMP3 in our analyses. None SNPs was associated with reste-
nosis. Combining both approaches strengthened our findings of the lack of association 
between the two MMP genes and coronary restenosis after successful PCI.










hr 95% ci p-value
rs893226 G T 0.40 GWAS -10496 1,00 (0.840 1,20) 0,97
rs1005913 A C 0.29 GWAS -8871 Promoter 0.99 (0.82 - 1.20) 0.95
rs1347653 G T 0.17 GWAS -8352 Promoter 0.92 (0.72 - 1.17) 0.42
rs16955194 G A 0.06 GWAS -8064 Promoter 1.38 (0.90 - 2.11) 0.14
rs243866 G A 0.24 Candid. -1855 Promoter 0.90 (0.74 - 1.09) 0.28
rs857403 A T 0.18 Candid. 3316 Intron 0.83 (0.67 - 1.04) 0.11
rs17301608 C T 0.39 GWAS 5219 Intron 1.09 (0.92 - 1.29) 0.32
rs1053605 C T 0.08 GWAS 6216 Coding exon 1.15 (0.84- 1.57) 0.40
rs9302671 G T 0.37 GWAS 8334 Intron 1.09 (0.92- 1.30) 0.32
rs243849 C T 0.17 Candid. 10313 Coding exon 0.82 (0.65- 1.04) 0.11
rs243842 T C 0.34 GWAS 14031 Intron 0.96 (0.80 1.15) 0.63
rs183112 G A 0.15 GWAS 14291 Intron 1.24 (0.97- 1.58) 0.09
rs1992116 C T 0.46 GWAS 14500 Intron 1.16 (0.98- 1.37) 0.09
rs243840 A G 0.20 GWAS 14768 Intron 0.83 (0.65 - 1.04) 0.10
rs2287076 T C 0.47 Candid. 19066 Intron 1.17 (0.99 - 1.38) 0.08
rs243834 A G 0.47 GWAS 23296 Intron 0.88 (0.74- 1.04) 0.14
rs10775332 C T 0.46 Candid. 23335 Coding exon 1.10 (0.93 - 1.30) 0.22
rs1861320 G T 0.47 GWAS 27649 Downstream 1.12 (0.94 - 1.33) 0.19
rs8054459 A G 0.44 GWAS 31158 Downstream 0.84 (0.71- 1.01) 0.06
SNP, single nucleotide polymorphism; MAF, minor allele frequency; Rel., relative; HR, hazard ratio; CI, 
confidence interval; candid., candidate approach; GWAS, genome wide association scan.
Cox regression analysis with additive model with correction for sex, age and ethnicity in the GWAS SNPs 
and also correction for diabetes, total occlusion, stenting and type C lesions in the candidate SNPs.
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Previously, Hojo et al. reported a significant association of increased serum level of 
MMP2 four hours after PCI and the occurrence of restenosis.4 Their study population 
was however very small and the patient characteristics of the 29 patients with follow-up 
were not well described. Recently, Katsaros et al. reported that in a population of 85 
patients with stable angina pectoris receiving DES, increased MMP2 serum activity was 










hr 95% ci p-value
rs645419 A G 0.48 GWAS -2045 Promoter 1.04 (0.87 - 1.25) 0.66
rs3025058 5A 6A 0.50 Candid. -1676 Promoter 1.09 (0.92 - 1.28) 0.33
rs522616 A G 0.21 GWAS -772 Promoter 1.03 (0.83 - 1.27) 0.80
rs679620 A G 0.50 Candid. 657 Coding exon 1.07 (0.90 - 1.26) 0.46
rs3025066 A G 0.06 GWAS 3794 Intron 1.09 (0.78 - 1.54) 0.61
rs566125 C T 0.15 GWAS 3806 Intron 0.89 (0.69 - 1.15) 0.38
rs646910 T A 0.13 Candid. 4755 Intron 1.06 (0.83 - 1.35) 0.67
rs595840 T C 0.48 GWAS 9380 Downstream 1.03 (0.86 - 1.24) 0.72
rs527832 C T 0.12 GWAS 12393 Downstream 0.94 (0.72 - 1.23) 0.67
rs1010698 A C 0.48 GWAS 13256 Downstream 1.03 (0.86 - 1.24) 0.72
rs1034375 A C 0.07 GWAS 18805 Downstream 1.23 (0.90 - 1.67) 0.19
SNP, single nucleotide polymorphism; MAF, minor allele frequency; Rel., relative; HR, hazard ratio; CI, 
confidence interval; candid., candidate approach; GWAS, genome wide association scan.
Cox regression analysis with additive model with correction for sex, age and ethnicity in the GWAS SNPs 
and also correction for diabetes, total occlusion, stenting and type C lesions in the candidate SNPs.
Table 4 Haplotype analysis of MMP2
haplotype frequency hr 95% ci p-value
Block 1 AG* 54.56%
CG 28.12% 1.00 (0.85 – 1.17) 0.99
AT 17.28% 0.91 (0.75 – 1.11) 0.37
Block 2 AA 57.67%
GA* 23.89% 0.87 (0.72 – 1.05) 0.15
AT 18.05% 0.82 (0.66 – 1.02) 0.08
Block 3 CTCTATAC 35.77%
CGCCACAT 35.42% 0.88 (0.73 – 1.06) 0.18
CGTTGCGT 15.43% 0.90 (0.72 – 1.12) 0.35
TGCTATAC 7.11% 1.08 (0.81 – 1.44) 0.61
Block 4 TTA 45.60%
CGG 44.40% 0.89 (0.76 – 1.05) 0.16
CGA* 9.47% 1.10 (0.86 – 1.42) 0.44
* wild type; HR, hazard ratio; CI, confidence interval.
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associated with dramatically increased restenosis rates.8 Although these results look 
promising for possible identification of patients prone to develop restenosis, larger 
studies are needed to replicate these results. In our, much larger patient population, we 
could not confirm their results with genotypic data.
The increased risk of restenosis with the 6A6A MMP3 genotype was described by de 
Maat et.al. and Humphries et.al. in patients after balloon angioplasty without stenting.3,5 
The latter study also analyzed a subpopulation of patients who received an intracoro-
nary stent and they could not identify an association with the 6A6A MMP3 genotype 
and restenosis. This difference probably indicates that different processes are involved 
in these two patient groups. However, since balloon angioplasty without stenting 
becomes more rare, the clinical relevance of this finding is decreasing. In the GENDER 
no significant association with TVR of any of the SNPs was detected in neither of the 
subpopulations. Also, the 5A6A polymorphism was also not related to restenosis, not in 
the total population nor in the one of the subgroups.
In the GENDER study all patients that were stented received one or more bare-metal 
stents (BMS). It could be argued that a possible role of investigated MMPs might be 
ascribed in restenosis in a patient group receiving drug-eluting stents (DES). This is how-
ever highly unlikely since DES are associated with a reduction in the development of 
restenosis, which would more likely diminish a possible genotype-dependent difference 
in neointima formation. Definite data on this topic is however lacking.
A limitation of our study is that the patients included in the GENDER study were 
mostly patients with a Caucasian ancestry (96.9%). Different results may be obtained in 
other ethnic groups. Furthermore, we did not test all known polymorphisms in the two 
genes of interest, but since SNPs were selected taking into account the LD measure-
ments, all haplotype blocks were covered. Moreover, no significant associations were 
obtained by means of haplotype analysis. We therefore think it is valid to conclude that 
no major effects are to be expected from these genes. Also, our findings are based on 
one single study. However, since the GENDER study is a large prospective follow-up 
study and taken in account that the previous reports are heterogeneous and in smaller 
patients groups, the power of these results is large enough to draw these conclusions.
In conclusion, with this study we provide evidence that, with regard to restenosis, a 
solid association with genetic variation of MMP2 and MMP3 is absent. Although we did 
not test all the known polymorphisms of the MMP2 and MMP3 genes, using tagging 
analyses we examined those SNPs covering all known haplotypes of MMP2 and MMP3 to 
conclude that genetic variation of these genes does not correlate with a genetic risk of 
coronary restenosis after successful PCI. As the search for genetic factors involved in the 
process of restenosis continues, we merely exclude genetic variation in two previously 
proposed candidate genes for involvement in the increased risk for restenosis, so future 
research may focus on other targets.
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abstract
background: Coronary restenosis after percutaneous coronary intervention still re-
mains a significant problem, despite all medical advances. Unraveling the mechanisms 
leading to restenosis development remains challenging. Many studies have identified 
genetic markers associated with restenosis, but consistent replication of the reported 
markers is scarce. The aim of the current study was to analyze the joined effect of previ-
ously in literature reported candidate genes for restenosis in the GENetic DEterminants 
of Restenosis (GENDER) databank.
methods and results: Candidate genes were selected using a MEDLINE search includ-
ing the terms ‘genetic polymorphism’ and ‘coronary restenosis’. The final set included 36 
genes. Subsequently, all single nucleotide polymorphisms (SNPs) in the genomic region 
of these genes were analyzed in GENDER using set-based analysis in PLINK. The GENDER 
databank contains genotypic data of 2,571,586 SNPs of 295 cases with restenosis and 
571 matched controls. The set, including all 36 literature reported genes, was indeed 
significantly associated with restenosis, p = 0.024 in the GENDER study. Subsequent 
analyses of the individual genes demonstrated that the observed association of the 
complete set was determined by 6 of the 36 genes.
conclusion: Despite overt inconsistencies in literature, with regard to individual candi-
date gene studies, this is the first study demonstrating that the joint effect of all these 
genes together, indeed is associated with restenosis.
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introDuction
Restenosis is a complex disease for which the causative mechanisms have not yet been 
fully identified. Despite medical advances, restenosis still remains a significant com-
plication after percutaneous coronary intervention (PCI).1 Identification of risk factors 
and underlying mechanisms could not only be useful in risk stratification of patients, 
they also contribute to our understanding of this condition. In addition, these factors 
could provide evidence on which to base individually tailored treatment and aid in the 
development of novel therapeutic modalities.2 Unraveling the mechanisms leading to 
restenosis development remains challenging. Genetic susceptibility is known to play a 
role in the individuals risk of developing this complication.1 Many studies have focused 
on identification of genetic markers associated with restenosis. Over the last decades 
genetic research has developed from candidate gene approaches3-5 to multiplex arrays6 
and finally to genome wide association studies (GWAS).7 Genetic variation in large array 
of plausible candidate genes have been associated with restenosis, however, consistent 
replication of the reported markers is scarce.1 Possible explanations for this lack of 
consistency are the small sample size of many (especially relative more dated) studies, 
phenotype heterogeneity and lack of proper replication cohorts.
Currently more and more GWAS are being performed, investigating many diseases, 
including cardiovascular diseases.8,9 An advantage of GWAS is the hypothesis-free ap-
proach of this method, enabling identification of new genetic loci associated with the 
disease of interest. With respect to restenosis, a disadvantage of the GWAS approach is 
that due to the complexity of the disease the effect size of individual genetic markers 
is likely to be small and therefore hard to detect. Moreover, the availability of (large) 
replication cohorts is very limited. In 2011, the first GWAS on restenosis in the GENetic 
DEterminants of Restenosis (GENDER) study identified a new susceptibility locus on 
chromosome 12.7 The fact that this GWAS only identified this previously unknown lo-
cus does not mean that genetic variation in the previously proposed candidate genes 
does not affect restenosis development. It merely indicates that the influence of other 
individual markers is probably too small to detect in the GWAS setting. Especially for the 
complex traits, a more appropriate approach to interpret GWAS data is to analyze the 
combined effect of a single nucleotide polymorphism (SNP) set, grouped per pathway 
or gene region.10 To date, investigation into a possible joined effect of multiple genetic 
markers for restenosis has not been performed.
The goal of the current study is to investigate whether the last decade of research 
on genetics of restenosis has led to a set of genes that is associated with restenosis in a 
set-based analysis using the available genotypic data of the GENDER databank.
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Gene selection
Candidate genes previously associated with restenosis were selected after a search of 
literature of papers published up to November 2011. Genes were identified searching 
MEDLINE using keywords as ‘genetic polymorphism’, ‘candidate gene’, ‘restenosis’ and 
‘percutaneous coronary intervention’. Selection criteria included a sample size of > 250 
patients and the observation of a significant association of a SNP with restenosis. The fi-
nal set included 36 genes (Table 2). All available SNPs from the GENDER GWAS databank 
within a 10-Kb window around these genes were analyzed.
study Population
The design of GENDER and the genome-wide association study (GWAS), which has been 
performed in a subset of this study population, have both been described previously.7,11 
In brief, GENDER included 3,104 consecutive unrelated symptomatic patients treated 
successfully by PCI for angina. The study protocol conforms to the Declaration of Helsinki 
and was approved by the ethics committees of each participating institution. Written 
informed consent was obtained from each participant before the PCI procedure. During 
a follow-up period of 9 months, the endpoint clinical restenosis, defined as renewed 
symptoms requiring target vessel revascularization (TVR) either by repeated PCI or 
CABG, by death from cardiac causes or myocardial infarction not attributable to another 
coronary event than the target vessel, was recorded. During follow-up, 346 patients de-
veloped clinical restenosis. Blood samples were collected at the index procedure for DNA 
isolation. The GWAS was performed in 325 cases of restenosis and 630 controls matched 
by gender, age, and some possible confounding clinical variables for restenosis in the 
GENDER study such as total occlusion, diabetes, current smoking and residual stenosis. 
Genotyping was performed using the Illumina Human 610-Quad Beadchips following 
the manufacturer’s instructions. After genotyping, samples and genetic markers were 
subjected to a stringent quality control protocol. The final dataset consisted of 866 indi-
viduals (295 cases, 571 controls) and 556,099 SNPs that passed all quality control criteria, 
together covering 89% of the common genetic variation in the European population.7,12 
Imputation was performed with MACH software based on the HapMap II release 22 CEU 
build 36 using the default settings.13 This program infers missing genotypes based on 
the known genotypic data of the samples together with haplotypes from a reference 
population provided by HapMap taken into account the degree of linkage disequilib-
rium (LD). After subsequent quality control, we excluded SNPs for further analyses with a 
call rate lower than 95% (n = 3335) or with a significant deviation from Hardy–Weinberg 
equilibrium (HWE) in controls (P < 0.00001) (n = 79). The final GENDER Biobank dataset 
consisted of 866 (295 cases, 571 controls) individuals and 2,571,586 SNPs.
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statistical analysis
The statistical analyses were performed using the set-based test of PLINK v1.07.14 During 
this test, first a single SNP analysis of all SNPs within the set is performed. Subsequently 
a mean SNP statistic is calculated from the single SNP statistics of a maximum amount of 
independent SNPs below a certain p-value threshold. If SNPs are not independent and 
the LD (expressed in R2) is above a certain threshold, the SNP with the lowest p-value 
in the single SNP analysis is selected. This analysis is repeated in a certain amount of 
permutations of the phenotype. An empirical p-value for the SNP set is computed by 
calculating the number of times the test statistic of the simulated SNP sets exceeds that 
of the original SNP set. For the analysis of this study, the parameters were set to p-value 
threshold < 0.05, R2 threshold < 0.1, maximum number of SNPs = 5 and 10,000 permuta-
tions.
Initially, the set including all 36 genes is tested as a whole for the association with 
restenosis. Subsequent analysis of the individual genes will be justified only when the 
complete set is significantly associated with the endpoint.
resuLts
Patient characteristics are presented in Table 1. No significant differences were found 
between cases and controls regarding the known risk factors for restenosis (age, diabe-
tes, smoking, stenting and previous restenosis). Hypertension and multivessel disease 
were more common in the cases compared to the controls.
In Figure 1 the QQ-plot of the GENDER GWAS after imputation is shown, demon-
strating that no genomic inflation has occurred in this analysis (lambda = 1.027). The 
complete set of 36 genes, previously associated with restenosis in literature, contained 
2,581 SNPs. A detailed description of the individual studies and candidate genes can be 
found in Table 2. The largest gene was chemokine (C-X3-C motif ) receptor 1 (CX3CR1) of 
316.54kb, contributing 384 SNPs (14.8%), and glutathione peroxidase 1 (GPX1) was with 
1.18kb the smallest gene, only contributing 8 SNPs (0.3%). Analysis of the complete set 
using the set-based test demonstrated a significant association with clinical restenosis, 
with an empirical p-value of 0.024.
To determine which genes are mainly responsible for this association we subse-
quently investigated the association of the individual gene based sets. Six of the 36 
genes were demonstrated to have an empirical p-value below 0.05 (Table 3). In order 
of descending p-values the associated genes are; angiotensin II receptor type 1 (AGTR, 
p = 0.028), glutathione peroxidase 1 (GPX1, p = 0.025), K(lysine) acetyltransferase 2B 
(KAT2B, also known as PCAF, p = 0.023), matrix metallopeptidase 12 (MMP12, p = 0.019), 
fibrinogen beta chain (FGB, p = 0.013) and vitamin D receptor (VDR, p = 0.012). Detailed 
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Table 1, Demographic, clinical and lesion characteristics of the study population.
cases (n = 295) controls (n = 571) p-value
Age (years) 62.8 ± 10.6 62.4 ± 10.9 0.59
BMI (kg.m−2) 26.7 ± 3.6 27.1 ± 3.7 0.20
Male sex 213 (72) 421 (74) 0.63
Diabetes 58 (20) 119 (21) 0.68
Hypercholesterolemia 179 (61) 341 (60) 0.79
Hypertension 138 (47) 211 (37) 0.005
Current smoker 68 (23) 148 (26) 0.36
Family history of MI 117 (40) 210 (37) 0.41
Previous MI 119 (40) 246 (43) 0.44
Stable angina 188 (64) 400 (68) 0.06
Multivessel disease 155 (53) 248 (43) 0.01
Restenotic lesion 23 (8) 48 (8) 0.76
Total occlusion 57 (19) 97 (17) 0.40
Type C lesion 95 (38) 154 (27) 0.11
Stenting 199 (68) 385 (67) 0.99
Values were given as n (%) or mean ± SD. Patients using anti-diabetic medication or insulin at study 
entry were considered to be diabetics. Hypertension was defined as a blood pressure of either above 
160 mmHg systolic or 90 mmHg diastolic. Hypercholesterolaemia was defined as total cholesterol 
concentrations of above 5 mmol/L. BMI: body mass index, MI: myocardial infarction. P-values are 
determined by Pearsons Chi-Square (discrete variables) or unpaired 2-sided t-test (continuous variables)
Table 2 Candidate genes and the studies that reported their association with restenosis.




















177 6p21.3 267 UK 6-9 rs1800624 ↓ [15]
297 25.9 6 rs2070600 NS [16]
angiotensin II receptor, 
type 1 (AGTR1)
184 3q24 272 29.8 6 rs5186 NS [17]





590 3q26.1-q26.2 461 23.2 6 rs1803274 OR 5.5
(1.6-21.4)
[19]
chemokine (C-C motif ) 
ligand 11 (CCL11)
6356 17q21.1-q21.2 3104 9.8 9 rs4795895 HR 0.73
(0.58-0.93)
[6]
CD14 929 5q31.1 129 24 6 rs2569190 RR 3.8
(1.2-11.6)
[20]
3104 9.8 9 rs2569190 HR 0.74
(0.55-0.99)
[6]
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Table 2 Candidate genes and the studies that reported their association with restenosis. (continued)













inhibitor 1B (p27, Kip1) 
(CDKN1B)
1027 12p13.1-p12 433 11.3 12 rs34330 NS [21]
2309 8.8 9 rs36448499 HR 0.61
(0.40-0.93)
[22]
collagen, type III, alpha 1 
(Col3A1)
1281 2q31 527 9.1 6 rs1800255 OR 4.2
(1.4-11.2)
[23]
colony stimulating factor 
2 (CSF2)




tif ) receptor 1 (CX3CR1)
1524 3p21.3 365 25.5 6 rs3732379 OR 2.4
(1.3-4.2)
[24]
cytochrome b-245, alpha 
polypeptide (CYBA)
1535 16q24 730 35.8 6 rs4673 OR 0.5
(0.3-0.8)
[25]
cytochrome P450, family 
2, subfamily C, polypep-
tide 19 (CYP2C19)
1557 10q24 928 19.1 12 rs12248560 ↓ [26]
fibrinogen beta chain 
(FGB)
2244 4q28 527 9.1 6 rs1800790 OR 2.7
(1.2-6.2)
[23]
2257 8.8 9 rs1800790 NS [27]





2876 3p21.3 461 23.2 6 rs1050450 OR 2.1
(1.2-3.8)
[19]
interleukin 10 (IL10) 3586 1q31-q32 162 39.5 UK rs1800871 HR 0.39
(0.16-0.94)
[29]
1850 17.6 12 NS [30]
3104 9.8 9 rs3024498 HR 2.0
(1.4-2.8)
[31]
interleukin 1 receptor 
antagonist (IL1RN)




779 43.9 6 VNTR NS [33]
1850 20.3 12 rs419598 OR 0.73
(0.58-0.92)
[3]
insulin receptor (INSR) 3643 19p13.3-p13.2 461 23.2 6 7,067,365C>A OR 1.9
(1.2-3.1)
[19]
integrin, beta 2 (ITGB2) 3689 21q22.3 1207 21.2 12 rs235326 OR 0.71
(0.55-0.92)
[4]










4318 20q11.2-q13.1 461 23.2 6 rs2664538 OR 2.0
(1.0-3.9)
[19]
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Table 2 Candidate genes and the studies that reported their association with restenosis. (continued)













late reductase (NAD(P)H) 
(MTHFR)
4524 1p36.3 260 36.9 6 rs1801133 OR 3.58
(1.51-8.46)
[35]
800 18.9 12 rs1801133 NS [36]
nitric oxide synthase 3 
(NOS3)
4846 7q36 205 29.3 6 rs2070744 OR 2.06
(1.08-3.94)
[37]
901 10.2 9 rs1799983 HR 1.67
(1.09–2.54)
[38]
1556 20.8 12 rs1799983 NS [39]
purinergic receptor P2Y, 
G-protein coupled, 12 
(P2RY12)






tor, clade E, member 1 
(SERPINE1)
5054 7q21.3-q22 1850 20.3 12 rs1799899 NS [41]




ase 2B (KAT2B, PCAF)






5468 3p25 565 28.7 6 rs3856806 ↓ [43]
935 18.3 12 rs3856806 NS [44]
c-ros oncogene 1 , recep-
tor tyrosine kinase (ROS1)
6098 6q22 461 23.2 6 rs529038 HR 1.8
(1.1-2.8)
[19]





7060 5q13 628 UK 6-10 rs1866389 OR 2.67
(1.04-6.80)
[45]
thrombopoietin (THPO) 7066 3q27 527 9.1 6 rs6141 OR 2.4
(1.1-5.3)
[23]
tumor necrosis factor 
(TNF)
7124 6p21.3 1850 17.6 12 rs1800629 NS [30]
3104 9.8 9 rs361525 HR 0.60
(0.37-0.98)
[5]
tumor protein p53 (TP53) 7157 17p13.1 132 0 UK rs1042522 ↑ [46]
433 11.3 12 rs1042522 NS [21]





uncoupling protein 3 
(UCP3)
7352 11q13.4 527 9.1 6 rs1800849 OR 5.2
(1.9-13.0)
[23]






aThe direction of the association between genetic variation and the risk of restenosis, when effect size 
is not available; ↓ protective effect, ↑ deleterious effect. Entrez nr; unique gene ID number used in NCBI 
database. Abbreviations: FU, follow-up; UK, unknown; NS, not significant; OR, odds ratio; HR, hazard ratio; 
RR, relative risk; Ref, reference.
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6information on the individual SNPs in these genes is depicted in Table 4. The SNP with the lowest individual p-value was rs11574027 in the VDR gene, p = 1.4 × 10−4. In the complete GWAS analysis, which has been published in 2011,7 this SNP ranked 116th. The 
strongest association in that analysis was found with a SNP in an intergenic region on 
chromosome 12, p = 1.0 × 10−6.
Logistic regression models with and without the 11 SNPs described in Table 4 dem-
onstrated that together these SNPs explained 9.0% (R Square improved from 0.008 to 
0.098) of the occurrence of clinical restenosis in this cohort.
As a final analysis we removed the 6 significantly associated genes from the com-
plete set. Subsequent analysis of the subset of the other 30 genes did not demonstrate 
a remaining joined effect, p = 0.65 after 10,000 permutations.
Discussion
With this study we aimed at clarifying the ambiguities regarding genetic predisposi-
tion for developing restenosis after PCI. We show that the joined effect of the complete 
spectrum of candidate genes, so far proposed to be involved in the restenotic process, 
results in a significant association with restenosis. This association is determined by six 
individual genes. Analyzing a subset containing the 30 genes not associated with the 
endpoint on an individual basis, did not show a remaining joined effect, making the in-
volvement of genetic variation in these genes on restenosis development more unlikely.
The six associated genes span a wide range of different functions underlining the 
complexity of the disease. When examining the biological pathways with involvement 
Figure 1 Q-Q plot for the GWAS after imputation on clinical restenosis in the GENDER study population.
Lambda = 1.027
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Table 3 Results of individual gene set-based analysis of genes previously associated with restenosis.
Gene Chr Start (bp) End (bp) Size (kb) SNPs Sign. SNPs Indep. SNPs P-value
ADRB2 5 148 186 349 148 188 381 2.03 32 8 2 0.088
AGER 6 32 256 724 32 260 001 3.28 37 1 1 0.228
AGTR1 3 149 898 348 149 943 480 45.13 100 5 1 0.028
BCHE 3 166 973 387 167 037 944 64.56 101 8 2 0.314
CCL11 17 29 636 800 29 639 312 2.51 18 0 0 1.000
CD14 5 139 991 501 139 993 439 1.94 22 4 2 1.000
CDKN1B 12 12 761 576 12 766 569 4.99 13 0 0 1.000
Col3A1 2 189 547 344 189 585 717 38.37 97 2 2 0.649
CSF2 5 131 437 384 131 439 757 2.37 28 0 0 0.965
CX3CR1 3 39 279 990 39 596 531 316.54 384 3 1 0.358
CYBA 16 87 237 199 87 244 958 7.76 14 1 1 0.182
CYP2C19 10 96 512 453 96 602 660 90.21 43 1 1 1.000
FGB 4 155 703 596 155 711 686 8.09 25 2 1 0.013
F5 1 167 747 816 167 822 393 74.58 200 1 1 1.000
GPX1 3 49 369 615 49 370 795 1.18 8 1 1 0.024
IL10 1 205 007 571 205 012 462 4.89 30 5 1 0.053
IL1RN 2 113 601 609 113 608 063 6.45 62 0 0 0.991
INSR 19 7 063 266 7 245 011 181.75 172 20 5 0.263
ITGB2 21 45 130 299 45 165 303 35.00 57 6 4 0.663
LPL 8 19 841 058 19 869 049 27.99 75 14 5 1.000
MMP12 11 102 238 675 102 250 922 12.25 36 3 3 0.019
MMP9 20 44 070 954 44 078 606 7.65 23 10 3 0.067
MTHFR 1 11 768 374 11 788 702 20.33 61 1 1 1.000
NOS3 7 150 319 080 150 342 608 23.53 20 0 0 0.987
P2RY12 3 152 538 066 152 585 234 47.17 121 0 0 1.000
SERPINE1 7 100 556 303 100 558 421 2.12 27 0 0 0.863
KAT2B 3 20 056 528 20 170 898 114.37 144 19 4 0.023
PPARG 3 12 304 349 12 450 854 146.51 144 14 5 1.000
ROS1 6 117 716 223 117 853 711 137.49 206 1 1 0.631
THBD 20 22 974 271 22 978 301 4.03 22 0 0 1.000
THBS4 5 79 366 747 79 414 861 48.11 61 3 2 0.292
THPO 3 185 572 467 185 578 626 6.16 16 1 1 0.165
TNF 6 31 651 329 31 654 089 2.76 41 2 2 0.370
TP53 17 7 512 445 7 531 642 19.20 17 1 1 0.120
UCP3 11 73 388 958 73 397 778 8.82 34 1 1 0.183
VDR 12 46 521 589 46 585 081 63.49 93 2 2 0.012
Chromosome and genomic region based on HapMap Rel 28 Phase II+III. P-value based on permutation 
(10,000). Abbreviations: SNPs, number of SNPs in genomic region including 10kb window; Sign.SNPs, 
number of SNPs with p < 0.05; Indep.SNPs, number of significant and independent SNPs, considering 
threshold of R2 < 0.1.
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of these genes, only the VDR and KAT2B genes share a common pathway. The genes are 
both involved in the Vitamin D receptor pathway described by BioCarta.15 This pathway 
mainly involves the transcriptional regulating capacities of this receptor and is involved 
in controlling cellular growth, differentiation and apoptosis. Since these processes are all 
thought to be important contributors to the restenotic process, this indeed is a plausible 
pathway to be involved in restenosis development.1
The rationale of set-based analysis is to overcome the marginally weak effect of 
single SNPs by analyzing a set of SNPs, since these SNPs could jointly have strong ge-
netic effects. Most studies utilizing the candidate gene approach analyzed only one or 
at most a few SNPs within the gene of interest. The likelihood that exactly those SNPs are 
the causal or associated SNPs is of course small. A broader approach, like this set-based 
analysis, is therefore more likely to detect an associated gene by combining multiple 
SNPs with a possible marginal individual effect.16,17 For the current study we used the 
PLINK software14, although multiple statistical programs are available for this type of 
analysis. Gui et al. compared 7 tests analyzing the WTCCC Crohn’s Disease dataset.18 One 
of their overall conclusions was that the set-based test in PLINK was the most powerful 
algorithm. Another study, applying PLINK set-based test, Global test, GRASS and SNP ra-
tio test, for the analysis of three pathways regarding human longevity observed similar 
results with the different tests.19
Table 4 Significantly associated SNPs of the 6 top genes.
Gene SNP Chr bp Function Alleles MAF OR p-value Origin Imputation 
qualitycase control
AGTR1 rs5182 3 149942085 Exon, syn-
onymous
T/C 0.43 0.50 0.75 0.0040 Geno-
typed
-
FGB rs1044291 4 155712802 3’UTR T/C 0.38 0.30 1.40 0.0028 Imputed 0.970
GPX1 rs8179164 3 49372288 Promoter A/T 0.02 0.04 0.42 0.0077 Imputed 0.993
MMP12 rs12808148 11 102238373 Downstream C/T 0.16 0.09 1.82 0.00021 Imputed 0.953
rs17099726 11 102257062 Promoter G/T 0.03 0.06 0.54 0.032 Imputed 0.957
KAT2B rs6776870 3 20126544 Intron G/C 0.14 0.21 0.62 0.00064 Imputed 0.999
rs2929404 3 20069570 Intron T/C 0.21 0.15 1.49 0.0026 Imputed 0.981
rs17796904 3 20096353 Intron T/C 0.16 0.12 1.43 0.012 Geno-
typed
-
rs4858767 3 20141941 Intron G/C 0.29 0.34 0.79 0.037 Imputed 0.994
VDR rs11574027 12 46573640 Intron T/G 0.03 0.007 4.19 0.00014 Geno-
typed
-
rs11574077 12 46539194 Intron G/A 0.07 0.04 1.60 0.029 Geno-
typed
-
SNP, single nucleotide polymorphism; Chr, chromosome; bp, base pair; MAF, minor allele frequency in 
control group; OR, odds ratio. The imputation quality indicates the average posterior probability for the 
most likely genotype generated by MACH, ranging from 0-1.
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For the current study we analyzed the data using a threshold of linkage disequilib-
rium defined by R2 ≥ 0.1. The standard setting in PLINK is a R2 of 0.5. In our opinion this 
threshold is too high for the intended analysis for this study. A higher threshold will 
include more SNPs in higher LD, which would be unfavorable, since we were interested 
in independent loci contributing to the risk of restenosis. By decreasing this threshold, 
only SNPs were selected that had a R2 below 0.1, and thus independent of each other.
Although hypertension and multivessel disease were more frequent in cases com-
pared to controls we decided not to correct for these variables. In the complete GENDER 
population these variables were not independent predictors for restenosis develop-
ment11, so the differences in the current subpopulation likely resulted by chance during 
the selection process. Also, other studies provide no convincing data that hypertension 
is related to restenosis.1 It is therefore unlikely that previous associations of some of 
the current candidates genes (VDR, FGB, AGTR1 and GPX1) with hypertension20-23, have 
influenced our results, although this cannot be completely excluded.
A limitation of the current study could be that we analyzed imputed genotypic data, 
which introduces some amount of uncertainty. However, since we were interested in 
the combined effect of SNPs, an extensive genomic coverage was paramount for this 
analysis. Only analyzing the genotyped GWAS data would have resulted in the coverage 
of some of the smaller genes by only 1 or 2 SNPs. Therefore we decided that the more 
extensive genomic coverage of the imputed dataset outweighed the small introduction 
of possible error. A second limitation is that the analyses were only performed in the 
GENDER population. Availability of other populations with thorough genetic data on 
restenosis is however very limited. To our knowledge, the GWAS on restenosis in the 
GENDER population is the first, and only, examining this endpoint on a genome wide 
scale. Finally, the conclusions of this study are only based on genetic analyses. Functional 
studies should be performed to elucidate the biological consequences of these findings.
In conclusion, with these results we demonstrate that the efforts in unraveling the 
genetic factors influencing the risk of restenosis of the last years has resulted in a set of 
genes that joint together is indeed likely to be associated with restenosis, despite the 
overt inconsistencies of the individual studies. Confirmation of the association of these 
genes with the occurrence of restenosis after PCI helps our understanding of the genetic 
etiology of the disease. Future additional research strategies, like biological pathway 
analysis of GWAS data or even (exome) sequencing, might help us find the missing heri-
tability of restenosis after PCI and increase our knowledge of the biological mechanistic 
background of restenosis development. This knowledge could subsequently result in 
identification of new treatment targets or development of novel preventive measure or 
risk stratification models.
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abstract
background: Coronary restenosis after percutaneous coronary intervention (PCI) still 
remains a significant limitation of the procedure. The causative mechanisms of reste-
nosis have not yet been fully identified. The goal of the current study was to perform 
gene-set analysis of biological pathways related to inflammation, proliferation, vascular 
function and transcriptional regulation on coronary restenosis to identify novel genes 
and pathways related to this condition.
methods: The GENetic DEterminants of Restenosis (GENDER) databank contains ge-
notypic data of 556,009 SNPs of 295 cases with restenosis and 571 matched controls. 
Fifty-four pathways, related to known restenosis-related processes, were selected. 
Gene-set analysis was performed using PLINK, GRASS and ALIGATOR software. Pathways 
with a p<0.01 were fine-mapped and significantly associated SNPs were analyzed in an 
independent replication cohort.
results: Six pathways (cell-extracellular matrix (ECM) interactions pathway, IL2 signal-
ing pathway, IL6 signaling pathway, platelet derived growth factor pathway, vitamin D 
receptor pathway and the mitochondria pathway) were significantly associated in one 
or two of the software packages. Two SNPs in the cell-ECM interactions pathway were 
replicated in an independent restenosis cohort. No replication was obtained for the 
other pathways.
conclusion: With these results we demonstrate a potential role of the cell-ECM interac-
tions pathway in the development of coronary restenosis. These findings contribute to 
the increasing knowledge of the genetic etiology of restenosis formation and could 
serve as a hypothesis-generating effort for further functional studies.
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introDuction
Although interventional cardiology has advanced tremendously in recent years, reste-
nosis after percutaneous coronary intervention (PCI) still remains a significant limitation 
of the procedure.1 Restenosis is a complex disease for which the causative mechanisms 
have not yet been fully identified. Genetic susceptibility is known to play a role in the 
development of this complication.1 Many studies have focused to identify these genetic 
markers associated with restenosis. Candidate gene approaches investigating restenosis 
have resulted in identification of genetic variation in genes involved in the inflammatory 
response2,3 and genes related to vascular remodeling4,5 and proliferation6. In 2012, our 
group analyzed the joint effect of the genetic variation of 36 previously described candi-
date genes of restenosis, demonstrating that the joint effect of all the single nucleotide 
polymorphisms (SNPs) in these genes together was indeed significantly associated with 
restenosis development.7 This association was mainly driven by SNPs in 6 individual 
genes, together spanning a wide range of different functions.
The first genome-wide association study (GWAS) on restenosis only identified one 
intergenic region on chromosome 12.8 Although this finding, after further functional 
confirmation, potentially helps our understanding of the molecular background of 
restenosis, it also complicates things since none of the previously described markers 
were identified at a GWAS significant level. The main explanation for this is likely the 
multifactorial nature of the disease and thus the small individual effect size of the SNPs. 
It has been described that instead of examining individual SNPs, analyzing the joint ef-
fect of multiple SNPs is a better method to find genetic variation in complex diseases.9-11 
Incorporating biological knowledge of the interplay of several genes within functional 
pathways may improve the power to detect associated genes not previously identified 
for their involvement. Thus far, the reported genetic variants only explain a small part 
of the expected genetic component of restenosis development.7 This so-called “miss-
ing heritability” is not uncommon in complex diseases, and pathway approaches are 
expected to fill at least part of this gap.12,13 During the last years, several studies have 
been reported that successfully applied this approach, for instance, identifying bio-
logical pathways related to human longevity14, pancreatic cancer15, crohn’s disease16 and 
psychiatric disorders.17,18
The goal of the current study was to examine the joint effect of genetic variation 
in biological pathways related to inflammation, proliferation, vascular function and 
transcriptional regulation on coronary restenosis in the GENetic DEterminants of Reste-
nosis (GENDER) study population to identify novel genes and pathways related to this 
condition.
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methoDs
GenDer study population
The main results of the GENDER study19 and the design and results of the genome-wide 
association study (GWAS)8,20, have been described previously. In brief, GENDER included 
3,104 consecutive unrelated symptomatic patients treated successfully by PCI for an-
gina. During a follow-up period of 9 months, the endpoint clinical restenosis, defined as 
renewed symptoms requiring target vessel revascularization (TVR) either by repeated 
PCI or CABG, by death from cardiac causes or myocardial infarction not attributable to 
another coronary event than the target vessel, was recorded. During follow-up, 346 pa-
tients developed clinical restenosis. Blood samples were collected at the index procedure 
for DNA isolation. The study protocol conforms to the Declaration of Helsinki and was 
approved by the ethics committees of each participating institution (the ethics commit-
tee of the Leiden University Medical Center, the ethics committee of the Academic Medi-
cal Center Amsterdam, the ethics committee of the University Medical Center Groningen 
and the ethics committee of the Maastricht University Medical Center). Written informed 
consent was obtained from each participant before the PCI procedure.
 The GWAS was performed in a subpopulation of GENDER of 325 cases of restenosis 
and 630 controls matched by gender, age, and several other known risk factors for reste-
nosis like total occlusion, diabetes, current smoking and residual stenosis. Genotyping 
was performed using the Illumina Human 610-Quad Beadchips following the manu-
facturer’s instructions. After genotyping, samples and genetic markers were subjected 
to a stringent quality control protocol.20 The population substructure was analyzed by 
means of multidimensional scaling. The vast majority of the individuals fell in the same 
cluster along with the European population but 67 individuals were outside this cluster 
and were considered as genetic outliers and therefore excluded from further analyses. 
The final dataset consisted of 866 individuals (295 cases, 571 controls) and 556,099 SNPs 
that passed all quality control criteria, together covering 89% of the common genetic 
variation in the European population.20
Pathway selection
Pathways related to known restenosis-related processes (inflammation, vascular func-
tion, proliferation and transcription) were selected from the MSigDB database21, which 
included curated gene sets from KEGG22, BioCarta23 and Reactome24,25. A total of 54 
pathways were selected (Supplementary Table S1).
replication cohort
The replication cohort consisted of a German restenosis cohort, i.e. patients presenting 
with ischemic symptoms or evidence of myocardial ischemia in the presence of ≥ 50% de 
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novo stenosis located in native coronary vessels. All patients were treated with PCI and 
stent implantation at Deutsches Herzzentrum München or 1. Medizinische Klinik rechts 
der Isar der Technischen Universität München. The study protocol conformed to the Decla-
ration of Helsinki and was approved by the institutional ethics committee responsible for 
both participating centers, Deutsches Herzzentrum München and 1. Medizinische Klinik, 
Klinikum rechts der Isar, Technische Universität München. All subjects gave their written, 
informed consent for participation in the study. The main characteristics of this cohort 
and the protocols of stent placement and post-stenting therapy have been described 
previously26,27. Briefly, this population included 1537 patients treated with implantation 
of bare-metal stents (BMS) and 1920 patients treated with implantation of drug-eluting 
stents (DES). Target lesion revascularization (TLR) within 1 year after PCI was considered as 
the primary endpoint. Re-hospitalization for repeat angiography was scheduled between 
6 and 8 months or earlier if non-invasive evaluation or clinical presentation suggested the 
presence of ischemia. For the current study we only analyzed the patients receiving BMS, 
since this was the only type of stent implanted during the GENDER study.
The samples during the replication stage were genotyped by means of iPLEX assays28. 
The SNPs were selected for replication after step-down fine-mapping of the significant 
associated pathways. Finally only SNPs within these pathways showing a p-value <0.10 
and linkage disequilibrium (LD) <0.5 in the GENDER study were selected. Two assays were 
designed using MassArray design software (Sequenom, San Diego, CA). Genotyping was 
performed using iPLEX assays with use of the MassARRAY methodology (Sequenom), 
with alleles discriminated by mass spectrometry, following manufacturer’s instructions. 
One SNP, rs5764560, did not fit the assay. All the genotyped SNPs had a call rate >95%. 
One SNP, rs7292425, was out of Hardy Weinberg equilibrium (p-value<0.001), and was 
excluded for further analysis. Duplicate samples (~2.5%) showed identical genotypes. 
Finally, 39 SNPs passed all quality criteria and were further analyzed.
statistical analysis
Analyses were performed using PLINK29,GRASS30 and ALIGATOR31 software. We will 
briefly describe all three methods. During the set-based test of PLINK the joint effect of 
all genetic variation, fulfilling the test constraints, within the set of genes of pathway of 
interest is evaluated. First a single SNP analysis of all SNPs within the pathway set is per-
formed. Subsequently, a mean SNP statistic is calculated from the single SNP statistics 
of a maximum amount of independent SNPs with a p-value < 0.2. SNPs are considered 
independent when the LD expressed in R2 is < 0.5. Of the SNPs that are in LD with R2 > 
0.5, the SNP with the lowest p-value in the single SNP analysis is selected. This analysis 
is repeated 10,000 times in simulated datasets with permutation of the phenotype. An 
empirical p-value for the SNP set is computed by calculating the number of times the 
test statistic of the simulated SNP sets exceeds that of the original SNP set.
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GRASS calculates “eigenSNPs” for each gene in the pathway set by summarizing the 
variation of a gene using principal component analysis. Subsequently, one or more 
of these “eigenSNPs” per gene are selected using regularized logistic regression to 
calculate a test statistic for each pathway set. This analysis is repeated 10,000 times in 
simulated datasets with permutation of the phenotype. The p-value per pathway SNP 
set is calculated by comparing the test statistic of the original pathway SNP set with that 
of the combined simulated pathway SNP sets.
ALIGATOR (Association LIst Go AnnoTatOR) analyses gene sets for genes enriched 
with significant SNPs. Enrichment is defined as a gene set containing a larger number 
of significant genes than expected by chance. Replicate gene lists of the same length 
as the original are generated by randomly sampling SNPs (thus correcting for variable 
gene size). The lists are used to obtain p-values for enrichment for each gene set (by 
comparing the number of significant genes observed on the actual gene list to that 
observed on each replicate list), to correct these for testing multiple non-independent 
categories, and to test whether the number of significantly enriched categories is higher 
than expected. ALIGATOR uses data from all the SNPs tested in a gene and corrects for 
the variable numbers of SNPs per gene. Each gene is counted once regardless of how 
many significant SNPs it contains, thus eliminating the influence of LD between SNPs 
within genes. We used p-value cutoff < 0.005 for SNPs, 5000 replicate gene lists and 1000 
permutations as parameters to run ALIGATOR. Pathways were included when 2 or more 
individual genes contained significantly associated SNPs.31,32
Considering the exploratory nature of the analysis and the considerate overlap 
between the pathways, associations of pathways with restenosis were considered worth-
while exploring with P<0.01. Since it has been suggested that PLINK, GRASS and ALIGATOR 
provide complementary information13,33, we proceeded with the secondary analysis when 
a pathway was associated with restenosis with p<0.01 in at least one of the analyses. The 
pathways meeting this criterion were explored in more detail by fine-mapping of firstly 
the genes within those pathways and secondly the individual SNPs. For these secondary 
analyses, as well as during the replications stage p<0.05 was considered significant. When 
applying a strict Bonferroni correction, correcting for the 54 tested pathways and three 
different tests, the threshold for statistical significance was set at p<0.0003 (=0.05/(54*3).
resuLts
The 295 patients with restenosis were well matched with the 571 patients without 
restenosis, for the known risk factors for restenosis, like age, diabetes, current smok-
ing, stenting of the culprit lesion and previous restenosis (Table 1). Hypertension and 
multivessel disease were more common in the cases compared to the controls.
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A total of 54 pathways were analyzed in the current study. Half of these pathways 
(n=27) were related to inflammation, 13 pathways were related to proliferation, six 
pathways were related to vascular function and finally, eight pathways were related 
to transcriptional regulation. The pathways associated with restenosis with a p-value 
below 0.01 in either PLINK, GRASS or ALIGATOR are shown in Table 2. An overview of 
the results of all the pathways can be found in Supplementary Table S1. When applying 
Bonferroni correction none of the pathways were significantly associated.
In the set-based analysis using PLINK, the IL6 signaling pathway described by Bio-
Carta was associated most significantly with clinical restenosis with a p-value of 0.0008. 
Using the GRASS software, this pathway had a p-value of 0.08 and the ALIGATOR analysis 
resulted in p=0.01. The strongest associated pathway using GRASS was the BioCarta 
mitochondria pathway with a p-value of 0.006. However, this pathway was not associ-
ated with restenosis using PLINK (p=0.80) or ALIGATOR. The insulin signaling pathway, 
described by BioCarta, was the strongest associated pathway using ALIGATOR (p=0.001). 
Using PLINK this pathway had a p-value of 0.02, whereas GRASS resulted in p=0.14. 
Other pathways that were associated in one of the analyses, considering the p<0.01 
cut-off, include the inflammatory IL2 signaling pathway (PLINK p=0.006, GRASS p=0.012 
Table 1, Baseline characteristics of the GENDER study population.
cases (n = 295) controls (n = 571) p-value
Age (years) 62.8 ± 10.6 62.4 ± 10.9 0.59
BMI (kg.m−2) 26.7 ± 3.6 27.1 ± 3.7 0.20
Male sex 213 (72) 421 (74) 0.63
Diabetes 58 (20) 119 (21) 0.68
Hypercholesterolemia 179 (61) 341 (60) 0.79
Hypertension 138 (47) 211 (37) 0.01
Current smoker 68 (23) 148 (26) 0.36
Family history of MI 117 (40) 210 (37) 0.41
Previous MI 119 (40) 246 (43) 0.44
Stable angina 188 (64) 400 (68) 0.06
Multivessel disease 155 (53) 248 (43) 0.01
Restenotic lesion 23 (8) 48 (8) 0.76
Total occlusion 57 (19) 97 (17) 0.40
Type C lesion 95 (38) 154 (27) 0.11
Stenting 199 (68) 385 (67) 0.99
Values were given as n (%) or mean ± SD. Diabetes was defined by treatment with anti-diabetic 
medication or insulin at study entry. Hypertension was defined as a blood pressure of either > 160 mmHg 
systolic or > 90 mmHg diastolic. Hypercholesterolaemia was defined as total cholesterol concentrations 
> 5 mmol/L.
BMI: body mass index, MI: myocardial infarction. P-values are determined by Pearsons Chi-Square (discrete 
variables) or unpaired 2-sided t-test (continuous variables)
134 Part I – Genetics of restenosis
and ALIGATOR p=0.08) and the IL4 signaling pathway (PLINK p=0.02, GRASS p=0.04 and 
ALIGATOR p=0.008), the proliferation platelet derived growth factor (PDGF) pathway 
(PLINK p=0.008, GRASS p=0.03 and ALIGATOR p=0.02) and a transcriptional regulatory 
pathway, the vitamin D receptor (VDR) pathway (PLINK p=0.008, GRASS p=0.07 and 
ALIGATOR p=0.003). Finally, the cell-extracellular (ECM) matrix interactions pathway, as 
described by Reactome, was demonstrated to be associated in PLINK (p=0.009), but not 
in GRASS (p=0.17) or ALIGATOR (p=0.14).
Subsequently, fine mapping analysis was performed of six pathways with a p-value 
<0.01 in one of the three analyses. The individual genes of each pathway were analyzed 
using set-based analysis of PLINK (Supplementary Table S2). Five of the 22 genes of the 
IL6 signaling pathway were significantly associated, as shown in Table 3. These genes 
were the RAF1 gene with a p-value of 0.001, the JAK2 gene with p=0.006, the STAT3 
gene with p=0.006, the IL6 gene with p=0.04, and the GRB2 gene with a p-value of 0.04 
(Table 3). The IL2 signaling pathway and the PDGF signaling pathway showed consider-
able overlap with the IL6 pathway. Thirteen of the 22 genes (59%) of the IL2 pathway and 
14 of the 32 genes (44%) of the PDGF pathway are also involved in the IL6 pathway. In 
addition to RAF1, JAK2 and GRB2, mentioned above, STAT5A, STAT5B and PIK3R1 were 
also significantly associated, p=0.04, p=0.01 and p=0.04 respectively. The association 
of the VDR pathway was driven by three genes, NCOR1 (p=0.003), VDR (p=0.01) and 
BAZ1B (p=0.02). The association of the cell-ECM interactions pathway was caused by 
two genes. The PARVB gene was associated with restenosis with a p-value of 0.001 and 
the LIMS2 gene with a p-value of 0.01. Finally, DIABLO was the only associated gene of 
the mitochondria pathway with a p-value of 0.03.
In Table 3 the results of the single SNP analysis of the significantly associated genes 
is reported showing which SNPs are responsible for the significant association of these 
genes. Of the in total 54 individual SNPs, 34 were associated with restenosis with a p-
Table 2 Pathways associated with restenosis with PLINK or GRASS
Pathway Database PLink Grass
inflammation
IL2 signaling pathway BioCarta 0.006 0.012
IL6 signaling pathway BioCarta < 0.001 0.08
Proliferation
Role of Mitochondria in Apoptotic Signaling BioCarta 0.80 0.006
PDGF Signaling Pathway BioCarta 0.008 0.03
Vascular function
Cell-extracellular matrix interactions Reactome 0.009 0.17
transcription
Control of Gene Expression by Vitamin D Receptor BioCarta 0.008 0.07
A complete overview of all pathways can be found in Supplementary Table S1.
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value below 0.05. The strongest associated SNP was located in the PARVB gene of the 
cell-ECM interactions pathway (rs139107, p<0.001)
Baseline characteristics of the replication cohort can be found in Supplementary 
Table S3. In the replication stage, two SNPs in the PARVB gene, which was part of the 
cell-ECM interactions pathway, were the only SNPs found to be significantly associ-
ated with restenosis (Table 3). The minor allele of rs5764455 was significantly more 
prevalent in the control group than in the cases, 42% and 36% respectively, p=0.007. 
In GENDER the minor allele frequency (MAF) of this SNP was 44% and 39% in controls 
and cases respectively, p=0.03. For rs5764066 the MAF was 22% in controls and 26% in 
cases, p=0.05, compared to 18% versus 22% in GENDER. In addition, two SNPs in the 
JAK1 gene, which was part of the IL6 pathway, the IL2 pathway and the PDGF pathway, 
showed a borderline significant association with target lesion revascularization in the 
replication cohort. No wet-lab experiments were performed to elucidate the function 
of the two PARVB SNPs, rs5764455 and rs5764066, but online databases were explored 
for available data. Both SNPs were located in introns and the UCSC genome browsers 
database (http://genome.ucsc.edu) did not indicate that they were located in a DNAse 
I hypersensitive site or in other important regulatory regions. Moreover, neither of two 
SNPs were reported in two publically available eQTL databases (VarySysDB34 and the 
eQTL database of the Pritchard lab35).
Discussion
We explored the joint effect of genetic variation in biological pathways on coronary 
restenosis development. When using a strict Bonferroni correction, none of the pathways 
reached the threshold of significance. However, we show a potential role for the cell-ECM 
interactions pathway as described by Reactome. This pathway, related to vascular remodel-
ing, was associated with coronary restenosis in the GENDER study, in particular the PARVB 
gene and several SNPs in this gene were replicated in an independent study cohort. The 
SNPs of the five other pathways, associated in the GENDER study, did not replicate.
ECM remodeling and vascular smooth muscle cell migration and proliferation are 
thought to be the key processes in restenosis development.1 Cell-ECM interactions, 
as described by the cell-ECM interactions pathway, play a critical role in regulating a 
variety of cellular processes in multicellular organisms including motility, shape change, 
survival, proliferation and differentiation. The PARVB (beta-parvin, also known as affixin, 
Gene ID: 29780) in particular, encodes a member of the parvin family of actin-binding 
proteins, which play a role in cytoskeleton organization and cell adhesion. Unlike other 
family members like alpha-parvin and gamma-parvin, beta-parvin has been shown 
to be expressed the highest in heart and skeletal muscle tissue.36 PARVB is known to 
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interact with integrin-linked kinase (ILK) and this complex is involved in the early stage 
of cell-substrate interaction through integrins.37 Moreover, it has been suggested that it 
is a crucial modulator of cell survival38 and that it has an important role in the angiogenic 
process39, making it a likely candidate for restenosis development.
Since the introduction of GWAS many new insights on a wide array of disease have 
been reported.40 However, extending these findings to biological mechanisms that 
explain disease development is a major ongoing challenge. The most likely explanation 
for this problem is that GWAS only focuses on single SNP associations. The reported loci 
often are located in intergenic regions or gene deserts and often are of unknown func-
tion. Furthermore, these loci have exhibited only modest effect sizes. Since biological 
pathways are the natural causative mechanisms resulting in disease and it is conceiv-
able that genes functioning within these pathways interact within biological networks, 
it is only logical that the next step in the post-GWAS era is the exploration of these 
pathways. The rationale of set-based analysis is to overcome the marginally weak effect 
of single SNPs by analyzing a set of SNPs, since these SNPs could jointly have strong 
genetic effects. Examination of genetic variation of complete biological pathways, like 
in this set-based analysis, is therefore more likely to detect an associated mechanism 
by combining multiple SNPs with a possible marginal individual effect.41,42 In this study, 
the SNP with the strongest association with restenosis in the GENDER population was 
located in the PARVB gene of the cell-ECM interactions pathway (rs139107, p<0.001). As 
a reference, none of the SNPs currently examined, were located in the top 100 strongest 
associated SNPs of the complete GWAS analysis.8
For the current study we performed the analyses with PLINK, GRASS and ALIGATOR 
software. To date, many different statistical programs have been described to perform 
this type of analysis with. All methods have advantages and disadvantages.9 In the case 
of PLINK and GRASS, both methods use the raw genotypes as input data. An advantage 
of this method is that they can take into account the LD structure within genes during 
their computations, which is not the case with methods performing their analyses using 
p-values as input data. Furthermore they both are self-contained tests that deal with 
the complexity of the SNP sets by permutation of the case-control status. However, dif-
ferences between PLINK and GRASS include that PLINK analyzes SNP sets as a whole, 
and does not take the SNP distribution over the genes within the pathway into account, 
whereas GRASS first calculates “eigenSNPs” for each gene in the pathway set by sum-
marizing the variation of a gene using principal component analysis. Compared to PLINK 
and GRASS, ALIGATOR is not a self-contained test but a competitive test, using SNP 
p-values instead of raw-genotypes, aiming to test whether genes in one pathway are 
enriched with a greater number of associated SNPs. Several comparative analyses have 
been performed, not resulting in a consensus of the best method, but rather suggesting 
to use two or more algorithms resulting in complementary findings.14,33
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For the current study we analyzed the data using a p-value threshold for including 
individual SNPs in the PLINK analyses of p<0.2 for their association with restenosis in the 
primary single SNP analysis. A standard setting in PLINK is often p<0.05, on relatively 
arbitrary grounds. Since we aimed at analyzing the combined effect of SNPs with small 
individual effect sizes we decided to increase this threshold to p<0.2. By increasing this 
threshold, more SNPs will be selected for further analyses ensuring that also the SNPs that 
were not associated with restenosis on their own, but that potentially did contribute to 
the overall effect of a pathway were taken into account. Before the start of this study we 
decided to apply a threshold of p<0.01 for the association of a pathway with restenosis, 
to identify pathways of interest. Although this threshold could be considered arbitrary, 
we decided that is was appropriate considering the considerate overlap between the 
pathways and the exploratory nature of this study. When using a strict Bonferroni cor-
rection for the 54 analyzed pathways and 3 applied tests (0.05/(54*3)=p<0.0003), none 
of the pathways would have qualified for further investigation. This could indicate that 
either the population is too small to detect the subtle genetic influence on this complex 
phenotype or that no solid genetic association is present. However, since to our knowl-
edge, other (larger) restenosis study populations with GWAS data do not exist, we are 
limited in exploring this hypothesis regarding the sample size issue. A more strict mul-
tiple testing correction than currently used increases the risk of false negative results. 
Future functional studies are needed to further elucidate the biological background of 
restenosis development. The first step of the functional analyses would likely be to see 
whether the SNPs affect expression or function of the gene they are located in. If this is 
not the case, they could influence on other (nearby) genes, which could for instance be 
explored by mRNA expression analyses or allelic expression imbalance.43 Furthermore, 
sequencing of the genes of interest could result in identifying functional variants in LD 
with the SNPs identified in the current study.
Limitations
Proper replication of these analyses requires other datasets with GWAS data. To our 
knowledge, the GWAS performed in the GENDER study population is the first and 
unfortunately is currently the only GWAS on coronary restenosis. The desired replica-
tion cohorts are therefore unavailable. Since we did want to analyze our findings in an 
independent study cohort we decided to genotype only the top SNPs of the associated 
pathways instead. Considering the minimal replication of the analyzed SNPs, the robust-
ness of the reported associations is limited. However, the presented data do provide 
evidence that ECM interactions and inflammation contribute to coronary restenosis 
development. And the results of the current study can serve as a hypothesis-generating 
effort for further functional studies.
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All patients in the GENDER study and in the replication cohort were either treated 
with balloon-angioplasty (33% in GENDER) or BMS implantation. It is unknown whether 
these findings are generalizable to patients treated with DES or endothelial-progenitor-
cell covered stents.
conclusion
In conclusion, although these results do not comply to the required strict multiple test-
ing correction, we do demonstrate a potential role of the cell-ECM interactions pathway 
in the development of coronary restenosis. After performing additional studies, these 
findings could contribute to the increasing knowledge of the genetic etiology of 
restenosis formation. Unraveling the mechanisms leading to restenosis development 
remains challenging. There is a need for larger study populations specifically designed 
for genetic association analyses. In the select population that will still develop coronary 
restenosis despite advances in therapy, it will remain an imported cause of morbidity 
and therefore further understanding of the condition will be essential if we want to 
achieve personalized treatment and eradicate this costly and clinically very relevant 
limitation of PCI.
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10-year mortality risk of patients 
undergoing elective PCI: Long-term 
follow-up of the GENetic Determinants 
of Restenosis (GENDER) study
No increased mortality risk by 
restenosis, only by coronary 
artery disease itself
Jeffrey J.W. Verschuren, Stella Trompet, René A. Tio, Rob J. de Winter, 
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abstract
background: Data on long-term follow-up of patients developing coronary restenosis 
after percutaneous coronary intervention (PCI) are scarce. To explore the relation of re-
stenosis with long-term mortality, we analysed the 10-year survival data of the GENetic 
DEterminants of Restenosis (GENDER) study population.
methods: GENDER was designed to study the genetic background of restenosis devel-
opment after successful PCI. This multicentre prospective follow-up study had clinical 
restenosis within nine months as its primary endpoint. After this follow-up period, 
patients returned to usual clinical care. In total 3104 patients were included between 
March 1999 and June 2001 of which 304 developed restenosis. Long-term mortality data 
were obtained from the Dutch Central Bureau of Statistics. As a control population, a 
random sample of 15,000 individuals, matched for age and gender, was extracted from 
the Dutch general population.
results: Of the patients with restenosis, 86 (28.6%) died, which was similar to the 770 
(27.7%) of the patients without restenosis, p = 0.28. Also no difference was observed 
for cardiovascular death (12.3% versus 11.4%, respectively, p = 0.64). When comparing 
the total GENDER population with the general population, a higher mortality rate was 
observed in the GENDER population, 27.8% versus 21.6%, P < 0.001.
conclusion: The current study demonstrates that, in the long-term, patients suffering 
from restenosis do not have an increased mortality risk. However, this study population 
does have an increased mortality risk compared with the general population, indicating 
that it seems that there is still room to improve current treatment strategies for cardio-
vascular disease.
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introDuction
Although the death rates from cardiovascular diseases (CVD) have declined over the 
last decades, the burden of disease remains high and CVD remains one of the leading 
causes of morbidity and mortality in Western developed countries1,2 including the 
Netherlands.3-6 Tremendous efforts worldwide are put into research and development of 
novel treatment modalities for CVD to further halt the disease burden, and frequent up-
dates of primary and secondary prevention guidelines should result in the most optimal 
treatment of each patient with CVD. Besides major improvements in pharmacological 
treatment with for instance statins, beta-blockers, angiotensin-converting-enzyme 
inhibitors and antiplatelet agents, interventional treatment modalities such as percu-
taneous coronary intervention (PCI) have markedly improved the outcome of patients 
with coronary artery disease.
An important complication of percutaneous coronary intervention (PCI) that is still 
present is coronary restenosis.7 Coronary restenosis - the renarrowing of the treated 
obstruction - results in high morbidity 8 and is even reported to be associated with an 
increased risk of mortality.9,10 Data on long-term follow-up of patients with restenosis 
are, however, scarce. To explore the relation of restenosis development with long-term 
mortality, we analysed the 10-year survival of the patients included in the GENetic DE-
terminants of Restenosis (GENDER) study.11 The second objective of this report was to 
investigate whether the treatment strategies after PCI, applied in daily clinical practice 
over the past 10 years, resulted in a shift in mortality rates and causes of death of these 
confirmed coronary artery disease (CAD) patients compared with the general population.
methoDs
The GENDER project was designed to study the genetic background of coronary reste-
nosis development after successful PCI. It is a multicentre prospective follow-up study 
with clinical restenosis within nine months as its primary endpoint. The first patient was 
included in March 1999 and inclusion lasted up to June 2001. In total 3104 consecutive 
patients were treated successfully by PCI for stable angina, non-ST-elevation acute coro-
nary syndromes or silent ischaemia in four referral centres for interventional cardiology 
in the Netherlands: Academic Medical Center in Amsterdam, University Medical Center 
Groningen, Leiden University Medical Center and University Hospital Maastricht. Only pa-
tients treated for acute ST-elevation myocardial infarction (MI) were excluded. The study 
was primarily supported by the Interuniversity Cardiology Institute of the Netherlands.
The study protocol conforms to the Declaration of Helsinki and was approved by 
the ethics committees of each participating institution. After having obtained written 
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informed consent, blood was sampled for DNA isolation and future analysis. Clinical 
and procedural data were gathered prospectively. Clinical restenosis was defined as the 
composite of death, myocardial infarction and target vessel revascularisation. An inde-
pendent endpoint committee evaluated all potential endpoints. During the in-study 
follow-up period, 346 of the patients developed clinical restenosis. After the follow-up 
period patients returned to usual guideline-based clinical care, either with the general 
practitioner or if deemed necessary with the cardiologist. Currently, approximately 10 
years after completion of the study, we have obtained long-term mortality data, in-
cluding specific causes of death, for the complete GENDER population from the Dutch 
Central Bureau of Statistics (CBS). Data were available up to 31 December 2011 and the 
primary cause of death was described by ICD-10 codes.
As a control population for the GENDER study we extracted a random sample of 
15,000 individuals, matched for age and gender, from the general population of individu-
als born in the Netherlands and living in the Netherlands in the timeframe 1995-2011. 
Individuals who died before March 1999 were excluded from further analyses (N = 644) 
(Fig. 1).




















Baseline characteristics of the GENDER study population are shown in Table 1. Twenty 
patients (0.6%) of the total GENDER population could not be identified in the CBS data-
base and were considered lost to follow-up. A total of 865 patients died between inclusion 
in the GENDER study and 1 January 2012. When comparing the patients suffering from 
coronary restenosis after PCI with those who did not develop restenosis, no differences in 
mortality rates were observed (Fig. 2). Of the 300 patients with restenosis, 86 (28.7%) died, 
Table 1 Baseline characteristics of the GENDER study population
Parameter GenDer study population (n = 3,104)
Age 62.1 ± 10.7




Current smoker 762 (24.5%)
Multi-vessel disease 1,462 (46.1%)
Total occlusion 428 (13.8%)
Stenting 2,309 (74.4%)
Residual stenosis > 20% 350 (11.3%)
Figure 2 Kaplan-Meijer curve comparing mortality of patients with and without coronary restenosis of the 
GENDER study population
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which was similar to the 770 (27.7%) of the patients without restenosis (N = 2,784), hazard 
ratio (HR) 1.13, 95% confidence interval (CI) 0.90-1.41, p = 0.28, with adjustment for age 
and sex. Also no difference was observed for death due specifically to CVD (12.3% versus 
11.4% in the group with restenosis and the group without respectively, p = 0.64).
all-cause mortality in GenDer compared with the general population
When comparing the total GENDER population with a random sample from the general 
population, we observed a higher mortality rate in the GENDER study population than 
in the control cohort, 27.8% versus 21.6%, P < 0.001. This difference is visualised in Fig. 
3. However, when adjusting for age and sex, this increased 10-year mortality risk was 
no longer statistically significant, HR of 1.05, 95% CI 0.97-1.14, p = 0.24. This was mainly 
caused by the influence of sex. The male subjects of GENDER did not have an increased 
all-cause mortality risk compared with the general population (HR 0.97, 95% CI 0.87-
1.05). In contrast, female patients with known coronary artery disease had an 1.39-fold 
(95% CI 1.18-1.63, p < 0.001) increased risk to die during long-term follow-up, compared 
with the female individuals in the general population.
Primary cause of death
In Table 2, the primary causes of death are shown. The majority of the patients died of 
a cardiovascular cause (N = 355, 11.5% of the total population and 41.5% of all-cause 
mortality). Compared with the random sample from the general Dutch population, car-
diovascular causes of death were more frequent in the GENDER study, 11.5% (N = 355) 
Figure 3 Kaplan Meijer curves comparing mortality of the GENDER study population (n = 3,084) with a 
random sample from the Dutch general population (n = 14,356)
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versus 6.7% (N = 957), p < 0.001. Patients in the GENDER cohort had a 1.29-fold increased 
risk (95% CI 1.13-1.48, p < 0.001) for CVD death compared with the control cohort, 
adjusted for age and sex. Most of these CVD deaths were caused by acute myocardial 
infarction in both cohorts, 91 (3.0% of the total population) in GENDER and 244 (1.6% of 
the total population) in the control group respectively. Death due to stroke accounted 
for a similar percentage of all deaths in both populations, N = 47 (1.5%) in GENDER versus 
N = 199 (1.3%) in the control cohort.
The second major cause of death in GENDER was cancer-related. A total of 2,045 
patients (7.9% of the population and 28.6% of all-cause mortality) died of cancer, which 
was slightly less frequent than in the general population (8.6% of the population and 
41.3% of all-cause mortality). However, this difference was not statistically significant 
(p = 0.08). The patients included in GENDER did have a higher risk of dying from a meta-
bolic disease, mostly diabetes, a well-known risk factor for CVD. Moreover, also death 
caused by urological disorders or diseases of the reproductive organs was higher in the 
GENDER population than in the general population. No differences were observed be-
tween other causes of death. Approximately 4% of deaths were of infectious nature, 2% 
due psychiatric disorders, 3% due pulmonary disease and 2% due to non-natural causes.
Table 2 Causes of death of the GENDER study population and of the Dutch general population from 
March 1999 up to December 2011





n (%) %* n (%) %*
Cardiovascular disease I000-I999 355 
(11.5%)
41.5% 957 (6.7%) 30.8% < 0.001
Cancer C000-D489 245 (7.9%) 28.6% 1,283 (8.9%) 41.3% 0.08
Infectious A000-B999, 
J120-J180
34 (1.1%) 4.0% 140 (1.0%) 4.5% 0.39
Metabolic disease E000-E909 36 (1.2%) 4.2% 80 (0.6%) 2.6% < 0.001
Psychic disorders F000-F999 17 (0.6%) 2.0% 56 (0.4%) 1.8% 0.21
Respiratory system** J000-J999 (excl. 
J120-J180)
41 (1.3%) 4.8% 192 (1.3%) 6.2% 0.97
Gastro-intestinal system K000-K939) 29 (0.9%) 3.4% 101 (0.7%) 3.2% 0.17
Urinary tract and 
reproductive organs
N000-N999 23 (0.7%) 2.7% 43 (0.3%) 1.4% < 0.001
Non-natural cause of death V010-Y899 20 (0.6%) 2.3% 68 (0.5%) 2.2% 0.21
Others 21 (0.7%) 2.5% 79 (0.6%) 2.5% 0.41
Unknown R000-R999 35 (1.1%) 4.1% 109 (0.8%) 3.5% 0.04
total 856 
(27.8%)
100.0% 3,108 (21.6%) 100% < 0.001
* Percentage of all-cause mortality. ** Excluding pneumonia
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cardiovascular death in GenDer
When looking more specifically into the cardiovascular causes of death in the GENDER 
population, ischaemic heart disease was the most frequent cause of death, responsible 
for almost half (47%) of all CVD deaths (Table 3). Of these 167 patients dying from 
ischaemic heart disease, 91 died as the consequence of an acute myocardial infarction. 
Heart failure was the next most frequent occurring CVD death (15.4%), followed by 
cerebrovascular disease (13.1%) and valvular disease (7.9%). Rhythm and conductions 
disorders and aneurysmal disease each accounted for approximately 4% of the CVD 
related deaths.
Limitations
One study limitation should be mentioned. For this study we analysed the primary cause 
of death recorded by the Dutch CBS. Although this is the most specific mortality data 
available a small margin of error should be taken into account. For instance, the coronary 
artery disease patients in GENDER who are now classified with diabetes as their primary 
cause of death, likely died from a cardiovascular cause of death instead. Autopsy would 
result in the most specific cause of death, but this is not performed in most individuals.
concLusions
The data presented above allow two conclusions. First, although previous studies have 
shown that patients developing coronary restenosis after PCI have a higher (CVD) mor-
bidity and mortality9,10, the current study demonstrates that, in the long-term, no differ-
Table 3, Specific cardiovascular causes of death of the GENDER population
cause of death icD-10 code GenDer
n %*
All cardiovascular disease I000-I999 355 100%
Ischaemic heart disease I200-I259 167 47.0%
Acute myocardial infarction I210-I219 91 25.6%
Valve disease I340-I389 28 7.9%
Rhythm and conduction disorders I440-I499 16 4.5%
Heart failure and cardiomyopathies I420-I439, I500-I509 54 15.2%
Cerebrovascular disease I600-I699 47 13.2%
Aneurysmal disease I710-I729 15 4.2%
Other cardiovascular disease 28 7.8%
* Percentage of all cardiovascular death. Other cardiovascular disease includes hypertensive heart disease, 
rheumatic heart disease, pulmonary heart disease, peripheral vascular disease and unspecified heart 
disease
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ences in mortality rates are present between patients who develop restenosis and those 
who do not develop restenosis. This indicates that the current treatment of coronary 
restenosis, by repeated intervention, is good enough to prevent an increased mortal-
ity risk in the long-term. However, this patient population with confirmed coronary 
artery disease, despite guideline-based treatment, does have an increased mortality 
risk compared with the general population, especially pronounced in female patients. 
Since this increased risk is still attributable to CVD mortality, and not to other causes of 
death, there still seems room to improve current treatment strategies for CVD. Although 
speculative, likely the most room for improvement is in primary prevention and not 
secondary prevention as in the current study population. Future studies in both primary 
and secondary prevention cohorts will show us whether we are still heading in the right 
direction for optimal treatment of our patients, ultimately shifting their mortality risk all 
the way back to that of the general population.
156 Part I – Genetics of restenosis
reference List
 1. Murray CJ, Lopez AD: Mortality by cause for eight regions of the world: Global Burden of Disease 
Study. Lancet (1997) 349: 1269-1276.
 2. Roger VL, Go AS, Lloyd-Jones DM et al.: Executive summary: heart disease and stroke statis-
tics--2012 update: a report from the American Heart Association. Circulation (2012) 125: 188-197.
 3. Vaartjes I, O’Flaherty M, Grobbee DE, Bots ML, Capewell S: Coronary heart disease mortality 
trends in the Netherlands 1972-2007. Heart (2011) 97: 569-573.
 4. van NF, Davies GM, Jukema JW et al.: Economic evaluation of ezetimibe combined with simvas-
tatin for the treatment of primary hypercholesterolaemia. Neth Heart J (2011) 19: 61-67.
 5. Liew D, Webb K, Meerding WJ, Buskens E, Jukema JW: Potential cardiovascular consequences of 
switching from atorvastatin to generic simvastatin in the Netherlands. Neth Heart J (2012) 20: 
197-201.
 6. Dharma S, Juzar DA, Firdaus I et al.: Acute myocardial infarction system of care in the third world. 
Neth Heart J (2012) 20: 254-259.
 7. Jukema JW, Verschuren JJ, Ahmed TA, Quax PH: Restenosis after PCI. Part 1: pathophysiology and 
risk factors. Nat Rev Cardiol (2012) 9: 53-62.
 8. Weintraub WS, Ghazzal ZM, Douglas JS, Jr. et al.: Long-term clinical follow-up in patients with 
angiographic restudy after successful angioplasty. Circulation (1993) 87: 831-840.
 9. Espinola-Klein C, Rupprecht HJ, Erbel R et al.: Impact of restenosis 10 years after coronary angio-
plasty. Eur Heart J (1998) 19: 1047-1053.
 10. Schuhlen H, Kastrati A, Mehilli J et al.: Restenosis detected by routine angiographic follow-up and 
late mortality after coronary stent placement. Am Heart J (2004) 147: 317-322.
 11. Agema WR, Monraats PS, Zwinderman AH et al.: Current PTCA practice and clinical outcomes in 








pathway associated with occurrence 
of myocardial infarction
Gene set analysis of genome-
wide association study data
Jeffrey J.W. Verschuren, Stella Trompet, Joris Deelen, David J. Stott, Naveed Sattar, 
Brendan M. Buckley, Ian Ford, Bastiaan T. Heijmans, Henk-Jan Guchelaar, Jeanine J. 
Houwing-Duistermaat, P. Eline Slagboom and J. Wouter Jukema
PLoS One. (2013) 8(2):e56262
162 Part II –  Genetics of (cardio)vascular diseases
abstract
Purpose: DNA repair deficiencies have been postulated to play a role in the develop-
ment and progression of cardiovascular disease (CVD). The hypothesis is that DNA 
damage accumulating with age may induce cell death, which promotes formation of 
unstable plaques. Defects in DNA repair mechanisms may therefore increase the risk of 
CVD events. We examined whether the joint effect of common genetic variants in 5 DNA 
repair pathways may influence the risk of CVD events.
methods: The PLINK set-based test was used to examine the association to myocardial 
infarction (MI) of the DNA repair pathway in GWAS data of 866 subjects of the GENetic 
DEterminants of Restenosis (GENDER) study and 5,244 subjects of the PROspective Study 
of Pravastatin in the Elderly at Risk (PROSPER) study. We included the main DNA repair 
pathways (base excision repair, nucleotide excision repair, mismatch repair, homologous 
recombination and non-homologous end-joining (NHEJ)) in the analysis.
results: The NHEJ pathway was associated with the occurrence of MI in both GENDER 
(P = 0.0083) and PROSPER (P = 0.014). This association was mainly driven by genetic varia-
tion in the MRE11A gene (PGENDER = 0.0001 and PPROSPER = 0.002). The homologous 
recombination pathway was associated with MI in GENDER only (P = 0.011), for the other 
pathways no associations were observed.
conclusion: This is the first study analyzing the joint effect of common genetic varia-
tion in DNA repair pathways and the risk of CVD events, demonstrating an association 
between the NHEJ pathway and MI in 2 different cohorts.
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introDuction
Cardiovascular disease (CVD) is caused by interplay of environmental factors and multiple 
predisposing genes. DNA damage, caused by for instance oxidative stress and cigarette 
smoking, has been recognized as a significant contributor to the pathogenesis of CVD.1,2 
Mechanistically, in cells where the DNA damage is beyond repair apoptosis is induced.3 
The effect of this damage induced cell death is dependent on the cell type. Death of 
endothelial cells is implicated in plaque erosion and subsequent vessel thrombosis.4 
Vascular smooth muscle cell (VSMC) death has been associated with thinning of the 
fibrous cap and increasing the risk of plaque rupture.5,6 To further complicate matters, 
apoptosis is not the only response of cells to DNA damage, also cellular senescence has 
been described.7,8 Cellular senescence is a state in which cells remain in cell cycle arrest 
and in which they have lost their optimal function. With respect to the pathogenesis 
of atherosclerosis, senescence of for instance vascular endothelial cells can result in a 
provasoconstrictor and a proinflammatory phenotype.7 So besides cell death, DNA dam-
age could also increases the risk of CVD by inducing cell senescence.
Adequate DNA repair is crucial for survival of an organism, as the DNA is continu-
ously exposed to various types of external factors, like mutagenic chemicals and radia-
tion, and endogenously generated triggers like reactive oxygen species (ROS) and DNA 
replication errors, all capable of inducing DNA damage. Human cells possess several 
innate DNA repair processes to protect against the harmful consequences of DNA dam-
age.9 Single-strand DNA damage can be repaired by excision repair and mismatch repair 
pathways that use the undamaged strand as template during the repair process. For 
the repair of double-strand breaks other repair mechanisms like non-homologous end-
joining (NHEJ) or homologous recombination are required.10
Evidence of the relation between genomic integrity and cardiovascular disease in 
the ageing population has been growing over the last years. Up to now, this evidence 
consists in various forms, ranging from cellular biology studies in vascular endothelial 
cells11,12, vascular smooth muscle cells13,14 and macropahges15, histological examination 
of human atherosclerotic plaques14,16 and animal studies in telomerase deficient mice17 
and DNA repair defective mice.8,18,19 In contrast, only limited studies have focused on 
single nucleotide polymorphisms (SNPs) in genes related to DNA repair processes and 
CVD events, although some associations have been reported. The only SNP with some 
consistent results is the Arg399Gln (rs25487) SNP in the XRCC1 base excision repair (BER) 
gene which was reported to be associated with stroke20 and coronary atherosclerosis21. 
Other genes from the excision repair pathway such as OGG1, XRCC3, ERCC2 (XPD)and 
ERCC5, were found to moderately associated as a combined score to the risk of large 
artery atherosclerotic stroke in the smoking subset of a Chinese population 22. The 
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authors suggested that the individual vulnerability to smoking-induced oxidative stress 
was influenced by carriers of these SNPS.
In genome-wide association studies (GWAS) investigating the genetic background 
of CVD, no association was found with SNPs in genes related to DNA repair processes.23,24 
However, considering the multifactorial nature of the condition, it is possible that by a 
joint effect, genetic variants with small individual effect sizes, could contribute to dis-
ease risk and are undetected in a GWAS.25,26 The goal of the current study was to examine 
whether common genetic variants in DNA repair genes are related to the risk of CVD 




The design of the GENetic DEterminants of Restenosis (GENDER) study has been described 
previously.27 In brief, GENDER included 3,104 consecutive unrelated symptomatic patients 
treated successfully by PCI for angina. The study protocol conforms to the Declaration of 
Helsinki and was approved by the ethics committees of each participating institution. Writ-
ten informed consent was obtained from each participant before the PCI procedure. Ex-
perienced operators, using a radial or femoral approach, performed standard angioplasty 
and stent placement. During the study, no drug-eluting stents were used. Blood samples 
were collected at the index procedure for DNA isolation. During a follow-up period of 9 
months, the endpoint clinical restenosis, defined as renewed symptoms requiring target 
vessel revascularization (TVR) either by repeated PCI or CABG, by death from cardiac 
causes or myocardial infarction (MI) not attributable to another coronary event than the 
target vessel, was recorded. Furthermore, of each patient the occurrence of MI or stroke 
prior to inclusion into the study, as well as during the follow up period, was recorded. For 
this study the combination of prevalent and incident MI or stroke was analyzed.
ProsPer study population
The design and population of the PROSPective study for the Elderly at Risk (PROSPER) 
has been described previously.28 PROSPER is a prospective multicenter randomized 
placebo-controlled trial to assess whether treatment with pravastatin diminishes the 
risk of major vascular events in elderly individuals. Between December 1997 and May 
1999, subjects were screened and enrolled in Scotland (Glasgow), Ireland (Cork), and 
The Netherlands (Leiden). Men and women aged 70-82 years were recruited if they 
had pre-existing vascular disease or increased risk of such disease because of smoking, 
hypertension, or diabetes. A total number of 5,804 subjects were randomly assigned to 
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pravastatin or placebo. In this study several cardiovascular endpoints were evaluated 
during a mean follow-up of 3.2 years; the primary endpoint consisted of a composite of 
fatal/non-fatal MI or fatal/non-fatal stroke. Secondary and tertiary endpoints included 
stroke and MI separately, all-cause mortality and death due to a vascular cause.29 The in-
stitutional ethics review boards of all centers approved the protocol, and all participants 
gave written informed consent. The protocol was consistent with the Declaration of 
Helsinki. For the current study we combined the incident events ,myocardial infarction 
and stroke, that occurred during the follow-up period with the prevalent events that 
occurred before inclusion into PROSPER, to obtain a lifetime risk for these events.
Genotyping
In GENDER, a GWAS was performed in 325 cases of restenosis and 630 controls matched 
by gender, age, and some confounding clinical variables for restenosis in the GENDER 
study such as total occlusion, diabetes, current smoking and residual stenosis.30 Ge-
notyping was performed using the Illumina Human 610-Quad Beadchips following 
manufacturer’s instructions. . After stringent quality control, bad performing samples 
(call rate < 99%) and assays (call rate < 95%, minor allele frequency < 1% and deviation 
from Hardy-Weinberg equilibrium) were excluded from further analysis. The final dataset 
consisted of 866 individuals (295 cases, 571 controls) and 556,099 SNPs.
In PROSPER, a GWAS was performed using Illumina Human 660-Quad Beadchips 
following manufacturer’s instructions. After stringent quality control, bad performing 
samples and assays were excluded from further analysis. Genotypic data was available 
in 5,244 subjects and a total of 557,192 SNPs31.
Both datasets were imputed using MaCH software32 up to ~2.5 million SNPs based on 
the HapMap Phase I + II CEU release 22 (hg18/build36) reference.
Gene set analysis
We analyzed SNPs within a 10-kb window around the genes encoding proteins belong-
ing to the 5 DNA repair pathways described in the Kyoto Encyclopedia of Genes and 
Genomes (KEGG) pathway database33,34; the BER pathway, the nucleotide excision repair 
(NER) pathway, the mismatch repair (MMR) pathway, the homologous recombination 
pathway and the NHEJ pathway. Gene set analyses were performed with the PLINK 
set-based test v1.07 in a case-control setting.35 In the first step of this test, a single SNP 
analysis of all SNPs within the set is performed. Subsequently, a mean SNP statistic is 
calculated from the single SNP statistics of a maximum amount of SNPs below a certain 
P-value threshold. For the current study this threshold was set on 0.20 to ensure that 
all SNPs with minor effect will be analyzed. If SNPs are not independent, i.e. the LD 
(expressed in R2) is above a certain threshold, the SNP with the lowest P-value in the 
single SNP analysis is selected. This analysis is repeated with 10,000 simulated SNP sets, 
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in which the phenotype status of the individuals is permuted. An empirical P-value for 
the SNP set is computed by calculating the number of times the test statistic of the 
simulated SNP sets exceeds that of the original SNP set. For the set-based analysis of 
this study, the parameters were set to P-value threshold < 0.20, R2 threshold < 0.5, and 
maximum number of SNPs = 99999. The associations were considered significant, after 
correction for the 5 analyzed pathways, if the P-value < 0.01 (0.05/5). For the pathway 
analysis we only used the genotyped GWAS sets of both studies, since imputed SNPs 
were obtained based on their LD pattern with the genotyped SNPs and the LD threshold 
of the set-based analysis corrects for this, making their added value minimal.
resuLts
Participant characteristics of the two study populations are presented in table 1. The 
main differences in the baseline characteristics between the two study populations 






Age (years) 62.5 ± 10.8 75.3 ± 3.4
Male gender (N) 634 (73) 2,524 (48)
Current smoking (N) 216 (25) 1,392 (27)
History of diabetes (N) 177 (20) 544 (10)
History of hypertension (N) 349 (40) 3,257 (62)
History of angina (N) 288 (68) 1,424 (27)
History of myocardial infarction (N) 365 (42) 708 (14)
Total cholesterol (mmol/L) 4.9 ± 1.0a 5.7 ± 0.9
Body mass index (kg/m2) 27.0 ± 3.7 26.8 ± 4.2
Statin treatment 465 (54) 2,605 (50)
Endpoints
Myocardial infarction b 389 (45) 1145 (22)
Stroke b 49 (6) 731 (14)
Myocardial infarction or stroke b 416 (48) 1714 (33)
Clinical restenosis c 295 (34) NA
All cause mortality 237 (27)d 548 (11)c
Vascular mortality c NA 266 (5)
Data are presented as mean ± SD or number (%). a Cholesterol levels available in only 177 patients.
b Before inclusion or during follow-up period. c During follow-up period. d During follow up of 10 years 
after inclusion in GENDER.
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are the mean age of the participants (GENDER; 62.5 years, PROSPER; 75.3 years) and 
the proportion of women (GENDER; 27%, PROSPER; 52%) Moreover, diabetes and com-
plaints of stable angina pectoris were more frequent in GENDER, whereas a history of 
hypertension was more frequent in PROSPER. The incidence of MI in GENDER was 45% 
and in PROSPER 22%.
Of the 5 selected DNA repair pathways, as described by the KEGG pathway database, 
the NER pathway was the largest one (44 genes), (Table S1), while the NHEJ pathway was 
the smallest (13 genes). The BER pathway consisted of 35 genes, the MMR pathway of 23 
genes and the homologous recombination pathway of 28 genes.
The set-based analysis of the 5 pathway sets in the GENDER population resulted in 
a significant association of the homologous recombination pathway with MI (P = 0.011) 
and the combined endpoint of MI or stroke (P = 0.0039) (Table 2). A significant asso-
ciation with the same endpoints was also found for the NHEJ pathway (P = 0.0083 for 
MI and P = 0.0089 for MI or stroke). No significant association of any of the DNA repair 
pathways was found with stroke alone.
Analysis in the PROSPER dataset resulted in an association of the NHEJ pathway 
with MI (P = 0.014). A borderline significant association of the BER pathway with MI was 
also observed (P = 0.049). The other pathways did not show significant associations in 
PROSPER (Table 2).
To determine by which genes the association of the NHEJ pathway with MI was driv-
en, we examined the SNP set from each gene of this pathway separately. We found that 
Table 2, Set-based analysis of DNA repair pathways in the GENDER and PROSPER study populations
Pathway
Genes SNPs
MIa Strokea MI or Strokea
SNPs P SNPs P SNPs P
GENDERb N = 389/477 N = 49/817 N = 416/450
Base excision 35 315 37 0.48 36 0.47 37 0.59
Nucleotide excision 44 401 57 0.38 49 0.34 60 0.38
Mismatch repair 23 285 39 0.34 40 0.42 47 0.35
Homologous recombination 28 418 64 0.011 51 0.71 60 0.0039
Non-homologous end joining 13 137 19 0.0084 14 0.43 19 0.0089
PROSPERb N = 1,145/4,099 N = 731/4,513 N = 1,714/3,530
Base excision 35 298 43 0.049 42 0.39 39 0.43
Nucleotide excision 44 392 62 0.34 57 0.47 49 0.49
Mismatch repair 23 285 39 0.43 33 0.46 31 0.91
Homologous recombination 28 426 61 0.14 42 0.49 51 0.24
Non-homologous end joining 13 144 19 0.014 30 0.35 22 0.11
The SNPs per endpoint indicate the number of independent SNPs that passed the test constrains (P < 0.2 
and R2 < 0.5) and were thus jointly analyzed in 10,000 permutations. a Before inclusion or during follow-
up period. MI, myocardial infarction. b Cases/controls
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the association was driven by several genes from this pathway. In GENDER the XRCC4 
gene demonstrated a borderline significant association (P = 0.055) and in PROSPER the 
genes PRKDC (P = 0.029) and LIG4 (P = 0.030) were individually associated with MI. The 
strongest association was found with the MRE11A gene in both GENDER (P = 0.0001) 
and PROSPER (P = 0.0017), driven by 3 and 2 SNPs, respectively, which differ between 
the studies (Table 3).
By using imputed data we performed in silico fine mapping of the individual SNPs 
in the MRE11A genetic region on chromosome 11 (Figure 1). Within the range of 10Kb 
around the MRE11A gene genotypic data of 104 SNPs were available. We identified 8 
sets of SNPs that were in high LD (R2 > 0.8) but only one set (10 SNPs) associated with 
MI in both GENDER and PROSPER (P = 0.0033 and P = 0.0023 respectively). This set 
contained the top SNP in MRE11A in PROSPER (rs2155209), that was identified in the 
individual gene analysis (Table 4). This SNP is located in a DNase I hypersensitivity site 
(UCSC genome browsers database 36). The promotor 2.0 Prediction Server37 reported 
Table 4, Genomic region of MRE11A divided in LD blocks for the association with myocardial infarction
Set SNPs R2 Tagging SNP MAF* GENDER PROSPER
OR (95% CI) P OR (95% CI) P
1 10 0.91 rs2155209 0.36 0.74 (0.61-0.91) 0.0033 0.86 (0.78-0.96) 0.0023
2 10 0,90 rs535801 0.31 1.52 (1.24-1.87) 0.000059 1.00 (0.90-1.11) 0.94
3 17 0.88 rs1270146 0.43 1.32 (1.09-1.60) 0.0049 1.02 (0.93-1.13) 0.63
4 13 0.91 rs529126 0.26 1.44 (1.16-1.80) 0.00090 1.02 (0.91-1.12) 0.71
5 5 0.85 rs499952 0.35 1.32 (1.08-1.61) 0.0059 1.03 (0.92-1.12) 0.54
6 4 0.91 rs13447720 0.23 0.94 (0.75-1.18) 0.57 1.18 (1.05-1.30) 0.0027
7 18 0.91 rs10765682 0.09 0.91 (0.65-1.27) 0.58 1.01 (0.87-1.20) 0.95
8 18 1.00 rs12788248 0.01 1.22 (0.43-3.49) 0.71 1.02 (0.58-1.72) 0.95
other** 9 -
R2 indicates lowest LD between SNPs within the set. Tagging SNP is a genotyped SNP with the lowest 
P-value per set. * MAF, minor allele frequency in GENDER. ** SNPs not in LD with other SNPs within the gene.
Figure 1 Fine mapping from DNA damage through the identification of an associated DNA repair 
pathway, the responsible gene in this pathway, to the single nucleotide polymorphism (SNP)
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that the region surrounding rs2155209 is not a promotor region. In addition, the is-rSNP 
algorithm38 reported that the DNA binding affinity of three transcription factors is sig-
nificantly affected by rs2155209 (LM221 P = 0.014, estrogen receptor 2 (ESR2) P = 0.028 
and LM168 P = 0.037). Unfortunately, rs2155209 is not reported in three publically avail-
able eQTL databases (mRNA by SNP browser39,40, VarySysDB41 and the eQTL database of 
the Pritchard lab42).
To explore whether the found associations were caused by specific subgroups we 
analyzed the NHEJ pathway in male and female patients, smokers and non-smokers and 
in patients with and without diabetes separately. Moreover, in the PROSPER study we 
also performed the analyses in the pravastatin and placebo group. No clear associations 
were detected in these subgroups (Table S2).
Discussion
The current study is the first to use a DNA repair pathway approach for the identifi-
cation of new candidate genes related to cardiovascular outcomes. We show that 
genetic variation in several of these genes are indeed associated with cardiovascular 
related endpoints and that the joint analyses of these genetic markers demonstrates 
a significant association of the NHEJ pathway with prevalent and incident MI in two 
study populations. Variation in the gene encoding meiotic recombination 11 homolog 
A (MRE11A) drives the association.
This is the first study that demonstrates a relation between the NHEJ pathway and MI 
or even with CVD. This particular DNA repair pathway is mainly involved in the repair of 
double-strand breaks (DSBs), which are considered to have the highest risk of evoking 
deleterious events, such as chromosomal translocations, cancer and cell death. The main 
driver of this association, MRE11A, is a highly conserved protein, existing in vivo as a 
dimer, forms together with RAD50 and NBS1 the MRN complex.43 The MRN complex has 
a critical role in the recognition of DNA damage lesions or the chromatin alterations that 
follow DNA damage3 and a key role in the cellular response to DSBs.44 Moreover, the 
MRN complex has been implicated in telomere maintenance, meiosis, DNA replication 
and checkpoint activation.45-47 Genetic variation in MRE11A has previously been associ-
ated with several types of cancer 48-50 and antaxia-telangiectasis-like disease.51 To our 
knowledge, no association of this gene with CVD events has yet been described, also 
not in the previous GWAS on CVD.23,52,53 The SNP rs2155209, significantly associated with 
MI in both of our study populations, has been associated with an 1.5-fold increased risk 
of bladder cancer, although the authors of that study suggest that it might has been a 
false-positive finding. 49 This MRE11A SNP is located in the 3’UTR of the gene, and the 
possible functional effect has not yet been studied.
DNA repair pathways in CVD 171
9
When examining the LD structure of MRE11A, we found that the structure is not 
conform the expected LD block formation, meaning that nearby SNPs are organized into 
regions of high LD separated by short segments of very low LD. This discontinuous LD 
structure is not uncommon, and has been described before for this gene.54 Allen-Brady 
et al.54 describe 4 tagging SNPs together accounting for 99% of the genetic variance 
within the gene region. In the current study the genetic coverage of the gene was more 
thorough (104 SNPs compared to 11 in the former study), resulting in 8 tagging SNPs. In-
terestingly, one of the 4 described tagging SNPs, rs556477, is in very high LD (R2 = 0.92) 
with our top SNP rs2155209. It is unknown whether rs2155209 has any direct functional 
effects. That this SNP is located in a DNase I hypersensitivity site, which often associated 
with cis-regulatory sequences, including promoters, insulators, enhancers and locus 
control regions, increases the likelihood that rs2155209 influences one of these features 
and thereby exerting its clinical effects, although this remains to be proven. Another 
method of predicting the possible regulatory abilities of non-coding SNPs is the in silico 
rSNP algorithm38. This approach indicated that rs2155209 affects binding of ERS2. The 
estrogen receptor 2 belongs to a family of nuclear receptor transcription factors, activat-
ing transcription upon binding to specific DNA sequences. Moreover, the SNP was as-
sociated with LM221 and LM168, two conserved motifs in the human genome described 
to be involved in gene regulation, likely serving as insulators.55 Wet lab confirmation 
of these bioinformatic predictions will be necessary before definite conclusions can be 
drawn from these findings.
Cigarette smoking is considered to be an important risk factor in atherosclerotic 
vascular disease and it is a well-known external factor associated with DNA damage, 
like single- and double strand breaks and the formation of oxidative DNA-adducts.56,57 
The association of the NHEJ pathway with MI, demonstrated in the current study, could 
indicate that this pathway is the underlying mechanism of the strong relation between 
smoking and CVDs. However, this hypothesis could not be confirmed in subgroup 
analyses. Whether this absence of association is caused by lack of power of the subgroup 
analysis, or because the underlying mechanism causing MI is not through smoking, is 
uncertain. Moreover, the hypothesis that patients with diabetes mellitus have increased 
oxidative stress which could lead to DNA damage58,59, could also not be confirmed in 
our population. However, considering that the incidence of diabetes was 20% in GEN-
DER and only 10% in PROSPER, there was not enough power to detect a small effect. 
Furthermore, we cannot exclude that another DNA repair pathway than NHEJ might be 
responsible for the DNA repair in diabetic patients, but considering the small subgroup 
size and the fact that the other DNA repair pathways were not significantly associated 
in the complete populations, we did not perform further analyses for these pathways. 
The subgroup analysis did demonstrate that the association of the NHEJ pathway with 
MI was possibly driven by the male subjects, since in PROSPER no association was found 
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in female subjects. Although in GENDER a similar trend was observed, these results were 
not significant.
The strength of gene set analysis, opposed to GWAS analysis, is that it tests the joint 
effect of multiple individual SNPs within a larger set. Considering the a priori small effect 
size of the individual SNPs on complex disease endpoints, like MI, analysis of the joint 
effect of multiple markers, in this study comprising complete DNA repair pathways, will 
increase the likelihood of finding biological plausible associations.
Several possible limitations to our study have to be mentioned. For the current study 
we performed the pathway analysis using the PLINK software.35 Other software pack-
ages have been described, although to date none has been proven to be clearly superior 
to the others. Gui and colleagues compared 7 tests analyzing the WTCCC Crohn’s Disease 
dataset.60 One of their overall conclusions was that the set-based test in PLINK was the 
most powerful algorithm. Another study, applying PLINK set-based test, Global test, 
GRASS and SNP ratio test, for the analysis of three pathways regarding human longevity 
observed similar results with the different tests.61 Although other software packages 
could lead to different results, the fact that our fine mapping strategy led to the identi-
fication of a single LD block associated in two independent populations, increased the 
likelihood of a true positive association.
The five DNA repair pathways analyzed were derived from the publically available 
KEGG database34. The KEGG database is however not the only database providing bio-
logical pathways and there is no consensus on the best database. In our opinion these 
particular pathways were more elaborately described by KEGG than in other databases 
(for instance Reactome or BioCarta). Moreover, only the KEGG database provided a de-
scription of all 5 DNA repair pathways. Since the overlap of certain pathways of different 
databases is substantial, we decided only to test the DNA repair pathways described by 
KEGG.33 It is important to realize that probably none of these databases provide a perfect 
representation of the actual biological mechanism, simple because our current knowl-
edge is not that far evolved yet. Likely not all genes incorporated within the current 
pathways directly influence the actual DNA repair process of interest. These unrelated 
gene product could therefore interfere with the actual associations, however to what 
extent this is the case in the current study remains unknown.
As stated above, DNA damage and DNA damage repair are associated with cancer. 
Since we are interested in the effects of DNA damage repair on clinical events other than 
cancer, and because the two included study populations are of rather old age, especially 
PROSPER, we cannot exclude that the competing risk of cancer related mortality and CVD 
events have led to a selection bias of the patients. Therefore, it could be possible that the 
role of DNA repair pathways is being underestimated. However, since we cannot correct 
for this potential selection bias, this remains speculative. Another potential confounder 
is age. The GENDER study is considerably younger than the PROSPER cohort, possibly 
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explaining part of the different results of both studies. However, since in the set-based 
analysis of PLINK correction for confounders is not possible, the actual magnitude of the 
influence of age on the current results remains therefore uncertain.
In conclusion, with this study we demonstrate that genetic variation in the NHEJ 
pathway of the human DNA repair machinery, and specifically genetic variation in the 
MRE11A gene, is associated with the occurrence of MI. Results of this study need to be 
validated by functional studies to further elucidate the precise mechanistic role of NHEJ 
in atherosclerotic lesion formation.
suPPLementary materiaL
Supplementary Material is available at PLoS One online.
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abstract
background: Arteriovenous fistula (AVF) failure remains an important cause of mor-
bidity in hemodialysis patients. The exact underlying mechanisms responsible of AVF 
failure are unknown but processes like proliferation, inflammation, vascular remodeling 
and thrombosis are thought to be involved. The current objective was to investigate 
the association between AVF failure and single nucleotide polymorphisms (SNPs) in 
genes related to these pathophysiological processes in a large population of incident 
hemodialysis patients.
methods: A total of 479 incident hemodialysis patients were included between January 
1997 and April 2004. Follow-up lasted two years or until AVF failure, defined as surgery, 
percutaneous endovascular intervention, or abandonment of the vascular access. Forty-
three SNPs in 26 genes, related to proliferation, inflammation, endothelial function, vas-
cular remodeling, coagulation and calcium/phosphate metabolism, were genotyped. 
Relations were analyzed using Cox regression analysis.
results: In total, 207 (43.2%) patients developed AVF failure. After adjustment, two SNPs 
were significantly associated with an increased risk of AVF failure. The hazard ratio of 
LRP1 rs1466535 was 1.75 (95% CI 1.15-2.66) and patients with factor V Leiden had a 
hazard ratio of 2.54 (95% CI 1.41-4.56) to develop AVF failure. The other SNPs were not 
associated with AVF failure.
conclusion: In this large cohort of hemodialysis patient, only two of the 43 candidate 
SNPs were associated with an increased risk of AVF failure. Whether other factors, like 
local hemodynamic circumstances, are more important or that other SNPs play a role in 
AVF failure remains to be elucidated.
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introDuction
A durable vascular access to the bloodstream is of vital importance for patients undergo-
ing chronic hemodialysis. However, vascular access dysfunction is currently the Achilles’ 
heel of hemodialysis therapy, accounting for 20% of all hospitalizations in hemodialysis 
patients leading to unacceptable high morbidity and economic burden.1,2 For chronic 
hemodialysis, arteriovenous fistulas (AVFs) are the preferred modality in view of the 
superior patency rates as compared to arteriovenous synthetic grafts. Nonetheless, the 
durability of AVFs is far from optimal with one-year primary patency rates ranging from 
60-65%.3,4
The vast majority of arteriovenous (AV) access failure is caused by thrombosis, sec-
ondary to disproportionate intimal hyperplasia (IH) and impaired outward remodeling 
of the venous outflow tract.5-8 The stimuli responsible for the localized intimal hyperplas-
tic response in the venous outflow tract are multifactorial and include hemodynamic 
factors such as turbulent flow, the prothrombotic environment that results from endo-
thelial damage as well as vascular inflammation.9 The stenotic vascular lesions that arise 
from this intimal hyperplastic response mainly consist of vascular smooth muscle cells 
(VSMCs), myofibroblasts and extracellular matrix proteins.10 Excessive accumulation of 
extracellular matrix is mediated by several growth factors.5,9,11 Morphologically, these 
stenotic lesions closely resemble restenotic lesions after percutaneous coronary inter-
vention (PCI).12,13 Additional specific pathophysiological stimuli for IH in vascular access 
stenosis include the abnormal calcium/phosphate metabolism in patients with chronic 
kidney disease that result in arterial as well as venous calcification of the tunica media.14 
Therefore, processes related to vascular function and remodeling, growth factors for 
extracellular matrix formation, inflammation, coagulation and calcium/phosphate me-
tabolism probably play an important role in AVF failure. Currently, it is unknown why AVF 
failure occurs in some individuals but not in others. It has been suggested that genetic 
factors could play a role in the development of AVF failure.15 However, limited studies 
have investigated the effects of genetic risk factors that play a role in these processes 
on AVF failure.
The aim of the current study was to investigate the association between AVF failure 
and single nucleotide polymorphism (SNPs) involved in processes related to endothe-
lial function and vascular remodeling, growth factors, inflammation, coagulation, and 
calcium/phosphate metabolism in a large population of incident hemodialysis patients.
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methoDs
Patients
The Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD) is a prospec-
tive multicenter cohort study in which incident end-stage renal disease patients from 38 
dialysis centers in the Netherlands were included. The study was in accordance with the 
Declaration of Helsinki and was approved by all local medical ethics committees. All pa-
tients gave informed consent. We followed patients until AVF failure (defined as surgery, 
percutaneous endovascular intervention, or abandonment of the vascular access in the 
first two years on dialysis), death or censoring, i.e. transfer to a nonparticipating dialysis 
center, withdrawal from the study, switch to peritoneal dialysis, transplantation, or end 
of the follow-up period (April 2006).
Eligibility included age older than 18 years, no previous renal replacement therapy, 
and survival of the initial three months of dialysis. For the current analyses, we used 
data from patients included between January 1997 and April 2004 with a functional 
fistula within three months after the first dialysis session from whom DNA was available. 
Patients that were dialyzed using a central venous catheter and patients on peritoneal 
dialysis were excluded.
Demographic and clinical data
Data on age, sex, and primary kidney disease were collected at the start of dialysis 
treatment. Primary kidney disease was classified according to the codes of the Euro-
Table 1 Baseline characteristics
arteriovenous fistula
n = 479
Age (years) (IQR) 65.3 (54.3-73.7)
Sex, female (n, %) 174 (36.3%)
Race, white (n, %) 440 (91.9%)
Primary kidney disease (n, %)
Diabetes mellitus 73 (15.2%)
Glomerulonephritis 54 (11.3%)
Renal vascular disease 99 (20.7%)
Others 253 (52.8%)
interstitial nephropathy 48 (10.0%)
cystic kidney disease 63 (13.2%)
congenital and hereditary kidney disease 5 (1.0%)
Multisystem disease 28 (5.8%)
other 18 (3.8%)
unknown 91 (19.0%)
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pean Renal Association-European Dialysis and Transplant Association (ERA-EDTA).16 
We grouped patients into four classes of primary kidney disease: glomerulonephritis, 
diabetes mellitus, renal vascular disease, and other kidney diseases. Other kidney dis-
eases consisted of patients with interstitial nephritis, polycystic kidney diseases, other 
multisystem diseases, and unknown diseases.
snP selection and genotyping
Single nucleotide polymorphisms, previously associated with AV access failure, were 
selected after a systematic search of literature. Furthermore, we also selected SNPs that 
were associated with coronary restenosis13,17,18 and vascular aneurysm formation,19,20 
since underlying mechanisms of these diseases are thought to overlap. Searching MED-
LINE using keywords including ‘hemodialysis’, ‘arteriovenous access failure’, and ‘single 
nucleotide polymorphism’ identified 6 genes previously associated with AV access fail-
ure (tumor necrosis factor alpha (TNF),21 klotho,22 fibrinogen beta (FGB),23 factor V,24 and 
matrix metallopeptidase 1 (MMP1).25 To broaden the search to coronary restenosis and 
vascular aneurysm formation, the keywords ‘coronary restenosis’, ‘percutaneous coronary 
intervention’ and ‘aortic aneurysm’ were added, identifying another 20 candidate genes. 
Only SNPs with a minor allele frequency higher than 1% were included. Two multiplex 
assays were designed using Assay designer software. The final set included 43 SNPs in 
26 genes, involved in processes related to endothelial function and vascular remodel-
ing, growth factors, inflammation, coagulation and calcium/phosphate metabolism 
(Supplementary Table S1). All SNPs were genotyped by MALDI-TOF mass spectrometry, 
using the MassARRAYtm methodology (Sequenom Inc., San Diego, CA, USA), following 
manufacturer’s instructions. As quality control, 5% of the samples were genotyped in 
duplicate. No inconsistencies were observed. All the negative controls (2%) were nega-
tive. All SNPs were in Hardy-Weinberg equilibrium (p ≥ 0.01) and had a call rate above 
90% (Supplementary Table S2).
statistical analysis
Continuous variables are presented as median and interquartile range (IQR). Categorical 
variables are presented as numbers with percentages. We calculated hazard ratios (HRs) 
with 95% confidence intervals (95% CIs) using Cox regression analysis for heterozygote 
and mutant genotypes as compared with wild-type genotypes for AVF failure (first 
event) within two-years of follow-up for the 43 SNPs. For the purposes of epidemio-
logical comparison, we used false discovery rate (FDR) to adjust for multiple-testing.26 
Although no universal FDR significance threshold has been defined, a cut-point of 0.20 
has been suggested for candidate gene association studies, meaning that one should 
expect at most 20% of declared discoveries to be false.27 We therefore used a cut-point 
of 0.20, which resulted in a corrected level of significance of p = 0.009 instead of p = 0.05. 
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We also investigated the association between clinical factors and AVF failure and the 
interaction between these clinical factors and SNPs associated with AVF failure using the 
relative excess risk due to interaction (RERI) method. All analyses have been performed 
using SPSS statistical software version 20.0 (SPSS, Chicago, Ill, USA).
resuLts
A total of 479 incident hemodialysis patients with an AVF from the NECOSAD cohort 
were genotyped. Of the 479 patients, 207 (43.2%) reached the endpoint of AVF failure 
during follow up. The absolute incidence of AVF failure was 340 per 1000 person-years. 
Baseline characteristics of the patients are shown in Table 1. The median age was 65.3 
years, 36.3% were female, and 15.2% had diabetes mellitus as their primary kidney 
disease.
Genes implicated in endothelial function and vascular remodeling
The results of the analyses of this set of SNPs are summarized in Table 2. Carriers of the 
AA genotype of the low-density lipoprotein receptor-related protein 1 (LRP1) rs1466535 
had a significant 1.75-fold (95% CI 1.15-2.66) higher risk of AVF failure with a p-value of 
0.009 and a FDR of 0.009. The Annexin A5 SNPs, MMP1 rs11292517, nitric oxide synthesis 3 
(NOS3) rs1799983, Elastin rs2071307 and Quaking rs3763197 were not associated with AVF 
failure. The two intergenic SNPs, identified in a genome-wide association study (GWAS) 
for coronary restenosis, were also not associated with AVF failure, although they both 
demonstrated a non-significant trend towards a higher risk in the variant allele carriers.
Growth factors and related genes
We genotyped 12 SNPs in 8 growth factor related genes (Table 3). None of the SNPs 
showed a significant association with AVF failure.
Genes implicated in inflammation
In total, 8 SNPs were genotyped in several genes implicated inflammatory pathways 
(Table 4). We did not find an association between AVF failure and the SNPs in interleukin 
6 (IL6), interleukin 10 (IL10), lymphotoxin alpha, CD180 and toll-like receptor 4. The TNF 
rs1800629 AA genotype was associated with a 1.97-fold higher AVF failure risk as com-
pared with the GG genotype with a 95% CI of 1.00 to 3.87, a p-value of 0.05 and a FDR of 
0.01, which was just not significant considering the threshold of FDR < 0.009. Both IL10 
rs1800896 and rs3024498 GG genotypes as compared with AA genotypes were associ-
ated with a non-significant lower risk of AVF failure (HR 0.73, 95% CI 0.49-1.10, p = 0.14 
and HR 0.73, 95% CI 0.42-1.25, p = 0.25).
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Table 2 Polymorphisms related to endothelial function and vascular remodeling and association with AVF 
failure
Gene name snP Genotype n hr with 95% ci P
mmP1
Matrix metallopeptidase 
1 rs11292517 -/- 132 1 Reference
-/C 213 0.92 (0.67-1.28) 0.64
CC 103 0.86 (0.58-1.28) 0.47
nos3 Nitric oxide synthesis 3 rs1799983 GG 224 1 Reference
GA 188 1.26 (0.94-1.69) 0.12
AA 44 0.88 (0.52-1.50) 0.64
eLn Elastin rs2071307 GG 185 1 Reference
GA 207 1.30 (0.96-1.75) 0.09
AA 62 1.01 (0.64-1.60) 0.97
anXa5 Annexin A5 rs4833229 CC 146 1 Reference
TC 218 0.85 (0.62-1.16) 0.30
TT 91 0.85 (0.57-1.26) 0.42
anXa5 Annexin A5 rs6830321 GG 132 1 Reference
GA 216 0.79 (0.57-1.09) 0.15
AA 106 0.88 (0.61-1.29) 0.52
LrP1 low density lipoprotein 
receptor-related protein 1
rs1466535 GG 192 1 Reference
GA 207 1.31 (0.97-1.78) 0.08
AA 56 1.75 (1.15-2.66) 0.009
Qki Quaking rs3857504 CC 308 1 Reference
TC 126 1.16 (0.85-1.58) 0.35
TT 12 1.67 (0.78-3.57) 0.19
Qki Quaking rs3763197 TT 323 1 Reference
TC 122 1.10 (0.81-1.50) 0.54
CC 9 1.10 (0.41-2.96) 0.86
Qki Quaking rs2759393 CC 268 1 Reference
CA 157 0.96 (0.72-1.30) 0.80
AA 24 0.56 (0.26-1.20) 0.13
- 12q23.2 rs10861032 316 1 Reference
122 0.99 (0.72-1.37) 0.97
17 1.48 (0.76-2.92) 0.25
- 12q23.2 rs9804922 385 1 Reference
68 0.81 (0.53-1.24) 0.33
2 1.32 (0.18-9.40) 0.78
SNP, single nucleotide polymorphism; N, number of individuals; HR, hazard ratio; CI confidence interval.
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Table 3 Polymorphisms in growth factor related genes and association with AVF failure
Gene name snP Genotype n hr with 95% ci P
cDkn1b Cyclin-dependent kinase inhibitor 
1B
rs36228499 CC 147 1 Reference
(p27kip1) CA 234 1.01 (0.74-1.39) 0.93
AA 73 1.16 (0.76-1.76) 0.49
ctGf Connective tissue growth factor rs6918698 CC 128 1 Reference
GC 216 0.87 (0.63-1.20) 0.40
GG 108 0.87 (0.59-1.28) 0.48
fGfr4 Fibroblast growth factor receptor 4 rs351855 GG 210 1 Reference
GA 170 1.10 (0.82-1.49) 0.53
AA 52 0.69 (0.41-1.16) 0.16
kLf5 Kruppel-like factor 5 rs3812852 AA 393 1 Reference
GA 62 0.97 (0.65-1.44) 0.86
GG 1 1.95 (0.27-13.95) 0.51
PDGfD Platelet derived growth factor D rs974819 CC 225 1 Reference
TC 183 0.93 (0.69-1.25) 0.62
TT 46 1.18 (0.75-1.86) 0.48
PDGfD Platelet derived growth factor D rs496339 AA 366 1 Reference
GA 84 0.99 (0.69-1.42) 0.95
GG 4 0.49 (0.07-3.51) 0.48
tGfbr1 Transforming growth factor, beta rs1626340 AA 282 1 Reference
receptor1 GA 136 1.06 (0.77-1.44) 0.74
AA 19 1.01 (0.50-2.07) 0.97
tGfbr2 Transforming growth factor, beta rs1036095 GG 266 1 Reference
receptor2 GC 165 0.86 (0.64-1.17) 0.34
CC 24 0.64 (0.32-1.32) 0.23
tGfbr2 Transforming growth factor, beta rs4522809 AA 126 1 Reference
receptor2 GA 237 1.34 (0.94-1.89) 0.10
GG 90 1.42 (0.93-2.16) 0.10
VeGf Vascular endothelial growth factor rs2010963 GG 200 1 Reference
GC 196 1.17 (0.87-1.58) 0.30
CC 59 1.01 (0.65-1.58) 0.96
VeGf Vascular endothelial growth factor rs3025039 CC 344 1 Reference
TC 102 0.95 (0.68-1.33) 0.77
TT 10 1.20 (0.49-2.92) 0.69
VeGf Vascular endothelial growth factor rs699947 CC 124 1 Reference
CA 226 1.00 (0.72-1.40) 0.99
AA 100 1.01 (0.68-1.50) 0.98
SNP, single nucleotide polymorphism; N, number of individuals; HR, hazard ratio; CI confidence interval.
Genetics of arteriovenous fistula failure 187
10Genes implicated in calcium/phosphate metabolism
Eight SNPs were genotyped in the klotho, vitamin D receptor (VDR), and fetuin-A gene 
(Table 5). We did not find an association between AVF failure and the SNPs in the klotho 
gene (rs9527025, rs564481, rs397703 and rs577912), the VDR (rs11574027, rs2238135, 
and rs4516035) or the fetuin-A gene (rs4918).
Genes implicated in coagulation
Factor V rs6025, also known as factor V Leiden, was associated with a 2.54-fold (95% CI 
1.41-4.56, p = 0.002, FDR 0.005) higher risk of AVF failure. Rs1044291 and rs1800787 in 
the FGB gene were not associated with AVF failure (Table 6).
Table 4 Polymorphisms related to inflammatory genes and association with AVF failure
Gene name snP Genotype n hr with 95% ci P
iL6 Interleukin 6 rs1800795 GG 175 1 Reference
GC 217 1.06 (0.78-1.43) 0.73
CC 63 1.11 (0.72-1.71) 0.65
iL10 Interleukin 10 rs1800896 AA 130 1 Reference
GA 222 1.01 (0.73-1.39) 0.96
GG 102 0.73 (0.49-1.10) 0.14
iL10 Interleukin 10 rs3024498 AA 238 1 Reference
GA 176 1.03 (0.76-1.38) 0.87
GG 42 0.73 (0.42-1.25) 0.25
Lta lymphotoxin alpha (TNF rs1799964 TT 264 1 Reference
superfamily, member 1) TC 168 0.99 (0.74-1.33) 0.95
CC 24 0.71 (0.35-1.45) 0.35
rP105 CD180 rs5744478 TT 386 1 Reference
TC 67 0.97 (0.66-1.44) 0.88
CC 3 2.36 (0.75-7.38) 0.14
tnf Tumor necrosis factor alpha rs1800629 GG 311 1 Reference
GA 129 1.05 (0.77-1.44) 0.75
AA 16 1.97 (1.00-3.87) 0.05
tnf Tumor necrosis factor alpha rs361525 GG 420 1 Reference
GA 34 0.74 (0.41-1.33) 0.31
AA 1 NE
tLr4 Toll-like receptor 4 rs4986790 AA 393 1 Reference
GA 61 0.79 (0.51-1.23) 0.29
GG 2 2.91 (0.72-11.74) 0.13
SNP, single nucleotide polymorphism; N, number of individuals; HR, hazard ratio; CI confidence interval; 
NE, not estimable
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Our results did not change when we calculated hazard ratios in another model by 
combining heterozygote genotypes and mutant genotypes or heterozygote genotypes 
and wild-type genotypes. The 41 SNPs that were not associated with AVF failure re-
mained unassociated in other models.
interactions and combined effects
Female sex was associated with a 1.48-fold (95% CI 1.12-1.95) higher risk of AVF fail-
ure, p = 0.005. Furthermore, diabetes mellitus as primary kidney disease, as compared 
with other causes, was associated with a 2.01-fold (95% CI 1.42-2.85) higher risk of AVF 
failure, p < 0.001. The combination of factor V Leiden with diabetes mellitus or female 
sex and the combination of LRP1 rs1466535 AA genotype and female sex did not result 
Table 5 Polymorphisms related to calcium/phosphate metabolism and association with AVF failure
Gene name snP Genotype n hr with 95% ci P
klotho rs9527025 GG 358 1 Reference
GC 89 0.94 (0.66-1.34) 0.72
CC 6 0.69 (0.17-2.80) 0.61
klotho rs564481 CC 161 1 Reference
TC 204 1.25 (0.90-1.72) 0.18
TT 82 1.28 (0.86-1.92) 0.23
klotho rs397703 * TT 296 1 Reference
TC 133 1.16 (0.85-1.57) 0.35
CC 26 0.70 (0.34-1.43) 0.33
klotho rs577912 GG 328 1 Reference
TG 114 0.88 (0.63-1.22) 0.43
TT 11 0.72 (0.27-1.95) 0.52
VDr Vitamin D Receptor rs11574027 GG 443 1 Reference
TG 12 0.80 (0.33-1.93) 0.61
TT 0 NE
VDr Vitamin D Receptor rs2238135 GG 258 1 Reference
GC 163 1.15 (0.86-1.54) 0.36
CC 30 0.60 (0.30-1.19) 0.14
VDr Vitamin D Receptor rs4516035 AA 140 1 Reference
GA 209 1.04 (0.75-1.43) 0.82
GG 98 0.90 (0.60-1.35) 0.61
ahsG
alpha-2-HS-
glycoprotein rs4918 CC 212 1 Reference
(Fetuin-A) GC 193 1.06 (0.79-1.43) 0.70
GG 44 1.31 (0.82-2.09) 0.26
* rs397703 is a proxy for rs1207568 (R2 = 0.70). SNP, single nucleotide polymorphism; N, number of 
individuals; HR, hazard ratio; CI confidence interval; NE, not estimable
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in an higher risk on an additive scale using the RERI method (Supplementary Table 
S3). Patients with LRP1 rs1466535 AA genotype with diabetes mellitus had a 2.97-fold 
higher risk (95% CI 1.10-8.05, p = 0.03) of AVF failure as compared with patients without 
diabetes mellitus and without LRP1 rs1466535 AA genotype (reference), while patients 
without LRP1 rs1466535 AA genotype with diabetes mellitus had a 2.11-fold (95% CI 
1.48-3.01, p < 0.001) higher risk of AVF failure and patients with LRP1 rs1466535 AA 
genotype without diabetes mellitus had a 1.63-fold (95% CI 1.07-2.47, p = 0.02) higher 
risk of AVF failure (Supplementary Table S3).
When analyzing the two significantly associated SNPs (LRP1 rs1466535 and factor V 
Leiden) together, 269 patients were carrier of at least 1 risk allele of these two SNPs. Of 
these carriers, 48.3% developed AVF failure. In comparison, 36.7% of the patients with 
the wild type genotype of these SNPs (n = 210) developed AVF failure (p = 0.01).
Discussion
We investigated the association between AVF failure and 43 SNPs in 26 genes involved 
in processes related to endothelial function and vascular remodeling, growth factors, 
inflammation, coagulation, and calcium/phosphate metabolism. To our knowledge, 
this study is the largest study that investigated genetic risk factors of AVF failure. We 
showed that, after adjustment for multiple comparisons by using FDR, LRP1 rs1466535 
and factor V rs6025 (factor V Leiden) were significantly associated with a higher risk of 
Table 6 Polymorphisms related to coagulation and association with AVF failure
Gene name snP Genotype n hr with 95% ci P
fbG Fibrinogen-beta rs1044291 CC 204 1 Reference
TC 193 1.20 (0.89-1.62) 0.23
TT 56 1.12 (0.71-1.77) 0.63
fbG Fibrinogen-beta rs1800787 * CC 292 1 Reference
TC 137 0.90 (0.65-1.23) 0.50
TT 21 0.68 (0.32-1.46) 0.33
f5 Factor 5 rs6025 GG 435 1 Reference
GA 17 2.54 (1.41-4.56) 0.002
AA 1 NE
itGb3 integrin, beta 3 rs17218711 † GG 326 1 Reference
(platelet glycoprotein IIIa) GC 115 1.05 (0.76-1.45) 0.78
CC 15 1.12 (0.53-2.40) 0.76
* rs1800787 was a proxy for rs1800790 (R2 = 1.0). † rs1718711 was a proxy for rs5918 (R2 = 0.93). SNP, single 
nucleotide polymorphism; N, number of individuals; HR, hazard ratio; CI, confidence interval; NE, not 
estimable
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AVF failure. TNF rs1800629 was not significantly associated with AVF after adjustment. 
No significant associations of AVF failure were observed with the other SNPs.
The rs1466535 SNP in the LRP1 gene was the only SNP in the ‘endothelial function 
and vascular remodeling’ group that was significantly associated with AVF failure. In 
2011, this SNP was identified in a GWAS on abdominal aortic aneurysms and that this 
SNP has a possible functional role in LRP1 expression.20 The mechanism, by which LRP1 
could influence vascular remodeling leading to aneurysm formation, was suggested to 
involve regulation of MMP9 expression.20,28 Moreover, LRP1 was shown to be essential 
for the maintenance of vascular wall integrity mediated through PDGF receptor beta 
and Smad signaling.29 Interestingly, in our study patients carrying the variant A allele 
had a higher risk of developing AVF failure, whereas in the above mentioned study,20 the 
wild type allele was the risk allele. Whether this opposite effect indicates that AVF failure 
is mediated through a lack of vascular expansion, which is necessary for AVF matura-
tion, of that another function LRP1 is involved in AVF failure is unclear. Nevertheless, the 
observed association of the LRP1 SNP with AVF failure suggests a potential role for LRP1 
in vascular remodeling and AVF maturation.
We also showed that factor V Leiden was associated with a 2.54-fold (95% CI 1.41-
2.56, p = 0.002) higher risk of AVF failure. Factor V Leiden is one of the most common 
inherited pro-coagulatory defects and is a well-known risk factor for venous thrombo-
sis.30 A previous study also showed that factor V Leiden was associated with vascular ac-
cess failure.31 In agreement with these observations, another recent study showed that 
another SNP in the factor V gene was associated with AV access failure in hemodialysis 
patients.24 Furthermore, thrombophilia (including factor V Leiden) was associated with 
an increased risk of vascular access dysfunction in a yet another study.32 Together, these 
studies provide growing evidence of a role of factor V Leiden mutation in AV access 
failure.
Although the -308G>A (rs1800629) SNP in the TNF gene did not remain significantly 
associated with AVF failure after multiple testing correction, we think it is worthwhile 
discussing. Since the vascular inflammatory response is likely an important contributor 
to AVF failure, genetic variation in inflammatory related genes could be associated with 
AVF failure. In our study, individuals with the AA genotype of rs1800629 had a non-sig-
nificant higher risk of AVF failure. This SNP has been the focus of several previous studies, 
focusing on a wide variety of endpoints, including cardiovascular events in rheumatoid 
arthritis patients,33 irritable bowel syndrome,34 life-expectancy,35 tuberculosis suscepti-
bly,36 mortality after acute renal failure37 and comorbidity and functional status scores in 
hemodialysis patients.38 The other analyzed SNP in the TNF gene (rs361525) was also not 
associated with AVF failure in our study, although it was previously associated with coro-
nary restenosis.39 The two SNPs in the anti-inflammatory cytokine IL10 demonstrated 
a non-significant lower risk of AVF failure development, possibly due to lack of power. 
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Remarkably, these two SNPs were shown to increase the risk of coronary restenosis18 
and cardiovascular events during hemodialysis.40 Whether this discrepancy is caused by 
the differences in the mechanisms of AVF failure and coronary restenosis remains to be 
elucidated.
For this study, besides previously reported candidate genes for AV access failure, 
we also selected SNPs in genes related to coronary restenosis and aortic aneurysm 
formation. Processes involved in AVF patency, in particular VSMC proliferation and 
inflammation, play also a key role in the development of coronary restenosis after PCI.13 
In contrast with the scarcely available data on genetic determinants of AV access failure, 
the genetic background of coronary restenosis has been more established.12,13 Although 
our SNP selection covered a wide range of candidate genes in all involved mechanisms, 
the obtained results do not indicate an important role for our selected SNPs in the devel-
opment of AVF failure. One explanation for these observations could be that other SNPs 
are involved in AVF failure or that genetic susceptibility does not play an important role 
in the development of AVF failure. Based on other studies that also did not find an as-
sociation between most candidate SNPs and AV access failure,23-25,41 it might be that local 
factors, such as hemodynamics and vascular damage, have a more important role in the 
failure of the vascular access required for hemodialysis than the genetic background.
Diabetes mellitus is a well-known risk factor for both renal disease and cardiovascular 
complications as well as for AVF failure in dialysis patients.42-44 The prevalence of diabetes 
among dialysis patients differs considerably worldwide. According to the European Re-
nal Association-European Dialysis and Transplant Association (ERA-EDTA) Registry, the 
prevalence of diabetes mellitus among dialysis patients in Europe is 22%,45 in line with 
the relative low prevalence in our study population. Although the interaction analysis 
does show some influence of diabetes on the genetic associations, elaborate subgroup 
analyses are not appropriate considering the low proportion of diabetic patientsin our 
population.
Our study has several potential limitations. We had no information about AVF failure 
before the first successful dialysis session. Whether inclusion of non-maturating fistula 
would have affected our results is questionable. It is conceivable that the maturating 
process of an AVF is mechanistically different compared to AVF failure of a well-maturated 
fistula. Excluding the non-maturating AVF likely resulted in a more homogeneous study 
endpoint. However, this hypothesis remains speculative since we do not have data to 
explore this. Also we had no information about the protocols that were used in the vari-
ous centers for access surveillance to detect stenosis prior to failure. Furthermore, we 
had no information about the cause of fistula failure (i.e. thrombosis, stenosis or other). 
A previous suggested that hospital specific aspects contribute to AVF failure.46 Unfortu-
nately, we do not have information about differences of fistula creation in the involved 
centers, about the experience of surgeons in fistula creation or about the surgical tech-
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niques used to create a fistula. Another limitation is that, despite of our large number of 
patients, we had limited power to find an association between AVF failure and several 
SNPs. In addition, we investigated the association between multiple SNPs and fistula fail-
ure, thereby increasing the chance of false positive findings. However, since we selected 
only candidate genes based on previous studies, and because we adjusted for multiple 
comparisons by using false discovery rates (with the threshold set at 20%, previously 
suggested to be an appropriate threshold for candidate gene association studies27), we 
have tried to minimize the chance of false positive findings. The general strength of this 
study was the large and well-defined Dutch cohort of incident hemodialysis patients 
with available DNA for investigation of genetic risk factors. Another potential strength 
of our study was that we only included incident hemodialysis patient, thereby limiting 
survivor bias.
Current guidelines for prevention of vascular access failure recommend uniform 
surveillance of all patients.47 Identification of genetic risk factors might lead to a more di-
rected approach for surveillance techniques. Risk factors for primary patency loss could 
be used to focus on specific patient groups for more intensive surveillance. Furthermore, 
increasing your understanding to the molecular mechanisms of AVF failure, could aid 
the development of better preventive measures or new treatment modalities.
In conclusion, we found that LRP1 rs1466535 and factor V Leiden were associated 
with an increased risk of AVF failure. Other SNPs in vascular function and remodeling re-
lated genes, growth factors genes, inflammation genes, coagulation genes, and calcium 
metabolism genes were not significantly associated with AVF failure. Further studies on 
the genetics of AVF failure are needed to unravel the underlying mechanisms of this 
deleterious condition and thereby help us improve prevention and treatment of AVF 
failure in this diseased population.
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Supplementary Material is available at PLoS One online.
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abstract
Pharmacogenetics is the search for heritable genetic polymorphisms that influence 
responses to drug therapy. The most important application of pharmacogenetics is 
to guide choosing agents with the greatest potential of efficacy and smallest risk of 
adverse drug reactions. Many studies focussing on drug-gene interactions have been 
published in recent years, some of which led to adaptation of FDA recommendations, 
indicating that we are on the verge of the clinical application of genetic information in 
drug therapy. This systematic review provides a comprehensive overview of the current 
knowledge on pharmacogenetics of all major drug classes currently used in the treat-
ment of cardiovascular diseases.
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introDuction
Pharmacogenetic studies search for heritable genetic polymorphisms that influence 
responses to drug therapy. Pharmacogenetics has many possible applications in car-
diovascular pharmacotherapy including screening for polymorphisms to choose agents 
with the greatest potential for efficacy and least risk of toxicity. Pharmacogenetics also 
informs dose adaptations for specific drugs in patients with aberrant metabolism.
Each year an estimated 785 000 Americans suffer a myocardial infarction (MI) and 
610 000 people experience a new stroke. Despite advances in management, 470 000 
recurrent MIs and 185 000 recurrent strokes occur annually.1 The numbers from Europe 
are not much better, indicating the importance of optimizing treatment strategies.2
Although several reviews on pharmacogenetics in cardiology have been published, 
most focused on specific drug subgroups. This systematic review offers a comprehen-
sive summary of the current knowledge of pharmacogenetics in cardiology, elaborates 
on progress towards individualized drug therapy, and incorporates conclusions made 
during the Colloquium “Pharmacogenetics of cardiovascular drugs: implications for a 
safer and more efficient drug therapy” held by the Royal Netherlands Academy of Arts 
and Sciences in October 2010. In particular, the review considers the most relevant and 
well studied polygenic markers for some pressing clinical issues: (i) statins: focusing on 
variability in efficacy and risk of myopathy; (ii) resistance to antiplatelet medication; (iii) 
dosing issues with oral anticoagulants; (iv) suboptimal responses to β-blockers; and (v) 
the variable response in blood pressure and clinical events in patients taking angioten-
sin converting enzyme (ACE) inhibitors (Table 1).
Table 1 Major issues in cardiovascular drug pharmacogenetics and the strength of the genetic evidence
Drug class Problem evidence
Statins
Variable lipid lowering Mediocre
Risk of myopathy Strong
Antiplatelet drugs Resistance Strong
Anticoagulants Dosing problems Strong
β-blockers Variable response Poor
ACE-inhibitors
Variable blood pressure reduction Mediocre
Variable benefit to decrease risk of events Mediocre
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methoDs
Relevant articles were identified by searching MEDLINE using the following keywords 
and Medical Subject Headings (MeSH) terms: pharmacogenetics, genetic heterogeneity, 
genetic polymorphism, single nucleotide polymorphism (SNP), haplotypes, treatment 
outcome, adverse effects, drug therapy, cardiovascular diseases (CVDs), and/or coronary 
disease. We screened the title and abstract of possibly relevant citations and retrieved, if 
potentially interesting, full reports or abstracts. We checked the references of retrieved 
publications for additional relevant papers and included all available literature until May 
2011. We excluded reviews, editorials and articles in languages other than English.
statins: VariabiLity in efficacy anD risk of myoPathy
Statins, or 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, are 
widely prescribed to lower plasma cholesterol levels, thereby reducing cardiovascular 
risk. Despite the clinical effectiveness of statins, proven in large randomized controlled 
trials,3,4 inter-individual variation in response means that many patients fail to achieve 
adequate reduction of cholesterol levels even after multiple dose adjustments.5 Genetic 
factors are thought to be partly responsible for this inter-individual variation Indeed, 
more than 40 candidate genes have been described with respect to the differential ef-
fect of statins in decreasing the risk of clinical endpoints including cardiovascular death, 
MI and lipid lowering abilities (see Supplementary material online, Table S1).
Variability in lipid lowering
Several pharmacogenetic studies examined the gene encoding the cholesterol ester 
transfer protein (CETP) involved in cholesterol metabolism and, in particular, the TaqIB 
variant (rs708272). Initial studies associated the B2B2 genotype with lower CETP levels,6 
higher high density lipoprotein cholesterol (HDL-C) levels and lower risk of progression 
of coronary artery disease (CAD), compared with the B1B1 genotype.7-11 However, on 
statin treatment B1B1 patients showed lower progression of CAD than B2B2 carriers. 
A meta-analysis confirmed the firm association between TaqIB and HDL-C levels and 
CAD risk, while no significant interaction between this polymorphism and pravastatin 
treatment could be demonstrated.12 This meta-analysis included studies that enrolled 
patients with and without a history of CAD. In contrast, the original study included 
only patients with significant CAD.7 Furthermore, long-term results from the Regres-
sion Growth Evaluation Statin Study (REGRESS), the first study to report the possible 
pharmacogenetic interactions between the CETP polymorphism and statin treatment,13 
also contrast with the meta-analysis. REGRESS demonstrated significantly higher 10-
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year mortality in statin-treated male patients carrying the B2 allele, compared with the 
B1B1 genotype.14 Therefore, although untreated B2B2 patients have a lower risk of CAD 
progression, statin treatment is more beneficial in patients with the B1B1 genotype, 
negating the initial advantage of the B2 allele in CAD.
The extensive studies of apolipoprotein E (APOE), and in particular the ε2/ε3/ε4 
variants defined by combinations of two polymorphisms (Cys112Arg, rs429358 and 
Arg158Cys, rs7412) are equivocal.15 Several studies report an association between ε2 
carriers and an increased lipid lowering response to statins or reduced cardiovascular 
outcomes, such as nonfatal MI and cardiovascular-related mortality, whereas other stud-
ies did not find significant associations.16 Although the first genome-wide association 
study (GWAS) on statin effects showed a significant association between the three APOE 
polymorphisms and the low-density lipoprotein cholesterol (LDL-C) response,17 a recent 
meta-analysis did not confirm this association.18 Therefore, it seems unlikely that a true 
association exists between APOE polymorphisms and the lipid lowering response to 
statin treatment.
Since most studies discussed so far had insufficient power to detect the small effect 
produced by individual genetic loci, Barber et al.19 combined three statin GWASs en-
compassing 3936 patients. Carriers of a polymorphism (rs8014194) in the calmin (CLMN) 
gene on chromosome 14 had a significantly greater reduction of 3% in total cholesterol 
compared to non-carriers. The exact function of calmin is unknown, but it contains a 
calponin-domain expected to have actin-binding activity20 and is strongly expressed by 
liver and adipose tissue.21 Nevertheless, this polymorphism explained only 1% of the 
variability in statin response.19 A SNP near APOE, in the APOC1 gene (rs4420638), showed 
moderate evidence for being associated with statin-induced LDL-C changes. Most other 
putative associations appeared to be independent of statin treatment and were in loci 
previously associated with lipid or lipoprotein traits.19
kinesin-like protein 6 and variability in clinical outcome
Next, carriers of the arginine-coding allele (rs20455) of kinesin-like protein 6 (KIF6) 
showed a substantially higher benefit with pravastatin treatment compared with 
non-carriers in three large clinical trials, which appeared to be independent from lipid 
and C-reactive protein-lowering effects.22-24 Kinesin-like protein 6 is a member of the 
molecular motor super family involved in the intracellular transport of several important 
molecules, including mRNA.25 A recent meta-analysis of 19 studies (in total 17 000 CAD 
cases and 39 369 controls) concluded that the SNP in question was not associated with 
the risk of CAD.26 This study was, however, unable to explore the effect of statins, since 
this information was not available of all included studies, but the probability of a strong 
influence on the effect of statin decreases with this publication. Nevertheless, further 
(functional) studies are needed to explore the role of KIF6.
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risk of myopathy
Genetic variations are also associated with an altered risk of adverse drug reactions 
(ADRs), especially statin-induced myopathy. The incidences of myopathy and rhabdo-
myolysis are estimated at 11.0 and 3.4 per 100 000 person-years respectively. The case 
mortality rate with rhabdomyolysis is 10%.27
The polypeptide organic anion transporter P1B1 (OATP1B1) encoded by the SLCO1B1 
gene is involved in the hepatic uptake of statins.28,29 Two common polymorphisms 
(521T>C, rs4149056 and 388A>G, rs2306283) influence the transporter function of 
OATP1B1,30 markedly altering statin pharmacokinetics.31 A GWAS showed a strong 
association between a non-coding polymorphism (rs4363657) and statin-induced my-
opathy in patients treated with high-dose simvastatin.32 This polymorphism is in almost 
complete linkage disequilibrium (R2 = 0.97) with the 521T>C polymorphism and was 
expressed by more than 60% of patients who developed myopathy with an odds ratio of 
4.7 per copy of the C allele.32 A subsequent study confirmed this pharmacogenetic effect 
in simvastatin-induced myopathy,33 but not with either atorvastatin or pravastatin,33 
probably indicating a simvastatin specific effect.34
In conclusion, the reports on genetic variability and response to statin treatment are 
difficult to interpret. Variability in study designs and endpoint definitions probably con-
tribute to these mixed results. Since statins’ full pharmacodynamic spectrum, besides 
their lipid-lowering properties, remains largely unknown, it is not surprising that clear 
cut pharmacogenetic results are lacking. It is likely that future research will further elu-
cidate statins’ exact mechanisms of action and help explain the variability in response. 
Newly identified loci influencing lipid concentration identified in recent GWAS, might 
also prove to have pharmacogenetic associations with statin treatment.35,36 Pharmaco-
genetic data on ADRs of statin is limited and more research dedicated to this problem is 
needed before concrete advises can be given on this notion.
resistance to antiPLateLet meDication
Blood platelets maintain appropriate hemostasis upon vascular injury, but also contrib-
ute to the pathophysiology of thrombosis. Thrombosis of atherosclerotic plaques is the 
most important underlying mechanism of CAD and embolic stroke, and consequently 
antiplatelet therapy is the cornerstone of secondary prevention in modern CVD treat-
ment.37-40 Inter-patient variations in platelet reactivity and responses to antithrombotic 
treatment result in marked differences in the benefits derived from antiplatelet treat-
ment. Indeed, up to 25% of patients continue to experience new thrombotic events 
despite guideline therapy.41,42 The term ‘resistance’ is widely used in such cases, although 
a clear-cut definition is lacking.43 The current clinical definition regards resistance as 
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recurrent cardiovascular events despite supposed adequate therapy. Biochemical 
definitions which are based on residual platelet activity during treatment measured 
ex-vivo by several laboratory tests, are however also clinically relevant. Trenk et al.44 for 
example, found a three-fold increase (95% confidence interval (CI) 1.4-6.8, P = 0.004) in 
the 1-year incidence of death and MI among patients with high residual platelet activity 
at discharge after percutaneous coronary intervention (PCI) despite clopidogrel. How-
ever, although it is likely that biochemically non-responsive patients are also clinically 
non-responsive, biochemical ‘resistance’ is neither constant in an individual nor over 
time.42 Furthermore, there is an evident lack of concordance between laboratory tests 
used to express resistance.45-47
Against this background, recent research suggests that genetic variation makes 
an important contribution to variation in responses to the three main groups of anti-
platelet therapy: aspirin (see Supplementary material online, Table S2); thienopyridine 
derivates [clopidogrel (see Supplementary material online, Table S3), prasugrel (see 
Supplementary material online, Table S4), and the P2Y12 receptor antagonist ticagrelor]; 
and GP IIb/IIIa receptor inhibitors (orbofiban and abciximab) (see Supplementary mate-
rial online, Table S5).
aspirin
The antiplatelet effects of aspirin (acetylsalicylic acid) arise from irreversible acetylation 
of cyclooxygenase (COX)-1, which catalyzes the formation of thromboxane A2, prosta-
glandin and related metabolites from arachidonic acid.48,49 Blocking COX-1 decreases 
the formation of thromboxane A2, thereby reducing platelet aggregation.50 Aspirin 
resistance is poorly defined: a patient can be a non-responder in one test and a normal 
responder in another. Because of this lack of uniformity, the reported prevalence of 
aspirin resistance differs widely between studies. A recent systematic review reported 
a mean prevalence of aspirin resistance of 24% with a range between 0% and 57%.51
conflicting results on aspirin efficacy
Of the many pharmacogenetic studies on aspirin, Hanlushka et al.49 were the first to 
describe an effect of two polymorphisms in the COX-1 gene, -842A>G (rs10306114) and 
50C>T (rs3842787), that are in complete linkage disequilibrium. Healthy individuals 
heterozygous for these polymorphisms showed greater inhibition of platelet aggrega-
tion compared to homozygotes of the wild-type allele. Two later studies confirmed this 
relationship in CAD patients.52,53 However, many other studies failed to find significant 
associations between variation of the COX-1 gene and residual platelet activity54,55 or 
clinical events, including non-fatal MI or cardiac death.56
Platelet glycoprotein (GP) IIb/IIIa receptors bind fibrinogen, thereby cross-linking 
platelets and von Willebrand factor (vWF).57 Studies that focused on the 1565T>C 
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polymorphism (rs5918; PlA1/A2) of the GP IIIa (integrin β3) gene produced highly vari-
able conclusions (see Supplementary material online, Table S2). A meta-analysis that 
included most of these studies concluded that the PlA1/A2 variant was significantly as-
sociated with aspirin resistance, but only in healthy individuals.45 Co-medications used 
by CVD patients potentially obscured aspirin resistance, while differences in laboratory 
techniques may have also influenced outcome.
The meta-analysis also revealed that variations of four other genes [GP Ia (807C>T, 
rs1126643), COX-1 (-842A>G/50C>T), P2Y12 (H1/H2, constituted by rs10935838, 
rs2046934, rs5853517 and rs6809699) and P2Y1 (1622A>G, rs701265)] were not as-
sociated with aspirin resistance.45 However, a later relatively large study, including 200 
high-risk atherosclerosis patients, found a strong association between aspirin resistance 
and the T allele of the 807C>T polymorphism of the GP Ia gene.58 A further study ruled 
out any influence of the -842A>G/50C>T polymorphism of COX-1 and PlA1/A2 of GP IIIa 
on platelet response in a healthy Chinese population, in which these sites were non-
polymorphic. However, the study showed attenuated antiplatelet effect during aspirin 
treatment in the presence of the P2Y1 893CC genotype (rs1065776).
55 This last association 
contrasts with results from 469 Caucasian patients with a history of MI. Here, carriers of 
the 893T allele had an almost three-fold increased risk of aspirin resistance compared to 
the CC genotype.59
complications of aspirin therapy
A small number of studies focused on genes involved in aspirin-related ADRs. Park et 
al.60,61 reported that the promoter polymorphisms -863C>A (rs1800630) and -1031T>C 
(rs1799964) of TNF-α and -509C>T (rs1800469) of TGF-β1 may contribute to aspirin-
induced urticaria. Piazuelo et al.62 related the carriage of the A allele of the 27 bp variable 
number tandem repeats of eNOS with a decreased risk of upper GI bleeding. Further 
pharmacogenetic reports on ADRs of aspirin are necessary given the widespread pre-
scription of aspirin.
In conclusion, the precise role of genetic variation in the variability of response to 
aspirin treatment has yet to be defined. The only consistent association is that of the 
PlA2 variant of the GP IIIa gene and aspirin resistance in healthy individuals. Standardiza-
tion of techniques to measure and define response is a prerequisite for future studies, 
and to establish genetic variation’s contribution to aspirin resistance.
thienopyridine derivates/P2y12 receptor inhibitors
Clopidogrel resistance is common: the incidence was 21% (95% CI 17-25%) in a meta-
analysis of patients after PCI.42 Estimates of the incidence vary widely between studies, 
mainly due to differences in the time of measurement and dose of clopidogrel. However, 
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the technique used to assess clopidogrel responses did not result in a different preva-
lence of clopidogrel resistance between studies.42
Clopidogrel is an orally administered prodrug. Intestinal absorption is limited by 
P-GP, an efflux pump encoded by the ABCB1 gene. Most of the bioavailable fraction 
undergoes hydrolysis to an inactive metabolite. Approximately 15% is oxidized by the 
hepatic cytochrome (CYP) P450 system in two sequential steps to generate an active 
metabolite,63 which binds to, and irreversibly inhibits, the platelet ADP receptor P2Y12. 
By blocking this receptor, clopidogrel prevents platelet degranulation and inhibits 
conversion of the GP IIb/IIIa receptor to the form that binds fibrogen and links platelets, 
thereby inhibiting platelet aggregation.64-67
metabolism and resistance
Several studies examined the influence of genetic variation in one or more enzymes of 
the CYP450 system on clopidogrel resistance. The most consistent finding is that the *2 
allele of the CYP2C19 gene (rs4244285) (involved in both hepatic oxidative steps) leads 
to the formation of an inactive enzyme and, therefore, decreased platelet responsive-
ness to clopidogrel68 (Figure 1). After the first report,68 which enrolled healthy male vol-
unteers, studies replicated the reduced platelet responsiveness in vitro and established 
an increased risk of cardiovascular events and death during clopidogrel treatment in 
different patient populations (see Supplementary material online, Table S3). Other 
loss-of-functions alleles (*3, rs4986893; *4, rs28399504 and *5, rs56337013) have been 
associated with clopidogrel resistance although not as strongly and as consistently as 
the *2 allele, probably reflecting their lower allele frequencies.69-72 Furthermore, recent 
studies associated a gain-of-function allele (*17, rs1248560) and a higher platelet inhibi-
tion by clopidogrel and, as a consequence, increased bleeding risk.73,74
The CYP2C9 loss-of-function allele *3 (rs1057910) has been associated with increased 
residual platelet activity and poor responder status after a 300 mg clopidogrel loading 
dosage in healthy subjects69 and CVD patients.76 Surprisingly, the latter study could not 
detect a similar effect of the risk allele during clopidogrel maintenance therapy. The 
authors hypothesized that since this enzyme is involved in the second metabolization 
step, the reduced enzyme capacity of the *3 allele becomes critical only with higher 
clopidogrel plasma concentrations.63
Studies on genetic variation in other involved CYP450 enzymes, especially CYP3A4 
and CYP3A5, did not show a significant influence on platelet responsiveness after clopi-
dogrel treatment (see Supplementary material online, Table S3). From a clinical point of 
view, an important finding came from Gladding et al.,77 who demonstrated that increas-
ing the clopidogrel dose in patients with non-responder CYP2C19 polymorphisms can 
increase the antiplatelet response, indicating that personalizing doses using pharmaco-
genetics could potentially optimize treatment.
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Drug transport and receptors
Although CYP2C19 polymorphisms probably account for most of the variability in 
clopidogrel response, variations in the function of intestinal efflux transporters might 
also influence clopidogrel bioavailability. For instance, the 3435C>T SNP of ABCB1 
(rs1045642) was shown to influence P-glycoprotein transporter expression, resulting in 
two- to four-fold lower peak concentrations of clopidogrel and its active metabolite in 
TT carriers after oral administration.78 Two recent studies confirmed these findings70,79. 
Mega et al.79 also reported that the increased risk of events of 3435TT homozygotes 
increased further in combination with a CYP2C19 loss-of-function allele. However, not all 
published papers show consistent results76 and a recent GWAS could not reproduce the 
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association between this polymorphism and clopidogrel pharmacodynamics in healthy 
volunteers.80
Another candidate gene encodes the P2Y12 receptor, which is essential for platelet 
inhibition exerted by clopidogrel, prasugrel and ticagrelor.81-83 Ziegler et al.84 reported 
a four-fold increased risk for cerebrovascular events in patients that carried the 34C>T 
(rs6809699) variant of the P2Y12 receptor receiving clopidogrel for peripheral artery 
disease. Moreover, Staritz et al.85 associated another polymorphism (52G>T, rs6785930) 
to clopidogrel resistance in patients receiving dual antiplatelet therapy (clopidogrel and 
aspirin) after PCI. However, other studies could not confirm these findings with respect 
to platelet response or cardiovascular events.70,86,87
Finally, T allele carriers of the GP Ia gene 807C>T (rs1126643) polymorphism show 
increased platelet aggregation during clopidogrel treatment than non-carriers, increas-
ing their thrombotic risk.88 The same group confirmed these results in patients receiving 
dual antiplatelet therapy.89 However, another study could not confirm these results in 
600 acute coronary syndrome (ACS) patients on dual antiplatelet therapy.90 The PlA poly-
morphism of the platelet GP IIIa gene (rs5918) probably does not influence the effect 
of thienopyridine derivates, although small studies report positive as well as negative 
effects.91,92 Simon et al.70 did not find a significant association of the PlA polymorphism in 
a population consisting of 2208 patients with acute MI treated with clopidogrel and the 
rate of cardiovascular events (225 deaths and 94 non-fatal MIs or strokes).
In conclusion, resistance to clopidogrel is a major problem, and prediction of the 
problem could be of great value. The CYP2C19 loss-of-function allele *2 shows the most 
promise in predicting clopidogrel resistance and subsequent treatment failure, although 
this was not demonstrated by all studies.93 Many other polymorphisms in theoretically 
promising target genes do not produce consistent results. Furthermore, proton pump 
inhibitors, especially omeprazol, show high affinity for CYP2C19 and might inhibit clopi-
dogrel metabolism, raising concerns about concomitant use.94 Clinical evidence of this 
adverse drug-drug interaction, however, derives mainly from observational studies. A 
recent review concluded that although definite evidence is lacking and further studies 
are needed, clinicians should keep in mind this possibly clinically relevant interaction 
when considering prescribing this combination.94
Prasugrel
The pharmacogenetics of prasugrel, a newer thienopyridine, has not been as compre-
hensively investigated as clopidogrel. Nevertheless, several studies indicate that the 
main contributor to clopidogrel resistance, CYP2C19*2, does not affect prasugrel’s effi-
cacy.69,95 In a large study, no significant attenuation of the prasugrel response was found 
in carriers of at least one of the known loss-of-function alleles of the tested CYP 450 
genes. Furthermore, in ACS patients none of the genotypes was associated with clinical 
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cardiovascular events95. Prasugrel’s metabolic pathway explains this lack of association; 
CYP2C19 makes only a minor contribution to prasugrel’s metabolism. CYP3A4 and 
CYP2B6 are largely responsible for converting prasugrel to its active form.95,96 CYP3A4 
appears not to be very polymorphic and no clear association emerged between CYP2B6 
variants and prasugrel function.95 Prasugrel’s strong antiplatelet effect leads to a highly 
reduced residual platelet activity, making any effect of genetic variation difficult to 
determine. Prasugrel inhibits platelets sufficiently to reduce clinical endpoints despite 
decreased efficacy arising from the polymorphisms.
ticagrelor
The newest P2Y12 receptor antagonist, ticagrelor, appears to be superior to clopidogrel
81,83 
and has similar potency as prasugrel.82 A genetic sub study of the largest ticagrelor trial 
to date, the PLATelet inhibition and patient Outcomes (PLATO) trial, genotyped 10,285 
patients randomized to ticagrelor or clopidogrel treatment. No interaction between ti-
cagrelor and any loss-of-function CYP2C19 allele (*2 till *8), gain-of-function CYP2C19*17 
allele or ABCB1 3435C>T genotype emerged with regard to the either primary efficacy 
endpoint (composite of cardiovascular death, MI or stroke) or any type of major bleed-
ing after up to 12 months treatment.74
Glycoprotein iib/iiia antagonists
Glycoprotein IIb/IIIa antagonists are mechanistically different from aspirin, thienopyri-
dine derivates and other P2Y12 inhibitors. Glycoprotein IIb/IIIa antagonists act primarily 
outside the platelet by competitively inhibiting the receptor essential for platelet bridg-
ing and aggregation97. Several studies have focused on polymorphisms in the GP IIIa gene 
and antiplatelet effect, but the results appear inconclusive. One study on orbofiban98 
and two on abciximab99,100 found a relationship between the PlA2 allele with reduced 
platelet inhibition and increased cardiovascular event rate. However, other studies did 
not replicate this association.101-103 In addition, Shields et al. developed a model to predict 
recurrent events during orbofiban treatment that included 10 candidate genes: platelet 
receptors GP IIIa, PlA1/A2 (rs5918) , GP Ia 807C>T (rs1126643), GP Ibα, -5C>T (rs2243093); 
platelet ligands β-fibrinogen, -455G>A (rs1800790) and vWF, -1051G>A; interleukins 
IL-1RN*2, and IL-6, -174G>C (rs1800795); adhesion proteins E-selectin, 128A>C (rs5361) 
and P-selectin, 715A>C; and metalloproteinase MMP-9, -1562C>T. In 924 ACS patients an 
association emerged between a combination of genetic variants and both recurrent MIs 
and bleeding outcomes during orbofiban treatment.104 Since the influence of individual 
genetic polymorphisms is usually small, combining multiple variants in a model might 
be useful. However, interpreting the results may be more difficult.
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DosinG issues With oraL anticoaGuLants
Coumarin anticoagulants (vitamin K antagonists), are widely used to treat and prevent 
venous and arterial thromboembolisms. However, anticoagulants’ narrow therapeutic 
range necessitates frequent monitoring of the INR (International Normalized Ratio) 
coagulation status, which is expensive for health care systems and inconvenient for 
patients. The large individual variability in drug response with all three of the most 
frequently prescribed anticoagulants (warfarin, acenocoumarol and phenprocoumon) 
complicates therapy and makes defining a standard fixed dose unachievable. Besides 
several patient-related (amongst others age, weight, body surface area and diet) and 
clinical factors (hepatic or renal disease, anemia, co-medication), pharmacogenetics 
explains a large part of the variability in dose requirements105-107 (see Supplementary 
material online, Table S6).
increased metabolism
Furuya et al.108 first reported the influence of polymorphisms in CYP2C9, the primary 
enzyme involved in warfarin metabolism, on dose requirement in vivo. Carriers of the *2 
allele (rs1799853) required a 20% lower warfarin dose to maintain a target INR between 
2 and 4. Later studies associated the *3 (rs1057910) allele with an increased sensitivity to 
warfarin.109 In vitro, the *2 and *3 genotypes decrease CYP2C9 activity by 30% and 80% 
respectively.110,111 A large meta-analysis of 39 studies encompassing 7907 patients112 
concluded that, compared to the wild type CYP2C9*1/*1 genotype, all variant genotypes 
(*1/*2, *1/*3, *2/*2, *2/*3 and *3/*3) required lower maintenance doses of warfarin. For 
instance, maintenance doses in the *2 and *3 homozygotes were 36% and 78.1% lower 
respectively.
However, using this pharmacogenetic knowledge in clinical practice is difficult. 
A meta-analysis investigating the safety and efficacy of genotype-guided dosing of 
warfarin in reducing the occurrence of major bleeding events and over-anticoagulation 
found a non-significant trend towards more rapid achievement of a stable dose in the 
genotype-guided dosing arm.113 Several ongoing randomized controlled trials, which 
are expected to encompass more than 2500 patients will help elucidate the role of 
genetic testing in warfarin management.113
a second contributor
Another extensively studied gene is that encoding VKORC1 (vitamin K epoxide reduc-
tase complex subunit 1), which converts the oxidized, inactive form of vitamin K to the 
reduced, active form. Coumarins inhibit VKORC1, thereby inhibiting activation of the 
vitamin K dependent clotting factors II, VII, IX and X.114 A recent meta-analysis analyzed 
the relationship between mean maintenance dose of warfarin and three VKORC1 
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polymorphisms (1173T>C, rs9934438; 3730G>A, rs7294 and -1639A>G, rs9923231).115 
Carriers of 1173T>C and -1639A>G needed higher maintenance warfarin doses.
Genetic variation in several other genes—including APOE, glutamyl carboxylase 
(GGCX), calumenin (CALU), CYP4F2, epoxide hydrolase 1 (EPHX1) and factor VII (F7)—may 
also influence warfarin dosage requirements. However, although some studies found 
significant associations, results were inconsistent.106,116-120 Finally, recent GWASs identi-
fied CYP2C9 and VKORC1 only as major hotspots, indicating that polymorphisms in other 
genes probably only have minor influence on warfarin dosing117,121.
Although warfarin is usually the anticoagulant of choice, acenocoumarol and phen-
procoumon are used in most European countries.122 All three drugs are metabolized by 
CYP2C9. However, phenprocoumon appears to be less influenced by CYP2C9 polymor-
phisms123 due to significant metabolism by the non-polymorphic CYP3A4.122 The effect of 
the VKORC1 polymorphism is similar for all three drugs.122,124,125
Dosing advice with genetic guidance
In conclusion, the association between warfarin dose and polymorphisms of the CYP2C9 
and VKORC1 genes seems unquestionable, as demonstrated by numerous studies and 
several meta-analyses. Polymorphisms in CYP2C9 and VKORC1 together with additional 
clinical factors including co-medication, account for 50-60% of the inter-individual 
warfarin variability.106,126-128 Based on this evidence, a free web site is available to help 
clinicians estimate the therapeutic dose in patients new to warfarin (http://www.war-
farindosing.org) (Figure 2). Furthermore, the U.S. Food and Drug Administration (FDA) 
now recommends considering lower initiation doses of warfarin for patients with certain 
polymorphisms in CYP2C9 and VKORC1.129
suboPtimaL resPonses to β-bLockers
β-blockers competitively antagonize β-adrenergic receptors (β-AR). Chronic β1-AR 
activation contributes to the pathogenesis of heart failure and β-AR blockade improves 
survival, remodeling and left ventricular ejection fraction (LVEF).130-132 Other major indi-
cations for β-blocker therapy are hypertension, angina pectoris and MI. As with most 
other drugs, not all patients benefit from β-blockers to the same extent, possibly due to 
genetic variation (see Supplementary material online , Table S7).
receptors and treatment efficacy
The primary focus of studies examining pharmacogenetic determinants of β-blocker 
response has been the β-AR genes and two polymorphisms - Ser49Gly (rs1801252) and 
Arg389Gly (rs1801253) - in the beta-1 adrenergic receptor (ADRB1) gene in particular. 
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Ser49Gly and Arg389Gly are in linkage disequilibrium and 65% of the population carry 
the Ser49/Arg389 haplotype.133 Not all studies reported consistent results, but a meta-
analysis combining 3 studies (encompassing 504 heart failure patients), concluded that 
Arg389 homozygote individuals showed significantly greater improvement of LVEF 
when treated with β-blockers, compared to Gly389 carriers.133 Other more recent stud-
ies drew the same conclusion.134,135 However, two large studies reported inconsistent 
results on mortality and heart failure related hospitalization. In the BEST study, the 
combination of Arg389 homozygote genotype and bucindolol treatment was associ-
ated with decreased mortality and hospitalization.136 However, no association emerged 
in MERIT-HT.137 Furthermore, several,138-140 but not all,141-143 studies associated Arg389 
homozygotes with an increased effect of β-blockers in decreasing systolic and diastolic 
blood pressure or heart rate. Furthermore, the Gly allele of Ser49Gly was more com-
monly associated with a favorable outcome or improved response to β-blockers.144-146 
However, many studies did not find any association.143,147,148
Most studies assessing two common polymorphisms in ARDB2 (Gly16Arg, rs104213 
and Gln27Glu, rs1042714) did not observe any association.147,148 However, two small stud-
ies associated the Glu27 allele with increased LVEF after β-blocker treatment compared 

























The flow chart illustrates the publically available warfarin dosing algorithm (http://www.warfarindosing.
org). This algorithm incorporates patient factors, clinical parameters and genetic information to provide 
an estimation of the loading dose as well as the maintenance dose of warfarin in patient new to this drug. 
Clinical testing of the algorithm is currently ongoing (GIFT trial, NCT01006733). ↓, lower warfarin dose; ↑, 
higher warfarin dose. a Higher dose with higher body surface area. b Severe liver disease may predispose 
to an elevated INR. c Concomitant statin use (except pravastatin) decreases warfarin maintenance dose.
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to the Gln27 allele.149,150 A third polymorphism in ARDB2, Thr164Ile (rs1800888), occurs in 
only 1% of Caucasians.135,147 Although the Ile164 variant did not have a major impact on 
outcome in a population of 443 heart failure patients, multivariate analysis suggested a 
possible negative impact of β-blocker therapy on survival in heterozygous subjects.151
Dosing problems of β-blockers
Many β-blockers are metabolized predominately by hepatic CYP2D6,152 which is highly 
polymorphic with many alleles having a decreased or absent function.153 Several studies 
report that CYP2D6 genotype profoundly affects β-blocker concentrations and the ef-
fect seems especially pronounced with metoprolol.154-157 Poor metabolizing genotypes 
increase metoprolol plasma concentrations, which results in greater reductions of heart 
rate and blood pressure,158-160 and an increased risk of ADRs.160 Although the evidence is 
derived from a few studies, dose adjustments should be considered in patients vulner-
able to complications, such as heart failure patients.161
The use of different β-blockers between, and even within, studies complicates the 
evaluation of the evidence on the pharmacogenetics of β-blocker therapy. Differences 
in receptor specificity of the individual β-blockers could explain this heterogeneity. For 
instance, metoprolol and bisoprolol are β1-AR selective, while carvedilol and bucindolol 
are non-selective.162 In summary, the most convincing evidence suggests that the vari-
able benefit from β-blocker treatment is influenced by the Arg389Gly polymorphism 
of the ADRB1 gene. Furthermore, indisputable evidence shows that polymorphisms of 
the CYP2D6 gene influence β-blocker metabolism and several reports indicate that poor 
metabolizers have increased efficacy and a greater risk of side effects. The data on other 
possible related polymorphisms is too thin to draw definite conclusions. Combining 
different risk alleles could provide more answers.163
the VariabLe resPonse in Patients takinG anGiotensin-conVertinG 
enzyme-inhibitors
the angiotensin-converting enzyme gene insertion/deletion polymorphism
Most studies examining genetic factors influencing responses to ACE-inhibitor treat-
ment evaluated the ACE gene insertion/deletion (I/D) polymorphism (rs4646994) (see 
Supplementary material online, Table S8), which correlates strongly with ACE plasma 
concentrations.164,165 Nevertheless, initial results were inconsistent, partly due to limited 
sample size. Recently, however, the Genetics of Hypertension-Associated Treatment 
(GenHAT) study did not find an association between the I/D ACE polymorphism and the 
6-year non-fatal cardiac events.166 Similarly, the Perindopril Protection Against Recurrent 
Stroke Study (PROGRESS) did not found find an association between this polymorphism 
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and 4-year risk of cardiac events, mortality, neurologic events or decline or with blood 
pressure reduction during perindopril treatment.167 In contrast, in the population-based 
Rotterdam Study, hypertensive patients on ACE-inhibitors had an increased 10-year 
mortality risk when carrying the DD genotype compared to the II genotype, with the ID 
genotype in an intermediate position.168 However, the Rotterdam Study’s observational 
nature represents a limitation.
In conclusion, although the ACE gene I/D polymorphism was a prime candidate, an 
association with therapeutic response seems unlikely. Indeed, since Cambien et al.169 
classified this polymorphism as a potent risk factor for coronary heart disease, many 
predominantly small positive trials reported similar observations. But a meta-analysis, 
examining the ACE I/D polymorphism with regard to restenosis, showed that small posi-
tive studies were much more likely to be published than negative ones. This publication 
bias distorted the actual association.170
other targets in the renin–angiotensin–aldosteronesystem
Angiotensinogen (AGT) is another candidate gene in pharmacogenetic research on ACE-
inhibitors. In another cohort of the Rotterdam study, 4097 subjects were analyzed for 
the Met235Thr (rs699) polymorphism of AGT.171 The Thr allele increased the risk of MI 
and stroke in ACE-inhibitor users. No significant association was found with β-blockers. 
The same authors published a paper on a different cohort of 2216 subjects from the 
Rotterdam study investigating whether the Met235Thr AGT polymorphism modified the 
risk of atherosclerosis associated with β-blocker or ACE-inhibitor therapy.172 They also 
examined the possible relation with the I/D ACE polymorphism and the angiotensin II 
receptor type 1 (AGTR1) 573C>T (rs5182) polymorphism. None of the candidate poly-
morphisms strongly modified the risk of atherosclerosis, measured by arterial disease, 
carotid atherosclerosis and aortic atherosclerosis in hypertensives taking a β-blocker or 
ACE-inhibitor.
Furthermore, Su et al. genotyped a Chinese population of 1447 hypertensive pa-
tients from a benazepril trial for several polymorphisms in AGT, AGTR1 and AGTR2.173 
No association with blood pressure response emerged for the Met235Thr AGT polymor-
phism. However, subjects with the AA genotype of the rs7079 polymorphism of the AGT 
gene showed an enhanced antihypertensive effect. Although mortality risk seems to be 
higher among 235Thr allele carriers of the AGT gene receiving an ACE-inhibitor based 
regimen,171 the risk of atherosclerosis172 or blood pressure reduction173 does not seem to 
be increased. Further studies examining the influence of this AGT polymorphism might 
better characterize this relationship. Moreover, common haplotypes composed of 7 
polymorphisms in the AGTR1 gene were also associated with a greater antihypertensive 
effect on ACE-inhibitor therapy
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Prediction of benefit
Finally, the first results of the Perindopril Genetic Association study (PERGENE) were 
recently published.174 PERGENE included 8907 subjects and was designed to assess 
the feasibility of pharmacogenetic profiling of treatment benefit of ACE-inhibitors in 
patients with stable CAD. PERGENE investigated 52 haplotype-tagging polymorphisms 
in 12 candidate genes within the pharmacodynamic pathway of ACE-inhibitors and their 
relation with cardiovascular mortality, non-fatal MI, and resuscitated cardiac arrest dur-
ing 4.2 years of follow-up. Two polymorphisms located in the AGTR1 gene (rs275651 and 
rs5182) and one in the bradykinin type I receptor (rs12050217) gene were significantly 
associated with perindopril’s treatment benefit. Combining these 3 polymorphisms in a 
pharmacogenetic score identified patients who did not benefit from perindopril (26.5%) 
(Figure 3). The event rate increased significantly in patients allocated to perindopril (6.3 
to 10.4%, Pinteraction < 0.0001). The authors replicated this pharmacogenetic score in a sub-
group of the PROGRESS trial174. Five polymorphisms of the ACE gene (one in complete 













Results of the PERGENE study indicated that carriage of 3 or more minor alleles (risk alleles) of rs275651 
A>T, rs5182 C>T and rs12050217 A>G corresponded with an increased risk of cardiovascular mortality, 
myocardial infarction or resuscitated cardiac arrest during treatment with perindopril compared to 
placebo. Clinical consequences of these findings, whether indeed patients with this specific risk profile 
should not receive angiotensin-converting enzyme -inhibitor treatment, remain to be prospectively 
studied. Modified from Brugts et al.174
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linkage disequilibrium with the I/D polymorphism) were shown not to be associated 
with the endpoints, again stressing that the ACE I/D gene variation does not seems to 
carry clinical value. The PERGENE trial takes an important step closer to realizing indi-
vidualized therapy for ACE-inhibitors, but requires replication.
Angiotensin receptor blockers (ARB) inhibit the renin-angiotensin-aldosteron sys-
tem through a different mechanism than ACE-inhibitors. Although some small studies 
investigated pharmacogenetics of ARBs, replication in larger populations is necessary 
before drawing conclusions (see Supplementary material online, Table S8).
future PersPectiVes anD concLusion
During the Colloquium, mentioned in the introduction, all above discussed subjects 
were covered and the following conclusions were made. Elucidating genetic variation 
in patients with CVD may enable tailored therapy, thereby optimizing efficacy while 
minimizing costs and adverse effects. Nevertheless, despite the vast amount of avail-
able publications, pharmacogenetics of CVD is not yet established in clinical practice. 
Indeed, studies of most polymorphisms produced inconsistent results due to the com-
plex systems underlying CVD, which means variation in a single gene usually produces 
only a small effect on clinical phenotypes. Very large patient cohorts are needed to 
convincingly detect these subtle differences. Large studies designed to detect pharma-
cogenetic association, (e.g. large GWAS) are ongoing and will probably be of great value 
in unraveling the current inconsistencies as well as elucidating associations of genetic 
variation in other target genes. Moreover, new approaches like sequencing might result 
in new targets for subsequent research.
The relevance and usefulness of GWAS have recently been reviewed by Daly175 (Table 
2) and commercially available arrays, like the Drug Metabolizing Enzymes and Trans-
porters (DMET) platform, offer systematic exploration of potential relevant pathways.176 
However, pharmacogenetics needs evidence other than GWAS to convince cardiologists 
of its clinical utility. In particular, large prospective studies should investigate the effect of 
genetic testing on clinical outcomes and stratify patients to determine groups for which 
genetic testing is relevant. For example, the JUPITER trial showed that statin treatment is 
more beneficial in subjects with high C-reactive protein.177 Development of risk models 
combining clinical characteristics (age, gender, and history), patient characteristics (for 
instance blood pressure, weight, and echocardiographic parameters), biomarkers and 
genetics will be most useful and informative.
Besides the genetic variation depicted in Table 3, the evidence for most other phar-
macogenetic associations is not strong enough for clinical application. Nevertheless, 
currently several guidelines on drug prescription already contain pharmacogenetic infor-
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mation. Very recently Swen et al.178 published an update of the current Dutch guidelines 
implementing pharmacogenetics in several therapeutic recommendations. Also, over 
60 FDA-approved drug labels contain pharmacogenetic information.179 For instance, in 
2007, the FDA recommended initiation warfarin doses for carriers of certain CYP2C9 and 
VKORC1 polymorphisms. Moreover, in 2009 the FDA added a warning to the clopidogrel 
prescribing information to highlight the impact of the poor metabolizer genotypes of 
CYP2C19. Finally, the pharmacogenetic score developed in the PERGENE trial seems to 
be able to identify patients that will not benefit from ACE-inhibitor treatment and the 
clinical consequences of this knowledge, whether indeed patients with this specific risk 
profile should not receive ACE-inhibitor treatment, should be prospectively tested.
Ongoing large clinical trials, primarily designed as pharmacogenetic studies, and 
GWAS with large study populations promise to provide more convincing evidence. 
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a Combined number of patients included in the meta-analysis. b Case|control. TNT, Treating to New Targets 
study; CAP, Cholesterol And Pharmacogenetics study ; PRINCE, PRavastatin/Inflammation CRP Evaluation 
study; SEARCH, Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine; 
HPS, Heart Protection Study; PAPI, the Amish Pharmacogenomics of Anti-Platelet Intervention study; 
WARG, WARfarin Genetics study; disc., discovery cohort; repl., replication cohort
Table 3 Best explored single nucleotide polymorphisms in field of cardiovascular pharmacogenetics
Gene snP Drug effect of variant









ACE I/D (rs4646994) ACE-inhibitors No effect
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Overall, there are enough reasons to remain optimistic that, even though we are taking 
small steps at a time, we are heading to an era where we can finally use pharmacogenet-
ics in clinical practice to optimize treatment for the individual patient.
suPPLementary materiaL
Supplementary Material is available at European Heart Journal online.
acknoWLeDGments anD funDinG
Our thanks goes out to the speakers during the “Pharmacogenetics of cardiovascular 
drugs Academy Colloquium” of the Royal Netherlands Academy of Arts and Sciences 
for their contribution to the symposium; A. Isaacs, Professor A. Uitterlinden, Professor 
A. Zwinderman, Professor M.L. Simoons, Professor H.-J. Guchelaar, B.R. Winkelmann, A. 
Briggs, R. van Schaik, M. Ingelman-Sundberg, Professor J.W. Jukema, A.-H. Maitland v/d. 
Zee, Professor Schaefer, D. Voora, G. Rudez, J. Oldenburg, P. Sharma, G. Pare, P. v/d. Harst, 
J.J. Brugts, Professor W. van Gilst, C.R. Bezzina and Professor J. Danser.
The research leading to these results has received funding from the European Union’s 
Seventh Framework Programme (FP7/2007-2013) under grant agreement [n° HEALTH-
F2-2009-223004]. Supported by grants from the Interuniversity Cardiology Institute of 
the Netherlands (ICIN) and the Durrer Center for Cardiogenetic Research both Institutes 
of the Netherlands Royal Academy of Arts and Sciences (KNAW), the Netherlands Heart 
Foundation, the Center for Medical Systems Biology (CMSB), a center of excellence ap-
proved by the Netherlands Genomics Initiative/Netherlands Organization for Scientific 
Research (NWO), the Netherlands Consortium for Healthy Ageing (NCHA). J.W. Jukema 
is an established clinical investigator of the Netherlands Heart Foundation (2001D032).
The funders had no role in study design, data collection and analysis, decision to publish 
or the preparation of the manuscript.
222 Part III – Pharmacogenetics of cardiovascular diseases
reference List
 1. Lloyd-Jones D, Adams RJ, Brown TM et al.: Heart disease and stroke statistics--2010 update: a 
report from the American Heart Association. Circulation (2010) 121: e46-e215.
 2. Vaartjes I, van Dis I, Visseren FLJ, Bots ML: Hart- en vaatziekten in Nederland 2010, cijfers over 
leefstijl- en risicofactoren, ziekte en sterfte, Den Haag, 2010
 3. Baigent C, Keech A, Kearney PM et al.: Efficacy and safety of cholesterol-lowering treatment: pro-
spective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 
(2005) 366: 1267-1278.
 4. LaRosa JC, He J, Vupputuri S: Effect of statins on risk of coronary disease: a meta-analysis of 
randomized controlled trials. JAMA (1999) 282: 2340-2346.
 5. Mangravite LM, Thorn CF, Krauss RM: Clinical implications of pharmacogenomics of statin treat-
ment. Pharmacogenomics J (2006) 6: 360-374.
 6. Kuivenhoven JA, De KP, Boer JM et al.: Heterogeneity at the CETP gene locus. Influence on plasma 
CETP concentrations and HDL cholesterol levels. Arterioscler Thromb Vasc Biol (1997) 17: 560-568.
 7. Kuivenhoven JA, Jukema JW, Zwinderman AH et al.: The role of a common variant of the choles-
teryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression 
Growth Evaluation Statin Study Group. N Engl J Med (1998) 338: 86-93.
 8. Freeman DJ, Samani NJ, Wilson V et al.: A polymorphism of the cholesteryl ester transfer protein 
gene predicts cardiovascular events in non-smokers in the West of Scotland Coronary Prevention 
Study. Eur Heart J (2003) 24: 1833-1842.
 9. Ordovas JM, Cupples LA, Corella D et al.: Association of Cholesteryl Ester Transfer Protein-TaqIB 
Polymorphism With Variations in Lipoprotein Subclasses and Coronary Heart Disease Risk : The 
Framingham Study. Arterioscler Thromb Vasc Biol (2000) 20: 1323-1329.
 10. Liu S, Schmitz C, Stampfer MJ et al.: A prospective study of TaqIB polymorphism in the gene cod-
ing for cholesteryl ester transfer protein and risk of myocardial infarction in middle-aged men. 
Atherosclerosis (2002) 161: 469-474.
 11. Carlquist JF, Muhlestein JB, Horne BD et al.: The cholesteryl ester transfer protein Taq1B gene 
polymorphism predicts clinical benefit of statin therapy in patients with significant coronary 
artery disease. Am Heart J (2003) 146: 1007-1014.
 12. Boekholdt SM, Sacks FM, Jukema JW et al.: Cholesteryl ester transfer protein TaqIB variant, high-
density lipoprotein cholesterol levels, cardiovascular risk, and efficacy of pravastatin treatment: 
individual patient meta-analysis of 13,677 subjects. Circulation (2005) 111: 278-287.
 13. Jukema JW, Bruschke AV, van Boven AJ et al.: Effects of lipid lowering by pravastatin on progres-
sion and regression of coronary artery disease in symptomatic men with normal to moderately 
elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). 
Circulation (1995) 91: 2528-2540.
 14. Regieli JJ, Jukema JW, Grobbee DE et al.: CETP genotype predicts increased mortality in statin-
treated men with proven cardiovascular disease: an adverse pharmacogenetic interaction. Eur 
Heart J (2008) 29: 2792-2799.
 15. Utermann G: Apolipoprotein E polymorphism in health and disease. American Heart Journal 
(1987) 113: 433-440.
Overview of pharmacogenetics in CVD 223
11
 16. Nieminen T, Kahonen M, Viiri LE, Gronroos P, Lehtimaki T: Pharmacogenetics of apolipoprotein 
E gene during lipid-lowering therapy: lipid levels and prevention of coronary heart disease. 
Pharmacogenomics (2008) 9: 1475-1486.
 17. Thompson JF, Hyde CL, Wood LS et al.: Comprehensive whole-genome and candidate gene 
analysis for response to statin therapy in the Treating to New Targets (TNT) cohort. Circ Cardiovasc 
Genet (2009) 2: 173-181.
 18. Zintzaras E, Kitsios GD, Triposkiadis F, Lau J, Raman G: APOE gene polymorphisms and response 
to statin therapy. Pharmacogenomics J (2009) 9: 248-257.
 19. Barber MJ, Mangravite LM, Hyde CL et al.: Genome-wide association of lipid-lowering response to 
statins in combined study populations. PLoS One (2010) 5: e9763.
 20. Ishisaki Z, Takaishi M, Furuta I, Huh N: Calmin, a protein with calponin homology and transmem-
brane domains expressed in maturing spermatogenic cells. Genomics (2001) 74: 172-179.
 21. Hirosawa M, Nagase T, Ishikawa K et al.: Characterization of cDNA clones selected by the GeneMark 
analysis from size-fractionated cDNA libraries from human brain. DNA Res (1999) 6: 329-336.
 22. Iakoubova OA, Tong CH, Rowland CM et al.: Association of the Trp719Arg polymorphism in 
kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective 
trials: the CARE and WOSCOPS trials. J Am Coll Cardiol (2008) 51: 435-443.
 23. Iakoubova OA, Sabatine MS, Rowland CM et al.: Polymorphism in KIF6 gene and benefit from 
statins after acute coronary syndromes: results from the PROVE IT-TIMI 22 study. J Am Coll Cardiol 
(2008) 51: 449-455.
 24. Iakoubova OA, Robertson M, Tong CH et al.: KIF6 Trp719Arg polymorphism and the effect of statin 
therapy in elderly patients: results from the PROSPER study. Eur J Cardiovasc Prev Rehabil (2010) 
17: 455-461.
 25. Miki H, Setou M, Kaneshiro K, Hirokawa N: All kinesin superfamily protein, KIF, genes in mouse 
and human. Proc Natl Acad Sci U S A (2001) 98: 7004-7011.
 26. Assimes TL, Holm H, Kathiresan S et al.: Lack of association between the Trp719Arg polymorphism 
in kinesin-like protein-6 and coronary artery disease in 19 case-control studies. J Am Coll Cardiol 
(2010) 56: 1552-1563.
 27. Law M, Rudnicka AR: Statin Safety: A Systematic Review. The American Journal of Cardiology (2006) 
97: S52-S60.
 28. Pasanen MK, Fredrikson H, Neuvonen PJ, Niemi M: Different effects of SLCO1B1 polymorphism on 
the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther (2007) 82: 726-733.
 29. Niemi M, Pasanen MK, Neuvonen PJ: SLCO1B1 polymorphism and sex affect the pharmacokinet-
ics of pravastatin but not fluvastatin. Clin Pharmacol Ther (2006) 80: 356-366.
 30. Tirona RG, Leake BF, Merino G, Kim RB: Polymorphisms in OATP-C: identification of multiple allelic 
variants associated with altered transport activity among European- and African-Americans. J Biol 
Chem (2001) 276: 35669-35675.
 31. Pasanen MK, Neuvonen M, Neuvonen PJ, Niemi M: SLCO1B1 polymorphism markedly affects the 
pharmacokinetics of simvastatin acid. Pharmacogenet Genomics (2006) 16: 873-879.
 32. Link E, Parish S, Armitage J et al.: SLCO1B1 variants and statin-induced myopathy--a genomewide 
study. N Engl J Med (2008) 359: 789-799.
224 Part III – Pharmacogenetics of cardiovascular diseases
 33. Voora D, Shah SH, Spasojevic I et al.: The SLCO1B1*5 genetic variant is associated with statin-
induced side effects. J Am Coll Cardiol (2009) 54: 1609-1616.
 34. Brunham LR, Lansberg PJ, Zhang L et al.: Differential effect of the rs4149056 variant in SLCO1B1 
on myopathy associated with simvastatin and atorvastatin. Pharmacogenomics J (2011).
 35. Willer CJ, Sanna S, Jackson AU et al.: Newly identified loci that influence lipid concentrations and 
risk of coronary artery disease. Nat Genet (2008) 40: 161-169.
 36. Kathiresan S, Willer CJ, Peloso GM et al.: Common variants at 30 loci contribute to polygenic 
dyslipidemia. Nat Genet (2009) 41: 56-65.
 37. Kushner FG, Hand M, Smith SC, Jr. et al.: 2009 Focused Updates: ACC/AHA Guidelines for the Man-
agement of Patients With ST-Elevation Myocardial Infarction (updating the 2004 Guideline and 
2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention 
(updating the 2005 Guideline and 2007 Focused Update): a report of the American College of 
Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 
(2009) 120: 2271-2306.
 38. Van de Werf F, Bax J, Betriu A et al.: Management of acute myocardial infarction in patients pre-
senting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment 
Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J (2008) 
29: 2909-2945.
 39. Pollack CV, Jr., Braunwald E: 2007 update to the ACC/AHA guidelines for the management of 
patients with unstable angina and non-ST-segment elevation myocardial infarction: implications 
for emergency department practice. Ann Emerg Med (2008) 51: 591-606.
 40. Rapezzi C, Biagini E, Branzi A: Guidelines for the diagnosis and treatment of non-ST-segment 
elevation acute coronary syndromes: the task force for the diagnosis and treatment of non-ST-
segment elevation acute coronary syndromes of the European Society of Cardiology. Eur Heart J 
(2008) 29: 277-278.
 41. Matetzky S, Shenkman B, Guetta V et al.: Clopidogrel resistance is associated with increased risk 
of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 
(2004) 109: 3171-3175.
 42. Snoep JD, Hovens MM, Eikenboom JC et al.: Clopidogrel nonresponsiveness in patients undergo-
ing percutaneous coronary intervention with stenting: a systematic review and meta-analysis. 
Am Heart J (2007) 154: 221-231.
 43. Szczeklik A, Musial J, Undas A, Sanak M: Aspirin resistance. J Thromb Haemost (2005) 3: 1655-1662.
 44. Trenk D, Hochholzer W, Fromm MF et al.: Cytochrome P450 2C19 681G>A polymorphism and 
high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elec-
tive percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol 
(2008) 51: 1925-1934.
 45. Goodman T, Ferro A, Sharma P: Pharmacogenetics of aspirin resistance: a comprehensive system-
atic review. Br J Clin Pharmacol (2008) 66: 222-232.
 46. Fontana P, Nolli S, Reber G, de MP: Biological effects of aspirin and clopidogrel in a randomized 
cross-over study in 96 healthy volunteers. J Thromb Haemost (2006) 4: 813-819.
 47. Lordkipanidze M, Pharand C, Schampaert E et al.: A comparison of six major platelet function 
tests to determine the prevalence of aspirin resistance in patients with stable coronary artery 
disease. Eur Heart J (2007) 28: 1702-1708.
Overview of pharmacogenetics in CVD 225
11
 48. Shimokawa T, Smith WL: Prostaglandin endoperoxide synthase. The aspirin acetylation region. J 
Biol Chem (1992) 267: 12387-12392.
 49. Halushka MK, Walker LP, Halushka PV: Genetic variation in cyclooxygenase 1: effects on response 
to aspirin. Clin Pharmacol Ther (2003) 73: 122-130.
 50. Preston FE, Whipps S, Jackson CA et al.: Inhibition of prostacyclin and platelet thromboxane A2 
after low-dose aspirin. N Engl J Med (1981) 304: 76-79.
 51. Hovens MMC, Snoep JD, Eikenboom JCJ et al.: Prevalence of persistent platelet reactivity despite 
use of aspirin: A systematic review. American Heart Journal (2007) 153: 175-181.
 52. Maree AO, Curtin RJ, Chubb A et al.: Cyclooxygenase-1 haplotype modulates platelet response to 
aspirin. J Thromb Haemost (2005) 3: 2340-2345.
 53. Lepantalo A, Mikkelsson J, Resendiz JC et al.: Polymorphisms of COX-1 and GPVI associate with 
the antiplatelet effect of aspirin in coronary artery disease patients. Thromb Haemost (2006) 95: 
253-259.
 54. Kunicki TJ, Williams SA, Nugent DJ et al.: Lack of association between aspirin responsiveness 
and seven candidate gene haplotypes in patients with symptomatic vascular disease. Thromb 
Haemost (2009) 101: 123-133.
 55. Li Q, Chen BL, Ozdemir V et al.: Frequency of genetic polymorphisms of COX1, GPIIIa and P2Y1 in 
a Chinese population and association with attenuated response to aspirin. Pharmacogenomics 
(2007) 8: 577-586.
 56. Clappers N, van Oijen MG, Sundaresan S et al.: The C50T polymorphism of the cyclooxygenase-1 
gene and the risk of thrombotic events during low-dose therapy with acetyl salicylic acid. Thromb 
Haemost (2008) 100: 70-75.
 57. Feher G, Feher A, Pusch G et al.: The genetics of antiplatelet drug resistance. Clin Genet (2009) 75: 
1-18.
 58. Su G, Wang Z, Ding Y: Association of the platelet membrane glycoprotein I a C807T gene polymor-
phism with aspirin resistance. J Huazhong Univ Sci Technolog Med Sci (2007) 27: 664-667.
 59. Jefferson BK, Foster JH, McCarthy JJ et al.: Aspirin resistance and a single gene. Am J Cardiol (2005) 
95: 805-808.
 60. Choi JH, Kim SH, Cho BY et al.: Association of TNF-alpha promoter polymorphisms with aspirin-
induced urticaria. J Clin Pharm Ther (2009) 34: 231-238.
 61. Park HJ, Ye YM, Hur GY, Kim SH, Park HS: Association between a TGFbeta1 promoter polymor-
phism and the phenotype of aspirin-intolerant chronic urticaria in a Korean population. J Clin 
Pharm Ther (2008) 33: 691-697.
 62. Piazuelo E, Fuentes J, Garcia-Gonzalez MA, Jimenez P, Lanas A: A case-control study of the associa-
tion between polymorphisms of the endothelial nitric oxide synthase and glycoprotein IIIa genes 
and upper gastrointestinal bleeding in users of low-dose aspirin. Clin Ther (2008) 30: 121-130.
 63. Mega JL, Close SL, Wiviott SD et al.: Cytochrome p-450 polymorphisms and response to clopido-
grel. N Engl J Med (2009) 360: 354-362.
 64. Ellis KJ, Stouffer GA, McLeod HL, Lee CR: Clopidogrel pharmacogenomics and risk of inadequate 
platelet inhibition: US FDA recommendations. Pharmacogenomics (2009) 10: 1799-1817.
 65. Sugunaraj JP, Palaniswamy C, Selvaraj DR, Chaitanya Arudra SK, Sukhija R: Clopidogrel resistance. 
Am J Ther (2010) 17: 210-215.
226 Part III – Pharmacogenetics of cardiovascular diseases
 66. Ford NF: Clopidogrel resistance: pharmacokinetic or pharmacogenetic? J Clin Pharmacol (2009) 
49: 506-512.
 67. Marin F, Gonzalez-Conejero R, Capranzano P et al.: Pharmacogenetics in cardiovascular anti-
thrombotic therapy. J Am Coll Cardiol (2009) 54: 1041-1057.
 68. Hulot JS, Bura A, Villard E et al.: Cytochrome P450 2C19 loss-of-function polymorphism is a major 
determinant of clopidogrel responsiveness in healthy subjects. Blood (2006) 108: 2244-2247.
 69. Brandt JT, Close SL, Iturria SJ et al.: Common polymorphisms of CYP2C19 and CYP2C9 affect the 
pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb 
Haemost (2007) 5: 2429-2436.
 70. Simon T, Verstuyft C, Mary-Krause M et al.: Genetic determinants of response to clopidogrel and 
cardiovascular events. N Engl J Med (2009) 360: 363-375.
 71. Geisler T, Schaeffeler E, Dippon J et al.: CYP2C19 and nongenetic factors predict poor responsive-
ness to clopidogrel loading dose after coronary stent implantation. Pharmacogenomics (2008) 9: 
1251-1259.
 72. Gladding P, Webster M, Zeng I et al.: The pharmacogenetics and pharmacodynamics of clopido-
grel response: an analysis from the PRINC (Plavix Response in Coronary Intervention) trial. JACC 
Cardiovasc Interv (2008) 1: 620-627.
 73. Sibbing D, Koch W, Gebhard D et al.: Cytochrome 2C19*17 allelic variant, platelet aggregation, 
bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent place-
ment. Circulation (2010) 121: 512-518.
 74. Wallentin L, James S, Storey RF et al.: Effect of CYP2C19 and ABCB1 single nucleotide poly-
morphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary 
syndromes: a genetic substudy of the PLATO trial. Lancet (2010) 376: 1320-1328.
 75. Sangkuhl K, Klein TE, Altman RB: Clopidogrel pathway. Pharmacogenet Genomics (2010) 20: 463-
465.
 76. Harmsze A, van Werkum JW, Bouman HJ et al.: Besides CYP2C19*2, the variant allele CYP2C9*3 is 
associated with higher on-clopidogrel platelet reactivity in patients on dual antiplatelet therapy 
undergoing elective coronary stent implantation. Pharmacogenet Genomics (2010) 20: 18-25.
 77. Gladding P, White H, Voss J et al.: Pharmacogenetic testing for clopidogrel using the rapid INFINITI 
analyzer: a dose-escalation study. JACC Cardiovasc Interv (2009) 2: 1095-1101.
 78. Taubert D, von BN, Grimberg G et al.: Impact of P-glycoprotein on clopidogrel absorption. Clin 
Pharmacol Ther (2006) 80: 486-501.
 79. Mega JL, Close SL, Wiviott SD et al.: Genetic variants in ABCB1 and CYP2C19 and cardiovascular 
outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharma-
cogenetic analysis. Lancet (2010) 376: 1312-1319.
 80. Shuldiner AR, O’Connell JR, Bliden KP et al.: Association of cytochrome P450 2C19 genotype with 
the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA (2009) 302: 849-857.
 81. Wallentin L, Becker RC, Budaj A et al.: Ticagrelor versus clopidogrel in patients with acute coronary 
syndromes. N Engl J Med (2009) 361: 1045-1057.
 82. Biondi-Zoccai G, Lotrionte M, Agostoni P et al.: Adjusted indirect comparison meta-analysis of 
prasugrel versus ticagrelor for patients with acute coronary syndromes. Int J Cardiol (2010).
Overview of pharmacogenetics in CVD 227
11
 83. Storey RF, Angiolillo DJ, Patil SB et al.: Inhibitory Effects of Ticagrelor Compared With Clopidogrel 
on Platelet Function in Patients With Acute Coronary Syndromes The PLATO (PLATelet inhibition 
and patient Outcomes) PLATELET Substudy. J Am Coll Cardiol (2010).
 84. Ziegler S, Schillinger M, Funk M et al.: Association of a functional polymorphism in the clopidogrel 
target receptor gene, P2Y12, and the risk for ischemic cerebrovascular events in patients with 
peripheral artery disease. Stroke (2005) 36: 1394-1399.
 85. Staritz P, Kurz K, Stoll M et al.: Platelet reactivity and clopidogrel resistance are associated with the 
H2 haplotype of the P2Y12-ADP receptor gene. Int J Cardiol (2009) 133: 341-345.
 86. Cuisset T, Frere C, Quilici J et al.: Role of the T744C polymorphism of the P2Y12 gene on platelet 
response to a 600-mg loading dose of clopidogrel in 597 patients with non-ST-segment elevation 
acute coronary syndrome. Thromb Res (2007) 120: 893-899.
 87. Giusti B, Gori AM, Marcucci R et al.: Cytochrome P450 2C19 loss-of-function polymorphism, 
but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response 
variability to dual antiplatelet treatment in high-risk vascular patients. Pharmacogenet Genomics 
(2007) 17: 1057-1064.
 88. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E et al.: 807 C/T Polymorphism of the glycoprotein Ia 
gene and pharmacogenetic modulation of platelet response to dual antiplatelet treatment. Blood 
Coagul Fibrinolysis (2004) 15: 427-433.
 89. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E et al.: Variability in platelet aggregation following 
sustained aspirin and clopidogrel treatment in patients with coronary heart disease and influ-
ence of the 807 C/T polymorphism of the glycoprotein Ia gene. Am J Cardiol (2005) 96: 1095-1099.
 90. Cuisset T, Frere C, Quilici J et al.: Lack of association between the 807 C/T polymorphism of gly-
coprotein Ia gene and post-treatment platelet reactivity after aspirin and clopidogrel in patients 
with acute coronary syndrome. Thromb Haemost (2007) 97: 212-217.
 91. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E et al.: PlA polymorphism and platelet reactivity 
following clopidogrel loading dose in patients undergoing coronary stent implantation. Blood 
Coagul Fibrinolysis (2004) 15: 89-93.
 92. Dropinski J, Musial J, Jakiela B et al.: Anti-thrombotic action of clopidogrel and P1(A1/A2) 
polymorphism of beta3 integrin in patients with coronary artery disease not being treated with 
aspirin. Thromb Haemost (2005) 94: 1300-1305.
 93. Pare G, Mehta SR, Yusuf S et al.: Effects of CYP2C19 genotype on outcomes of clopidogrel treat-
ment. N Engl J Med (2010) 363: 1704-1714.
 94. Tran M, Tafreshi J, Pai RG: Combination of Clopidogrel and Proton Pump Inhibitors : Implications 
for Clinicians. J Cardiovasc Pharmacol Ther (2010).
 95. Mega JL, Close SL, Wiviott SD et al.: Cytochrome P450 genetic polymorphisms and the response 
to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circula-
tion (2009) 119: 2553-2560.
 96. Rehmel JLF, Eckstein JA, Farid NA et al.: INTERACTIONS OF TWO MAJOR METABOLITES OF 
PRASUGREL, A THIENOPYRIDINE ANTIPLATELET AGENT, WITH THE CYTOCHROMES P450. Drug 
Metabolism and Disposition (2006) 34: 600-607.
 97. Schror K, Weber AA: Comparative pharmacology of GP IIb/IIIa antagonists. J Thromb Thrombolysis 
(2003) 15: 71-80.
228 Part III – Pharmacogenetics of cardiovascular diseases
 98. O’Connor FF, Shields DC, Fitzgerald A et al.: Genetic variation in glycoprotein IIb/IIIa (GPIIb/IIIa) as 
a determinant of the responses to an oral GPIIb/IIIa antagonist in patients with unstable coronary 
syndromes. Blood (2001) 98: 3256-3260.
 99. Wheeler GL, Braden GA, Bray PF et al.: Reduced inhibition by abciximab in platelets with the PlA2 
polymorphism. Am Heart J (2002) 143: 76-82.
 100. Michelson AD, Furman MI, Goldschmidt-Clermont P et al.: Platelet GP IIIa Pl(A) polymorphisms 
display different sensitivities to agonists. Circulation (2000) 101: 1013-1018.
 101. Aalto-Setala K, Karhunen PJ, Mikkelsson J, Niemela K: The effect of glycoprotein IIIa PIA 1/A2 
polymorphism on the PFA-100 response to GP IIb IIa receptor inhibitors-the importance of anti-
coagulants used. J Thromb Thrombolysis (2005) 20: 57-63.
 102. Weber AA, Jacobs C, Meila D et al.: No evidence for an influence of the human platelet antigen-1 
polymorphism on the antiplatelet effects of glycoprotein IIb/IIIa inhibitors. Pharmacogenetics 
(2002) 12: 581-583.
 103. Weber AA, Meila D, Jacobs C et al.: Low incidence of paradoxical platelet activation by glycopro-
tein IIb/IIIa inhibitors. Thromb Res (2002) 106: 25-29.
 104. Shields DC, Fitzgerald AP, O’Neill PA et al.: The contribution of genetic factors to thrombotic and 
bleeding outcomes in coronary patients randomised to IIb/IIIa antagonists. Pharmacogenomics J 
(2002) 2: 182-190.
 105. Hillman MA, Wilke RA, Caldwell MD et al.: Relative impact of covariates in prescribing warfarin 
according to CYP2C9 genotype. Pharmacogenetics (2004) 14: 539-547.
 106. Caldwell MD, Berg RL, Zhang KQ et al.: Evaluation of genetic factors for warfarin dose prediction. 
Clin Med Res (2007) 5: 8-16.
 107. Klein TE, Altman RB, Eriksson N et al.: Estimation of the warfarin dose with clinical and pharmaco-
genetic data. N Engl J Med (2009) 360: 753-764.
 108. Furuya H, Fernandez-Salguero P, Gregory W et al.: Genetic polymorphism of CYP2C9 and its effect 
on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy. 
Pharmacogenetics (1995) 5: 389-392.
 109. Aithal GP, Day CP, Kesteven PJ, Daly AK: Association of polymorphisms in the cytochrome P450 
CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet (1999) 353: 
717-719.
 110. Rettie AE, Wienkers LC, Gonzalez FJ, Trager WF, Korzekwa KR: Impaired (S)-warfarin metabolism 
catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics (1994) 4: 39-42.
 111. Haining RL, Hunter AP, Veronese ME, Trager WF, Rettie AE: Allelic variants of human cytochrome 
P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate 
stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms. Arch Biochem 
Biophys (1996) 333: 447-458.
 112. Lindh JD, Holm L, Andersson ML, Rane A: Influence of CYP2C9 genotype on warfarin dose 
requirements--a systematic review and meta-analysis. Eur J Clin Pharmacol (2009) 65: 365-375.
 113. Kangelaris KN, Bent S, Nussbaum RL, Garcia DA, Tice JA: Genetic testing before anticoagulation? 
A systematic review of pharmacogenetic dosing of warfarin. J Gen Intern Med (2009) 24: 656-664.
 114. Schalekamp T, de BA: Pharmacogenetics of oral anticoagulant therapy. Curr Pharm Des (2010) 16: 
187-203.
Overview of pharmacogenetics in CVD 229
11
 115. Yang L, Ge W, Yu F, Zhu H: Impact of VKORC1 gene polymorphism on interindividual and intereth-
nic warfarin dosage requirement--a systematic review and meta analysis. Thromb Res (2010) 125: 
e159-e166.
 116. Voora D, Koboldt DC, King CR et al.: A polymorphism in the VKORC1 regulator calumenin predicts 
higher warfarin dose requirements in African Americans. Clin Pharmacol Ther (2010) 87: 445-451.
 117. Takeuchi F, McGinnis R, Bourgeois S et al.: A genome-wide association study confirms VKORC1, 
CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet (2009) 5: 
e1000433.
 118. D’Ambrosio RL, D’Andrea G, Cappucci F et al.: Polymorphisms in factor II and factor VII genes 
modulate oral anticoagulation with warfarin. Haematologica (2004) 89: 1510-1516.
 119. Wadelius M, Chen LY, Downes K et al.: Common VKORC1 and GGCX polymorphisms associated 
with warfarin dose. Pharmacogenomics J (2005) 5: 262-270.
 120. Pautas E, Moreau C, Gouin-Thibault I et al.: Genetic factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) 
are predictor variables for warfarin response in very elderly, frail inpatients. Clin Pharmacol Ther 
(2010) 87: 57-64.
 121. Cooper GM, Johnson JA, Langaee TY et al.: A genome-wide scan for common genetic variants 
with a large influence on warfarin maintenance dose. Blood (2008) 112: 1022-1027.
 122. Beinema M, Brouwers JR, Schalekamp T, Wilffert B: Pharmacogenetic differences between warfa-
rin, acenocoumarol and phenprocoumon. Thromb Haemost (2008) 100: 1052-1057.
 123. Ufer M, Kammerer B, Kahlich R et al.: Genetic polymorphisms of cytochrome P450 2C9 causing 
reduced phenprocoumon (S)-7-hydroxylation in vitro and in vivo. Xenobiotica (2004) 34: 847-859.
 124. Puehringer H, Loreth RM, Klose G et al.: VKORC1 -1639G>A and CYP2C9*3 are the major genetic 
predictors of phenprocoumon dose requirement. Eur J Clin Pharmacol (2010) 66: 591-598.
 125. Teichert M, Eijgelsheim M, Rivadeneira F et al.: A genome-wide association study of acenocouma-
rol maintenance dosage. Hum Mol Genet (2009) 18: 3758-3768.
 126. Gage BF, Eby C, Johnson JA et al.: Use of pharmacogenetic and clinical factors to predict the 
therapeutic dose of warfarin. Clin Pharmacol Ther (2008) 84: 326-331.
 127. Tham LS, Goh BC, Nafziger A et al.: A warfarin-dosing model in Asians that uses single-nucleotide 
polymorphisms in vitamin K epoxide reductase complex and cytochrome P450 2C9. Clin Pharma-
col Ther (2006) 80: 346-355.
 128. Wadelius M, Chen LY, Lindh JD et al.: The largest prospective warfarin-treated cohort supports 
genetic forecasting. Blood (2009) 113: 784-792.
 129. Kuehn BM: Warfarin Label Update. JAMA (2007) 298: 1389-138a.
 130. Bristow MR, Gilbert EM, Abraham WT et al.: Carvedilol produces dose-related improvements in 
left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. 
Circulation (1996) 94: 2807-2816.
 131. Hjalmarson A, Goldstein S, Fagerberg B et al.: Effects of controlled-release metoprolol on total 
mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL 
Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. 
JAMA (2000) 283: 1295-1302.
 132. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention 
Trial in Congestive Heart Failure (MERIT-HF). Lancet (1999) 353: 2001-2007.
230 Part III – Pharmacogenetics of cardiovascular diseases
 133. Muthumala A, Drenos F, Elliott PM, Humphries SE: Role of beta adrenergic receptor polymor-
phisms in heart failure: systematic review and meta-analysis. Eur J Heart Fail (2008) 10: 3-13.
 134. Lobmeyer MT, Gong Y, Terra SG et al.: Synergistic polymorphisms of beta1 and alpha2C-adrenergic 
receptors and the influence on left ventricular ejection fraction response to beta-blocker therapy 
in heart failure. Pharmacogenet Genomics (2007) 17: 277-282.
 135. Chen L, Meyers D, Javorsky G et al.: Arg389Gly-beta1-adrenergic receptors determine improve-
ment in left ventricular systolic function in nonischemic cardiomyopathy patients with heart 
failure after chronic treatment with carvedilol. Pharmacogenet Genomics (2007) 17: 941-949.
 136. Liggett SB, Mialet-Perez J, Thaneemit-Chen S et al.: A polymorphism within a conserved beta(1)-
adrenergic receptor motif alters cardiac function and beta-blocker response in human heart 
failure. Proc Natl Acad Sci U S A (2006) 103: 11288-11293.
 137. White HL, de Boer RA, Maqbool A et al.: An evaluation of the beta-1 adrenergic receptor Arg-
389Gly polymorphism in individuals with heart failure: a MERIT-HF sub-study. Eur J Heart Fail 
(2003) 5: 463-468.
 138. Liu J, Liu ZQ, Yu BN et al.: beta1-Adrenergic receptor polymorphisms influence the response to 
metoprolol monotherapy in patients with essential hypertension. Clin Pharmacol Ther (2006) 80: 
23-32.
 139. Johnson JA, Zineh I, Puckett BJ et al.: Beta 1-adrenergic receptor polymorphisms and antihyper-
tensive response to metoprolol. Clin Pharmacol Ther (2003) 74: 44-52.
 140. Sofowora GG, Dishy V, Muszkat M et al.: A common beta1-adrenergic receptor polymorphism 
(Arg389Gly) affects blood pressure response to beta-blockade. Clin Pharmacol Ther (2003) 73: 
366-371.
 141. O’Shaughnessy KM, Fu B, Dickerson C, Thurston D, Brown MJ: The gain-of-function G389R variant 
of the beta1-adrenoceptor does not influence blood pressure or heart rate response to beta-
blockade in hypertensive subjects. Clin Sci (Lond) (2000) 99: 233-238.
 142. Karlsson J, Lind L, Hallberg P et al.: Beta1-adrenergic receptor gene polymorphisms and response 
to beta1-adrenergic receptor blockade in patients with essential hypertension. Clin Cardiol (2004) 
27: 347-350.
 143. Filigheddu F, Argiolas G, Degortes S et al.: Haplotypes of the adrenergic system predict the blood 
pressure response to beta-blockers in women with essential hypertension. Pharmacogenomics 
(2010) 11: 319-325.
 144. Terra SG, Hamilton KK, Pauly DF et al.: Beta1-adrenergic receptor polymorphisms and left 
ventricular remodeling changes in response to beta-blocker therapy. Pharmacogenet Genomics 
(2005) 15: 227-234.
 145. Terra SG, Pauly DF, Lee CR et al.: beta-Adrenergic receptor polymorphisms and responses during 
titration of metoprolol controlled release/extended release in heart failure. Clin Pharmacol Ther 
(2005) 77: 127-137.
 146. Magnusson Y, Levin MC, Eggertsen R et al.: Ser49Gly of beta1-adrenergic receptor is associated 
with effective beta-blocker dose in dilated cardiomyopathy. Clin Pharmacol Ther (2005) 78: 221-
231.
 147. de Groote P., Helbecque N, Lamblin N et al.: Association between beta-1 and beta-2 adrenergic 
receptor gene polymorphisms and the response to beta-blockade in patients with stable conges-
tive heart failure. Pharmacogenet Genomics (2005) 15: 137-142.
Overview of pharmacogenetics in CVD 231
11
 148. Pacanowski MA, Gong Y, Cooper-Dehoff RM et al.: beta-adrenergic receptor gene polymorphisms 
and beta-blocker treatment outcomes in hypertension. Clin Pharmacol Ther (2008) 84: 715-721.
 149. Troncoso R, Moraga F, Chiong M et al.: Gln(27)-->Glubeta(2)-adrenergic receptor polymorphism 
in heart failure patients: differential clinical and oxidative response to carvedilol. Basic Clin Phar-
macol Toxicol (2009) 104: 374-378.
 150. Kaye DM, Smirk B, Williams C et al.: Beta-adrenoceptor genotype influences the response to 
carvedilol in patients with congestive heart failure. Pharmacogenetics (2003) 13: 379-382.
 151. Littlejohn MD, Palmer BR, Richards AM et al.: Ile164 variant of beta2-adrenoceptor does not influ-
ence outcome in heart failure but may interact with beta blocker treatment. Eur J Heart Fail (2008) 
10: 55-59.
 152. Brodde OE, Kroemer HK: Drug-drug interactions of beta-adrenoceptor blockers. Arzneimittelforsc-
hung (2003) 53: 814-822.
 153. Zanger UM, Raimundo S, Eichelbaum M: Cytochrome P450 2D6: overview and update on phar-
macology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol (2004) 369: 23-37.
 154. Ismail R, Teh LK: The relevance of CYP2D6 genetic polymorphism on chronic metoprolol therapy 
in cardiovascular patients. J Clin Pharm Ther (2006) 31: 99-109.
 155. Lefebvre J, Poirier L, Poirier P, Turgeon J, Lacourciere Y: The influence of CYP2D6 phenotype on the 
clinical response of nebivolol in patients with essential hypertension. Br J Clin Pharmacol (2007) 
63: 575-582.
 156. Fux R, Morike K, Prohmer AM et al.: Impact of CYP2D6 genotype on adverse effects during treat-
ment with metoprolol: a prospective clinical study. Clin Pharmacol Ther (2005) 78: 378-387.
 157. Rau T, Heide R, Bergmann K et al.: Effect of the CYP2D6 genotype on metoprolol metabolism 
persists during long-term treatment. Pharmacogenetics (2002) 12: 465-472.
 158. Rau T, Wuttke H, Michels LM et al.: Impact of the CYP2D6 genotype on the clinical effects of 
metoprolol: a prospective longitudinal study. Clin Pharmacol Ther (2009) 85: 269-272.
 159. Yuan H, Huang Z, Yang G et al.: Effects of polymorphism of the beta(1) adrenoreceptor and 
CYP2D6 on the therapeutic effects of metoprolol. J Int Med Res (2008) 36: 1354-1362.
 160. Bijl MJ, Visser LE, van Schaik RH et al.: Genetic variation in the CYP2D6 gene is associated with a 
lower heart rate and blood pressure in beta-blocker users. Clin Pharmacol Ther (2009) 85: 45-50.
 161. Swen JJ, Wilting I, de Goede AL et al.: Pharmacogenetics: from bench to byte. Clin Pharmacol Ther 
(2008) 83: 781-787.
 162. Reiter MJ: Cardiovascular drug class specificity: beta-blockers. Prog Cardiovasc Dis (2004) 47: 11-
33.
 163. Petersen M, Andersen JT, Hjelvang BR et al.: Association of beta-adrenergic receptor polymor-
phisms and mortality in carvedilol-treated chronic heart-failure patients. Br J Clin Pharmacol 
(2011) 71: 556-565.
 164. Rigat B, Hubert C, Alhenc-Gelas F et al.: An insertion/deletion polymorphism in the angiotensin 
I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 
(1990) 86: 1343-1346.
 165. Tiret L, Rigat B, Visvikis S et al.: Evidence, from combined segregation and linkage analysis, that a 
variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels. Am J Hum 
Genet (1992) 51: 197-205.
232 Part III – Pharmacogenetics of cardiovascular diseases
 166. Arnett DK, Boerwinkle E, Davis BR et al.: Pharmacogenetic approaches to hypertension therapy: 
design and rationale for the Genetics of Hypertension Associated Treatment (GenHAT) study. 
Pharmacogenomics J (2002) 2: 309-317.
 167. Harrap SB, Tzourio C, Cambien F et al.: The ACE gene I/D polymorphism is not associated with the 
blood pressure and cardiovascular benefits of ACE inhibition. Hypertension (2003) 42: 297-303.
 168. Bleumink GS, Schut AF, Sturkenboom MC et al.: Mortality in patients with hypertension on 
angiotensin-I converting enzyme (ACE)-inhibitor treatment is influenced by the ACE insertion/
deletion polymorphism. Pharmacogenet Genomics (2005) 15: 75-81.
 169. Cambien F, Poirier O, Lecerf L et al.: Deletion polymorphism in the gene for angiotensin-converting 
enzyme is a potent risk factor for myocardial infarction. Nature (1992) 359: 641-644.
 170. Agema WR, Jukema JW, Zwinderman AH, van der Wall EE: A meta-analysis of the angiotensin-
converting enzyme gene polymorphism and restenosis after percutaneous transluminal coro-
nary revascularization: evidence for publication bias. Am Heart J (2002) 144: 760-768.
 171. Schelleman H, Klungel OH, Witteman JC et al.: Angiotensinogen M235T polymorphism and the 
risk of myocardial infarction and stroke among hypertensive patients on ACE-inhibitors or beta-
blockers. Eur J Hum Genet (2007) 15: 478-484.
 172. Schelleman H, Klungel OH, Witteman JC et al.: Pharmacogenetic interactions of three candidate 
gene polymorphisms with ACE-inhibitors or beta-blockers and the risk of atherosclerosis. Br J Clin 
Pharmacol (2007) 64: 57-66.
 173. Su X, Lee L, Li X et al.: Association between angiotensinogen, angiotensin II receptor genes, and 
blood pressure response to an angiotensin-converting enzyme inhibitor. Circulation (2007) 115: 
725-732.
 174. Brugts JJ, Isaacs A, Boersma E et al.: Genetic determinants of treatment benefit of the angioten-
sin-converting enzyme-inhibitor perindopril in patients with stable coronary artery disease. Eur 
Heart J (2010) 31: 1854-1864.
 175. Daly AK: Genome-wide association studies in pharmacogenomics. Nat Rev Genet (2010) 11: 241-
246.
 176. Sissung TM, English BC, Venzon D, Figg WD, Deeken JF: Clinical pharmacology and pharmacoge-
netics in a genomics era: the DMET platform. Pharmacogenomics (2010) 11: 89-103.
 177. Ridker PM, MacFadyen J, Libby P, Glynn RJ: Relation of baseline high-sensitivity C-reactive protein 
level to cardiovascular outcomes with rosuvastatin in the Justification for Use of statins in Preven-
tion: an Intervention Trial Evaluating Rosuvastatin (JUPITER). Am J Cardiol (2010) 106: 204-209.
 178. Swen JJ, Nijenhuis M, de BA et al.: Pharmacogenetics: from bench to byte- an update of guide-
lines. Clin Pharmacol Ther (2011) 89: 662-673.
 179. Frueh FW, Amur S, Mummaneni P et al.: Pharmacogenomic biomarker information in drug labels 
approved by the United States food and drug administration: prevalence of related drug use. 
Pharmacotherapy (2008) 28: 992-998.

Chapter 
Value of platelet pharmacogenetics 
in common clinical practice 
of patients with ST-segment 
elevation myocardial infarction
Jeffrey J.W. Verschuren, Helèn Boden, Judith A.M. Wessels, Bas L. van der Hoeven, 
Stella Trompet, Bastiaan T. Heijmans, Hein Putter, Henk-Jan Guchelaar, Martin J. 
Schalij and J. Wouter Jukema
Int. J. Cardiol. (2012) August 29 [Epub ahead of print]
236 Part III – Pharmacogenetics of cardiovascular diseases
abstract
background: Antiplatelet drug resistance is a well-known problem, causing recurrent 
cardiovascular events. Multiple genetic polymorphisms have been related to antiplatelet 
resistance by several large trials, however data from common clinical practice is limited. 
We examined the influence of previously described polymorphisms, related to aspirin 
and clopidogrel resistance, on treatment outcome in a real life unselected population 
of patients presenting with ST-segment elevation myocardial infarction (STEMI) treated 
with percutaneous coronary intervention.
methods and results: This cohort study consisted of 1327 patients with STEMI. Patients 
were treated according to a standardized guideline-based protocol. Nine polymor-
phisms, COX1 (-842A>G), P2Y1 (893C>T), GPIa (807C>T), GPIIIa (PlA1/A2), CYP2C19 (*2, 
*3 and *17), ABCB1 (3435T>C) and PON1 (576A>G), were genotyped. During 1 year of 
follow-up the primary endpoint, a composite of cardiac death or recurrent myocardial 
infarction, was reached in 86 patients. The COX1 and CYP2C19*2 polymorphisms were 
associated with the primary endpoint, HR 2.55 (95% CI 1.48-4.40), p = 0.001 and HR 2.03 
(1.34-3.09) P = 0.001, respectively. The combined analysis demonstrated a 2.5-fold in-
creased risk for individuals with ≥ 2 risk alleles, p = 6.9x10−9. The association of COX1 was 
driven by mortality related events whereas that of CYP2C19*2 was mainly attributed to 
myocardial infarction and stent thrombosis.
conclusion: In this unselected, real life population of STEMI patient on dual-antiplatelet 
therapy, the polymorphisms COX1 -842A>G and CYP2C19*2 were determinants of 
thrombotic complications during follow-up. We show that in a clinical setting, testing 
for these polymorphisms could be of value in the identification of STEMI patients at risk 
for recurrent cardiovascular events.
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introDuction
Insufficient platelet inhibition during adequate guideline antiplatelet therapy is a 
well-known problem in the secondary prevention of coronary artery disease, causing a 
considerable amount of patients to suffer from recurrent thrombotic events.1 Individual 
differences in the intrinsic rate of platelet reactivity and variability in the response to 
antiplatelet therapy are the main underlying mechanisms responsible for this so-called 
antiplatelet therapy resistance. For both aspirin and clopidogrel this problem has been 
recognized. Several factors play a role in this inadequate response to antiplatelet agents. 
Clinical factors like increased body mass index (BMI), diabetes mellitus and drug-drug 
interactions have been implicated.1 Moreover, genetic polymorphisms causing individ-
ual variability in drug absorption, metabolism and availability of biological targets, like 
platelet receptors, influence the platelet inhibition during therapy in each individual.1
Pharmacogenetics is the upcoming field of research exploring the influence of ge-
netic variation on response on drug therapy, to pursue achievement of individualized 
therapy. There is growing evidence that aspirin- and especially clopidogrel resistance is 
partially determined by carrying risk alleles of several single nucleotide polymorphisms 
(SNPs) in genes resulting in altered drug efficacy.1 In comparison with the largely incon-
sistent pharmacogenetic evidence on aspirin resistance due to the high variability in 
laboratory tests and the small sample size of most studies,2 clopidogrel pharmacogenet-
ics has become a well-recognized risk factor for resistance to treatment. Over the last 
years, multiple studies consistently reported an association of the reduced-function 
alleles of CYP2C19 and clopidogrel resistance and occurrence of thrombotic events.3-5 
However, the most recent meta-analyses did not demonstrate this association.6,7 The 
studies included in these analyses comprise several patient groups, including patients 
with stable and unstable angina and the spectrum acute coronary syndromes. Specific 
data on patients with ST-segment elevation myocardial infarction (STEMI), a subpopu-
lation specifically at high risk for thrombotic events, is limited. Furthermore, data on 
the generalizability of this evidence to the patients seen in the daily clinical practices is 
largely lacking.
The only large population based study on this subject is that of Simon et al. in the 
French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-
MI) population (n = 2208).8 Although this well designed study investigated probably 
a good representative population, they still applied several exclusion criteria such as 
pre-specified levels of biomarkers and duration of complaints. Moreover, of the total 
included population, only 53% were STEMI patients and only 70% of the patients were 
treated with percutaneous coronary intervention (PCI), making it a quite heterogeneous 
population. Also the genotypic analysis was limited to 4 candidate genes. All other 
cohort studies were smaller and had even less patients with STEMI.9-11
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To obtain answers on the role of pharmacogenetics in the outcome of patients 
suffering from STEMI, our study investigated the effect of the best described poly-
morphisms implicated in antiplatelet therapy efficacy on thrombotic complications in 
a prospectively gathered real life unselected population of patients presenting with 
STEMI. The goal was to evaluate whether the described effects of these polymorphisms 
were detectable in this high risk population and could therefore possibly be of value for 
application in the common clinical practice.
methoDs
study population
The population of the current study consists of patients who were admitted with the 
diagnosis STEMI to the Leiden University Medical Center (LUMC), Leiden, The Nether-
lands, between February 2004 and January 2010. All patients underwent primary PCI 
and were treated according to the previously described standardized guideline-based 
MISSION! AMI care program12. In brief, the protocol includes a pre-hospital triage system 
based on 12-lead electrocardiography and when eligible pre-hospital administration of 
aspirin (300mg), clopidogrel (600mg) and abciximab (25µg/kg bolus, followed by 10µg/
kg/min for 12 h) was performed to pursue early reperfusion. Patients were directly trans-
ferred to the catheterization laboratory for primary PCI. Beta-blockers and angiotensin-
converting enzyme (ACE) inhibitors were titrated to achieve an optimal heart rate and 
blood pressure control. Moreover statin treatment was started in all patients. Patients 
without complications were discharged at day 3 after education on lifestyle changes 
and drug compliance. Aspirin (100mg/day) was prescribed indefinitely, and clopidogrel 
(75mg/day) for 12 months, irrespective of implanted stent type. All patients were offered 
an outpatient rehabilitation program.
follow-up and study endpoints
During the first year, 4 outpatient clinic visits were scheduled. During this 1 year of 
follow-up all thrombotic cardiovascular events were recorded. In this study, the primary 
endpoint was the composite of cardiac death and recurrent myocardial infarction (MI). 
Secondary endpoints included cardiac death and MI separately, as well as definite stent 
thrombosis, repeat revascularization and all-cause mortality. All deaths were defined 
as cardiac, unless clearly proven non-cardiac. Myocardial infarction was defined as a 
troponin T level above the upper limit in the presence of ischemic complaints or PCI or 
a re-rise of > 25% after recent MI in the presence of symptoms or PCI. Stent thrombosis 
was defined as angiographic or pathological confirmation of a partial or total thrombotic 
occlusion within the stent or 5 mm proximally or distally to the stent.13 Finally, data on 
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revascularization of any coronary artery, irrespective of the treatment modality (PCI or 
CABG) was collected. Target vessel revascularizations were all clinically driven.
Genotyping
EDTA blood was prospectively collected on admission and DNA was extracted following 
standard procedures. DNA was available from 1370 of the 1674 consecutive patients, 
reasons for missing DNA were death before the collection of blood or failure of the DNA 
extraction.
The most well replicated genetic polymorphisms related to aspirin and clopidogrel 
resistance were selected after a systematic search of literature, as described previously.1 
In brief, relevant articles were identified by searching MEDLINE using keywords and 
Medical Subject Headings (MeSH) terms including the following: pharmacogenetics, 
single nucleotide polymorphism, treatment outcome, adverse effects, drug therapy 
and cardiovascular disease (CVD). All available literature until May 2011 was included 
and reviews, editorials, and articles in languages other than English were excluded. A 
multiplex assay was designed using Assay designer software. When a SNP did not fit the 
multiplex, a proxy of that SNP was selected with the highest R2 value. The final set includ-
ed cyclooxygenase 1 (COX1) -842A>G (rs10306114), P2Y purinoceptor 1 (P2Y1) 893C>T 
(rs1065776), P2Y12 52G>T (rs6809699), glycoprotein (GP) Ia 807C>T (rs1126643), GPIIIa 
rs8069732 (in complete linkage disequilibrium (LD) (R2 = 1.0) with PlA1/A2 [rs5918]), 
cytochrome P450 (CYP) 2C19*2 (rs4244285), CYP2C19*3 (rs4986893) and rs11188072 (in 
complete LD (R2 = 1.0) with CYP2C19*17 [rs12248560]), ATP-binding cassette sub-family 
B member 1 (ABCB1) rs2235048 (as a proxy for 3435T>C [rs1045642], in complete LD 
with R2 = 1.0) and paraoxonase-1 (PON1) 576A>G (rs662) (Supplementary table 1).
These SNPs, except the SNP in PON1, were genotyped by MALDI-TOF mass spec-
trometry, using the MassARRAYTM methodology (Sequenom Inc., San Diego, CA, USA), 
following the manufacturer’s instructions. The PON1 576A>G (rs662) SNP was geno-
typed using a TaqMan Drug Metabolism Genotyping Assay (Assay ID C___2548962_20; 
Applied Biosystems, Foster City, CA, USA). As quality control, 5% of the samples were 
genotyped in duplo. No inconsistencies were observed. All the negative controls (2%) 
were negative. Call rate of all SNPs was above 98%. Two SNPs deviated significantly 
from Hardy-Weinberg (HW) equilibrium. P2Y12 52G>T (rs6809699) (HW ChiSq 362.7 , 
P = 7.4x10−81) was excluded from further analysis. The CYP2C19*3 polymorphism (HW 
ChiSq 64.0, P = 1.3x10−15) was included, since the deviation was caused by 1 homozygote 
of the minor allele of this low frequency SNP (0.3% in the current population). This minor 
allele frequency was lower than the reported frequency in HapMap CEU reference panel 
(1.7%) (http://www.hapmap.org). All other SNPs matched with the reported frequencies. 
Finally, individuals with 50% or more failed SNPs were excluded (3%). The final analysis 
included 1327 patients.
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( n = 86) P-value
baseline
Sex – male (%) 949 (77) 61 (71) 0.24
Age – mean (SD), yr. 60.4 (11.8) 66.9 (13.3) < 0.001
BMI – median (IQR), kg/m2 26.0 (4.4) 26.5 (6.2) 0.28 a
Hypertension – no. (%) 416 (34) 38 (45) 0.03
Hypercholesterolemia – no. (%) 250 (20) 21 (25) 0.29
Diabetes mellitus – no. (%) 122 (10) 22 (26) < 0.001
Family history of CAD – no. (%) 528 (43) 23 (28) 0.008
Previous or current smoker – no. (%) 724 (58) 48 (57) 0.82
Previous MI – no. (%) 101 (8) 13 (15) 0.03
Previous PCI – no. (%) 75 (6) 6 (7) 0.73
Previous CABG – no. (%) 23 (2) 1 (1) 1.00
Procedural
Abciximab during intervention 1189 (96) 81 (94) 0.40
Killip class ≥2– no. (%) 42 (4) 13 (18) < 0.001
Culprit lesion – no. (%)
LAD 558 (45) 46 (54) 0.13
RCA 485 (40) 20 (23) 0.003
RCX 183 (15) 12 (14) 0.84
Left main 8 (1) 7 (8) < 0.001
Bypass 7 (1) 1 (1) 0.42
Multi vessel disease 662 (53) 65 (77) < 0.001
Stenting of culprit lesion – no. (%) 1213 (98) 82 (95) 0.15
Number of coronary stents - no (%)
1 752 (61) 47 (55) 0.28
> 1 461 (37) 35 (41) 0.51
Type of stent – no. (%)
Bare metal stent 377 (31) 38 (44) 0.008
Drug-eluting stent 802 (65) 41 (48) 0.001
EPC stent 11 (1) 3 (4) 0.06
Different types 18 (2) 0 (0) 0.63
Cardiac shock during PCIb – no. (%) 24 (2) 18 (21) < 0.001
TIMI flow < 3 after PCI – no. (%) 73 (6) 21 (25) < 0.001
Medication at discharge – no. (%)
Aspirin 1195 (96) 56 (90) 0.02
Clopidogrel 1238 (> 99) 61 (98) 0.18
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statistics
To compare the group with and the group without a primary outcome event, categorical 
parameters are compared with Pearson chi-square or Fisher’s exact test when appropri-
ate. Continuous data were compared with unpaired 2-sided Student’s t-test. In the case 
of non-Gaussian distribution, variables were compared with the Mann-Whitney test. 
All SNPs were tested for deviation from Hardy-Weinberg equilibrium using chi-square 
analysis.
Associations of SNPs with outcome events were calculated using multivariable, 
stepwise, forward Cox analyses assuming an additive genetic model. This multivariable 
model included the clinical variables that were significantly different between the 
primary event group and the group without. For the polymorphisms associated with 
p < 0.05, recessive and dominant models were tested. Statistical analysis was performed 
using SPSS software (SPSS Inc., Chicago, IL, USA). The authors of this manuscript have 




All patients were treated with a primary PCI and received dual antiplatelet therapy with 
aspirin and clopidogrel. In-hospital mortality of the final study population was 1.8% (24 
patients). At discharge from the hospital admission following the primary intervention, 
aspirin and clopidogrel were prescribed to 96.0% and 99.7% of the patients respectively. 
However, all patients received the loading of clopidogrel.
During follow-up 86 patients (6.5%) reached the primary composite endpoint con-
sisting of cardiac death or recurrent myocardial infarction. A total of 57 patients (4.3%) 
died, of which 48 of a cardiac cause. Forty-four patients (3.3%) suffered from a recur-






( n = 86) P-value
Statin 1230 (99) 60 (97) 0.12
Beta-blocker 1184 (95) 54 (87) 0.003
ACE inhibitor or ARB 1210 (98) 60 (97) 0.67
a P-value calculated with Mann-Whitney test, b cardiac shock requiring treatment with inotropic agents, 
an intra-aortic balloon pump or other medical devices. Abbreviations: SD, standard deviation; BMI, 
body mass index; IQR, interquartile range; CAD, coronary artery disease; MI, myocardial infarction; PCI, 
percutaneous cononary intervention; CABG, coronary artery bypass grafting; EPC, endothelial progenitor 
cell capturing stents; ACE, angiotensin-converting enzyme; ARB angiotensin-receptor blocker.
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rent myocardial infarction and 237 patients (17.9%) required repeat revascularization, 
of which 72 (30.3% of all revascularizations) were treated for an acute indication like 
unstable complaints or MI. Ninety-two procedures (6.9% of all patients) were revascu-
larizations of the target vessel. Stent thrombosis was recorded in 15 patients (1.1%). 
Several baseline and procedural characteristics were significantly different between the 
primary endpoint group and the patients without the primary endpoint (Table 1). The 
event group was older, more likely to have hypertension, diabetes mellitus and a previ-
ous myocardial infarction in their medical history, but less likely to have a positive family 
history for cardiovascular disease. The location of the culprit lesion in the right coronary 
artery (RCA) was less often found in the primary event group, whereas it was more 
frequent in the left main (LM) coronary artery. The patients with a primary event were 
more often found to have multivessel disease and had a higher Killip class. The type of 
the implanted stent was also associated with clinical outcome events. Patients receiving 
drug-eluting stents (DES) had a lower risk of an event. Moreover, during the primary 
intervention, in the event group more patients suffered from cardiac shock requiring 
medical intervention and the classification of the final TIMI flow after the intervention 
was lower compared to the group without an event. Aspirin and beta-blockers were less 
frequently prescribed at discharge to the patients that suffered from a primary event 
during follow up.
Genotypic analysis
Of the 9 SNPs that were analyzed, the COX1 -842A>G polymorphism and the CYP2C19*2 
reduced-function polymorphism were significantly associated with the primary end-
point (Table 2). For both SNPs there was an increase in the hazard ratio for an outcome 
event with each additional minor allele, HR 2.55 (95% CI 1.48-4.40), p = 0.001 for COX1 
-842A>G (Figure 1) and HR 2.03 (95% CI 1.34-3.09), p = 0.001 for CYP2C19*2 (Figure 2). 
The other SNPs were not significantly associated with the primary endpoint.
The additional testing of dominant and recessive models indicated that the association 
of the CYP2C19*2 with primary endpoints was best described with a the recessive ge-
Table 2 Cox analysis of pharmacogenetic SNPs in the MISSION! population.





( n = 86)
hr
(95% ci) PGenotype maf
COX1, -842A>G (rs10306114) 2.55 0.001
AA – no. (%) 7.5% 1063 (86) 66 (78) (1.48-4.40)
AG – no. (%) 163 (13) 16 (19)
GG – no. (%) 7 (1) 3 (4)
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Table 2 Cox analysis of pharmacogenetic SNPs in the MISSION! population. (continued)





( n = 86)
hr
(95% ci) PGenotype maf
P2Y1, 893C>T (rs1065776) NS 0.71
CC – no. (%) 3.5% 1145 (93) 80 (95)
CT – no. (%) 85 (7) 4 (5)
TT – no. (%) 2 (< 1) 0 (0)
GPIa, 807C>T (rs1126643) NS 0.38
CC – no. (%) 39.3% 426 (35) 39 (45)
CT – no. (%) 635 (52) 32 (37)
TT – no. (%) 169 (14) 15 (17)
GPIIIa, T>C (rs8069732)a NS 0.51
TT – no. (%) 15.2% 889 (72) 69 (81)
TC – no. (%) 317 (26) 11 (13)
CC – no. (%) 32 (3) 5 (6)
CYP2C19, 681G>A, *2 (rs4244385) 2.03 0.001
GG – no. (%) 16.7% 861 (70) 55 (65) (1.33-3.09)
GA – no. (%) 339 (28) 22 (26)
AA – no. (%) 31 (3) 8 (9)
CYP2C19, 636G>A, *3 (rs4986893) NS 0.50
GG – no. (%) 0.3% 1233 (99) 86 (100)
GA – no. (%) 7 (1) 0 (0)
AA – no. (%) 1 (< 1) 0 (0)
CYP2C19, C>T (rs11188072)b NS 0.93
CC – no. (%) 20.6% 773 (63) 55 (66)
CT – no. (%) 401 (33) 23 (27)
TT – no. (%) 51 (4) 6 (7)
ABCB1, 3435C>T (rs1045642) NS 0.91
CC – no. (%) 46.0% 354 (29) 26 (31)
CT – no. (%) 618 (50) 40 (48)
TT – no. (%) 256 (21) 18 (21)
PON1, (rs662) NS 0.23
TT – no. (%) 29.7% 592 (48) 45 (53)
TC – no. (%) 532 (44) 34 (40)
CC – no. (%) 100 (8) 6 (7)
a genotyped SNP is in complete LD with PlA1/A2 (rs5918) polymorphism. b genotyped SNP is in complete 
LD with CYP2C19*17 (rs12248560) polymorphism. P-values were calculated with a multivariable, stepwise, 
forward Cox analyses assuming an additive model and including adjustment for age, hypertension, 
diabetes, family history, previous myocardial infarction, Killip score, culprit lesion, multi vessel disease, 
stent type, cardiac shock during PCI, final TIMI flow < 3, aspirin at discharge and betablocker at discharge. 
Genotyping was not successful for all SNPs in each individual subject, therefore genotype counting per 
SNP might not compute to the total number of subjects in each group.
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netic model, and this model was therefore used for further analysis. Carriage of 2 variant 
alleles of the CYP2C19*2 polymorphism resulted in a significant increased risk of events 
during follow-up compared to carriage of 0 or 1 reduced function alleles (20.5% versus 
6.0%; adjusted hazard ratio 2.38, 95% CI 1.60-3.56, P = 2.1x10−5. The dominant model 
resulted in a hazard ratio of 1.36, 95% CI 1.03-1.78, P = 0.03. The recessive effect was 
visually confirmed by the Kaplan-Meier curve (Figure 2). The additive model proved to 
be the most appropriate for analysis of the COX1 SNP.
When considering both SNPs together, 779 (59%) patients were homozygote for the 
wild type alleles of both SNPs, 435 (33%) patients had 1 risk allele, 87 (7%) patients had 
2 risk alleles and 8 (1%) patients were carrying 3 risk alleles. In our population no patient 
was homozygote for both variant alleles of both SNPs. Compared to the patients with 0 
or 1 risk alleles, the patients who were carrying 2 or 3 risk alleles had an increased risk of 
the primary endpoint, HR 2.57 (95% CI 1.87-3.54), P = 6.9x10−9.
Analysis of the different stent type groups did not result in different results than 
the analysis of the total study population. Univariable analysis of the patients receiv-
Figure 1 Rates of primary outcome events (cardiac death and recurrent myocardial infarction) according 
to -842A>G COX1 genotype.
P-values were calculated with a multivariable, stepwise, forward Cox analyses assuming an additive model 
and including adjustment for age, hypertension, diabetes, family history, previous myocardial infarction, 
Killip score, culprit lesion, multi vessel disease, stent type, cardiac shock during PCI, final TIMI flow < 3, 
aspirin at discharge and betablocker at discharge.
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ing BMS (N = 415) did not result in significant associations of the COX1 SNP (P = 0.093) 
and CYP2C19*2 (P = 0.13) with the primary endpoint, whereas combination of these 
2 SNPs did demonstrate a significant association (P = 0.004). These three analyses did 
show significant associations in the DES subgroup (N = 843), P = 0.021 for COX1 -846A>G, 
P = 5.4x10-5 for CYP2C19*2 and P = 9.3x10-5 for the combined analysis.
When analyzing the outcome events such as death, recurrent MI, repeat revascu-
larization and stent thrombosis separately, the COX1 SNP was demonstrated to have a 
strong association with the mortality related endpoints. However, no significant associa-
tion was found with the thrombotic endpoints such as myocardial infarction and stent 
thrombosis, P = 0.20 and P = 0.59 respectively. In contrast, the CYP2C19*2 polymorphism 
was associated with all endpoints, except for the mortality related endpoints (Figure 3). 
Patients with the homozygote variant genotype of this SNP were especially at risk for 
myocardial infarction, HR 2.76 (95% CI 1.73-4.41), P = 2.3x10−5 and stent thrombosis, HR 
4.82 (95% CI 2.42-9.59), P = 7.7x10−6. In addition, a significant relation was also found 
with the different repeat revascularization related endpoints.
Figure 2 Rates of primary outcome events (cardiac death and recurrent myocardial infarction) according 
to CYP2C19*2 genotype.
P-values were calculated with a multivariable, stepwise, forward Cox analyses assuming an additive model 
and including adjustment for age, hypertension, diabetes, family history, previous myocardial infarction, 
Killip score, culprit lesion, multi vessel disease, stent type, cardiac shock during PCI, final TIMI flow < 3, 
aspirin at discharge and betablocker at discharge.
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Discussion
The key finding of this study is that in this unselected real life population of STEMI 
patients treated with PCI, the homozygous variant genotype of the CYP2C19*2 poly-
morphism is a strong determinant of the occurrence of thrombotic events during the 
first year of follow-up. In addition, the -842A>G polymorphism of COX1 is associated 
with the composite endpoint of cardiac death and recurrent myocardial infarction as 
well. Especially patients carrying 2 or more risk alleles of these 2 SNPs were at high risk. 
None of the other previously reported SNPs with proposed pharmacogenetic influence 
of antiplatelet therapy efficacy were associated with outcome events during 1 year 
follow-up after STEMI.
The vast amount of pharmacogenetic research of the last years resulted in a tremen-
dous increase of knowledge on pharmacogenetic gene-drug interactions, however in-
consistent results prevented reaching consensus and moving the field forward to clinical 
application. Even regarding the CYP2C19*2 polymorphism, the major enzyme involved 
in the metabolic conversion of the clopidogrel prodrug into its active form,2 that was 
Figure 3 Multivariable Cox analysis of COX1 -842A>G and CYP2C19*2 with the different cardiovascular 
endpoints
In black are indicated the hazard ratio and 95% confidence interval of the -842A>G COX1 polymorphism 
and in gray those of CYP2C19*2 with the different secondary endpoints. With urgent revascularization 
includes the revascularizations performed for the indications unstable angina pectoris and acute 
myocardial infarction. a Analyzed assuming a recessive model. TVR target vessel revascularization.
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thought to have a significant role in the outcome of patients treated with clopidogrel, 
recent meta-analyses report conflicting results.3,6,7 The current study demonstrates that 
this SNP and the COX1 polymorphism are significant determinants of thrombotic events 
in an unselected real life population of patients presenting with STEMI.
Cyclooxygenase 1 (COX1, or prostaglandin endoperoxide G/H synthase) catalyzes the 
metabolism of arachidonic acid to prostaglandin H2, which is subsequently metabolized 
to thromboxane A2.This enzyme is the therapeutic target of aspirin.
15 The -842A>G poly-
morphism, that is in complete linkage disequilibrium with 50C>T, was first described by 
Halushka et al. as a determinant of aspirin responsiveness in healthy individuals. How-
ever, subsequent studies investigating patient populations were largely inconsistent.16-20 
To date, the only studies that investigated the association of -842A>G or 50C>T with 
clinical events did not find a significant relation.21,22 The association of -842A>G with the 
primary endpoint of the current study appears to be caused by the strong relation with 
mortality and not with myocardial infarction. The exact mechanism of this relation is 
unclear, since a causal relation between mortality and aspirin resistance in the absence 
of an association with myocardial infarction seems unlikely.
Data on genetic variation associated with aspirin resistance comes only from studies 
with small sample sizes (< 500 subjects) and when considering the small effect size of 
the individual SNPs and the variability of laboratory tests for aspirin resistance,23 it is 
not surprising that the reported results are largely inconsistent.17,18,21,24-27 In the current 
study only COX1 -842A>G was shown to have a significant association with the primary 
endpoint. But as stated above, this effect seems to be driven by an increased risk of 
mortality of carriers of this SNP and not due to the more thrombotic specific endpoint 
myocardial infarction or stent thrombosis. However, even if an effect of a specific SNP on 
aspirin efficacy exists, it is likely that it will not be detectable in this population with dual 
antiplatelet therapy since the decreased antiplatelet inhibition will be overcome by the 
concomitant use of clopidogrel.
In contrast with the COX1 SNP, the association of CYP2C19*2 with the primary end-
point is determined by its effect on the risk of recurrent myocardial infarction and not 
on cardiac death. Unlike the controversy of its relation with cardiovascular events, the 
reduced platelet inhibition by clopidogel in carriers of the reduced function alleles is 
not questioned,7 making it likely that this is the causal mechanism of the relation with 
events found in the current study. In addition, patients that carry risk alleles for both of 
these SNPs are especially at risk as is shown by the combined risk analysis.
Early 2011, a SNP in the paraoxonase-1 gene, 576A>G (R192Q), was described as the 
major determinant of clopidogrel efficacy in platelet inhibition as well as stent thrombo-
sis,28 instead of CYP2C19*2. However, since then, several study groups failed to confirm 
these findings in other cohorts.29-31 Also in the current STEMI population no association 
between the PON1 genotype and cardiovascular events could be demonstrated.
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The results of the current study demonstrate the strong effect of the CYP2C19*2 poly-
morphism and the increased risk of thrombotic complications during 1 year of follow-up 
after presenting with STEMI. The question remains how this knowledge can contribute 
to improvement of the treatment outcome of these patients. Initially it was thought that 
increasing the dose of clopidogrel in patients with insufficient platelet inhibition on a 
normal dose of clopidogrel might improve the outcome.32 The results of the Gauging Re-
sponsiveness with A Verifynow assay-Impact on Thrombosis And Safety (GRAVITAS) trial 
could not endorse this hypothesis, probably because of the fact that also a higher dose 
of clopidogrel does not lead to significant platelet inhibition in these patients.33 In the 
ELEVATE-TIMI 56 (Escalating Clopidogrel by Involving a Genetic Strategy - Thrombolysis 
In Myocardial Infarction 56), Mega et al demonstrated that after tripling the clopidogrel 
dose to 225mg daily in CYP2C19*2 heterozygotes did achieve levels of platelet inhibi-
tion comparable to that seen with the standard 75mg dose in non-carriers. However in 
the *2 homozygotes even 300mg clopidogrel did not result in adequate platelet inhibi-
tion.34 In addition, similar results with respect to clinical events were reported by the RE-
sponsiveness to CLOpidogrel and Stent-related Events-2 in Acute Coronary Syndromes 
(RECLOSE-2 ACS) study.35 Patients with high residual platelet activity had an increased 
event risk compared to those with low platelet activity after clopidogrel loading, despite 
increasing the clopidogrel dose or switching to ticlopidine.35 In the current study, most 
patients (96%) received abciximab before or during the primary intervention. Although 
we observed no difference of abciximab treatment between cases and controls, it could 
have influenced our results by decreasing the occurrence of early events. However, 
since patients only receive abciximab once, it seems unlikely that it has an influence on 
thrombotic events later during follow up. Moreover, the found effect size of the SNPs in 
the current study is comparable to other studies,8,11 decreasing the likelihood of a major 
impact of abciximab treatment on the presented associations.
Recently, genetic substudies of the TRITON-TIMI-38 (TRial to assess Improvement in 
Therapeutic Outcomes by optimizing platelet iNhibition with prasugrel–Thrombolysis In 
Myocardial Infarction 38)36 and PLATO (PLATelet inhibition and patient Outcomes)37 trials, 
investigating the more potent prasugrel and ticagrelor, respectively, have demonstrated 
that these agents are not significantly affected by the genetic variation in the CYP2C19 
gene nor in other described genes. Prescribing one of these drugs to all patients probably 
would solve almost all of the pharmacogenetic problems, since the relative small effects 
of the SNPs are overbalanced by the much stronger platelet inhibition of these drugs. 
However, subsequent additional bleeding complications should be weighed against the 
benefit of these drugs, especially in individuals already at risk for bleeding complica-
tions. A well-validated score for estimating bleeding risk is however lacking.38 In the 
latest guidelines on myocardial revascularization by the European Society of Cardiology 
the recommended antiplatelet therapy for STEMI patients consists of dual antiplatelet 
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therapy with aspirin and prasugrel or ticagrelor. In this guideline, clopidogrel should 
only be used if the more effective platelet inhibitors are contraindicated or unavailable.38 
Nevertheless, an attractive application of the pharmacogenetic knowledge of CYP2C19 
could be genotypic guidance in the choice of prescribing clopidogrel to patients with 
0 or 1 reduced-function allele of CYP2C19 and prasugrel or ticagrelor to the carriers of 
2 variant alleles.39 Clinical benefit of this theory as well as economic cost-effectiveness 
remains to be proven by currently on-going trials (for instance ReAssessment of Anti-
Platelet Therapy Using an InDividualized Strategy Based on GENetic Evaluation [RAPID 
GENE, NCT01184300], Thrombocyte Activity Reassessment and GEnoTyping for PCI 
[TARGET-PCI, NCT01177592] and Genotyping Infarct patients to Adjust and Normalize 
Thienopyridine treatment [GIANT, NCT01134380]). The results of the first study were 
presented at the Transcatheter Cardiovascular Therapeutics (TCT) congress 2011. In the 
RAPID GENE study 200 patients were randomized to a treatment strategy genotyping 
and prasugrel prescription for CYP2C19*2 carriers, or to standard therapy with clopido-
grel. The authors demonstrated that treatment with prasugrel completely eliminated 
HPR in the CYP2C19*2 carriers compared to treatment with clopidogrel (unpublished 
results). Whether this strategy is also cost-effective compared to prasugrel prescription 
to all patients and if the rate of bleeding complication is lower remains to be shown.
Limitations
Some limitations of this study are worthwhile being mentioned. The fact that all patients 
in our population received dual antiplatelet therapy limits the possibility to investigate 
a true pharmacogenetic effect of these SNPs, since there is no placebo controlled group 
to compare with. Therefore, the relation we detected could theoretically be a direct 
relation between the SNP and the thrombotic events, independent of the antiplatelet 
therapy. However a recent meta-analysis of several genome wide associations studies 
on coronary artery disease did not detect any of the SNPs from the current study,40 
making the chance of an antiplatelet drug independent association unlikely. No platelet 
function tests were performed in the current study. In the current study three CYP2C19 
alleles (*2, *3 and *17 respectively) were analysed. Although, other alleles in this gene 
and in other CYP genes have also been associated with clopidogrel metabolism,36 we 
decided not to analyse these SNPs considering the low allele frequency of some of these 
SNPs and because the evidence of their involvement is not that solid as compared to the 
three CYP SNPs tested in the current study.2 The observational nature of our study could 
be seen as a limitation. However, to determine the clinical value of findings derived from 
earlier large trials in an unselected and clinically representative patient population can 
provide important additional value. Our population is suitable for this purpose for sev-
eral reasons. First, since we did not handle exclusion criteria on the type or duration of 
STEMI nor on the subsequent therapy, our cohort is a good representation of common 
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clinical practice. Second, since all patients were treated according to the standardized 
guideline-based MISSION! protocol, possible confounding factors during the follow-up 
period are kept to a minimum.
conclusion
The contribution to the existing evidence of the current study is that it demonstrates that 
in daily clinical practice of patients with STEMI, of all the previously proposed candidate 
SNPs involved in platelet pharmacogenetics, only the influence of the COX1 -842A>G 
and CYP2C19*2 polymorphisms on the 1 year combined thrombotic outcome could be 
demonstrated and seems of clinical significance. Considering the population size this 
does not implicate that the other genetic markers are not associated with antiplatelet 
treatment failure, but that their possible influence is so small that it is unlikely that they 
are of clinical relevance. The mortality driven association with COX1 -842A>G deserved 
further research in a study more specifically dedicated to this endpoint. Ongoing stud-
ies on pharmacogenetic guidance of antiplatelet therapy using the CYP2C19 reduced 
function alleles will provide answers whether this strategy can contribute to finding the 
balance between adequate platelet inhibition and avoidance of excessive bleeding risk.
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main finDinGs
Genetic variation plays an important role in cardiovascular disease development. Due 
to the complex nature of most cardiovascular diseases (CVD), these genetic factors 
are part of an intricate interplay with clinical factors and environmental factors, which 
together determines an individual’s risk to develop a certain condition. To date several 
genetic factors have been associated with different aspects of CVD, however consistent 
replication has proven to be difficult, often due to a limited sample size.1-4 The aim of this 
thesis was to further elucidate the genetic background of coronary restenosis and other 
cardiovascular diseases using large, well described study populations. Moreover we 
investigated the role of genetic variation on the individual’s response to drug therapy. 
These three topics are respectively addressed in Part I, II and III of this thesis.
Percutaneous coronary intervention (PCI) is a frequently used therapeutic modality 
in patients with coronary artery disease. Although the incidence of coronary restenosis 
after PCI has decreased considerably with improvements of the technique and materi-
als, in particular after the introduction of drug-eluting stents (DES)5, this complication 
is still not abolished and remains an important cause of morbidity and need for re-
intervention.6,7 In chapter 2 and chapter 3 of Part I, a comprehensive overview of all 
current knowledge regarding coronary restenosis is given. Despite the vast amount of 
research on restenosis the causative mechanisms of this complex disease have not yet 
been fully identified. It is thought that the main contributor to the process is the inflam-
matory response evoked by vascular damage during angioplasty.8,9 This inflammatory 
state subsequently activates several other processes like, proliferation and migration 
of vascular smooth muscle cells and extracellular matrix (ECM) remodeling, eventually 
leading to the development of restenosis. Not all individuals have a similar risk of devel-
oping restenosis. Diabetes mellitus is the most consistently reported clinical parameter 
increasing this risk.10 Moreover, some patients appear to have an inherent predisposi-
tion towards developing restenosis, which can be partly explained by their specific 
genetic background.11 Many innovative technologies, including DES (with or without 
specific polymers)5,12,13 and fully biodegradable stents14, have been and continue to be 
developed in the diligent search for an ideal preventive anti-restenosis therapy, that 
is both effective and safe in the long term. However, if restenosis does occur, patient 
should receive the most optimal treatment. Whether this treatment should consist of re-
implantation of either a bare-metal stent or a DES, a bypass surgery or a newer modality 
like a drug-eluting balloon should be tailored to the individual.15,16 Results of ongoing 
trails might shed more light on which treatment is more suitable in a particular situation. 
Furthermore, ongoing research on the genetic background of restenosis might make a 
more personalized approach feasible.
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As was described in the general introduction, genetic research has developed from 
single SNP analysis in candidate genes toward hypothesis-free genome-wide associa-
tion studies (GWAS). In chapter 4 we have described the results of the very first GWAS 
published on restenosis that was performed in the GENetic DEterminants of Restenosis 
(GENDER) study population. After the GWAS analysis in GENDER, three independent 
replication steps were performed, leading to the identification of a novel susceptibility 
locus on chromosome 12. The two associated single nucleotide polymorphisms (SNPs) 
at the 12q23.3 region, rs10861032 and rs9804922, were also associated with all-cause 
mortality in GENDER and in the PROspective Study of Pravastatin in the Elderly at Risk 
study (PROSPER) and also with coronary events in PROSPER, which indicates that this 
region might play an important role in the broader range of coronary events. Consider-
ing the intergenic nature of the locus, we speculate that the SNPs influences a regulatory 
function of this region. Further research will be needed to disentangle the biological 
implication of this region in restenosis.
After obtaining the GWAS data we wanted to clarify the previously reported mixed 
results regarding the association of genetic variation in the ECM remodeling genes, 
matrix metalloproteinase (MMP) 2 and 3, with restenosis. In chapter 5 we combined 
the genotypic data obtained in previous candidate gene studies in GENDER and the 
available GWAS data from the genetic region of these two genes, together providing a 
high coverage of their genetic variation. We concluded that a solid association between 
genetic variation in MMP2 or MMP3 and restenosis was absent, rendering further ge-
netic association studies involving these genes and this endpoint futile.
 Alongside the development of new genotyping techniques also novel statisti-
cal methods are being developed, better capable of handling the increasing amount 
of data generated by GWAS. One of these methods is set-based analysis using PLINK 
software.17 This analysis is capable of analyzing the joint effect of multiple SNPs. Since 
a joint effect is biologically more plausible than single SNP associations we decided to 
apply this analysis in chapter 6 to examine multiple SNPs in the genomic region of all 
previously described candidate genes of restenosis. This kind of proof-of-concept study 
had the aim to explore whether the joint effect of all these SNPs together was associated 
with restenosis, despite all the inconsistent results from previous studies. In this chapter 
we demonstrated that the joint effect of 36 candidate genes indeed was associated with 
restenosis in the GENDER study population. 
In chapter 7 we applied this joint effect analysis to entire biological pathways, to 
investigate their association with restenosis. In this study we demonstrated a potential 
role of the cell-ECM interactions pathway in the development of coronary restenosis. Of 
this pathway the PARVB gene was shown to have the strongest association with resteno-
sis, and several SNPs in this gene replicated in an independent replication cohort. PARVB 
could therefore be a novel candidate gene for restenosis.
Summary, conclusions and future perspectives 259
13
Finally, in the final chapter of part I, chapter 8, we present the 10-year follow-up data 
of the GENDER population. We show that despite previous reports, coronary restenosis 
after PCI is not associated with an increased risk of mortality, neither on the short term 
nor on the long term. An attractive conclusion could be that the current treatment of 
patients with restenosis is so good that patients no longer die from this condition and 
that we might not concern about restenosis anymore. Although this might be partly 
true, restenosis still causes considerate morbidity, which still justifies and requires fur-
ther studies to understand and prevent this phenomenon.
In part II of this thesis the focus shifts to other cardiovascular and vascular conditions 
related to restenosis. In chapter 9 we investigated the role of DNA repair mechanisms 
in the CVD events myocardial infarction and stroke in both GENDER and PROSPER. DNA 
damage and DNA repair processes have been suggested to play a role in CVD develop-
ment18, but only a few studies have explored this possible contributing aspect. We again 
used the set-based analysis of PLINK to explore the relations of five DNA repair pathways 
with these endpoints. We demonstrated that the non-homologous end-joining pathway 
was associated with the occurrence of myocardial infarction in both study populations 
and that this association was mainly driven by genetic variation in the MRE11A gene. 
This gene is part of the MRN complex, which has a critical role in the recognition of 
DNA damage lesions or the chromatin alterations that follow DNA damage18 and a key 
role in the cellular response to double strand breaks.19 To our knowledge, this is the first 
study to associate the MRE11A with CVD endpoints. Additional studies will be needed 
to confirm this result and to further explore the implications of this possible relation.
Next, we make a sidestep towards nephrology to study a condition with a likely 
mechanistic overlap with coronary restenosis, i. e. arteriovenous fistula (AVF) failure in 
hemodialysis patients. In chapter 10 we selected a wide range of SNPs in candidate 
genes for AVF failure, including genes previously related to coronary restenosis and 
aortic aneurysm formation. We genotyped and analyzed these SNPs in the Netherlands 
Cooperative Study on the Adequacy of Dialysis (NECOSAD) population and concluded 
that only the rs1466535 SNP in low density lipoprotein receptor-related protein 1 (LRP1) 
and the factor V Leiden mutation were significantly associated with AVF failure. Although 
our SNP selection covered a wide range of candidate genes, the obtained results did 
not indicate an important role of these SNPs in the development of AVF failure. One 
explanation for these observations could be that genetic susceptibility does not play 
an important role in the development of AVF failure. Local factors, such as the abnormal 
hemodynamics and vascular damage, might have a more important role in the failure of 
the vascular access required for hemodialysis than the genetic background.
Part III of this thesis focusses on pharmacogenetics of cardiovascular related drugs. 
Pharmacogenetics is the upcoming field of research that examines genetic variation that 
influences responses to drug therapy in the individual patient, with the very appealing 
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goal to realize personalized therapy using genotypic guidance of pharmacotherapy by 
selecting agents with the greatest potential for efficacy and the least risk of toxicity. In 
chapter 11 a comprehensive overview of the available pharmacogenetic evidence of 
the five major drug classes of cardiovascular diseases is provided. It discusses in detail 
the variability in efficacy of statins and their risk of myopathy, the genetic determinants 
of resistance to antiplatelet agents, the dosing issues of oral anticoagulants, genetic 
variation related to suboptimal responses to β-blockers and the variable response in 
blood pressure and clinical events in patients taking angiotensin converting enzyme 
(ACE) inhibitors. The overall conclusion of the review is that there are enough reasons to 
remain optimistic that, even though we are taking small steps at a time, we are heading 
to an era where we can finally use pharmacogenetics in clinical practice to optimize 
treatment for the individual patient.
In chapter 12, we explored the findings regarding the genetic determinants of 
antiplatelet drug resistance, obtained by the systematic review described in chapter 11, 
in a large real-life population of ST-segment elevation myocardial infarction patients. We 
investigated whether the eight best replicated SNPs, related to aspirin- and clopidogrel 
efficacy, were associated with recurrent thrombotic events in this unselected patient 
population and demonstrated that the CYP2C19*2 allele indeed was strongly associated 
with thrombotic events. In addition, the -842A>G polymorphism of COX1 was associated 
with the composite endpoint of cardiac death and recurrent myocardial infarction as 
well. Especially patients carrying two or more risk alleles of these two SNPs were at high 
risk. We showed that also in a clinical setting, testing for these polymorphisms could be 
of value in the identification of STEMI patients at risk for recurrent cardiovascular events.
future PersPectiVes
Genetic association studies have come a long way the last decades and our understand-
ing of the genetic background in many different diseases increased substantially. The 
completion of the Human Genome Project in 200320 boosted our knowledge and made 
the development of GWAS possible.21 Since then, the scientific world committed itself 
on this technique, studying all conceivable phenotypes (Figure 1). The National Human 
Genome Research Institute, part of the American National Institutes of Health, which 
also performed the Human Genome Projects, keeps record of all the published GWAS in 
a publicly available database (www.genome.gov/gwastudies).22 As of 21st of March 2013, 
this catalog includes 1542 publications and 8828 associated SNPs. 
However, the last years we reached a point where we had to broaden our thoughts 
beyond the traditional GWAS analyses. The single SNP GWAS analyses has resulted in 
many interesting and novel associations, but considering that common diseases are 
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multigenic traits, which involve groups of genes functioning at various stages of disease 
development, other more advanced statistical methods would be more appropriate to 
analyze this data. In this thesis we have applied some of these newer statistical methods 
to account for this joint effect of multiple genetic markers. The genetic research field 
is however far from the ultimate analyzing tool for handling the large amount of data 
generated by GWAS.
Future developments will surely result in even better and more sophisticated 
methods to help us interpret the data. Despite these newer tools, the explained vari-
ance remains low and the effect size of the encountered associations remains limited, 
requiring large study populations. Therefore, the formation of consortia that cooperate 
in combining data of separate studies will also greatly aid in the generation of more 
reliable results than the individual studies will do.
Another recent development in the genetic research field is the availability of next-
generation sequencing methods.23 With the falling costs of sequencing technology, the 
genetic research field is currently shifting from microarray-based genotyping studies to 
whole genome sequencing.24,25 However, one you should keep in mind that sequencing 
studies aim and finding rare variants, present in <1% of the population, that are not 
present on GWAS-chips consisting mainly of common variants. Whether the missing 
heritability will be explained by rare variants with large effect sizes of my many common 
variants with small effect sizes remains to be seen.26 For our complete understanding of 
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the complete biological background of CVD genetics alone will however not be enough, 
systems-level approaches, including the analysis of proteomes, are required for a more 
comprehensive understanding.27 An important project, regarding this integrated ap-
proach, is the Encyclopedia of DNA Elements (ENCODE) project.28 The ENCODE project 
has systematically mapped regions of transcription, transcription factor association, 
chromatin structure and histone modification. Using this data biochemical functions 
could be assigned to 80% of the genome.28 This dataset could be very helpful in un-
derstanding the mechanistical implications of genetic associations. A major problem 
of most genetic association studies is the difficulty of linking the results to a biological 
plausible mechanism of action. Especially the top hits of the GWAS studies are usually 
SNPs with an unknown function and are located in intergenic regions or even in so 
called gene-desserts. It is very easy to conclude that more ‘functional’ studies should be 
performed to further elucidate the actual effect of the obtained association, but these 
studies are often very time consuming, expensive and often fail to obtain the desired 
result. Therefore the evidence should be convincing enough to pursue a positive hit in 
more detail. Possible follow up analyses include investigating whether the SNPs affect 
expression or function of the gene they are located in. If this is not the case, they could 
influence other (nearby) genes, which could for instance be explored by mRNA expres-
sion analyses or allelic expression imbalance.29 Furthermore, sequencing of the genes of 
interest could result in identifying functional variants in linkage disequilibrium with the 
SNPs identified in the current GWAS studies. When a functional gene or region is identi-
fied with enough certainty, experimental models in vitro or in vivo in animal models, if 
available, could be employed.
In the meantime, clinical application of genetic data is already possible without our 
complete understanding of their exact effect, in the form of risk prediction. Risk predic-
tion is an important aspect of cardiovascular disease treatment and prevention. Many 
risk scores for several disease outcomes have been developed over the years, all using 
clinical parameters for the prediction of the risk of the individual patient.30-32 Our increas-
ing knowledge of the molecular background of cardiovascular diseases might provide 
a potential improvement of the current risk models. Several genetic markers have been 
identified to be associated with the risk of developing cardiovascular events.2,33,34 To 
date, several studies explored the added value of genetic polymorphisms to clinical 
risk scores, reporting mixed results.35-37 Further studies focusing on the genetic risk 
scores are needed. Risk scores including high impact genetic markers, like CYP2C19*2 
on thrombotic events during clopidogrel treatment as demonstrated in chapter 12, will 
likely have the highest chance to improve after including these markers.
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hoofDbeVinDinGen
Genetische variatie beïnvloedt de kans op het krijgen van hart- en vaatziekten (HVZ). 
Deze genetische factoren bepalen samen met meerdere klinische factoren (bijvoorbeeld 
diabetes mellitus en een verhoogd cholesterol) en omgevingsfactoren (bijvoorbeeld 
roken) het risico op het ontwikkelen van HVZ van de individu. Doordat al deze factoren 
in een ingewikkeld samenspel dit risico beïnvloeden worden HVZ onder de complexe 
ziektebeelden gerekend. Tot op heden zijn er meerdere genetische factoren in verband 
gebracht met verschillende aspecten van HVZ, maar consistente bevestiging van deze 
gerapporteerde bevindingen is schaars. Dit is waarschijnlijk voornamelijk te wijten aan 
het kleine aantal patiënten dat in de studies is onderzocht. Het doel van dit proefschrift 
was het verder uitzoeken van de genetische achtergrond van coronaire restenose en 
andere hart- en vaatziekten met behulp van grote, goed omschreven studie populaties. 
Bovendien onderzochten we de rol van genetische variatie op het verschil in respons 
op de behandeling met bepaalde medicijnen. Deze drie thema’s worden respectievelijk 
behandeld in deel I, II en III van dit proefschrift.
Percutane coronaire interventie (PCI) is een veel gebruikte behandeling van pa-
tiënten met coronair lijden. Een complicatie van PCI is het opnieuw gaan dichtzitten 
van het behandelde coronair (kransslagvat), ook wel restenose genoemd. Hoewel de 
incidentie van coronaire restenose na PCI aanzienlijk is afgenomen de laatste jaren, met 
name na de introductie van drug-eluting stents (DES), kunnen we deze complicatie nog 
niet geheel voorkomen en blijft het een belangrijke oorzaak van morbiditeit en be-
hoefte aan re-interventie. In de eerste 2 hoofdstukken van deel I wordt er een uitgebreid 
overzicht van alle huidige kennis met betrekking tot coronaire restenose beschreven. 
hoofdstuk 2 beschrijft de achtergrond en risicofactoren van restenose. Ondanks het 
vele onderzoek naar restenose weten we nog steeds niet precies welke mechanismen 
er ten grondslag van deze complexe ziekte liggen. Men denkt dat de ontstekingsreac-
tie, veroorzaakt door vasculaire schade die tijdens de PCI kan ontstaan, een grote rol 
speelt. Deze overactieve inflammatoire staat activeert vervolgens verschillende andere 
processen zoals, proliferatie en migratie van vasculaire gladde spiercellen en extracel-
lulaire matrix (ECM) vorming. Samen kunnen deze processen leiden tot het ontslaan van 
restenose. Niet iedereen heeft hetzelfde risico om restenose te ontwikkelen. Patiënten 
met diabetes hebben bijvoorbeeld een verhoogd risico. Verder blijkt uit meerdere 
studies dat bepaalde genetische factoren dit risico beïnvloeden. In hoofdstuk 3 wordt 
met name ingegaan op de praktische kant van het probleem, zoals de verschillende 
ontwikkelingen om restenose te voorkomen en de behandeling van restenose. Veel 
innovatieve technologieën, waaronder DES en volledig biologisch afbreekbare stents, 
zijn reeds ontwikkeld en onderzoek naar de beste preventieve anti-restenose therapie, 
die zowel effectief en veilig is op de lange termijn, is nog steeds in volle gang. Mocht 
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dan toch restenose ontstaan, zijn er verschillende behandelopties. Voorbeelden hiervan 
zijn re-implantatie van ofwel een bare-metal stent of een DES, een bypass operatie of 
de recent ontwikkelde drug-eluting ballon. Er is vooralsnog geen eenduidig advies 
over welke behandeling in welke situatie de voorkeur heeft. De resultaten van lopende 
onderzoeken zullen hier mogelijk meer houvast in gaan bieden.
Zoals werd beschreven in de algemene inleiding, heeft genetisch onderzoek zich 
ontwikkeld van analyses van losse polymorfismen in kandidaat genen naar hypothese-
vrije analyses van het hele genoom met genome wide association studies (GWAS). In 
hoofdstuk 4 beschrijven we de resultaten van de eerste GWAS die is gepubliceerd 
over restenose. Deze studie werd uitgevoerd in de GENetic DEterminants of Restenosis 
(GENDER) studie populatie. Na de analyses in GENDER werden de bevonden resultaten 
bevestigd in drie onafhankelijk studies, waarbij we uiteindelijk tot de conclusie kwamen 
dat er een, niet eerder beschreven, regio op chromosoom 12 geassocieerd was met 
restenose. De twee polymorfismen in deze regio werden behalve met restenose ook 
in verband gebracht met een verhoogd risico op sterfte in de GENDER studie en ook 
in de PROspective Study of Pravastatin in the Elderly at Risk study (PROSPER). Mogelijk 
heeft deze regio dus een bredere rol in HVZ. Omdat deze regio niet op een bepaald gen 
zit, maar tussen twee genen in ligt, denken wij dat het met name een rol speelt in de 
regulatie van genen. Verder onderzoek zal nodig zijn om dit uit te zoeken.
Na het verkrijgen van de GWAS data wilden wij dit gebruiken om eerdere tegen-
strijdige resultaten uit te zoeken over de rol van genetische variatie in twee ECM vor-
mende genen, matrix metalloproteinase (MMP) 2 en 3. In hoofdstuk 5 hebben we de 
genotypische data uit eerdere kandidaat-gen studies in GENDER gecombineerd met de 
beschikbare GWAS gegevens om zo nog een gedetailleerder overzicht van de geneti-
sche variatie binnen deze genen te krijgen. We concludeerden dat er geen duidelijke 
associatie was tussen de genetische variatie in MMP2 of MMP3 en restenose. Verder 
onderzoek hiernaar zal dus tot niets zinvols leiden en is dus nu niet langer nodig.
In hoofdstuk 6 hebben we een andere statistische methode gebruikt om te kijken 
naar het gezamenlijke effect van meerdere polymorfismen. Aangezien we naar een 
complexe ziekte onderzoek doen, is het biologisch gezien plausibeler dat meerdere 
genen samenwerken in het ontstaan van restenose. Deze methode is dus mogelijk een 
betere manier om naar de relatie met restenose te kijken. In dit hoofdstuk hebben we 
meerdere polymorfismen, gelegen in alle eerder beschreven kandidaat-genen van 
restenose, tezamen geanalyseerd. We kwamen tot de conclusie dat het gecombineerde 
effect van de genetische variatie van 36 kandidaat-genen inderdaad is geassocieerd 
met restenose in de GENDER studie populatie, ondanks alle inconsistente resultaten uit 
eerdere studies.
In hoofdstuk 7 hebben we deze techniek vervolgens toegepast om de invloed van 
hele biologische pathways op het ontstaan van restenose te onderzoeken. In deze studie 
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hebben we aangetoond dat er een mogelijke rol is van de cel-ECM interactie pathway in 
de ontwikkeling van restenose. Van de verschillende genen in deze pathway bleek het 
PARVB gen het sterkst geassocieerd met restenose. Verschillende polymorfismen in dit 
gen werden vervolgens ook gerepliceerd in een onafhankelijke studie populatie.
Tot slot presenteren we in het laatste hoofdstuk van deel I, hoofdstuk 8, de 10-jaars 
follow-up van de GENDER populatie. We laten zien dat ondanks eerdere publicaties, 
coronaire restenose na PCI niet is geassocieerd met een verhoogd risico op sterfte, 
niet op de korte termijn en ook niet op de lange termijn. Een aantrekkelijke conclusie 
zou kunnen zijn dat de huidige behandeling van patiënten met restenose is zo goed 
dat patiënten niet meer sterven aan deze aandoening en dat we ons daarom dus ook 
niet meer druk hoeven te maken over deze complicatie. Echter, ook al is dit misschien 
gedeeltelijk waar, restenose veroorzaakt nog steeds aanzienlijke morbiditeit. Dus is er 
nog steeds meer onderzoek naar restenose nodig.
In deel II van dit proefschrift richten we ons op andere cardiovasculaire en vasculaire 
aandoeningen. In hoofdstuk 9 hebben we onderzoek gedaan naar de rol van processen 
die DNA schade herstellen in het ontstaan van een myocardinfarct of een beroerte. DNA 
schade en DNA herstel processen spelen mogelijk een rol in HVZ, maar slecht enkele 
studies hebben hier onderzoek naar gedaan. Ook in deze studie hebben we de analyses 
naar het gezamenlijke effect van meerdere polymorfismen gebruikt om de relatie van 
vijf DNA herstel pathways te analyseren in de GENDER en de PROSPER studie populaties. 
We laten zien dat de non-homologous end-joining pathway geassocieerd is met het 
optreden van een myocardinfarct in beiden populaties en dat deze associatie vooral 
werd veroorzaakt door de genetische variatie in het MRE11A gen. Dit gen heeft een 
belangrijke rol bij de herkenning van DNA schade en tevens een rol in de respons op 
dubbelstrengs breuken van het DNA. Dit is de eerste studie die een relatie laat zien van 
dit gen met HVZ. Aanvullende studies zullen nodig zijn om dit resultaat te bevestigen en 
om vervolgens deze mogelijke relatie verder biologisch uit te zoeken.
In hoofdstuk 10 maken we een uitstap naar de nierziekten om onderzoek te doen 
naar het falen van dialyse fistels. Dit probleem lijkt namelijk op veel vlakken op reste-
nose en mogelijk spelen dus ook dezelfde mechanismen een rol in het ontstaan van het 
falen van deze fistels. In dit onderzoek hebben we diverse polymorfismen onderzocht, 
gelegen in kandidaat genen voor dialyse fistel falen, maar ook in genen eerder geas-
socieerd met restenose en aneurysma formatie van de aorta. Voor deze studie hebben 
we gebruik gemaakt van de Netherlands Cooperative Study on the Adequacy of Dialysis 
(NECOSAD) populatie. Van alle onderzochte polymorfismen waren alleen rs1466535 in 
het LRP1 gen en de factor V Leiden mutatie significant geassocieerd met fistel falen. 
In vergelijking met restenose spelen genetische factoren bij fistel falen mogelijk een 
kleinere rol. Lokale factoren, zoals de abnormale hemodynamiek en vaatschade, zijn 
mogelijk meer van invloed op het ontslaan van fistel falen.
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Deel III van dit proefschrift richt zich op de farmacogenetica van cardiovasculaire 
medicijnen. Farmacogenetica is het onderzoek naar genetische variatie die de respons 
beïnvloedt van een individuele patiënt op een bepaald geneesmiddel. De belangrijkste 
toepassing van deze farmacogenetische kennis is de ontwikkeling van gepersonali-
seerde behandeling, doordat op basis van de genetische achtergrond het beste middel 
geselecteerd zou kunnen worden. In hoofdstuk 11 wordt een uitgebreid overzicht 
beschreven van de beschikbare farmacogenetische gegevens van de vijf belangrijkste 
groepen van cardiovasculaire geneesmiddelen. Er wordt in detail ingegaan op de 
variabiliteit in het effect van statines en hun risico op myopathie, de genetische deter-
minanten van resistentie tegen plaatjesaggregatieremmers, de dosering problemen van 
orale anticoagulantia, de genetische variatie met betrekking tot suboptimale reacties 
op β-blokkers en de variabele respons van de bloeddruk en klinische uitkomstmaten 
bij patiënten die angiotensine converting enzyme (ACE)-remmers gebruiken. De 
algemene conclusie van dit overzicht is dat, ook al nemen we steeds kleine stapjes in 
de vooruitgang, er genoeg redenen zijn om optimistisch te zijn dat de tijd waarin we 
farmacogenetica kunnen gebruiken in de klinische praktijk om de behandeling van de 
individuele patiënt te optimaliseren in zicht komt.
Tenslotte hebben we in hoofdstuk 12 de acht best geschreven polymorfismen, die 
van invloed zijn op de werking van aspirine en clopidogrel, geanalyseerd in een grote 
ongeselecteerde populatie van patiënten met ST-segment elevatie myocardinfarct. 
We hebben onderzocht of deze polymorfismen waren geassocieerd met trombotische 
uitkomsten en we laten zien dat het *2 risico allel van het CYP2C19 gen inderdaad 
sterk geassocieerd was met nieuwe trombotische complicaties na het myocardinfarct. 
Daarnaast werd er ook een relatie gezien met het -842A>G polymorfisme in het COX1 
gen. Vooral patiënten die twee of meer risico allelen van deze twee polymorfismen dra-
gen hadden een hoog risico. Met deze studie laten we zien dat in patiënten die gezien 
worden in de dagelijkse klinische praktijk het testen op deze polymorfismen waardevol 
kunnen zijn bij de identificatie van de patiënten met een verhoogd risico op nieuwe 
cardiovasculaire problemen.
toekomstPersPectieVen
Tijdens de laatste decennia is er enorme progressie geboekt in het genetische onder-
zoek en onze kennis van de genetische achtergrond van veel ziekten is aanzienlijk toe-
genomen. Na de voltooiing van het Human Genome Project in 2003 en de ontwikkeling 
van GWAS in 2005 zijn er al ruim 1500 van deze studies gepubliceerd over bijna alle 
denkbare ziektebeelden. Echter, gedurende laatste jaren hebben we een punt bereikt 
waarop we onze gedachten weer moeten verbreden buiten de traditionele GWAS ana-
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lyses. Deze analyses hebben geleid tot vele interessante en nieuwe bevindingen, maar 
gezien het feit dat de meeste veelvoorkomende ziekten door meerdere genen worden 
beïnvloed, zijn andere meer geavanceerde statistische methoden waarschijnlijk meer 
geschikt om de GWAS data te analyseren. In dit proefschrift hebben we een aantal van 
deze nieuwere statistische methoden toegepast om naar het gezamenlijke effect van 
meerdere polymorfismen te kijken. Ook al zijn we nu een stap verder met deze analyses, 
we zijn nog verre van de ultieme analyse methode om de grote hoeveelheid informatie, 
die gegenereerd wordt tijdens een GWAS, volledig mee te analyseren. Toekomstige ont-
wikkelingen zullen zeker nog betere en meer geavanceerde methoden opleveren die 
ons bij de interpretatie van deze gegevens helpen. Tot nu toe blijft echter de variantie 
die verklaard wordt met de genetische variatie beperkt en ook is de grootte van het 
effect van de losse polymorfismen laag waardoor grote studie populaties nodig zijn om 
relaties aan te tonen. De vorming van consortia waarbinnen de gegevens van meerdere 
studies gecombineerd worden zullen dan ook meer betrouwbare resultaten opleveren 
dan de individuele studies.
Een andere recente ontwikkeling in het genetisch onderzoek is de beschikbaarheid 
van next-generation sequencing, waarmee in nog meer detail het genoom geanalyseerd 
kan worden. Voor ons volledige begrip van de biologische achtergrond van HVZ zal het 
analyseren van alleen genetische data echter niet voldoende zijn. Integratie met andere 
onderzoeksgebieden, zoals eiwitanalyses en epigenetica, zal nodig zijn om daadwerke-
lijk de biologische processen te begrijpen. Een groot probleem van de meeste genetische 
associaties studies is dan ook om de gevonden genetische associaties te vertalen naar 
biologische processen. Vooral de top hits van de GWAS studies zijn van polymorfismen 
met een onbekende functie, die niet in een gen liggen maar tussen genen in of zelfs 
gen-deserts. Het is heel gemakkelijk om te concluderen dat meer ‘functionele’ studies 
moeten worden uitgevoerd om deze relaties verder uit te zoeken. Deze studies zijn ech-
ter vaak zeer tijdrovend en duur en leiden vaak niet tot het gewenste resultaat. Daarom 
zal het bewijs van een genetische associatie overtuigend genoeg moeten zijn voordat 
er met verder onderzoek gestart wordt. Enkele voorbeelden van mogelijke follow-up 
analyses omvatten het onderzoeken of de polymorfismen de expressie of functie van 
een gen beïnvloeden, bijvoorbeeld met mRNA expressie analyses of allelische expressie 
onbalans. Sequentiebepaling van een regio kan leiden tot de identificatie van een  func-
tionele variant die in linkage disequilibrium is met het geassocieerde polymorfisme. 
Wanneer een functioneel gen of regio met voldoende bewijs is geïdentificeerd kunnen 
experimentele modellen in vitro of in vivo, in diermodellen indien beschikbaar, worden 
toegepast.
Echter ook zonder ons volledige begrip van het exacte effect van een polymorfisme, 
zouden we deze genetische gegevens al wel in de praktijk kunnen toepassen in de vorm 
van risicovoorspelling. Risicovoorspelling is een belangrijk aspect tijdens de preventie 
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en behandeling van HVZ. Door de jaren heen zijn er meerdere risicoscores ontwikkeld 
voor verschillende ziektebeelden voor het voorspellen van het risico van de individuele 
patiënt, allemaal met behulp van klinische parameters. Onze kennis van de molecu-
laire achtergrond van HVZ zou kunnen bijdragen aan de verbetering van de huidige 
risicomodellen. De tot op heden gepubliceerde studies naar de toegevoegde waarde 
van genetische polymorfismen op klinische risicoscores, rapporteren echter gemengde 
resultaten. Er zijn dus meer studies nodig. Met name genetische markers met een groot 
effect, zoals CYP2C19*2 op trombotische uitkomsten tijdens clopidogrel behandeling, 
aangetoond in hoofdstuk 12, hebben waarschijnlijk de grootste kans om de klinische 
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